



(51) International Patent Classification:

C07D 401/14 (2006.01) A61P 7/06 (2006.01)
 C07D 405/14 (2006.01) A61K 31/454 (2006.01)
 C07D 471/08 (2006.01) A61K 31/4545 (2006.01)
 A61P 7/00 (2006.01) A61K 31/55 (2006.01)

(21) International Application Number:

PCT/IB2022/055131

(22) International Filing Date:

01 June 2022 (01.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/196,422 03 June 2021 (03.06.2021) US

(71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **BONAZZI, Simone**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **CERNIJENKO, Artiom**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **COBB, Jennifer Stroka**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **DEWHURST, Janetta**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **KERRIGAN, John Ryan**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SUNG, Moo-Je**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **THOMSEN, Noel Marie-France**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TING, Pamela YF**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts

setts 02139 (US). **O'BRIEN, Gary**; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF



(57) Abstract: The application relates to compounds of formula (I), pharmaceutical compositions comprising them and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta- hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF

Claim of Priority

This application claims the benefit of priority to U.S. Provisional Application No. 63/196422 filed
5 June 3, 2021, the disclosure of which is incorporated by reference herein in its entirety.

Sequence Listing

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII
10 copy, created on June 3, 2021 is named PAT059130-US-PSP_SL.txt and is 4,096 bytes in size.

Field of the Disclosure

The present disclosure relates to 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc
15 Finger Motifs (WIZ) protein expression levels and/or inducing fetal hemoglobin (HbF) protein expression levels, and in the treatment of inherited blood disorders (hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

Background of the Disclosure


Sickle cell disease (SCD) is a group of severe inherited blood disorders that cause red
20 blood cells to contort into a sickle shape. These cells can cause blockages in blood flow, leading to intense pain, organ damage and premature death. Beta thalassemias are a group of inherited blood disorders that are caused by reduced or absent synthesis of beta globin, causing anemia.

Fetal hemoglobin (HbF) induction is known to ameliorate symptoms in SCD and beta-thalassemia patients, with both genetic (single nucleotide polymorphisms in the globin control
25 locus & BCL11A) and pharmacologic (hydroxyurea) validation in the clinic (Vinjamur, D. S., *et al.* (2018), *The British Journal of Haematology*, 180(5), 630-643). Hydroxyurea is the current standard of care for SCD and is thought to provide benefit via induction of HbF, but is genotoxic, causes dose-limiting neutropenia and has a response rate of less than 40%. Other mechanisms being targeted clinically and preclinically include inhibition of HDAC1/2 (Shearstone *et al.*, 2016, *PLoS One*, 11(4), e0153767), LSD1 (Rivers *et al.*, 2018, *Experimental Hematology*, 67, 60-64), DNMT1, PDE9a (McArthur *et al.*, 2019, *Haematologica*. doi:10.3324/haematol.2018.213462), HRI kinase (Grevet *et al.*, 2018, *Science*, 361(6399), 285-290) and G9a/GLP (Krivega *et al.*, 2015, *Blood*, 126(5), 665-672; Renneville *et al.*, 2015, *Blood*, 126(16), 1930-1939). Additionally, the immunomodulators pomalidomide and lenalidomide induce HbF *ex vivo* in human primary
35 erythroid cells (Moutouh-de Parseval, L. A. *et al.* (2008), *The Journal of Clinical Investigation*, 118(1), 248-258) and *in vivo* (Meiler, S. E. *et al.* (2011), *Blood*, 118(4), 1109-1112). WIZ is ubiquitously expressed and plays a role in targeting the G9a/GLP histone methyltransferases to genomic loci to regulate chromatin structure and transcription (Bian, Chen, *et al.* (2015), *eLife* 2015;4:e05606.

Summary of the Disclosure

The disclosure relates to 3-(5-oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione compounds, which are effective in reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression, pharmaceutically acceptable salts thereof, compositions thereof, and their use in therapies for the conditions and purposes detailed above.

The disclosure provides, in a first aspect, a compound of formula (I') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-\text{SO}_2R^6$, $-\text{C}(=\text{O})-R^{2a}$, $-\text{C}(=\text{O})-\text{O}-R^{2a}$, and $-\text{C}(=\text{O})\text{NR}^{2b}R^{2c}$;

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-\text{CN}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl;


n is 0, 1, 2, 3, 4, or 5; and

m is 0, 1 or 2;

with the proviso that formula (I') does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.

The disclosure provides, in a second aspect, a compound of formula (I'') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,

5 wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-SO_2R^6$, $-C(=O)-R^{2a}$, $-C(=O)-O-R^{2a}$, and $-C(=O)NR^{2b}R^{2c}$;

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;


each R^5 is independently selected from $-CN$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl;

n is 0, 1, 2, 3, 4, or 5; and

m is 1 or 2.

The disclosure provides, in a third aspect, a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



5

each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl,

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-CN$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

n is 0, 1, 2, 3 or 4; and

m is 0, 1 or 2;

with the proviso that the compound of formula (I) does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.

In a fourth aspect, the disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

In a fifth aspect, the disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a

therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

5 In a sixth aspect, the disclosure provides a method of degrading WIZ protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

10 In a seventh aspect, the disclosure provides a method of inhibiting WIZ protein expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

15 In a eighth aspect, the disclosure provides a method of inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression, the method comprising administering to the subject a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

20 In a ninth aspect, the disclosure provides a method of inducing or promoting fetal hemoglobin in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

25 In an tenth aspect, the disclosure provides a method of reactivating fetal hemoglobin production or expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

30 In a further aspect, the disclosure provides a method of increasing fetal hemoglobin expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

35 In a further aspect, the disclosure provides a method of treating a hemoglobinopathy, *e.g.*, a beta-hemoglobinopathy, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a method of treating a sickle cell disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a method of treating beta-thalassemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a method of treating a disease or disorder that is affected by the modulation of WIZ protein levels comprising administering to the patient in need thereof a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a method of treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a method of reducing WIZ protein levels in a subject comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use as a medicament.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder selected from sickle cell disease and beta-thalassemia.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating or preventing a disease or disorder in a subject in need thereof.

5 In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment or prevention of a disease or disorder that is affected by the reduction of WIZ protein levels.

10 In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inhibiting WIZ protein expression in a subject in need thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA),
15 (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in degrading WIZ protein in a subject in need thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
20 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression in a subject in need thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
25 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inducing or promoting fetal hemoglobin in a subject in need thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
30 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in reactivating fetal hemoglobin production or expression in a subject in need thereof.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in increasing fetal hemoglobin production or expression in a subject in need thereof.

35 In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment or prevention of a disease or disorder that is affected by the inhibition of WIZ protein expression.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment or prevention of a disease or disorder that is affected by the degradation
5 of WIZ protein.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a hemoglobinopathy.

10 In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a sickle cell disease.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA),
15 (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of beta-thalassemia.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
20 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder affected by an increase in fetal hemoglobin expression.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
25 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder affected by the inhibition, reduction, or elimination of the activity of WIZ protein or WIZ protein expression.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
30 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder affected by the induction or promotion of fetal hemoglobin.

In a further aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a
35 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder affected by the reactivation of fetal hemoglobin production or expression.

In a further aspect, the disclosure provides the use of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or

a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

In a further aspect, the disclosure provides the use of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing or promoting fetal hemoglobin.

In a further aspect, the disclosure provides the use of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

In a further aspect, the disclosure provides the use of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

In a further aspect, the disclosure provides the use of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

In a further aspect, the disclosure provides the use of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing fetal hemoglobin.

In a further aspect, the disclosure provides the use of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

In a further aspect, the disclosure provides the use of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

In a further aspect, the disclosure provides the use of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

In a further aspect, the disclosure provides the use of a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder that is affected by inducing fetal hemoglobin, reactivating fetal hemoglobin production or expression, or increasing fetal hemoglobin expression.

In a further aspect, the disclosure provides a pharmaceutical combination comprising a compound of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more additional therapeutic agent(s).

Various aspects of the disclosure are described herein and in the claims.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the specification and claims, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entireties for all purposes. The references cited herein are not admitted to be prior art to the claimed disclosure. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of compounds, compositions, and methods disclosed herein will be apparent from the following detailed description and claims.

Brief Description of the Drawings

FIG. 1A depicts a volcano plot of differentially expressed genes from WIZ KO cells as compared to a scrambled gRNA control. Each dot represents a gene. HBG1/2 genes are differentially upregulated with WIZ_6 and WIZ_18 gRNA targeting WIZ KO.

FIG. 1B depicts a bar graph showing the frequency of HbF+ cells due to shRNA-mediated loss of WIZ in human mobilized peripheral blood CD34+ derived erythroid cells.

FIG. 1C depicts a bar graph showing the frequency of HbF+ cells due to CRISPR/Cas9-mediated loss of WIZ in human mobilized peripheral blood CD34+ derived erythroid cells.

Detailed Description of the Disclosure

The compounds disclosed herein are effective in reducing WIZ protein expression levels, or inducing fetal hemoglobin (HbF) expression. Without wishing to be bound by any theory, it is believed that the disclosed compounds may treat blood disorders, such as inherited blood

disorders, e.g., sickle cell disease, and beta-thalassemia by inducing fetal hemoglobin HbF expression.

Definitions

Unless specified otherwise, the terms “compounds of the present disclosure”, “compounds of the disclosure”, or “compound of the disclosure” refer to compounds of formulae of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), exemplified compounds, salts thereof, particularly pharmaceutically acceptable salts thereof, hydrates, solvates, prodrugs, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C₁-C₁₀alkyl means an alkyl group or radical having 1 to 10 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, “alkylaryl” means a monovalent radical of the formula alkyl-aryl-, while “arylalkyl” means a monovalent radical of the formula aryl-alkyl-. Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups. The articles “a” and “an” refer to one or more than one (e.g., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “and/or” means either “and” or “or” unless indicated otherwise.

The term “substituted” means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.

As used herein the term “C₁-C₁₀alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. The terms “C₁-C₃alkyl”, “C₁-C₄alkyl”, “C₁-C₆alkyl”, and “C₁-C₈alkyl” are to be construed accordingly. Examples of C₁-C₁₀alkyl include, without limitations, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, 1-methylpropyl (*sec*-butyl), 2-methylpropyl (*iso*-butyl), 1,1-dimethylethyl (*t*-butyl), *n*-pentyl, *n*-hexyl, *n*-heptyl, 4-heptyl, *n*-octyl, 2-*isopropyl*-3-methylbutyl, *n*-nonyl and *n*-decyl.

As used herein, the term “C₁-C₆alkoxyl” refers to a radical of the formula -OR_a where R_a is a C₁-C₆alkyl radical as generally defined above. Examples of C₁-C₆alkoxyl include, without limitations, methoxy, ethoxy, propoxy, *iso*-propoxy, butoxy, *iso*-butoxy, *tert*-butoxy, *sec*-butoxy, pentoxy, and hexoxy.

"Alkenyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, *n*-butenyl, isobutenyl, pentenyl, and hexenyl. An alkenyl group can be unsubstituted or substituted and may be straight or branched. The term "C₂-C₆alkenyl" is to be construed accordingly.

Examples of C₂-C₆alkenyl include, without limitations, ethenyl (or vinyl), propenyl (e.g., prop-1-enyl, prop-2-enyl), butadienyl (e.g., buta-1,3-dienyl), butenyl (e.g., but-1-en-1-yl, but-2-en-1-yl but-3-en-1-yl), pentenyl (e.g., pent-1-en-1-yl, pent-2-en-2-yl), hexenyl (e.g., hex-1-en-2-yl, hex-2-en-1-yl), 1-ethylprop-2-enyl, 1,1-(dimethyl)prop-2-enyl, 1-ethylbut-3-enyl, and 1,1-(dimethyl)but-2-enyl.

"Alkynyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in the chain. The term "C₂-C₆alkynyl" is to be construed accordingly. Examples of alkynyl groups include ethynyl, propargyl, *n*-butynyl, isobutynyl, pentynyl, and hexynyl. An alkynyl group can be unsubstituted or substituted. Examples of "C₂-C₆alkynyl" include, without limitations, ethynyl, prop-1-ynyl, prop-2-ynyl, and but-2-ynyl.

As used herein, the term "C₁-C₆haloalkyl" refers to C₁-C₆alkyl radical, as defined above, substituted by one or more halo radicals, as defined herein. Examples of C₁-C₆haloalkyl include, without limitations, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-fluoropropyl, 3,3-difluoropropyl and 1-fluoromethyl-2-fluoroethyl, 1,3-dibromopropan-2-yl, 3-bromo-2-fluoropropyl and 1,4,4-trifluorobutan-2-yl.

As used herein, the term "C₁-C₆haloalkoxyl" means a C₁-C₆alkoxyl group as defined herein substituted with one or more halo radicals. Examples of C₁-C₆haloalkoxyl groups include, without limitations, trifluoromethoxy, difluoromethoxy, fluoromethoxy, trichloromethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, pentafluoroethoxy, 2-fluoropropoxy, 3,3-difluoropropoxy and 3-dibromopropoxy. Preferably, the one or more halo radicals of C₁-C₆haloalkoxyl is fluoro. For example, C₁-C₆haloalkoxyl may be selected from trifluoromethoxy, difluoromethoxy, fluoromethoxy, 1,1-difluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoromethyl-2-fluoroethoxy, and pentafluoroethoxy.

The term "halo" means fluorine, chlorine, bromine or iodine.

As used herein, the term "cycloalkyl" means a monocyclic or polycyclic saturated or partially unsaturated carbon ring containing 3-18 carbon atoms wherein there are no delocalized pi electrons (aromaticity) shared among the ring carbon. The terms "C₃-C₁₁cycloalkyl", "C₃-C₈cycloalkyl" and "C₃-C₆cycloalkyl" are to be construed accordingly. The term polycyclic encompasses bridged (e.g., norbornane), fused (e.g., decalin) and spirocyclic cycloalkyl. Preferably, cycloalkyl, e.g., "C₃-C₁₁cycloalkyl" and "C₃-C₈cycloalkyl", is a monocyclic or spirocyclic hydrocarbon group of 3 to 11 and 3 to 8 carbon atoms, respectively.

Examples of cycloalkyl groups include, without limitations, cyclopropenyl, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, spiro[2.3]hexanyl, spiro[3.3]heptyl, spiro[3.4]octanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[4.5]decanyl, spiro[5.5]undecanyl, spiro[4.4]nonanyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, bicyclo[1.1.1]pentanyl and derivatives thereof.

Examples of C₃-C₁₁cycloalkyl include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.3]hexanyl, spiro[3.3]heptyl, spiro[3.4]octanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[4.5]decanyl, spiro[5.5]undecanyl, spiro[4.4]nonanyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.1.1]heptyl, bicyclo[2.2.2]octyl, and bicyclo[1.1.1]pentanyl.

Examples of C₃-C₈cycloalkyl include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro[3.3]heptanyl, and cyclooctyl.

Examples of C₃-C₆cycloalkyl include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

"Heterocyclyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, and sulfur (O, N, and S) and wherein there are no delocalized pi electrons (aromaticity) shared among the ring carbon or heteroatoms. The terms "4- to 11-membered heterocyclyl" and "4- to 6-membered heterocyclyl" are to be construed accordingly. The heterocyclyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. The heterocyclyl may be bonded via a carbon atom or heteroatom. The term polycyclic encompasses bridged, fused and spirocyclic heterocyclyl.

Examples of heterocyclyl rings include, without limitations, oxetanyl, azetidiny, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidiny, oxazoliny, isoxazoliny, oxazolidiny, thiazolidiny, pyranly, thiopyranly, tetrahydropyranyl, dioxaliny, piperidiny, morpholiny, thiomorpholiny, thiomorpholiny S-oxide, thiomorpholiny S-dioxide, piperaziny, azepiny, oxepiny, diazepiny, tropanyl, oxazolidinonyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidiny, dihydroisoxazoliny, pyrroliny, pyrazoliny, oxazepiny, dithiolanyl, homotropanyl, dihydropyranyl (e.g., 3,6-dihydro-2H-pyranyl), 2-oxaspiro[3.3]heptanyl (e.g., 2-oxaspiro[3.3]heptan-6-yl), 7-oxaspiro[3.5]nonanyl (e.g., 7-oxaspiro[3.5]nonan-2-yl), 1-oxa-7-azaspiro[3.5]nonanyl, 2-azaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 7-azaspiro[3.5]nonanyl, and the like.

Examples of 4- to 11-membered heterocyclyl include, without limitations, azetidiny, pyrrolidiny, tetrahydrofuranyl, tetrahydrothienyl, piperidiny, piperaziny, dihydroisoxazoliny, tetrahydropyranyl, morpholiny, dihydropyranyl (e.g., 3,6-dihydro-2H-pyranyl) 2-oxaspiro[3.3]heptanyl (e.g., 2-oxaspiro[3.3]heptan-6-yl), 7-oxaspiro[3.5]nonanyl (e.g., 7-oxaspiro[3.5]nonan-2-yl), 1-oxa-7-azaspiro[3.5]nonanyl, 2-azaspiro[3.3]heptanyl (e.g., 2-azaspiro[3.3]heptan-6-yl), 2,7-diazaspiro[3.5]nonanyl, and 7-azaspiro[3.5]nonanyl.

Examples of 4- to 6-membered heterocyclyl include, without limitations, azetidiny, pyrrolidiny, tetrahydrofuranyl, tetrahydrothienyl, piperidiny, piperaziny, dihydroisoxazoliny,

tetrahydropyranyl, morpholinyl, dihydropyranyl (e.g., 3,6-dihydro-2H-pyranyl).

As used herein, the term “aryl” as used herein means monocyclic, bicyclic or polycyclic carbocyclic aromatic rings. Examples of aryl include, but are not limited to, phenyl, naphthyl (e.g., naphth-1-yl, naphth-2-yl), anthryl (e.g., anthr-1-yl, anthr-9-yl), phenanthryl (e.g., phenanthr-1-yl, phenanthr-9-yl), and the like. Aryl is also intended to include monocyclic, bicyclic or polycyclic carbocyclic aromatic rings substituted with carbocyclic aromatic rings. Examples of aryl include, without limitations, biphenyl (e.g., biphenyl-2-yl, biphenyl-3-yl, biphenyl-4-yl), phenylnaphthyl (e.g., 1-phenylnaphth-2-yl, 2-phenylnaphth-1-yl), and the like. Aryl is also intended to include partially saturated bicyclic or polycyclic carbocyclic rings with at least one unsaturated moiety (e.g., a benzo moiety). Examples include, without limitations, indanyl (e.g., indan-1-yl, indan-5-yl), indenyl (e.g., inden-1-yl, inden-5-yl), 1,2,3,4-tetrahydronaphthyl (e.g., 1,2,3,4-tetrahydronaphth-1-yl, 1,2,3,4-tetrahydronaphth-2-yl, 1,2,3,4-tetrahydronaphth-6-yl), 1,2-dihydronaphthyl (e.g., 1,2-dihydronaphth-1-yl, 1,2-dihydronaphth-4-yl, 1,2-dihydronaphth-6-yl), fluorenyl (e.g., fluoren-1-yl, fluoren-4-yl, fluoren-9-yl), and the like. Aryl is also intended to include partially saturated bicyclic or polycyclic carbocyclic aromatic rings containing one or two bridges. Examples include, without limitations, benzonorbornyl (e.g., benzonorborn-3-yl, benzonorborn-6-yl), 1,4-ethano-1,2,3,4-tetrahydronaphthyl (e.g., 1,4-ethano-1,2,3,4-tetrahydronaphth-2-yl, 1,4-ethano-1,2,3,4-tetrahydronaphth-10-yl), and the like. The term “C₆-C₁₀aryl” is to be construed accordingly.

Examples of C₆-C₁₀aryl include, without limitations, phenyl and naphthyl. In an embodiment, C₆-C₁₀aryl is phenyl.

As used herein, the term “heteroaryl” as used herein is intended to include monocyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Examples include, without limitations, pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isooxazolyl, triazolyl, (e.g., 1,2,4-triazolyl), oxadiazolyl, (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), tetrazolyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, thiadiazinyl, azepinyl, azecinyl, and the like.

Heteroaryl is also intended to include bicyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Examples include, without limitations, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, indazolyl, benzopyranyl, benzimidazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzoxazinyl, benzotriazolyl, naphthyridinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, quinoxalinyl, oxazolopyridinyl, isooxazolopyridinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, imidazopyridinyl, imidazopyrimidinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolotriazinyl, thiazolopyridinyl, thiazolopyrimidinyl, imdazothiazolyl, triazolopyridinyl, triazolopyrimidinyl, and the like.

Heteroaryl is also intended to include polycyclic heterocyclic aromatic rings containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur (O, N, and S). Examples include, without limitations, carbazolyl, phenoxazinyl, phenazinyl, acridinyl, phenothiazinyl, carbolinyl, phenanthrolinyl, and the like.

5 Heteroaryl is also intended to include partially saturated monocyclic, bicyclic or polycyclic heterocyclyls containing one or more heteroatoms selected oxygen, nitrogen, and sulfur (O, N, and S). Examples include, without limitations, imidazoliny, indoliny, dihydrobenzofuranyl, dihydrobenzothienyl, dihydrobenzopyranyl, dihydropyridooxazinyl, dihydrobenzodioxinyl (e.g., 2,3-dihydrobenzo[b][1,4]dioxinyl), benzodioxolyl (e.g., benzo[d][1,3]dioxole),
 10 dihydrobenzooxazinyl (e.g., 3,4-dihydro-2H-benzo[b][1,4]oxazine), tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydroimidazo[4,5-c]pyridyl, tetrahydroquinoliny, tetrahydroisoquinoliny, tetrahydroquinoxaliny, and the like.

The heteroaryl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. The heteroaryl ring may be bonded via a
 15 carbon atom or heteroatom.

The term “5-10 membered heteroaryl” is to be construed accordingly.

Examples of 5-10 membered heteroaryl include, without limitations, indolyl, imidazopyridyl, isoquinoliny, benzooxazolonyl, pyridinyl, pyrimidinyl, pyridinonyl, benzotriazolyl, pyridazinyl, pyrazolotriazinyl, indazolyl, benzimidazolyl, quinoliny, triazolyl, (e.g., 1,2,4-triazolyl),
 20 pyrazolyl, thiazolyl, oxazolyl, isooxazolyl, pyrrolyl, oxadiazolyl, (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), imidazolyl, pyrrolopyridinyl, tetrahydroindazolyl, quinoxaliny, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl), pyrazinyl, oxazolopyridinyl, pyrazolopyrimidinyl, benzoxazolyl, indoliny, isooxazolopyridinyl, dihydropyridooxazinyl, tetrazolyl, dihydrobenzodioxinyl (e.g., 2,3-
 25 dihydrobenzo[b][1,4]dioxinyl), benzodioxolyl (e.g., benzo[d][1,3]dioxole) and dihydrobenzooxazinyl (e.g., 3,4-dihydro-2H-benzo[b][1,4]oxazine).

“Cyano” or “-CN” means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, e.g., $-C\equiv N$.

As used herein, the term “C₁-C₃alkylene” refers to a straight or branched hydrocarbon
 30 chain bivalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to three carbon atoms. The term “C₁-C₂alkylene” is to be construed accordingly.

As used herein, the term “optionally substituted” includes unsubstituted or substituted.

As used herein, “” denotes the point of attachment of that particular group to the base
 35 molecule.

As used herein, the term nitrogen protecting group (abbreviated as PG) in a compound of formula (X) or (Y) or any intermediates in any of the General schemes 1 to 4 and subformulae thereof refers to a group that should protect the functional groups, concerned e.g., amino groups,

against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis and similar reactions. It may be removed under deprotection conditions. Depending on the protecting group employed, the skilled person would know how to remove the protecting group to obtain the free amine NH₂ group by reference to known procedures. These
5 include reference to organic chemistry textbooks and literature procedures such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973; T. W. Greene and P. G. M. Wuts, "Greene's Protective Groups in Organic Synthesis", Fourth Edition, Wiley, New York 2007; in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981; P. J. Kocienski, "Protecting Groups", Third Edition,
10 Georg Thieme Verlag, Stuttgart and New York 2005; and in "Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974.

Preferred nitrogen protecting groups generally comprise: C₁-C₆alkyl (e.g., *tert*-butyl), preferably C₁-C₄alkyl, more preferably C₁-C₂alkyl, most preferably C₁alkyl which is mono-, di- or
15 tri-substituted by trialkylsilyl-C₁-C₇alkoxy (e.g., trimethylsilyloxy), aryl, preferably phenyl, or a heterocyclic group (e.g., benzyl, cumyl, benzhydryl, pyrrolidinyl, trityl, pyrrolidinylmethyl, 1-methyl-1,1-dimethylbenzyl, (phenyl)methylbenzene) wherein the aryl ring or the heterocyclic group is unsubstituted or substituted by one or more, e.g., two or three, residues, e.g., selected from the group consisting of C₁-C₇alkyl, hydroxy, C₁-C₇alkoxy (e.g., para-methoxy benzyl (PMB)), C₂-C₈-
20 alkanoyl-oxy, halogen, nitro, cyano, and CF₃, aryl-C₁-C₂-alkoxycarbonyl (preferably phenyl-C₁-C₂-alkoxycarbonyl (e.g., benzyloxycarbonyl (Cbz), benzyloxymethyl (BOM), pivaloyloxymethyl (POM)), C₁-C₁₀-alkenyloxycarbonyl, C₁-C₆alkylcarbonyl (e.g., acetyl or pivaloyl), C₆-C₁₀-arylcarbonyl; C₁-C₆-alkoxycarbonyl (e.g., *tert*butoxycarbonyl (Boc), methylcarbonyl, trichloroethoxycarbonyl (Troc), pivaloyl (Piv), allyloxycarbonyl), C₆-C₁₀-arylC₁-C₆-alkoxycarbonyl
25 (e.g., 9-fluorenylmethyloxycarbonyl (Fmoc)), allyl or cinnamyl, sulfonyl or sulfenyl, succinimidyl group, silyl groups (e.g., triarylsilyl, trialkylsilyl, triethylsilyl (TES), trimethylsilylethoxymethyl (SEM), trimethylsilyl (TMS), *tri*isopropylsilyl or *tert*butyldimethylsilyl).

According to the disclosure, the preferred nitrogen protecting group (PG) can be selected from the group comprising *tert*-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), para-methoxy
30 benzyl (PMB), methyloxycarbonyl, trimethylsilylethoxymethyl (SEM) and benzyl. The nitrogen protecting group (PG) is preferably *tert*-butyloxycarbonyl (Boc) or trimethylsilylethoxymethyl (SEM).

In some embodiments, the compounds of the disclosure are selective over other proteins.

As used herein, the term "therapeutic agent" in connection with methods of reducing WIZ
35 protein expression levels and/or inducing fetal hemoglobin (HbF) expression, refers to a substance that results in a detectably lower expression of WIZ gene or WIZ protein or lower activity level of WIZ proteins as compared to those levels without such substance.

As used herein "modulator" or "degrader", means, for example, a compound of the disclosure, that effectively modulates, decreases, or reduces the levels of a specific protein (e.g.,

WIZ) or degrades a specific protein (e.g., WIZ). The amount of a specific protein (e.g., WIZ) degraded can be measured by comparing the amount of the specific protein (e.g., WIZ) remaining after treatment with a compound of the disclosure as compared to the initial amount or level of the specific protein (e.g., WIZ) present as measured prior to treatment with a compound of the disclosure.

As used herein “selective modulator”, “selective degrader”, or “selective compound” means, for example, a compound of the disclosure, that effectively modulates, decreases, or reduces the levels of a specific protein (e.g., WIZ) or degrades a specific protein (e.g., WIZ) to a greater extent than any other protein. A “selective modulator”, “selective degrader”, or “selective compound” can be identified, for example, by comparing the ability of a compound to modulate, decrease, or reduce the levels of or to degrade a specific protein (e.g., WIZ) to its ability to modulate, decrease, or reduce the levels of or to degrade other proteins. In some embodiments, the selectivity can be identified by measuring the EC₅₀ or IC₅₀ of the compounds. Degradation may be achieved through mediation of an E3 ligase, e.g., E3-ligase complexes comprising the protein Cereblon.

In one embodiment, the specific protein degraded is WIZ protein. In an embodiment, at least about 30% of WIZ is degraded compared to initial levels. In an embodiment, at least about 40% of WIZ is degraded compared to initial levels. In an embodiment, at least about 50% of WIZ is degraded compared to initial levels. In an embodiment, at least about 60% of WIZ is degraded compared to initial levels. In an embodiment, at least about 70% of WIZ is degraded compared to initial levels. In an embodiment, at least about 75% of WIZ is degraded compared to initial levels. In an embodiment, at least about 80% of WIZ is degraded compared to initial levels. In an embodiment, at least about 85% of WIZ is degraded compared to initial levels. In an embodiment, at least about 90% of WIZ is degraded compared to initial levels. In an embodiment, at least about 95% of WIZ is degraded compared to initial levels. In an embodiment, over 95% of WIZ is degraded compared to initial levels. In an embodiment, at least about 99% of WIZ is degraded compared to initial levels.

In an embodiment, the WIZ is degraded in an amount of from about 30% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 40% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 50% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 60% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 70% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 80% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 90% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 95% to about 99% compared to initial levels. In an embodiment, the WIZ is degraded in an amount of from about 90% to about 95% compared to initial levels.

As used herein, the terms "inducing fetal hemoglobin", "fetal hemoglobin induction", or "increasing fetal hemoglobin expression" refer to increasing the percentage of HbF in the blood of a subject. In an embodiment, the amount of total HbF in the blood of the subject increases. In an embodiment, the amount of total hemoglobin in the blood of the subject increases. In an embodiment, the amount of HbF is increased by at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 100%, or more than 100%, for example, at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 6-fold, or at least about 7-fold, or at least about 8-fold, or at least about 9-fold, or at least about 10-fold, or more than 10-fold as compared to either in the absence of a compound disclosed herein.

In an embodiment, the total hemoglobin in the blood, e.g., the blood in a subject, is increased by at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 100%, or more than 100%, for example, at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 6-fold, or at least about 7-fold, or at least about 8-fold, or at least about 9-fold, or at least about 10-fold, or more than 10-fold as compared to either in the absence of a compound disclosed herein.

The term "a therapeutically effective amount" of a compound of the disclosure refers to an amount of the compound of the disclosure that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the disclosure that, when administered to a subject, is effective to (1) at least partially alleviate, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by WIZ, or (ii) associated with WIZ activity, or (iii) characterized by activity (normal or abnormal) of WIZ; (2) reduce or inhibit the activity of WIZ; or (3) reduce or inhibit the expression of WIZ. In another embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the disclosure that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of WIZ; or at least partially reducing or inhibiting the expression of WIZ.

"HbF-dependent disease or disorder" means any disease or disorder which is directly or indirectly affected by the modulation of HbF protein levels.

As used herein, the term "subject" refers to primates (e.g., humans, male or female), dogs, rabbits, guinea pigs, pigs, rats and mice. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.

As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (*i.e.*, slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those
 5 which may not be discernible to the patient.

As used herein, the term "prevent", "preventing" or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder


As used herein, a subject is "in need of" a treatment if such subject would benefit
 10 biologically, medically or in quality of life from such treatment.

As used herein, the term "a," "an," "the" and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.

Various enumerated embodiments of the disclosure are described herein. It will be
 15 recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the disclosure.

Enumerated Embodiments

Embodiment 1. A compound of formula (I') or a pharmaceutically acceptable salt, hydrate,
 20 solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-SO_2R^6$, $-C(=O)-R^{2a}$, $-C(=O)-O-R^{2a}$, and $-C(=O)NR^{2b}R^{2c}$;

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-\text{CN}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;


R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl, e.g., R^6 is selected from C_3 - C_8 cycloalkyl, and C_1 - C_6 alkyl;

n is 0, 1, 2, 3, 4, or 5; and

m is 0, 1 or 2;

with the proviso that the compound of formula (I') does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.

Embodiment 2. A compound of formula (I'') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-\text{SO}_2\text{R}^6$, $-\text{C}(=\text{O})-\text{R}^{2a}$, $-\text{C}(=\text{O})-\text{O}-\text{R}^{2a}$, and $-\text{C}(=\text{O})\text{NR}^{2b}\text{R}^{2c}$;

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-

membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the C₆-C₁₀aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;


each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;

R⁶ is selected from C₃-C₈cycloalkyl, C₁-C₆alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C₆-C₁₀aryl, e.g., R⁶ is selected from C₃-C₈cycloalkyl, and C₁-C₆alkyl;

n is 0, 1, 2, 3, 4, or 5; and

m is 1 or 2.

Embodiment 3. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, C₆-C₁₀aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl,

wherein the C₆-C₁₀aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R^5 is independently selected from $-\text{CN}$, $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{C}_1\text{-C}_6\text{alkoxy}$, hydroxyl, and $\text{C}_1\text{-C}_6\text{haloalkyl}$;

n is 0, 1, 2, 3 or 4; and


m is 0, 1 or 2;

with the proviso that the compound of formula (I) does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.


Embodiment 4. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein m is 1 or 2.

Embodiment 5. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^2 is selected from $\text{C}_3\text{-C}_{11}\text{cycloalkyl}$, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, $\text{C}_1\text{-C}_6\text{haloalkyl}$, $\text{C}_2\text{-C}_6\text{alkenyl}$, $\text{C}_2\text{-C}_6\text{alkynyl}$, and $\text{C}_1\text{-C}_{10}\text{alkyl}$, wherein the $\text{C}_3\text{-C}_{11}\text{cycloalkyl}$, 4- to 11-membered heterocyclyl, $\text{C}_2\text{-C}_6\text{alkynyl}$, and $\text{C}_1\text{-C}_{10}\text{alkyl}$ are each independently substituted with 0-5, e.g., 0-4, 0-3, 0-2, 0-1, occurrences of R^3 .


Embodiment 6. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA):



Embodiment 7. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB):




Embodiment 8. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IC):




(IC).

Embodiment 9. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (ID):




(ID).

Embodiment 10. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 6, and 8, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (IC-i):




(IC-i).

Embodiment 11. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, 7, and 8, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (IC-ii):




(IC-ii).

Embodiment 12. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 6, and 9, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (ID-i):



(ID-i).

Embodiment 13. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, 7, and 9, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (ID-ii):



(ID-ii).

Embodiment 14. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1, 2, 3, and 5 to 13, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

5 each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms
10 to which they are attached form a bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, C₁-C₆haloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl, C₂-C₆alkynyl, and C₁-
15 C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

20 each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;

n is 0, 1, 2, 3, 4, or 5; and

25 m is 0, 1 or 2, e.g., m is 1 or 2.

Embodiment 15. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1, 2, 3, and 5 to 14, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on non-adjacent carbon
30 atoms together with the non-adjacent carbon atoms to which they are attached form a C₁-C₃ alkylene bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, C₁-C₆haloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

35 wherein the C₃-C₁₁cycloalkyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-3 occurrences of R^4 ;

5 each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl;

n is 0, 1, 2, 3, 4, or 5; and

m is 0, 1 or 2, e.g., m is 1 or 2.

Embodiment 16. The compound of formula (I'), (I'') or (I) according to any one of the
10 preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, fluoro, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent
15 carbon atoms to which they are attached form a C_3 - C_6 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a C_1 - C_2 alkylene bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_2 - C_6 alkynyl, and C_1 -
20 C_6 alkyl, wherein the C_3 - C_{11} cycloalkyl is substituted with 0-3 occurrences of R^3 , wherein the C_1 - C_6 alkyl is substituted with 0-1 occurrence of R^{3a} , and wherein the C_2 - C_6 alkynyl is substituted with 0-1 occurrence of R^{3b} ;

each R^3 is independently selected from C_1 - C_6 alkoxyl, and fluoro;

R^{3a} is selected from 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms
25 independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-3 occurrences of R^4 ;

R^{3b} is selected from C_1 - C_6 alkyl, and C_3 - C_8 cycloalkyl, preferably C_3 - C_8 cycloalkyl;

each R^4 is independently selected from C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, fluoro, and C_3 -
 C_8 cycloalkyl;

30 n is 0, 1, 2 or 3; and

m is 1.

Embodiment 17. The compound of formula (I'), (I'') or (I) according to any one of the
preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

35 each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, fluoro, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl;

R^2 is selected from C_3 - C_8 cycloalkyl, 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_2 - C_6 alkynyl, and C_1 - C_6 alkyl, wherein the

C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R³, wherein the C₁-C₆alkyl is substituted with 0-1 occurrence of R^{3a}, and wherein the C₂-C₆alkynyl is substituted with 0-1 occurrence of R^{3b};

each R³ is independently selected from C₁-C₆alkoxy, and fluoro;

- 5 R^{3a} is C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is independently substituted with 0-3 occurrences of R⁴;

R^{3b} is selected from C₁-C₆alkyl, and C₃-C₈cycloalkyl, preferably C₃-C₈cycloalkyl;


each R⁴ is independently selected from C₁-C₆alkyl, C₁-C₆alkoxy, fluoro, and C₃-C₈cycloalkyl;

- 10 n is 0, 1, 2 or 3; and
m is 1.

Embodiment 18. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R² is unsubstituted C₁-C₆alkyl, or -(CH₂)-R³, wherein
15 R³ is defined according to any one of the preceding Embodiments.

Embodiment 19. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R² is unsubstituted C₁-C₆alkyl, or -(CH₂)-R^{3a}, wherein R^{3a} is defined according to any one of Embodiments 16 and 17.

- 20 Embodiment 20. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R² is selected from unsubstituted C₁-C₆alkyl,



- 25 Embodiment 21. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R² is selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, and t-butyl.


Embodiment 22. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug,
30 stereoisomer, or tautomer thereof, wherein m is 1.

Embodiment 23. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein n is 0, 1, 2 or 3, for example, n is 1.

Embodiment 24. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R¹ is selected from C₁-C₆alkyl, hydroxyl, halo, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl.

Embodiment 25. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R¹ is selected from C₁-C₄alkyl, e.g., methyl, C₁-C₄alkoxyl, e.g., methoxyl, and fluoro; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl.

Embodiment 26. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, and 14 to 25, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (I-i), wherein:



(I-i)


R^{1a} is independently selected from hydrogen and C₁-C₆alkyl;
 R^{1b} is independently selected from hydrogen and C₁-C₆alkyl;
 or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1c} is independently selected from hydrogen and C₁-C₆alkyl;
 R^{1d} is independently selected from hydrogen, C₁-C₆alkyl, and C₁-C₆alkoxyl;
 or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1e} is independently selected from hydrogen and C₁-C₆alkyl; and

R² is defined according to any one of the preceding Embodiments.

Embodiment 27. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 6, and 14 to 26, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-i), wherein:



(IA-i)

R^{1a} is independently selected from hydrogen and C₁-C₆alkyl;

R^{1b} is independently selected from hydrogen and C₁-C₆alkyl;

or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1c} is independently selected from hydrogen and C₁-C₆alkyl;


R^{1d} is independently selected from hydrogen, C₁-C₆alkyl, and C₁-C₆alkoxyl;

5 or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1e} is independently selected from hydrogen and C₁-C₆alkyl; and


R² is defined according to any one of the preceding Embodiments.

Embodiment 28. The compound of formula (I'), (I'') or (I) according to any one of
10 Embodiments 1 to 6, 8, 10, and 14 to 27, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-ii):




(IA-ii).

Embodiment 29. The compound of formula (I'), (I'') or (I) according to any one of
15 Embodiments 1 to 6, 9, 12, and 14 to 27, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-iii):



(IA-iii).

Embodiment 30. The compound of formula (I'), (I'') or (I) according to any one of
20 Embodiments 1 to 5, 7, and 14 to 26, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-i), wherein:



(IB-i)

R^{1a} is independently selected from hydrogen and C₁-C₆alkyl;

25 R^{1b} is independently selected from hydrogen and C₁-C₆alkyl;

or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1c} is independently selected from hydrogen and C₁-C₆alkyl;


R^{1d} is independently selected from hydrogen, C₁-C₆alkyl, and C₁-C₆alkoxyl;

or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1e} is independently selected from hydrogen and C₁-C₆alkyl; and


R² is defined according to any one of the preceding Embodiments.

- 5 Embodiment 31. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, 7, 8, 11, 14 to 26, and 30, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-ii):



(IB-ii).

- 10 Embodiment 32. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 5, 7, 9, 13, 14 to 26, and 30, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-iii):



(IB-iii).

- 15 Embodiment 33. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 26 to 32, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1a} and R^{1b} are both hydrogen.

- Embodiment 34. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 26 to 33, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1e} is C₁-C₆alkyl, and R^{1a}, R^{1b}, R^{1c}, and R^{1d} are all hydrogen.


- Embodiment 35. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 26 to 32, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1a} and R^{1b} are each independently selected from hydrogen and C₁-C₆alkyl, or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl, and R^{1c}, R^{1d}, and R^{1e} are all hydrogen.

- Embodiment 36. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 26 to 32, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1c} and R^{1d} are each independently selected from hydrogen, C₁-C₆alkyl and C₁-C₆alkoxyl, e.g., R^{1c} is hydrogen and R^{1d} is C₁-C₆alkyl or C₁-C₆alkoxyl, or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl, and R^{1a}, R^{1b}, and R^{1e} are all hydrogen.


Embodiment 37. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R³ is independently selected from 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₃-C₈cycloalkyl, and halo, wherein the 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-2 occurrences of R⁴, wherein each R⁴ is independently selected from C₁-C₆alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl.

Embodiment 38. The compound of formula (I'), (I'') or (I) according to any one of the preceding Embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R⁴ is independently selected from C₁-C₆alkyl, and fluoro.


Embodiment 39. The compound according to any of the preceding Embodiments, wherein

the glutarimide moiety of the compound of formula (I'), (I'') or (I) is .



Embodiment 40. The compound according to any of the preceding Embodiments, wherein













the glutarimide moiety of the compound of formula (I'), (I'') or (I) is .









Embodiment 41. The compound according to any of the preceding Embodiments, wherein











the glutarimide moiety of the compound of formula (I'), (I'') or (I) is .











Embodiment 42. The compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 3, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, selected from:











 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione	 3-(1-oxo-5-(((R)-1-propylpiperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione
---	--











 3-(5-(((R)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((S)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(1-oxo-5-(((R)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione
 3-(1-oxo-5-(((S)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione	 3-(5-(((S)-5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(2-oxaspiro[3.3]heptan-6-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-(oxetan-3-ylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(oxetan-3-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-(4-(difluoromethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione











3-(5-(((R)-1-((4,4-difluorocyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-1-(cyclohexylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-1-((1-ethyl-1H-pyrazol-4-yl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-1-(cyclobutylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-1-(7-oxaspiro[3.5]nonan-2-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-6-((S)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione











 3-(5-(((R)-5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((1S,5S,6R)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(but-3-en-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((1R,5R,6S)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((1S,5R,6R)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-((R)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	











3-(5-(((1R,5S,6S)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3S,5S)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((3R,6R)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((R)-1-((S)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-1-(but-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3R,5R)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-1-(3-cyclopropylprop-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3R,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((R)-1-((1s,3S)-3-ethoxycyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3S,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione






3-(5-(((R)-1-(((1r,3R)-3-methoxycyclobutyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	
 3-(5-(((3R,4R)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-cyclopentylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-cyclohexylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((S)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((2R,3R)-1-ethyl-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((2S,3S)-1-ethyl-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,5R)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-isobutylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

 3-(5-(((R)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,5S)-5-ethoxy-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((S)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,5S)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,4S)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

 3-(5-(((3S,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3S,4R)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-((2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,4S)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5S)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5S)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((S)-1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5R)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((R)-1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((R)-1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

 3-(5-(((S)-1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-((2-ethyl-2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5R)-5-ethoxy-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-5-hydroxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxy-N-methylpiperidine-1-carboxamide
 ethyl (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate	 3-(5-(((3R,5R)-1-acetyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	


3-(5-(((3R,5R)-5-ethoxy-1-(methylsulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-(((3R,5R)-5-ethoxy-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-1-cyclobutyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5R)-5-ethoxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-1-isopropyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,5R)-1-isobutyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,5R)-5-methyl-1-(methylsulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,6S)-1-isopropyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 ethyl (2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate
 3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione











(2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-N,2-dimethylpiperidine-1-carboxamide	3-(5-(((3R,6S)-6-methyl-1-(methylsulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((3R,6S)-1-acetyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(1-oxo-5-(((3R,6S)-6-propylpiperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione
	
3-(5-(((3R,6S)-1-ethyl-6-propylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	3-(5-((6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and
	
3-(5-((1-ethyl-6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.	











Embodiment 43. A compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 3 and 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the absolute configuration at the glutarimide stereocentre is *S*.

- 5 Embodiment 44. A compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 3 and 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the absolute configuration at the glutarimide stereocentre is *R*.

- Embodiment 45. A compound of formula (I'), (I'') or (I) according to any one of Embodiments 1 to 3, and 42 to 44, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, selected from:



(R)-3-(5-(((3R,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	(R)-3-(5-(((3R,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (S)-3-(5-(((3R,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3R,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (R)-3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (R)-3-(5-(((3S,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (S)-3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3S,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (R)-3-(5-(((3R,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3R,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (R)-3-(5-(((3S,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3S,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

 (R)-3-(5-(((R)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (R)-3-(5-(((3S,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (S)-3-(5-(((R)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3S,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (S)-3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (R)-3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (R)-3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	 (S)-3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
 (S)-3-(5-(((3R,5R)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and	 (R)-3-(5-(((3R,5R)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.

Embodiment 46. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the preceding Embodiments, or a

pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

Embodiment 47. A method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective
5 amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 48. A method of degrading WIZ protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate,
10 solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 49. A method of inhibiting WIZ protein expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

15 Embodiment 50. A method of inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression, the method comprising administering to the subject a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 51. A method of inducing or promoting fetal hemoglobin in a subject in need
20 thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 52. A method of reactivating fetal hemoglobin production or expression in a subject in need thereof, the method comprising administering to the subject a therapeutically
25 effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 53. A method of increasing fetal hemoglobin expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt,
30 hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 54. A method of treating a hemoglobinopathy, e.g., a beta-hemoglobinopathy, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

35 Embodiment 55. A method of treating a sickle cell disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 56. A method of treating beta-thalassemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

5 Embodiment 57. A method of treating a disease or disorder that is affected by the modulation of WIZ protein levels comprising administering to the patient in need thereof a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 58. A method of treating or preventing a disorder that is affected by the
10 reduction of WIZ protein levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 59. A method for reducing WIZ protein levels in a subject comprising the step
15 of administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

Embodiment 60. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
20 for use as a medicament.

Embodiment 61. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder selected from sickle cell disease and beta-thalassemia.

25 Embodiment 62. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating or preventing a disease or disorder in a subject in need thereof.

Embodiment 63. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
30 for use in treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof.

Embodiment 64. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inhibiting WIZ protein expression in a subject in need thereof.

35 Embodiment 65. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in degrading WIZ protein in a subject in need thereof.

Embodiment 66. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,

for use in inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression in a subject in need thereof.

Embodiment 67. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
5 for use in inducing or promoting fetal hemoglobin in a subject in need thereof.

Embodiment 68. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in reactivating fetal hemoglobin production or expression in a subject in need thereof.

Embodiment 69. A compound according to any one of Embodiments 1 to 45, or a
10 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in increasing fetal hemoglobin expression in a subject in need thereof.

Embodiment 70. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a hemoglobinopathy in a subject in need thereof.

15 Embodiment 71. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a sickle cell disease in a subject in need thereof.

Embodiment 72. A compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
20 for use in treating beta-thalassemia in a subject in need thereof.

Embodiment 73. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

25 Embodiment 74. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing or promoting fetal hemoglobin.

Embodiment 75. Use of a compound according to any one of Embodiments 1 to 45, or a
30 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

Embodiment 76. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in
35 the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

Embodiment 77. The use according to any one of Embodiments 73 to 76, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.

Embodiment 78. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

5 Embodiment 79. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing fetal hemoglobin.

Embodiment 80. Use of a compound according to any one of Embodiments 1 to 45, or a
10 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

Embodiment 81. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in
15 the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

Embodiment 82. The use according to any one of Embodiments 78 to 81, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.


Embodiment 83. Use of a compound according to any one of Embodiments 1 to 45, or a
20 pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

Embodiment 84. Use of a compound according to any one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in
25 the treatment of a disease or disorder that is affected by inducing fetal hemoglobin, reactivating fetal hemoglobin production or expression, or increasing fetal hemoglobin expression.

Embodiment 85. The use according to any one of Embodiments 83 and 84, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.

Embodiment 86. A pharmaceutical combination comprising a compound according to any
30 one of Embodiments 1 to 45, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more additional therapeutic agent(s).

Embodiment 87. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use as a medicament, wherein:



each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring (e.g., C₁-C₃alkylene bridging ring);

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₁-C₆haloalkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 (or 0-4, 0-3, 0-2, 0-1) occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, C₆-C₁₀aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the C₆-C₁₀aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;

n is 0, 1, 2, 3, or 4; and

m is 0, 1 or 2.

Embodiment 88. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in a method defined by any one of Embodiments 61 to 72, wherein the compound of formula (I) is defined according to Embodiment 87.

Embodiment 89. A method as defined by any one of Embodiments 47 to 59, wherein the compound is defined according to Embodiment 87.

Embodiment 90. Use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in a method as defined by any one of Embodiments 73 to 85, wherein the compound of formula (I) is defined according to Embodiment 87.

Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereomeric mixtures, depending on the number of asymmetric centres. The disclosure is meant to include all such possible isomers, including racemic mixtures, enantiomerically enriched mixtures, diastereomeric mixtures and optically pure forms. Optically active (*R*)- and (*S*)- isomers may be prepared using

chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a disubstituted or trisubstituted cycloalkyl, the cycloalkyl substituent(s) may have a *cis*- or *trans*-configuration. The disclosure includes *cis* and *trans* configurations of substituted cycloalkyl groups as well as mixtures thereof. All tautomeric forms are also intended to be included. In particular, where a heteroaryl ring containing N as a ring atom is 2-pyridone, for example, tautomers where the carbonyl is depicted as a hydroxy (e.g., 2-hydroxypyridine) are included.

Pharmaceutically Acceptable Salts

As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the disclosure. "Salts" include in particular "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this disclosure and, which typically are not biologically or otherwise undesirable. The compounds of the disclosure may be capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, formic acid, trifluoroacetic acid, and the like.

Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.

In another aspect, the disclosure provides compounds in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlorotheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen

phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenatate, trifluoroacetate or xinafoate salt form.


In another aspect, the disclosure provides compounds in sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, copper, isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine or tromethamine salt form.

Preferably, pharmaceutically acceptable salts of compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii) are acid addition salts.

Isotopically Labelled Compounds

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{18}O , ^{15}N , ^{18}F , ^{17}O , ^{18}O , ^{35}S , ^{36}Cl , ^{123}I , ^{124}I , ^{125}I respectively. The disclosure includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as ^3H and ^{14}C , or those into which non-radioactive isotopes, such as ^2H and ^{13}C are present. Such isotopically labelled compounds are useful in metabolic studies (with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and General Schemes (e.g., General Schemes 5a and 5b) using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

In one embodiment of any aspect of the present disclosure, the hydrogens in the compound of formula (I'), (I'') or (I) are present in their normal isotopic abundances. In another embodiment, the hydrogens are isotopically enriched in deuterium (D), and in a particular embodiment of the invention the hydrogen(s) at the glutarimide portion in compounds of Formula



Further, substitution with heavier isotopes, particularly deuterium (i.e., ^2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is

understood that deuterium in this context is regarded as a substituent of a compound of the formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein
5 means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this disclosure is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium
10 incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the disclosure include those
15 wherein the solvent of crystallization may be isotopically substituted, e.g., D₂O, d₆-acetone, d₆-DMSO.

Compounds of the disclosure, e.g., compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-
20 crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii) with
25 the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate
30 the disclosure and does not pose a limitation on the scope of the disclosure otherwise claimed.

Any asymmetric center (e.g., carbon or the like) of the compound(s) of the disclosure can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)-configuration. In certain embodiments, for example, as a mixture of enantiomers, each asymmetric center is present in at least 10 % enantiomeric excess, at least 20 % enantiomeric
35 excess, at least 30 % enantiomeric excess, at least 40 % enantiomeric excess, at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess. In certain embodiments, for example, in enantiomerically enriched form, each asymmetric center is present in at least 50 % enantiomeric

excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess. Thus, compounds of the disclosure can be present in a racemic mixture or in enantiomerically enriched form or in an enantiopure form or as a mixture of diastereoisomers.

In the compound formulae in any one of the aspects, Embodiments or claims of the present application the term " " on a C-sp³ indicates the absolute stereochemistry, either (*R*) or (*S*). In the compound formulae in any one of the aspects, Embodiments or claims of the present application the term " " on a C-sp³ indicates the absolute stereochemistry, either (*R*) or (*S*). In the compound formulae in any one of the aspects, Embodiments or claims of the present application the term " " on a C-sp³ represents a covalent bond wherein the stereochemistry of the bond is not defined. This means that the term " " on a C-sp³ comprises an (*S*) configuration or an (*R*) configuration of the respective chiral centre or a mixture thereof. Therefore, mixtures of stereoisomers, e.g., mixtures of enantiomers, such as racemates, and/or mixtures of diastereoisomers are encompassed by the present disclosure.

Accordingly, as used herein a compound of the disclosure can be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (*cis* or *trans*) stereoisomers, diastereomers, optical isomers, racemates or mixtures thereof.

Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.


Any resulting racemates of compounds of the disclosure or of intermediates can be resolved into the optical isomers (enantiomers) by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the disclosure into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-*O,O'*-*p*-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic compounds of the disclosure or racemic intermediates can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.

Furthermore, the compounds of the disclosure, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the disclosure may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the disclosure embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound

of the disclosure (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water. The presence of solvates can be identified by a person of skill in the art with tools such as NMR.

The compounds of the disclosure, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.

In compounds of the present disclosure, as exemplified by formula (I), the stereocenter at the 3-position of the glutarimide moiety (marked with a *) may be prone to epimerization under basic conditions.



Separation of the diastereoisomers (or enantiomers as the case may be) at this position can be achieved according to known chiral separation techniques in the art, e.g., by chiral SFC. For example, separation may be carried out according to Example 65.

In one embodiment of the compounds of the present disclosure, the absolute configuration at the glutarimide stereocentre (marked with a * above) is *S*.

In another embodiment of the compounds of the present disclosure, the absolute configuration at the glutarimide stereocentre (marked with a * above) is *R*.


In one embodiment, there is provided a compound as described in any one of the Examples or according to any of Embodiments 1 to 42, wherein the absolute configuration at the glutarimide stereocentre (marked with a * above) is *S*.

In another embodiment, there is provided a compound as described in any one of the Examples or according to any of Embodiments 1 to 42, wherein the absolute configuration at the glutarimide stereocentre (marked with a * above) is *R*.

Methods of Making

The compounds of the disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.

Generally, the compounds of formula (I'), (I''), or (I) can be prepared according to the Schemes provided *infra*.


General scheme 1

The starting materials for the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein.

- 5 In general, the compounds of the disclosure are prepared in the above reaction **Scheme 1** as follows:


A metallaphotoredox reaction, such as an iridium (Ir)-catalysed photoredox coupling of INT-1 with an alcohol partner of formula INT-1A in the presence of a polar solvent, such as acetonitrile (ACN) can provide the cross-coupled ether product (I)-2 in Step 1. Removal of the
 10 protecting group (e.g., Boc) under acidic conditions can provide the free amine (I)-3 (Step 2), which can then be converted to (I)-4 via an alkylation reaction (Step 3-i) with an appropriate alkyl bromide or alkyl mesylate in the presence of an amine base and polar solvent, such as diisopropylethylamine (DIPEA) and acetonitrile (ACN) or dimethylformamide (DMF), or a
 15 reductive amination (Step 3-ii) with an appropriate aldehyde in the presence of a borohydride reagent, such as sodium borohydride acetate. For **Scheme 1**, R¹, R², m and n are as defined herein, in particular according to any one of enumerated Embodiments 1 to 45.

General scheme 2



The starting materials for the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein. In general, the compounds of the disclosure, especially compounds comprising non-linear R^1 and/or R^2 groups are prepared in the above reaction **Scheme 2** as follows: The compound of (I)-3 can be converted into (I)-5 via an alkylation reaction (Step 3-iii) with an appropriate non-linear alkyl iodide or mesylate in the presence of a base, such as K_2CO_3 , and a polar solvent, such as dimethylacetamide (DMA), or (I)-6 via a reductive amination (Step 3-iv) with an appropriate ketone in the presence of a borohydride reagent, such as sodium borohydride acetate. For **Scheme 2**, R^1 , R^2 , m and n are as defined herein, in particular according to any one of enumerated Embodiments 1 to 45.

General scheme 3




The starting materials for the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein. In general, the compounds of the disclosure are prepared in the above reaction **Scheme 3** as follows:

A metallaphotoredox reaction, such as an iridium (Ir)-catalysed photoredox coupling, of **(INT-3)** with an alcohol partner of formula **(INT-1B)** in the presence of a polar solvent, such as acetonitrile (ACN) can provide the cross-coupled ether product **(I)-7** in Step 1. Removal of the protecting group (e.g., Boc) under acidic conditions, can provide the free amine **(I)-8** (Step 2), which can then be converted to **(I)-9** via reductive amination (Step 3-i) with an appropriate aldehyde in the presence of a borohydride reagent, such as sodium borohydride acetate. Alternatively, **(I)-8** may be converted into **(I)-9** via an alkylation reaction (Step 3-ii) with an appropriate alkyl mesylate or halide (e.g., iodide) in the presence of an amine base and polar solvent, such as diisopropylethylamine (DIPEA) and dimethylformamide (DMF) as described in general schemes 1 and 2. Chlorination with a suitable agent, such as SOCl_2 and ring opening of lactone **(I)-9** affords **(I)-10**. Subsequent ring closing by amidation and nucleophilic substitution


(lactam formation) using INT-IC under basic conditions yields the final product of Formula (I), Formula (I') or Formula (I''). For **Scheme 3**, R¹, R², m and n are as defined herein, in particular according to any one of enumerated Embodiments 1 to 45.

General schemes 4a, 4b and 4c: Deuterated compounds of the disclosure

5 Scheme 4a:




Scheme 4b:



Compound (I)-10 can be prepared according to general scheme 3. Subsequent ring closing by amidation and nucleophilic substitution using deuterated INT-D (prepared according to WO 2012/068512) or deuterated INT-D-i (prepared according to WO 2012/079022) under basic conditions yields the final deuterated compounds of Formula (I), Formula (I'), or Formula (I''), i.e. (I)-12-i and (I)-12-ii, wherein R¹, R², m and n are as defined according to any one of enumerated Embodiments 1 to 45.


15 Scheme 4c:



Compound (I) can be prepared according to any of general schemes 1 to 3. Base mediated hydrogen–deuterium exchange in a deuterated solvent, such as CDCl₃ yields the final deuterated compounds of Formula (I), Formula (I') or Formula (I''), i.e. (I)-12-iii, wherein R¹, R², m and n are as defined according to any one of enumerated Embodiments 1 to 45.

Thus, in an embodiment, the disclosure provides a compound of formula (I)-12-i, (I)-12-ii or (I)-12-iii, wherein R¹, R², m and n are as defined according to any one of enumerated Embodiments 1 to 45.

In an embodiment, there is provided a compound of formula (X') or a salt thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

$R^{2'}$ is selected from a nitrogen protecting group, *e.g.*, Boc, hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-\text{SO}_2R^6$, $-\text{C}(=\text{O})-R^{2a}$, $-\text{C}(=\text{O})-\text{OR}^{2a}$, and $-\text{C}(=\text{O})\text{NR}^{2b}R^{2c}$;

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;


each R^5 is independently selected from $-\text{CN}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl, *e.g.*, R^6 is selected from C_3 - C_8 cycloalkyl, and C_1 - C_6 alkyl;

n is 0, 1, 2, 3, 4, or 5; and

m is 0, 1 or 2.

In an embodiment, there is provided a compound of formula (X) or a salt thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

$R^{2'}$ is selected from a nitrogen protecting group, e.g., Boc, hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, and C_1 - C_{10} alkyl,

wherein the C_3 - C_{11} cycloalkyl and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;


each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_3 - C_8 cycloalkyl, and C_2 - C_6 alkynyl, wherein the C_2 - C_6 alkynyl is substituted with 0-1 occurrence of R^4 , and wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-CN$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;


n is 0, 1, 2, 3, or 4; and
 m is 0, 1 or 2.

In a further embodiment, the compound of Formula (X') or Formula (X) is of Formula (X)-i



wherein R^1 , $R^{2'}$, m and n are defined according to Formula (X') or Formula (X) above.

In a further embodiment, the compound of Formula (X') or Formula (X) is of Formula (X)-ii













(X)-ii,











wherein R^1 , R^2 , m and n are defined according to Formula (X') or Formula (X) above.











In a further embodiment of Formula (X'), (X), (X)-i or (X)-ii, R^2 is selected from a nitrogen protecting group, e.g., Boc, hydrogen, and unsubstituted C_1 - C_{10} alkyl.











In a further embodiment of Formula (X), there is provided a compound selected from:

Tert-butyl (R)-4-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-6-azaspiro[2.5]octane-6-carboxylate	(R)-5-((5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one
(R)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one	(S)-5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one
(R)-5-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one	(R)-5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one
(R)-5-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one	tert-butyl (1R,5R,6S)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate


 5-(((R)-6-((S)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one	 tert-butyl (1S,5S,6R)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate
 tert-butyl (S)-7-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-5-azaspiro[2.5]octane-5-carboxylate	 5-(((1R,5R,6S)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one
 tert-butyl (R)-7-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-5-azaspiro[2.5]octane-5-carboxylate	 5-(((1S,5S,6R)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one
 (S)-5-((5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one	 5-(((1S,5S,6R)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one
 5-(((1R,5R,6S)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one	 tert-butyl (1R,5S,6S)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate

 tert-butyl (1S,5R,6R)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate	 5-(((1R,5S,6S)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one
 5-(((1S,5R,6R)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one	 5-(((1R,5S,6S)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one
 tert-butyl (S)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate	 (R)-5-((1-isobutylazepan-3-yl)oxy)isobenzofuran-1(3H)-one
 (S)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one	 tert-butyl (R)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)pyrrolidine-1-carboxylate
 (S)-5-((1-ethylazepan-3-yl)oxy)isobenzofuran-1(3H)-one	 (R)-5-(pyrrolidin-3-yloxy)isobenzofuran-1(3H)-one

 tert-butyl (R)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate	 (R)-5-((1-ethylpyrrolidin-3-yl)oxy)isobenzofuran-1(3H)-one
 (R)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one	 tert-butyl (S)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)pyrrolidine-1-carboxylate
 (S)-5-(pyrrolidin-3-yloxy)isobenzofuran-1(3H)-one	 tert-butyl (S)-4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate
 (S)-5-((1-ethylpyrrolidin-3-yl)oxy)isobenzofuran-1(3H)-one	 tert-butyl (R)-4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate
 (S)-5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one	 (R)-5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one

 (R)-5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one	 5-(((S)-1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one
 (S)-5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one	 5-(((R)-1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one
 tert-butyl (R)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-7-azaspiro[3.5]nonane-7-carboxylate	 (R)-5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one
 tert-butyl (S)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-7-azaspiro[3.5]nonane-7-carboxylate	 (S)-5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one
 (R)-5-((7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one	 (S)-5-((7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one

In a further embodiment, there is provided a compound of Formula (Y)




wherein R^1 , m and n are as defined according to Formula (X') or Formula (X) above; and each of PG^1 and PG^2 is independently a nitrogen protecting group as defined herein.

5 In an embodiment, PG^2 is a base labile protecting group and PG^1 is an acid labile protecting group.


In an embodiment, PG^2 is the SEM protecting group (trimethylsilylethoxymethyl) and PG^1 is the BOC protecting group (tert-butyloxycarbonyl).

In a further embodiment, the compound of Formula (Y) is of Formula (Y)-i



wherein R^1 , m , n , PG^1 and PG^2 are defined according to Formula (Y) above.











In a further embodiment, the compound of Formula (Y) is of Formula (Y)-ii



















wherein R^1 , m , n , PG^1 and PG^2 are defined according to Formula (Y) above.

In a further embodiment of Formula (Y), there is provided a compound selected from:

tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate	tert-butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate
tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate	tert-butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate

tert-butyl (3S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate	tert-butyl (2R,3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate
	
tert-butyl (3S,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate	tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate
	
tert-butyl (3R,4S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate	tert-butyl (3S,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate
	
tert-butyl (3S,4R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate	tert-butyl (3R,4R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate
	
	

tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)azepane-1-carboxylate	tert-butyl (3S,4S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate
	
tert-butyl (3S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)azepane-1-carboxylate	tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate
	
tert-butyl (3S,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate	tert-butyl (3S,4R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate
	
tert-butyl (3S,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate	tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate
	
	

tert-butyl (3S,4S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate	tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate
 tert-butyl (3R,4R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate	 tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate
 tert-butyl (3S,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate	 tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methoxypiperidine-1-carboxylate
 tert-butyl (3S,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methoxypiperidine-1-carboxylate	 tert-butyl 6-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate

In a further aspect, the disclosure provides to a process for the preparation of a compound of formula (I'), (I''), or (I), in free form or in pharmaceutically acceptable salt form, comprising the step of:

- 5 1) coupling an aryl bromide of formula (INT-1) or formula (INT-3) with an alcohol of formula (INT-1A) or (INT-1B) under photo redox coupling conditions, to give a compound of formula (I)-2 or formula (I)-7 as defined herein.

In a further aspect, the disclosure provides a process for the preparation of a compound of formula (I'), (I'') or (I), in free form or in pharmaceutically acceptable salt form, comprising the steps of:

- 1) coupling an aryl bromide of formula (INT-3) with an alcohol of formula (INT-1B) under photo redox coupling conditions, to give a compound of formula (I)-7 as defined herein;
- 2) deprotecting a compound of formula (I)-7 to give a compound of formula (I)-8 as defined herein;
- 3-i) reacting a compound of formula (I)-8 under reductive amination conditions to give a compound of formula (I)-9 as defined herein; or
- 3-ii) reacting a compound of formula (I)-8 under alkylation conditions to give a compound of formula (I)-9 as defined herein;
- 4) chlorinating a compound of formula (I)-9 with a nucleophilic chlorinating reagent, such as SOCl_2 , to give a compound of formula (I)-10 as defined herein;
- 5) reacting a compound of formula (I)-10 with a compound of formula (INT-1C) to give a compound of formula (I'), (I'') or (I) as defined herein;
- 6) optionally purifying the compound of formula (I'), (I'') or (I) as defined herein; and
- 7) optionally separating the resultant stereoisomers, e.g., by chromatography, e.g., by chiral chromatography.

In a further aspect, the disclosure provides a process for the preparation of a compound of formula (I'), (I''), or (I), in free form or in pharmaceutically acceptable salt form, comprising the steps of:

- 1) coupling an aryl bromide of formula (INT-1) with an alcohol of formula (INT-1A) under photo redox coupling conditions, to give a compound of formula (I)-2 as defined herein;
- 2) deprotecting a compound of formula (I)-2 to give a compound of formula (I)-3;
- 3-i) reacting a compound of formula (I)-3 under reductive amination conditions to give a compound of formula (I) as defined herein; or
- 3-ii) reacting a compound of formula (I)-3 under alkylation conditions to give a compound of formula (I'), (I'') or (I) as defined herein;
- 4) optionally purifying the compound of formula (I'), (I'') or (I) as defined herein; and
- 5) optionally separating the resultant stereoisomers, e.g., by chromatography, e.g., by chiral chromatography.

Photo redox coupling reaction conditions for any of the aforementioned process steps or hereinafter involve the use of an Ir(III) catalyst, such as $[\text{Ir}\{\text{dF}(\text{CF}_3)\text{ppy}\}_2\{\text{dtbbpy}\}]\text{PF}_6$, a Ni(II) complex, such as $[\text{NiCl}_2\cdot\text{dtbbpy}]$, base, such as TMP, a suitable solvent, such as acetonitrile, a light source, such as a 34 W blue LED, the reaction conducted at room temperature (r.t.) for a suitable amount of time, for example 12 hours.

Reductive amination conditions for any of the aforementioned process steps or hereinafter involve the use of a corresponding aldehyde or ketone, a suitable hydride reagent, such as $\text{NaBH}(\text{OAc})_3$, a suitable solvent, such as DMF, the reaction conducted at room temperature (r.t.).

Alkylation reaction conditions for any of the aforementioned process steps or hereinafter involve the use of a corresponding sulfonate ester, such as a corresponding mesylate, a suitable base, such as DIPEA, a suitable solvent, such as DMF, the reaction conducted at a suitable temperature, such as 100 °C, under microwave.

5 In a further embodiment there is provided a process for the preparation of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii) in free form or in pharmaceutically acceptable salt form according to any of General Schemes 1 to 4.

Compounds of formulae (X'), (X), (X-i), (X-ii), (Y), (Y-i), and (Y-ii) as defined herein are
10 useful in the preparation of compounds of the disclosure, e.g., compounds of (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii). Thus, in an aspect, the disclosure relates to a compound of formula (X'), (X), (X-i), (X-ii), (Y), (Y-i), or (Y-ii), or salts thereof. In another aspect, the disclosure relates to the use of a compound of formula (X'), (X), (X-i), (X-ii), (Y), (Y-i), or (Y-ii), or salts thereof in the manufacture of a compound
15 of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii). The disclosure further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed *in situ* under the reaction conditions, or in which the reaction components are used in the form of their salts or
20 optically pure material.

Pharmaceutical Compositions

In another aspect, the disclosure provides a pharmaceutical composition comprising one or more compounds of described herein or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more pharmaceutically acceptable
25 carriers. As used herein, the term "pharmaceutical composition" refers to a compound of the disclosure, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.

As used herein, the term "pharmaceutically acceptable carrier" refers to a substance useful in the preparation or use of a pharmaceutical composition and includes, for example, suitable diluents,
30 solvents, dispersion media, surfactants, antioxidants, preservatives, isotonic agents, buffering agents, emulsifiers, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegration agents, lubricants, wetting agents, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to those skilled in the art (see, for example, Remington The Science and Practice of Pharmacy, 22nd Ed. Pharmaceutical Press, 2013, pp. 1049-1070).

35 In an aspect of the present disclosure, there is provided a pharmaceutical composition comprising an agent which is effective in reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression. Such compositions include, but are not limited to, small molecule compounds (e.g., small molecule compounds that can target WIZ protein for degradation, e.g., through E3 ubiquitin pathway, e.g. a compound as described herein).

In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. For purposes of the disclosure, unless designated otherwise, solvates and hydrates are generally considered compositions. Preferably, pharmaceutically acceptable carriers are sterile. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the disclosure can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.

Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:

- a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
- b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol;
- c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone;
- d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and
- e) absorbents, colorants, flavors and sweeteners.

In an embodiment, the pharmaceutical compositions are capsules comprising the active ingredient only.

Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable compositions for oral administration include an effective amount of a compound of the disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs, solutions or solid dispersion. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn

starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.

Suitable compositions for transdermal application include an effective amount of a compound of the disclosure with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.

The compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), and (ID-ii), in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g., WIZ modulating properties or WIZ degrading properties or Hbf inducing properties e.g., as indicated in the *in vitro* tests as provided

in the examples, and are therefore indicated for therapy or for use as research chemicals, e.g., as tool compounds.

Additional properties of the disclosed compounds include having good potency in the biological assays described herein, favorable safety profile, and possess favorable pharmacokinetic properties.

Diseases and Disorders

The compounds of the disclosure can be used to treat one or more of the diseases or disorders described herein below. In one embodiment, the disease or disorder is affected by the reduction of WIZ protein expression levels and/or induction of fetal hemoglobin protein expression levels. In another embodiment, the disease or disorder is a hemoglobinopathy, e.g., beta hemoglobinopathy, including sickle cell disease (SCD) and beta-thalassemia.

Methods of Use

In an aspect of the present disclosure, there is provided a method of reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression comprising administering to a subject a therapeutically effective amount of an agent, e.g., a small molecule (e.g., a small molecule compound that can target WIZ protein for degradation, e.g., through E3 ubiquitin pathway, e.g. a compound as described herein). In an embodiment, the method of reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression is for the treatment of a hemoglobinopathy, e.g., beta hemoglobinopathy, including sickle cell disease (SCD) and beta-thalassemia.

All the aforementioned embodiments and embodiments hereinafter relating to the methods of reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression are equally applicable to:

A therapeutic agent, e.g., a small molecule (e.g., small molecule compounds that can target WIZ protein for degradation, e.g., through E3 ubiquitin pathway, e.g., a compound as described herein), for use in a method of reducing WIZ protein expression levels and/or inducing fetal hemoglobin (HbF) expression;

A therapeutic agent, e.g., a small molecule (e.g., small molecule compounds that can target WIZ protein for degradation, e.g., through E3 ubiquitin pathway, e.g., a compound as described herein), for use in the treatment of the aforementioned diseases or disorders according to the present disclosure;

Use of an agent, e.g., a small molecule (e.g. a compound as described herein), in the treatment of the aforementioned diseases or disorders according to the present disclosure; and

A pharmaceutical composition comprising an agent, e.g., a small molecule (e.g., small molecule compounds that can target WIZ protein for degradation, e.g., through E3 ubiquitin pathway, e.g., a compound as described herein), for use in the treatment of the aforementioned diseases or disorders according to the present disclosure.

Having regard to their activity as WIZ modulators or degraders, compounds of formulae (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i),

and (ID-ii), in free or pharmaceutically acceptable salt form, are useful in the treatment of conditions which may be treated by modulation of WIZ protein expression levels, reduction of WIZ protein expression levels, or induction of fetal hemoglobin (HbF), such as in a blood disorder, for example an inherited blood disorder, e.g., sickle cell disease, or beta-thalassemia. In one aspect, the disclosure provides a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of inhibiting WIZ protein expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of degrading WIZ protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression, the method comprising administering to the subject a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of inducing or promoting fetal hemoglobin in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of reactivating fetal hemoglobin production or expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i),

(IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of increasing fetal hemoglobin expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of treating a hemoglobinopathy, *e.g.*, a beta-hemoglobinopathy, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of treating a sickle cell disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a method of treating beta-thalassemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In an embodiment, the beta-thalassemia major or intermedia is the result of homozygous null or compound heterozygous mutations resulting with beta-globin deficiency and the phenotypic complications of beta-thalassemia, whether transfusion-dependent or not.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-

iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of inhibiting WIZ protein expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of degrading WIZ protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression, the method comprising administering to the subject a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of inducing or promoting fetal hemoglobin in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of reactivating fetal hemoglobin production or expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of

a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of increasing fetal hemoglobin expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating a hemoglobinopathy, e.g., a beta-hemoglobinopathy, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating a sickle cell disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In another aspect, the disclosure provides a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof for use in a method of treating beta-thalassemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

In an embodiment, the beta-thalassemia major or intermedia is the result of homozygous null or compound heterozygous mutations resulting with beta-globin deficiency and the phenotypic complications of beta-thalassemia, whether transfusion-dependent or not.

Dosage

The pharmaceutical composition or combination of the disclosure can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.

The above-cited dosage properties are demonstrable *in vitro* and *in vivo* tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the disclosure can be applied *in vitro* in the form of solutions, e.g., aqueous solutions, and *in vivo* either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage *in vitro* may range between about 10^{-3} molar and 10^{-9} molar concentrations. A therapeutically effective amount *in vivo* may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.

The activity of a compound according to the disclosure can be assessed by the *in vitro* methods described in the Examples.

Combination Therapy

In another aspect, the disclosure provides a pharmaceutical combination comprising a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy. In an embodiment, the additional therapeutic agent is a myelosuppressive agent, such as hydroxyurea.

Combination therapy includes the administration of the subject compounds in further combination with other biologically active ingredients (such as, but not limited to, a second and different antineoplastic agent or a therapeutic agent that targets Hbf or another cancer target) and non-drug therapies (such as, but not limited to, surgery or radiation treatment). For instance, the compounds of the application can be used in combination with other pharmaceutically active compounds, preferably compounds that are able to enhance the effect of the compounds of the application.

The compound of the disclosure may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the disclosure may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents. A therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the disclosure. Thus, in one embodiment, the disclosure provides a combination comprising a therapeutically effective amount of a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-

i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), or a pharmaceutically acceptable salt thereof and one or more additional therapeutically active agents.

In one embodiment, the disclosure provides a product comprising a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition modulated by WIZ. Products provided as a combined preparation include a composition comprising the compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), and the other therapeutic agent(s) in separate form, e.g., in the form of a kit.

In one embodiment, the disclosure provides a pharmaceutical composition comprising a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii), and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.

In one embodiment, the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I'), (I''), (I), (I-i), (IA), (IA-i), (IA-ii), (IA-iii), (IB), (IB-i), (IB-ii), (IB-iii), (IC), (IC-i), (IC-ii), (ID), (ID-i), or (ID-ii). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.

The kit of the disclosure may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the disclosure typically comprises directions for administration.

In the combination therapies of the disclosure, the compound of the disclosure and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the disclosure and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g., in the case of a kit comprising the compound of the disclosure and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g., during sequential administration of the compound of the disclosure and the other therapeutic agent.

35 **Preparation of Compounds**

It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such combinations result in stable compounds.

It will also be appreciated by those skilled in the art that in the processes described below,

the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, and the like. Suitable protecting groups for amino, amidino and guanidino include *t*-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.

Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. The use of protecting groups is described in detail in J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973; T. W. Greene and P. G. M. Wuts, "Greene's Protective Groups in Organic Synthesis", Fourth Edition, Wiley, New York 2007; P. J. Kocienski, "Protecting Groups", Third Edition, Georg Thieme Verlag, Stuttgart and New York 2005; and in "Methoden der organischen Chemie" (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974.

The protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin.

The following reaction schemes illustrate methods to make compounds of this disclosure. It is understood that one skilled in the art would be able to make these compounds by similar methods or by methods known to one skilled in the art. In general, starting components and reagents may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, Strem, other commercial vendors, or synthesized according to sources known to those skilled in the art, or prepared as described in this disclosure.

Analytical Methods, Materials, and Instrumentation

Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Proton nuclear magnetic resonance (NMR) spectra were obtained on either Bruker Avance spectrometer or Varian Oxford 400 MHz spectrometer unless otherwise noted. Spectra are given in ppm (δ) and coupling constants, *J*, are reported in Hertz. Tetramethylsilane (TMS) was used as an internal standard. Chemical shifts are reported in ppm relative to dimethyl sulfoxide (δ 2.50), methanol (δ 3.31), chloroform (δ 7.26) or other solvent as indicated in NMR spectral data. A small amount of the dry sample (2-5 mg) is dissolved in an appropriate deuterated solvent (1 mL). The chemical names were generated using ChemBioDraw Ultra v12 from CambridgeSoft.

Mass spectra (ESI-MS) were collected using a Waters System (Acquity UPLC and a Micromass ZQ mass spectrometer) or Agilent-1260 Infinity (6120 Quadrupole); all masses reported are the *m/z* of the protonated parent ions unless recorded otherwise. The sample was dissolved in a suitable solvent such as MeCN, DMSO, or MeOH and was injected directly into the column using an automated sample handler. The analysis is performed on Waters Acquity UPLC

system (Column: Waters Acquity UPLC BEH C18 1.7 μ m, 2.1 x 30mm; Flow rate: 1 mL/min; 55°C (column temperature); Solvent A: 0.05% formic acid in water, Solvent B: 0.04% formic acid in MeOH; gradient 95% Solvent A from 0 to 0.10 min; 95% Solvent A to 20% Solvent A from 0.10 to 0.50 min; 20% Solvent A to 5% Solvent A from 0.50 to 0.60 min; hold at 5% Solvent A from 0.6 min to 0.8 min; 5% Solvent A to 95% Solvent A from 0.80 to 0.90 min; and hold 95% Solvent A from 0.90 to 1.15 min.

Abbreviations:

	ACN	acetonitrile
	AcOH	acetic acid
10	AIBN	azobisisobutyronitrile
	aq.	aqueous
	B ₂ pin ₂	bis(pinacolato)diboron
	BAST	bis(2-methoxyethyl)aminosulfur trifluoride
	Boc ₂ O	di-tert-butyl dicarbonate
15	Bn	benzyl
	BnBr	benzyl bromide
	br	broad
	d	doublet
	dd	doublet of doublets
20	ddd	doublet of doublet of doublets
	ddq	doublet of doublet of quartets
	ddt	doublet of doublet of triplets
	dq	doublet of quartets
	dt	doublet of triplets
25	dtbbpy	4,4'-di-tert-butyl-2,2'-dipyridyl
	dtd	doublet of triplet of doublets
	Cs ₂ CO ₃	cesium carbonate
	DCE	1,2-dichloroethane
	DCM	dichloromethane
30	DHP	dihydropyran
	DIBAL-H	diisobutylaluminium hydride
	DIPEA (DIEA)	diisopropylethylamine
	DIPEA	<i>N,N</i> -diisopropylethylamine
	DMA	<i>N,N</i> -dimethylacetamide
35	DMAP	4-dimethylaminopyridine
	DME	1,2-dimethoxyethane
	DMF	<i>N,N</i> -dimethylformamide
	DMP	Dess-Martin periodinane or 1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one

	DMSO	dimethylsulfoxide
	EC ₅₀	half maximal effective concentration
	ELSD	evaporative light scattering detector
	EtOH	ethanol
5	Et ₂ O	diethyl ether
	Et ₃ N	triethylamine
	EtOAc	ethyl acetate
	HATU	1-[bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- <i>b</i>]pyridinium 3-oxid hexafluorophosphate
10	HCl	hydrogen chloride
	hept	heptet
	HPLC	high performance liquid chromatography
	h or hr	hour
	HRMS	high resolution mass spectrometry
15	g	gram
	g/min	gram per minute
	IC ₅₀	half maximal inhibitory concentration
	IPA (iPrOH)	isopropyl alcohol
20	Ir[(dF(CF ₃)ppy) ₂ dtbbpy]PF ₆	[4,4'- <i>Bis</i> (1,1-dimethylethyl)-2,2'-bipyridine- <i>N</i> 1, <i>N</i> 1'] <i>bis</i> [3,5-difluoro- 2-[5-(trifluoromethyl)-2-pyridinyl- <i>N</i>]phenyl- <i>C</i>]Iridium(III) hexafluorophosphate
	K ₂ CO ₃	potassium carbonate
	KI	potassium iodide
	KOAc	potassium Acetate
25	K ₃ PO ₄	tripotassium phosphate
	LCMS	liquid chromatography mass spectrometry
	LDA	lithium diisopropylamide
	m	multiplet
	MeCN	acetonitrile
30	MeOH	methanol
	mg	milligram
	MHz	megahertz
	min	minutes
	mL	milliliter
35	mmol	millimole
	M	molar
	MS	mass spectrometry
	NaH	sodium hydride
	NaHCO ₃	sodium bicarbonate

	NaBH(OAc) ₃	sodium triacetoxyborohydride
	Na ₂ SO ₄	sodium sulfate
	NBS	<i>N</i> -bromosuccinimide
	NiCl ₂ (glyme)	Nickel(II) chloride ethylene glycol dimethyl ether complex
5	NMM	<i>N</i> -methylmorpholine
	NMP	<i>N</i> -methyl-2-pyrrolidone
	NMR	nuclear magnetic resonance
	on	overnight
	Pd/C	palladium on carbon
10	PdCl ₂ (dppf)•DCM	[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane
	Pd(PPh ₃) ₄	tetrakis(triphenylphosphine)palladium(0)
	PMB	para-methoxybenzyl
	q	quartet
15	qd	quartet of doublets
	quint	quintet
	quintd	quintet of doublets
	rbf	round bottom flask
20	RockPhos G3 Pd	[(2-di- <i>tert</i> -butylphosphino-3-methoxy-6-methyl-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2-aminobiphenyl)]palladium(II) methanesulfonate
	rt or r.t.	room temperature
	Rt	retention time
	s	singlet
	i	2-(trimethylsilyl)ethoxymethyl
25	SnBu ₃	tributyltin
	t	triplet
	td	triplet of doublets
	tdd	triplet of doublet of doublets
	TBAI	tetrabutylammonium iodide
30	TEA (NEt ₃)	triethylamine
	TFA	trifluoroacetic acid
	TFE	trifluoroethanol
	TfOH	triflic Acid
	THF	tetrahydrofuran
35	THP	tetrahydropyran
	TMP	2,2,6,6-tetramethylpiperidine
	Ts	tosyl
	tt	triplet of triplets
	ttd	triplet of triplet of doublets

TLC	thin-layer chromatography
UPLC	ultra-Performance liquid Chromatography
XPhos Pd G2	chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)
5 μL or uL	microlitre
μW or uW	microwave

General Method I- Representative Procedure for Photoredox Catalysis with Lactone

A 40 mL vial was charged with 5-bromoisobenzofuran-1(3H)-one (1 equiv), an alcohol building block (1-1.1 equiv), NiCl₂(glyme) (0.05 equiv), dtbbpy (0.05 equiv), and
 10 Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (0.01 equiv). ACN (0.186-0.3 M) was then added, followed by 2,2,6,6-tetramethylpiperidine (1.05 equiv). The reaction flask was evacuated and backfilled with nitrogen three times. The resulting mixture was placed in PennOC m1 450nm Photoreactor under Blue LED light at r.t. for 18 hrs. The reaction mixture was filtered, concentrated and purified by reverse phase HPLC or silica gel chromatography to afford amino-ether lactone.

General Method II- Representative Procedure for Boc Deprotection

Amino-ether lactone (1 equiv) was suspended in dioxane (0.1-25 M) and TFE (0.59 – 1.75 M). 4M HCl in dioxane (6 equiv) was then added and the resulting mixture was stirred at r.t. for 18-37 hrs. The reaction mixture was concentrated under reduced pressure to afford free amino-ether lactone. The obtained product was carried on to the next step without purification.

General Method III- Representative Procedure for Reductive Amination

Free amino-ether lactone (1 equiv) was suspended in DMF (0.1-0.2 M). Aldehyde (1.5 equiv) was added. The reaction stirred for 15 minutes at r.t. then NaBH(OAc)₃ (2 equiv) was added. The reaction stirred at r.t. for 1-18 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The combined
 25 extracts were passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography to afford lactone.

General Method IV- Representative Procedure for SOCl₂ Lactone Opening

To a solution of lactone (1 equiv) in dichloroethane (0.1 M) and EtOH (0.1 M) stirred at 70 °C was added thionyl chloride (12 equiv) and the resulting mixture was stirred at 70 °C overnight.
 30 The reaction mixture was cooled to r.t., diluted with water and EtOAc and quenched with saturated aqueous sodium bicarbonate. The reaction mixture was extracted with EtOAc three times and the combined organic layers were passed through a phase separator and concentrated to afford α-chloro-ester. The crude material was purified by silica gel chromatography or used directly in the next step without purification.

General Method V- Representative Procedure for Lactam Ring Closing

3-aminopiperidine-2,6-dione hydrochloride (2 equiv) was dissolved in DMF (0.25 M) in a 2 mL microwave vial. DIPEA (5 equiv) was then added and the reaction was evacuated and backfilled with nitrogen three times. The resulting mixture stirred at r.t. for 15 minutes. α-chloro-ester (1 equiv) dissolved in DMF (0.17 M) and the reaction was evacuated and backfilled with

nitrogen three times. The reaction stirred at 85 °C for 18 hrs and then at 150 °C for 2 hrs under microwave radiation. The reaction mixture was concentrated onto CELITE® and purified by silica gel chromatography or reverse phase HPLC to afford the lactam product.

General Method VI- Representative Procedure for Photoredox Catalysis with 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione

To a capped vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (1 equiv), alcohol building block (1-1.2 equiv), dtbbpy (0.05 equiv), NiCl₂(glyme) (0.05 equiv), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (0.01 equiv) were added. ACN (0.2-0.3 M) was added and the reaction was purged with nitrogen for 5-10 minutes to ensure reaction turned green. 2,2,6,6-tetramethylpiperidine (1.05-1.5 equiv) was added. The resulting mixture was placed in PennOC m1 450nm Photoreactor under Blue LED light at r.t. for 18 hrs. The reaction mixture was filtered, concentrated and purified by reverse phase HPLC or silica gel chromatography to afford SEM protected glutarimide, Boc protected amine and isoindoline derivative.

General Method VII- Representative Procedure for Global Deprotection

To a solution of the compound containing a SEM protected glutarimide and Boc protected amine (1 equiv) in ACN (0.2-0.3 M) was added methanesulfonic acid (5-10.9 equiv). The resulting mixture was stirred at r.t. for 18 hrs and then cooled to 0 °C. Triethylamine (10-15 equiv) was then added, followed by N1,N2-dimethylethane-1,2-diamine (1.6-3 equiv). The reaction mixture was then stirred at r.t. for 2-70 hrs. The reaction was quenched with basic aqueous solution, extracted with DCM and polar protic solvent, and concentrated to afford free amine or purified by silica gel chromatography to afford the free amine product.

General Method VIII- Representative Procedure for Mesylation Formation

To a solution of alcohol (1 equiv) in DCM (0.5 M) was sequentially added DIPEA (2 equiv), 1-methylimidazole (2 equiv) and methanesulfonyl chloride (1.5 equiv) dropwise. The reaction was stirred at r.t. for 18 hrs. The reaction was diluted with DCM (20 mL). The organic layer was washed with 1 M aqueous HCl three times and saturated aqueous sodium bicarbonate twice. The organic layer was passed through a phase separator and concentrated to afford the mesylate product.

General Method IX- Representative Procedure for Alkylation with Alkyl Mesylate


Piperidine (1 equiv) and mesylate (1.5 equiv) were added to a microwave vial and suspended in ACN (0.2 M). DIPEA (2 equiv) was added and the reaction was evacuated and backfilled with nitrogen three times. The reaction stirred at 140 °C for 2-10 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography to afford alkylated piperidine compound.

General Method X- Representative Procedure for Reduction Amination

Free amino-ether lactone (1 equiv) was suspended in DMF (0.15-0.178 M). NaBH(OAc)₃ (2 equiv) followed by aldehyde (1.5 equiv) were added. The reaction stirred at r.t. for 1-18 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase
 5 separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography to afford the lactone product.


Stereochemical Representation

The compounds of formula (I) have at least two asymmetric carbon atoms as illustrated below wherein the asymmetric carbon atoms are identified by a *:




10

Throughout the following synthesis section describing the synthetic preparation of compounds of formula (I), compounds drawn whereby the bond from the N atom of the oxoisindolinyl moiety to the C atom of the glutarimide moiety is depicted as flat shall be taken
 15 to mean a compound mixture which comprises both the (*R*) and (*S*) stereoisomers in relation to this stereocenter. For illustrative purposes, this can be shown by reference to Example 29:



Example 29 (named as 3-(5-(((*R*)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione) thus exists as a diastereomeric mixture of both the (*R*)-
 20 3-(5-(((*R*)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione and (*S*)-3-(5-(((*R*)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.

In such cases where the compound has been separated into individual diastereomers or further mixtures of diastereomers, the stereochemical configuration of the diastereomer which is
 25 designated as (*R*^{*}, *S*^{*}) indicates the relative stereochemistry is known (as depicted by the wedged bonds) but not the absolute stereochemistry. Accordingly, any reference to a compound designated as (*R*^{*}, *S*^{*}) shall be taken to mean as either having the absolute (*R*, *S*) configuration or the (*S*, *R*) configuration. This also applies to compounds which have been synthesised from an intermediate compound whereby the relative stereochemistry is known but the absolute
 30 stereochemistry has not been determined. For illustrative purposes, this can be explained by reference to Example 55:




which is named as 3-(5-(((3*S**,4*S**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione and whereby the groups attached to the 3- and 4-position of the piperidiny moiety are represented by the wedged bonds to indicate the relative stereochemistry is known. This shall be taken to mean that the compound is either 3-(5-(((3*S*,4*S*)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or 3-(5-(((3*R*,4*R*)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (taking into account the flat bond to the glutarimide moiety as explained above). The same interpretation is to be applied throughout the following section for the synthesis of all compounds.

If the absolute stereochemistry of a specific chiral carbon atom in a diastereoisomeric compound or compound mixture was known the (*R**,*S**) designation will be replaced by the absolute (*R*,*S*) designation to indicate the compound has known absolute stereochemistry at that particular position.

Preparation of Intermediates

Preparation of *rac*-3-(5-bromo-1-oxoisindolin-2-yl)piperidine-2,6-dione (INT-XX)



Step 1. Ethyl 4-bromo-2-(chloromethyl)benzoate (1-1b)

A stirred suspension of 5-bromophthalide **1-1a** (1200 g, 5.633 mol) in EtOH (12 L) was heated to 68-72 °C. SOCl₂ (2.40 L, 33.0 mol) was then added dropwise over a period of 7 h. The reaction mixture was concentrated under reduced pressure to about 4 L, and then water (5 L) and MTBE (5 L) were added. The resulting mixture was stirred for 40 min. The phases were separated and the aqueous phase was extracted with MTBE (1 x 5 L). The combined organic layers were washed with 5% aq. NaHCO₃ (5 L), dried over Na₂SO₄, filtered, and concentrated to dryness to afford **1-1b** as a pale brown solid. MS [M+Na]⁺ = 298.9. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.85 (d, *J* = 8.4 Hz, 1H), 7.72 (d, *J* = 2.0 Hz, 1H), 7.52 (dd, *J* = 8.3, 2.0 Hz, 1H), 5.00 (s, 2H), 4.38 (q, *J* = 7.1 Hz, 2H), 1.40 (t, *J* = 7.1 Hz, 3H).

Step 2. 3-(5-bromo-1-oxoisindolin-2-yl)piperidine-2,6-dione (INT-XX)

To a stirred suspension of 3-aminopiperidine-2,6-dione hydrochloride **1-1c** (596.3 g, 3.623 mol) and *i*-Pr₂NEt (2.50 L, 14.3 mol) in DMF (5.0 L) was added **1-1b** (1000 g, 3.623 mmol) and the resulting reaction mixture was stirred at 85-90 °C for 24 h. The reaction mixture was then allowed to cool to room temperature, water (20 L) was added, and the resulting mixture was stirred for 12 h. The formed precipitate was filtered and washed with water (5 L) and MeOH (2 L). The

crude solid was slurried in MeOH (5 L) for 1 h, filtered, and washed with MeOH (2 L). The resulting solid was then taken in EtOAc (10 L) and stirred for 1 h. The obtained suspension was then filtered, washed with EtOAc (5 L), and dried under reduced pressure at 45-50 °C to afford INT-XX as an off-white solid. MS $[M+1]^+ = 323.2$. ^1H NMR (400 MHz, DMSO- d_6) δ 10.99 (s, 1H), 7.91-7.88 (m, 1H), 7.72 (dd, $J = 8.1, 1.6$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 5.11 (dd, $J = 13.3, 5.1$ Hz, 1H), 4.47 (d, $J = 17.7$ Hz, 1H), 4.34 (d, $J = 17.7$ Hz, 1H), 2.98-2.83 (m, 1H), 2.65-2.55 (m, 1H), 2.45-2.29 (m, 1H), 2.01 (dtd, $J = 12.7, 5.3, 2.3$ Hz, 1H).

Preparation of *rac*-3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione (INT-1)



10


To a stirred solution of INT-XX (10.0 g, 30.9 mmol) and DBU (6.9 mL, 46 mmol) in DMF (95 mL) was added SEMCl (6.6 mL, 37 mmol) at 0 °C and the resulting reaction mixture was allowed to warm to room temperature and then stirred for 5 h. An additional portion of DBU (3.5 mL, 23 mmol) and SEMCl (3.3 mL, 19 mmol) was added and stirring was continued for an additional 2 h.

The reaction mixture was then quenched with sat. aq. NH_4Cl (250 mL) and extracted with EtOAc (x 3). The combined organic phases were dried over Na_2SO_4 , filtered, and concentrated to dryness. The crude material was dissolved in minimal amount of EtOAc (~50 mL) and Et_2O :heptane (v/v = 1:2, 400 mL) was added. The resulting cloudy solution was left standing at -5 °C overnight. The formed precipitate was filtered, washed with heptane (x3), and dried under vacuum to afford INT-1 as an off-white solid. MS $[M+H]^+ = 453.4$. ^1H NMR (400 MHz, Chloroform- d) δ 7.75 (d, $J = 8.6$ Hz, 1H), 7.66-7.61 (m, 2H), 5.37-5.09 (m, 3H), 4.48 (d, $J = 16.2$ Hz, 1H), 4.32 (d, $J = 16.2$ Hz, 1H), 3.74-3.50 (m, 2H), 3.11-2.98 (m, 1H), 2.94-2.83 (m, 1H), 2.33 (qd, $J = 13.2, 4.7$ Hz, 1H), 2.24-2.15 (m, 1H), 0.97-0.90 (m, 2H), 0.00 (s, 9H).

20

Preparation of 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione (INT-2)

25




Step 1: Tert-butyl (3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate (1)

To a 40 mL vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (4.00 g, 8.82 mmol), (*R*)-1-boc-3-hydroxypiperidine (1.78 g, 8.82 mmol), dtbbpy (118 mg, 0.441 mmol), NiCl₂(glyme) (97 mg, 0.441 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (99 mg, 0.088 mmol) were added. ACN (29.4 mL) was added and the reaction was purged with nitrogen for 5-10 minutes to ensure reaction turned green. 2,2,6,6-tetramethylpiperidine (1.56 mL, 9.26 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl (3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate **1** as a yellow solid. LCMS [M+H-156.3]⁺: 418.3. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.05 – 6.99 (m, 1H), 6.96 (s, 1H), 5.25 (d, *J* = 9.4 Hz, 1H), 5.23 – 5.14 (m, 2H), 4.47 – 4.39 (m, 1H), 4.38 – 4.24 (m, 2H), 3.95 (q, *J* = 8.6 Hz, 3H), 3.66 – 3.59 (m, 2H), 3.35 – 3.16 (m, 1H), 3.06 – 2.98 (m, 1H), 2.94 – 2.83 (m, 1H), 2.38 – 2.26 (m, 1H), 2.23 – 2.14 (m, 1H), 2.10 – 2.04 (m, 1H), 1.91 – 1.72 (m, 2H), 1.61 – 1.50 (m, 1H), 1.42 (s, 9H), 0.94 (dd, *J* = 9.2, 7.3 Hz, 2H), 0.00 (s, 9H).

Step 2: 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione (INT-2)

To tert-butyl (3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate **1** (4.7 g, 8.2 mmol) dissolved in ACN (27 mL) was added methanesulfonic acid (5.8 mL, 89 mmol). The reaction stirred at r.t. overnight. The reaction was cooled to 0 °C and triethylamine (16.0 mL, 115 mmol) followed by N1,N2-dimethylethane-1,2-diamine (1.41 mL, 13.1 mmol) were added. The reaction stirred at r.t. for 2 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% ethanol with 1% TEA in dichloromethane) to afford 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 as a cream solid. LCMS [M+H]⁺: 344.3.

Preparation of (R)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one (INT-20)




Step 1: Tert-butyl (R)-4-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-6-azaspiro[2.5]octane-6-carboxylate (19)

To a 40 mL capped vial, 5-bromoisobenzofuran-1(3H)-one (220 mg, 1.03 mmol), tert-butyl (4R)-4-hydroxy-6-azaspiro[2.5]octane-6-carboxylate (CAS#1205542-21-7) (246 mg, 1.08 mmol), dtbbpy (28 mg, 0.10 mmol), NiCl₂(glyme) (23 mg, 0.10 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (23 mg, 0.021 mmol) were added. ACN (4.4 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.18 mL, 1.1 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford product tert-butyl (R)-4-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-6-azaspiro[2.5]octane-6-carboxylate **19** as a light cream solid. LCMS [M+H-tert-butyl]⁺: 304.2. ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, *J* = 8.5 Hz, 1H), 7.02 (dd, *J* = 8.5, 2.1 Hz, 1H), 6.91 (d, *J* = 2.2 Hz, 1H), 5.24 (s, 2H), 4.21 - 3.63 (m, 3H), 3.46 - 3.00 (m, 2H), 1.55 - 0.99 (m, 11H), 0.77 - 0.65 (m, 1H), 0.62 - 0.44 (m, 3H).

Step 2: (R)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one (INT-20)


Tert-butyl (R)-4-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-6-azaspiro[2.5]octane-6-carboxylate **19** (228 mg, 0.63 mmol) was dissolved in dioxane (3.2 mL) and trifluoroethane (0.5 mL). 4M HCl in dioxane (0.95 mL, 3.8 mmol) was added and the reaction stirred at r.t. for 18 hrs. The reaction was concentrated to afford (R)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one INT-20 as a light yellow oil. Material was used directly in the next reaction. LCMS [M+H]⁺: 260.2.

25 Preparation of (R)-sec-butyl methanesulfonate (INT-27)



Compound **INT-27** was made according to General Method VIII starting from (*R*)-butan-2-ol (0.2 mL, 2.177 mmol) to afford (*R*)-sec-butyl methanesulfonate **INT-27** as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 4.77 (h, *J* = 6.3 Hz, 1H), 3.02 (s, 3H), 1.82 - 1.63 (m, 2H), 1.44 (d, *J* = 6.3 Hz, 3H), 1.01 (t, *J* = 7.4 Hz, 3H).

Preparation of Enantiomers of 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one (INT-33).



Step 1: Tert-butyl 7-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-5-azaspiro[2.5]octane-5-carboxylate (31)

Compound **31** was made according to General Method I starting from 5-bromoisobenzofuran-1(3H)-one (0.2 g, 0.939 mmol) and tert-butyl 7-hydroxy-5-azaspiro[2.5]octane-5-carboxylate (CAS# 2167476-06-2) (235 mg, 1.03 mmol). The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl 7-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-5-azaspiro[2.5]octane-5-carboxylate **31** as a yellow oil. LCMS [M+H-t-butyl]⁺: 304.3.


Step 2: 5-((5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one (32)

Tert-butyl 7-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-5-azaspiro[2.5]octane-5-carboxylate **31** (271 mg, 0.754 mmol) was suspended in dioxane (7.54 mL). 4M HCl in dioxane (1.13 mL, 4.52 mmol) was added and the reaction stirred at r.t. for 18 hrs. Trifluoroethanol (2 mL) was added followed by additional 4M HCl in dioxane (1.13 mL, 4.52 mmol). The reaction stirred at r.t. for 72 hrs. The reaction was concentrated to afford 5-((5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one **32** as a white solid. Material was used directly in the next reaction. LCMS [M+H]⁺: 260.1.

Step 3: Enantiomers of 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one (INT-33)

Compound INT-33 was made according to General Method X starting from 5-((5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one **32** (196 mg, 0.754 mmol) and acetaldehyde (63.9 μ L, 1.13 mmol). The crude material was purified by silica gel chromatography (0-100% 3:1 EtOAc:EtOH with 1% TEA in heptane) to afford 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one INT-33 as an orange oil. LCMS $[M+H]^+$: 288.2. ^1H NMR (400 MHz, $CDCl_3$) δ 7.55 (d, J = 8.5 Hz, 1H), 6.83 - 6.74 (m, 1H), 6.74 - 6.64 (m, 1H), 4.98 (s, 2H), 4.46 - 4.38 (m, 1H), 3.00 - 2.92 (m, 1H), 2.32 - 2.16 (m, 2H), 2.08 (dd, J = 11.4, 1.3 Hz, 1H), 1.99 - 1.91 (m, 1H), 1.87 - 1.80 (m, 1H), 1.66 - 1.58 (m, 1H), 1.30 - 1.23 (m, 1H), 0.83 (t, J = 7.2 Hz, 2H), 0.29 - 0.00 (m, 5H). The enantiomeric mixture of isomers was separated via chiral SFC [Column 21 x 250 mm Chiralpak IG; CO_2 Co-solvent 25% MeOH with 10 mM NH_3 ; at 80 g/min at 125 bar] to afford two single enantiomers: **Peak 1**: Enantiomer 1 of 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one as an orange oil; **Peak 2**: Enantiomer 2 of 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one as an orange oil.

Preparation of 5-(((1S,5S,6R)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one and 5-(((1R,5R,6S)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one



Step 1: *rac*-Tert-butyl (1R,5R,6S)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate (38**)**

To a 40 mL capped vial, 5-bromoisobenzofuran-1(3H)-one (225 mg, 1.056 mmol), *rac*-tert-butyl (1R,5R,6S)-5-hydroxy-3-azabicyclo[4.1.0]heptane-3-carboxylate (CAS# 2305079-71-2;

also referred to as 5-exo-hydroxy-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid tert-butyl ester) (248 mg, 1.16 mmol), dtbbpy (28 mg, 0.11 mmol), NiCl₂(glyme) (23 mg, 0.11 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (24 mg, 0.021 mmol) were added. ACN (4.5 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.11 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford *rac*-tert-butyl (1*R*,5*R*,6*S*)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate **38** as a yellow oil. LCMS [M+H-tert-butyl]⁺: 290.0.

10 **Step 2: *rac*-5-(((1*R*,5*R*,6*S*)-3-Azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one (39)**


Compound **39** was made according to General Method II starting from *rac*-tert-butyl (1*R*,5*R*,6*S*)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate **38** (224 mg, 0.65 mmol). The reaction was concentrated to afford *rac*-5-(((1*R*,5*R*,6*S*)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **39** as a yellow oil. Material was used directly in the next reaction. LCMS [M+H]⁺: 246.2.

Step 3: 5-(((1*S*,5*S*,6*R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one and 5-(((1*R*,5*R*,6*S*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one

Compound INT-40 was made according to General Method X starting from *rac*-5-(((1*R*,5*R*,6*S*)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **39** (159 mg, 0.65 mmol) and acetaldehyde (55 µL, 0.974 mmol). The crude material was purified by silica gel chromatography (0-100% ethyl acetate in heptane) to afford *rac*-5-(((1*R*,5*R*,6*S*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-40** as a light yellow oil. LCMS [M+H]⁺: 274.2. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 8.5 Hz, 1H), 7.13 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.05 - 6.98 (m, 1H), 5.28 (s, 2H), 4.66 - 4.38 (m, 1H), 2.87 - 2.79 (m, 1H), 2.77 - 2.65 (m, 2H), 2.36 (d, *J* = 58.0 Hz, 3H), 1.69 - 1.50 (m, 1H), 1.32 - 1.21 (m, 1H), 1.16 - 1.00 (m, 3H), 0.82 - 0.71 (m, 1H), 0.57 - 0.47 (m, 1H). The enantiomeric mixture of isomers was separated via chiral SFC [Column 21 x 250 mm IH; CO₂ Co-solvent 12% MeOH with 0.5% IPA; at 80 g/min at 100 bar at 35 °C] to afford two single enantiomers: 5-(((1*S*^{*},5*S*^{*},6*R*^{*})-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-40 Peak 1**, Rt = 2.18 mins, as a cream solid; 5-(((1*R*^{*},5*R*^{*},6*S*^{*})-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-40 Peak 2**, Rt = 2.34 mins, as a cream solid. The absolute stereochemistry of the two enantiomers corresponding to the two product peaks was not determined.

Preparation of 5-(((1*S*,5*R*,6*R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one and 5-(((1*R*,5*S*,6*S*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one

(INT-47)



5

Step 1: *rac*-Tert-butyl (1*R*,5*S*,6*S*)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate (45)

To a 40 mL capped vial, 5-bromoisobenzofuran-1(3*H*)-one (225 mg, 1.06 mmol), *rac*-tert-butyl (1*R*,5*S*,6*S*)-5-hydroxy-3-azabicyclo[4.1.0]heptane-3-carboxylate (CAS# 2305079-37-0; also referred to as 5-endo-hydroxy-3-aza-bicyclo[4.1.0]heptane-3-carboxylic acid tert-butyl ester) (248 mg, 1.16 mmol), dtbbpy (28 mg, 0.11 mmol), NiCl₂(glyme) (23 mg, 0.11 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (24 mg, 0.021 mmol) were added. ACN (4.5 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.19 mL, 1.11 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford *rac*-tert-butyl (1*R*,5*S*,6*S*)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-carboxylate **45** as a light yellow solid. LCMS [M+H-tert-butyl]⁺: 290.3.

Step 2: *rac*-5-(((1*R*,5*S*,6*S*)-3-Azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one (46)


Compound **46** was made according to General Method II starting from *rac*-tert-butyl (1*R*,5*S*,6*S*)-5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-3-azabicyclo[4.1.0]heptane-3-

carboxylate **45** (302 mg, 0.87 mmol). Reaction was concentrated to afford *rac*-5-(((1*R*,5*S*,6*S*)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **46** (214 mg, 0.874 mmol) as a yellow oil. Material was used directly in the next reaction. LCMS [M+H]⁺: 246.2.

Step 3: 5-(((1*S*,5*R*,6*R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one and 5-(((1*R*,5*S*,6*S*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one


Compound **INT-47** was made according to General Method X starting from *rac*-5-(((1*R*,5*S*,6*S*)-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **46** (214 mg, 0.87 mmol) and acetaldehyde (74 μ L, 1.31 mmol). The crude material was purified by silica gel chromatography (0-20% methanol in DCM) to afford *rac*-5-(((1*R*,5*S*,6*S*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **INT-47** as an orange oil. LCMS [M+H]⁺: 274.2. The enantiomeric mixture of isomers was separated via chiral SFC [Column 21 x 250 mm IH; CO₂ Co-solvent 12% MeOH with 0.5% IPA; at 80 g/min at 100 bar at 35 °C] to afford two single enantiomers: 5-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **INT-47 Peak 1**, Rt = 1.55 mins, as a brown oil; 5-(((1*R**,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **INT-47 Peak 2**, Rt = 1.70 mins, as a brown oil. The absolute stereochemistry of the two enantiomers corresponding to the two product peaks was not determined.

Preparation of (1*r*,3*r*)-3-ethoxycyclobutyl methanesulfonate (**INT-55**)



A 40 mL vial was charged (1*r*,3*r*)-3-ethoxycyclobutan-1-ol (570 mg, 4.9 mmol), DIPEA (1.3 mL, 7.4 mmol), DMAP (60 mg, 0.49 mmol) and DCM (3.0 mL). MsCl (0.42 mL, 5.4 mmol) was added and reaction stirred at 0 °C for 1 hr and r.t. for 5 hrs. The reaction was quenched with saturated aqueous NaHCO₃ and extracted with DCM three times. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated to afford (1*r*,3*r*)-3-ethoxycyclobutyl methanesulfonate **INT-55** as a brown oil. Material was taken through to the next step without purification. ¹H NMR (400 MHz, CDCl₃) δ 5.21 (tt, *J* = 7.0, 5.0 Hz, 1H), 4.28 - 4.14 (m, 1H), 3.41 (q, *J* = 7.0 Hz, 2H), 3.01 (s, 3H), 2.62 - 2.45 (m, 4H), 1.22 (t, *J* = 7.0 Hz, 3H).

Preparation of ((1*r*,3*r*)-3-methoxycyclobutyl)methyl methanesulfonate (**INT-58**)




Step 1: ((1*r*,3*r*)-3-methoxycyclobutyl)methanol (57**)**

Trans-3-methoxycyclobutane-1-carboxylic acid (175 mg, 1.35 mmol) was dissolved in THF (4.5 mL) and cooled to 0 °C. 1M borane tetrahydrofuran complex in THF (4.0 mL, 4.0 mmol) was added dropwise. The reaction stirred at r.t. for 36 hrs. The reaction was cooled to 0 °C and quenched with methanol (3.26 mL, 81 mmol) and stirred at r.t. for 2 hrs. The reaction was concentrated to dryness then redissolved in methanol (5 mL). The reaction stirred at r.t. for 18 hrs. The reaction was concentrated to afford ((1*r*,3*r*)-3-methoxycyclobutyl)methanol **57** (156 mg, 1.35 mmol) as a clear oil. Material was carried on crude to the next step.

Step 2: ((1*r*,3*r*)-3-methoxycyclobutyl)methyl methanesulfonate (INT-58)

Compound INT-58 was made according to General Method VIII starting from ((1*r*,3*r*)-3-methoxycyclobutyl)methanol **57** (156 mg, 1.345 mmol) to afford ((1*r*,3*r*)-3-methoxycyclobutyl)methyl methanesulfonate INT-58 as a light yellow oil. ¹H NMR (400 MHz, CD₃OD) δ 4.26 (d, *J* = 6.8 Hz, 2H), 4.02 (p, *J* = 6.7 Hz, 1H), 3.24 (s, 3H), 3.09 (s, 3H), 2.67 - 2.57 (m, 1H), 2.23 - 2.10 (m, 4H).

Preparation of 7-oxaspiro[3.5]nonan-2-yl methanesulfonate (INT-60)




15

Compound INT-60 was made according to General Method VIII starting from 7-oxaspiro[3.5]nonan-2-ol (60 mg, 0.42 mmol) to afford 7-oxaspiro[3.5]nonan-2-yl methanesulfonate INT-60 as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 5.05 (p, *J* = 7.2 Hz, 1H), 3.67 - 3.56 (m, 4H), 3.01 (s, 3H), 2.53 - 2.43 (m, 2H), 2.17 - 2.09 (m, 2H), 1.70 - 1.60 (m, 4H).

20


Preparation of 3,3-difluorocyclobutyl methanesulfonate (INT-62)



Compound INT-62 was made according to General Method VIII starting from 3,3-difluorocyclobutan-1-ol (150 mg, 1.39 mmol) to afford 3,3-difluorocyclobutyl methanesulfonate INT-62 as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 5.04 - 4.94 (m, 1H), 3.19 - 3.09 (m, 2H), 3.07 (s, 3H), 3.02 - 2.85 (m, 2H).


25

Preparation of ((1*r*,4*r*)-4-methoxycyclohexyl)methyl methanesulfonate (INT-64)




Compound **INT-64** was made according to General Method VIII starting from ((1*r*,4*r*)-4-methoxycyclohexyl)methanol (250 mg, 1.73 mmol) to afford ((1*r*,4*r*)-4-methoxycyclohexyl)methyl methanesulfonate **INT-64** as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 4.06 (d, *J* = 6.4 Hz, 2H), 3.37 (s, 3H), 3.17 - 3.06 (m, 1H), 3.02 (s, 3H), 2.18 - 2.09 (m, 2H), 1.94 - 1.85 (m, 2H), 1.82 - 1.70 (m, 1H), 1.31 - 1.18 (m, 2H), 1.16 - 1.04 (m, 2H).

Preparation of Cyclobutyl methanesulfonate (**INT-66**)




Compound **INT-66** was made according to General Method VIII starting from cyclobutanol (0.2 mL, 2.55 mmol) to afford cyclobutyl methanesulfonate **INT-66** as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 4.99 (pd, *J* = 7.5, 1.0 Hz, 1H), 3.00 (s, 3H), 2.48 - 2.26 (m, 4H), 1.95 - 1.82 (m, 1H), 1.71 - 1.56 (m, 1H).

Preparation of (*S*)-sec-butyl methanesulfonate (**INT-68**)



Compound **INT-68** was made according to General Method VIII starting from (*S*)-butan-2-ol (0.2 mL, 2.17 mmol) to afford (*S*)-sec-butyl methanesulfonate **INT-68** as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 4.77 (h, *J* = 6.3 Hz, 1H), 3.02 (s, 3H), 1.85 - 1.63 (m, 2H), 1.44 (d, *J* = 6.3 Hz, 3H), 1.01 (t, *J* = 7.4 Hz, 3H).


Preparation of *rac*-tert-butyl (3*R*,5*S*)-3-hydroxy-5-methylpiperidine-1-carboxylate (**INT-108**)



To a solution of *rac*-(3*R*,5*S*)-5-methylpiperidin-3-ol (245 mg, 1.62 mmol) in MeOH (2.5 mL) was added Na₂CO₃ (257 mg, 2.42 mmol) and di-tert-butyl dicarbonate (529 mg, 2.42


mmol). The reaction mixture was stirred at r.t. overnight. The reaction mixture was diluted with H₂O (5.0 mL) and extracted with DCM three times. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated to afford *rac*-tert-butyl (3*R*,5*S*)-3-hydroxy-5-methylpiperidine-1-carboxylate **INT-108** as a colorless oil. Material was taken through to the
 5 next step without purification.

Preparation of enantiomers of tert-butyl 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate (INT-118**)**



To a 40 mL capped vial, 5-bromoisobenzofuran-1(3H)-one (0.5 g, 2.347 mmol), *rac*-tert-butyl 3-hydroxy-4,4-dimethylpiperidine-1-carboxylate (592 mg, 2.58 mmol), dtbbpy (63 mg, 0.235 mmol), NiCl₂(glyme) (52 mg, 0.235 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (53 mg, 0.047 mmol) were added. ACN (9.99 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.416 mL, 2.464 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue
 15 LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate **INT-118** as a cream solid. LCMS [M+H-tert-butyl]⁺: 306.2. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 8.5 Hz, 1H), 7.09 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.00 (s, 1H), 5.26 (s, 2H), 3.98 (dd, *J* = 7.7, 3.4 Hz, 1H), 3.61 - 3.28 (m, 3H), 1.76 -
 20 1.64 (m, 1H), 1.60 - 1.52 (m, 2H), 1.49 - 1.31 (m, 9H), 1.12 (s, 3H), 1.10 (s, 3H). The enantiomeric mixture of isomers was separated via chiral SFC [Column 21 x 250 mm ChiralPak IG; CO₂ Co-solvent 15% 1:1 Methanol:iPrOH; at 80 g/min at 125 bar] to afford two enantiomers:
Peak 1: Enantiomer 1 of tert-butyl 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate (364 mg, 1.007 mmol) as a light yellow clear oil; **Peak 2:**
 25 Enantiomer 2 of tert-butyl 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate (214 mg, 0.592 mmol) as light yellow clear oil.


Preparation of 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (INT-119**)**



Compound **INT-119** was made according to General Method II starting from Tert-butyl
 30 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate **INT-118**

peak 1 (364 mg, 1.007 mmol). The reaction was concentrated to afford 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **INT-119** as a cream solid. Material was used directly in the next reaction. LCMS $[M+H]^+$: 262.4.

Preparation of 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (INT-120)




5

Compound **INT-120** was made according to General Method II starting from Tert-butyl 4,4-dimethyl-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)piperidine-1-carboxylate **INT-118 peak 2** (214 mg, 0.592 mmol). The reaction was concentrated to afford 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **INT-120** as a cream solid. Material was used directly in the next reaction. LCMS $[M+H]^+$: 262.0.

10


Preparation of *rac*-tert-butyl (3*R*,5*R*)-3-hydroxy-5-methylpiperidine-1-carboxylate (INT-133)



To a solution of *rac*-(3*R*,5*R*)-5-methylpiperidin-3-ol (251 mg, 2.2 mmol) in EtOH (6 mL), a solution of boc-anhydride (523 mg, 2.4 mmol) in EtOH (3 mL) was added via syringe. The reaction was stirred at r.t. for 20 hrs. The reaction was concentrated to afford *rac*-tert-butyl (3*R*,5*R*)-3-hydroxy-5-methylpiperidine-1-carboxylate **INT-133** (520 mg, 2.42 mmol). Material was used directly in the next reaction without purification. ^1H NMR (400 MHz, CDCl_3) δ 4.06 - 3.85 (m, 2H), 2.99 (dd, J = 13.6, 1.9 Hz, 1H), 2.45 (s, 1H), 2.00 (dtd, J = 10.7, 6.7, 3.8 Hz, 1H), 1.85 (ddt, J = 13.7, 4.1, 2.1 Hz, 1H), 1.65 (d, J = 25.6 Hz, 1H), 1.46 (s, 9H), 1.32 - 1.17 (m, 2H), 0.89 (d, J = 6.7 Hz, 3H).

20

Preparation of *rac*-tert-butyl 5-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate (INT-139)




A 40 mL vial was charged with 7-azaspiro[3.5]nonan-5-ol (50 mg, 0.22 mmol), di-tert-butyl dicarbonate (57 mg, 0.26 mmol), Na_2CO_3 (27 mg, 0.26 mmol) and MeOH (1.0 mL). The reaction mixture stirred vigorously at r.t. for 18 hrs. The reaction mixture was diluted with brine and extracted with DCM four times. The organic layers were combined, passed through a phase separator and concentrated to afford tert-butyl 5-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate **INT-139** as a racemic mixture. Material was used directly in the next step without purification. ^1H

25

NMR (400 MHz, CDCl₃) δ 3.58 (dd, J = 5.8, 2.7 Hz, 1H), 3.54 - 3.43 (m, 2H), 3.28 (dd, J = 13.5, 2.8 Hz, 1H), 3.13 (ddd, J = 13.1, 9.2, 3.5 Hz, 1H), 2.16 - 2.06 (m, 1H), 2.00 - 1.82 (m, 4H), 1.77 - 1.63 (m, 3H), 1.54 - 1.49 (m, 1H), 1.47 (s, 9H).

Preparation of Benzyl (3S,4S)-4-fluoro-3-hydroxypiperidine-1-carboxylate and benzyl

5 (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate (INT-146)



Step 1: *rac*-Benzyl (1R,6S)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (145)

To a suspension of benzyl 3,6-dihydropyridine-1-carboxylate (8 g, 36.8 mmol) in dry DCM (80 mL) at 0°C under N₂ was added *m*-CPBA (9.53 g, 44.2 mmol, 85%). The reaction mixture stirred at r.t. for 12 hrs. The reaction mixture was diluted with DCM (20 mL) and washed with saturated aqueous Na₂S₂O₃ (2 x 80 mL). The organic layers were combined, washed with saturated aqueous NaHCO₃ (2 x 80 mL), brine (80 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated to afford *rac*-benzyl (1R,6S)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 145 as yellow oil. Material was used in the next step without purification. ¹H NMR (400 MHz, CDCl₃) δ 7.43 - 7.29 (m, 5H), 5.13 (s, 2H), 4.06 - 3.72 (m, 2H), 3.53 (br s, 1H), 3.34 - 3.16 (m, 3H), 2.19 - 1.84 (m, 2H)


Step 2: Benzyl (3S,4S)-4-fluoro-3-hydroxypiperidine-1-carboxylate and benzyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate

A neat mixture of *rac*-benzyl (1R,6S)-7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 145 (8 g, 34.3 mmol) and Et₃N·3HF (5.5 g, 34.3 mmol) stirred at 100 °C for 16 hrs. 20% BF₃·Et₂O in DCM (80 mL, 129.7 mmol) was added to reaction mixture at r.t., then the reaction mixture was diluted with saturated aqueous NaHCO₃ (80 mL) and extracted with DCM twice (40 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude material was purified by reverse phase HPLC (20-50% ACN in water with 0.1% formic acid). The fractions containing pure product were concentrated to remove ACN and lyophilized to afford *rac*-benzyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate INT-146 as yellow oil. LCMS [M+H]⁺: 254.1. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.45 - 7.26 (m, 5H), 5.46 (d, J = 4.4 Hz, 1H), 4.57 - 4.32 (m, 1H), 3.88 - 3.64 (m, 2H), 3.49 - 3.40 (m, 1H), 3.26 - 2.71 (m, 2H), 2.07 - 1.98 (m, 1H), 1.64 - 1.34 (m, 1H).

The racemic mixture of isomers was further separated via chiral SFC [Column: Chiralpak AD 250×30mm I.D; CO₂ Co-solvent 40% Methanol with 0.1% NH₃·H₂O; at 70 g/min at 100 bar, at 25 °C] to afford two enantiomers: INT-146 Peak 1, Rt = 2.1 min, as yellow oil. LCMS [M+H]⁺: 254.1. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 - 7.27 (m, 5H), 5.46 (d, J = 4.8 Hz, 1H), 5.07 (s,

2H), 4.55 - 4.32 (m, 1H), 3.85 - 3.62 (m, 2H), 3.56 - 3.42 (m, 1H), 3.16 - 2.84 (m, 2H), 2.05 - 1.92 (m, 1H), 1.54 - 1.51 (m, 1H); **INT-146 Peak 2**, Rt = 3.9 min, as yellow oil. LCMS [M+H]⁺: 254.1. ¹H NMR (400 MHz, DMSO-d₆) δ 7.42 - 7.27 (m, 5H), 5.46 (d, J = 4.8 Hz, 1H), 5.07 (s, 2H), 4.55 - 4.32 (m, 1H), 3.85 - 3.62 (m, 2H), 3.56 - 3.42 (m, 1H), 3.16 - 2.84 (m, 2H), 2.05 - 1.92 (m, 1H), 1.54 - 1.51 (m, 1H). The absolute stereochemistry of the two enantiomers corresponding to the two product peaks was not determined.

Preparation of Benzyl (3*S*,4*R*)-4-fluoro-3-hydroxypiperidine-1-carboxylate and benzyl (3*R*,4*S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate (INT-155)




Prepared to this point
according to WO2010016005

10

The enantiomeric mixture of **INT-155** (900 mg, 3.55 mmol) was separated via chiral SFC [Column: 250 mm x 30 mm, 5 μm DAICEL CHIRALPAK AD-H; CO₂ Co-solvent 30% MeOH + 0.1% NH₃·H₂O; at 60 g/min at 100 bar] to afford two enantiomers. **INT-155 Peak 1**, Rt = 5.76 min, as colorless oil; LCMS [M+23]⁺: 276.2. ¹H NMR (400 MHz, CDCl₃) δ 7.46 - 7.27 (m, 5H), 5.15 (s, 2H), 4.94 - 4.70 (m, 1H), 3.88 - 3.57 (m, 3H), 3.49 - 3.36 (m, 2H), 2.26 - 2.04 (m, 2H), 1.89 - 1.68 (m, 1H). ¹⁹F NMR (377 MHz, CDCl₃) δ -201.8. **INT-155 Peak 2**, Rt = 6.65 mins, as brown oil. LCMS [M+23]⁺: 276.2. ¹H NMR (400 MHz, CDCl₃) δ 7.52 - 7.29 (m, 5H), 5.16 (s, 2H), 4.93 - 4.74 (m, 1H), 3.95 - 3.57 (m, 3H), 3.50 - 3.35 (m, 2H), 2.23 - 2.04 (m, 2H), 1.94 - 1.68 (m, 1H). ¹⁹F NMR (377 MHz, CDCl₃) δ -201.8. The absolute stereochemistry of the two enantiomers corresponding to the two product peaks was not determined.

20

Preparation of (3*R*,5*S*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine (INT-164), (3*R*,5*R*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine (INT-165), and (2*S*,4*R*)-1-benzyl-4-(benzyloxy)-2-(fluoromethyl)pyrrolidine (165)



synthesized to
this point
according to
US2017/217970

(bis-(2-methoxyethyl)amino)sulfur trifluoride (11.32 mL, 61.39 mmol) was added to a solution of ((4*R*)-1-benzyl-4-(benzyloxy)pyrrolidin-2-yl)methanol (17.9 g, 60.2 mmol) in THF (180 mL) at 0 °C. The reaction mixture was warmed to r.t. and stirred for 3 hrs. The mixture was diluted with EtOAc (200 mL) and washed with brine (3 x 50 mL), dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by silica gel chromatography (0-40% EtOAc in

25


petroleum ether) and the fractions containing product were concentrated. Then resulting material was further purified by reverse phase HPLC (60-80% ACN in water with 0.05% ammonia hydroxide as modifier). Fractions containing pure product were concentrated to afford (3*R*,5*S*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-164 as light yellow oil, (3*R*,5*R*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-165 as light yellow oil, and (2*S*,4*R*)-1-benzyl-4-(benzyloxy)-2-(fluoromethyl)pyrrolidine 165 as light yellow oil.

(3*R*,5*S*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-164: LCMS [M+H]⁺: 300.4. ¹H NMR (400 MHz, CDCl₃) δ 7.40 - 7.27 (m, 10H), 4.73 - 4.44 (m, 3H), 3.62 - 3.59 (m, 3H), 3.10 (br s, 2H), 2.63 - 2.50 (m, 1H), 2.23 - 1.90 (m, 2H), 1.53 - 1.41 (m, 1H). ¹⁹F NMR (377 MHz, CDCl₃) δ -183.33.

(3*R*,5*R*)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-165: LCMS [M+H]⁺: 300.4. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (s, 10H), 5.01 - 4.81 (m, 1H), 4.54 (d, *J* = 1.6 Hz, 2H), 3.92 - 3.85 (m, 1H), 3.70 - 3.59 (m, 2H), 2.98 - 2.80 (m, 2H), 2.54 - 2.35 (m, 1H), 2.31 - 2.16 (m, 2H), 1.76 - 1.60 (m, 1H). ¹⁹F NMR (377 MHz, CDCl₃) δ -182.2.


(2*S*,4*R*)-1-benzyl-4-(benzyloxy)-2-(fluoromethyl)pyrrolidine 165: LCMS [M+H]⁺: 300.3. ¹H NMR (400 MHz, CDCl₃) δ 7.41 - 7.28 (m, 10H), 4.67 - 4.34 (m, 4H), 4.17 - 4.00 (m, 2H), 3.71 - 3.44 (m, 1H), 3.15 - 3.11 (m, 1H), 3.08 - 2.87 (m, 1H), 2.54 - 2.36 (m, 1H), 2.27 - 2.23 (m, 1H), 1.89 - 1.75 (m, 1H).

Preparation of tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate and tert-butyl 5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (INT-174A and INT-174B).




To a solution of tert-butyl 2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate (2 g, 10.24 mmol) in 50 ml anhydrous THF, was cooled to 0 °C in an ice water bath. A 1 M solution of BH₃·THF complex (21.0 mL, 20.5 mmol) was added, and stirring was continued at 0 °C for 2 hrs. The excess BH₃ was destroyed by careful addition of THF-H₂O (a 1:1 mixture, 100 mL). A 3 M NaOH solution (3 mL, 8 mmol) was added followed by dropwise addition of 50 % hydrogen peroxide (3.0 mL, 44 mmol), and the mixture was kept at 35-40 °C for 1.5 hr with stirring. After cooling to r.t., potassium carbonate (0.92 g, 6.7 mmol) was added, and the THF was removed under reduced pressure. The remaining solution was poured into an erlenmeyer flask containing methylene chloride and water. The organic layer was extracted and the aqueous layer was back extracted with more DCM. The combined organic extracts were poured through a phase separator, and concentrated to give a regioisomeric mixture of products INT-174A and INT-174B as a colorless oil. This material was taken on crude through to the next step without further purification.

Preparation of Final Compounds

Example 1: 3-(5-(((R)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-3)

- 5 In a reaction vial with stir bar, 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 (18.6 mg, 0.054 mmol) and bromoethane (7.9 mg, 0.072 mmol) were dissolved in ACN (0.5 mL). DIPEA (0.03 mL, 0.2 mmol) was added and the reaction stirred at r.t. for 1 hr then heated to 60 °C overnight. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers
- 10 were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in dichloromethane) to afford 3-(5-(((R)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-3 as a white solid. LCMS [M+H]⁺: 372.6. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.1 Hz, 1H), 7.05 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J*
- 15 = 13.3, 5.1 Hz, 1H), 4.50 (dt, *J* = 8.8, 4.6 Hz, 1H), 4.43 - 4.22 (m, 2H), 3.03 - 2.81 (m, 2H), 2.72 - 2.55 (m, 2H), 2.43 - 2.31 (m, 3H), 2.15 - 1.94 (m, 4H), 1.78 - 1.67 (m, 1H), 1.53 (dd, *J* = 13.3, 10.0 Hz, 1H), 1.44 - 1.31 (m, 1H), 0.99 (t, *J* = 7.2 Hz, 3H).

Example 2: 3-(5-(((S)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-6)**Step 1: Tert-butyl (3S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate (4)**

- To a 40 mL vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (220.2 mg, 0.486 mmol), tert-butyl (S)-3-hydroxypiperidine-1-carboxylate (116.4 mg, 0.578 mmol), dtbbpy (9.5 mg, 0.035 mmol),
- 25 NiCl₂(glyme) (9.3 mg, 0.042 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (5.7 mg, 5.1 μmol) were

added. The reaction was evacuated and backfilled with nitrogen three times. ACN (2.5 mL) was added followed by 2,2,6,6-tetramethylpiperidine (0.09 mL, 0.5 mmol). The reaction was placed in PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl (3S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate **4** as a yellow foam. LCMS [M+H-156.3]⁺: 418.2.


Step 2: 3-(1-oxo-5-(((S)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione (5)

Compound **5** was made according to General Method VII starting from tert-butyl (3S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)piperidine-1-carboxylate **4** (315.6 mg, 0.550 mmol). The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% EtOH:Et₃N (v/v = 100:1) in dichloromethane) to afford 3-(1-oxo-5-(((S)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **5** as a slightly off-white solid. LCMS [M+H]⁺: 344.6. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.20 (d, *J* = 2.2 Hz, 1H), 7.07 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.48 (s, 1H), 4.43 - 4.22 (m, 2H), 3.17 (d, *J* = 12.4 Hz, 1H), 2.98 - 2.80 (m, 2H), 2.75 - 2.55 (m, 4H), 2.38 (dd, *J* = 13.1, 4.5 Hz, 1H), 2.08 - 1.92 (m, 2H), 1.78 - 1.67 (m, 1H), 1.67 - 1.44 (m, 2H).

Step 3: 3-(5-(((S)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-6)


In a reaction vial with stir bar, 3-(1-oxo-5-(((S)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **5** (56.9 mg, 0.166 mmol) and bromoethane (22.3 mg, 0.205 mmol) were dissolved in ACN (1.0 mL). DIPEA (0.10 mL, 0.573 mmol) was added and the reaction stirred at 60 °C for 24 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in dichloromethane) to afford 3-(5-(((S)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-6** as an off-white solid. LCMS [M+H]⁺: 372.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.05 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.50 (tt, *J* = 8.5, 3.9 Hz, 1H), 4.44 - 4.17 (m, 2H), 3.02 - 2.82 (m, 2H), 2.70 - 2.55 (m, 2H), 2.43 - 2.30 (m, 3H), 2.16 - 1.93 (m, 4H), 1.78 - 1.67 (m, 1H), 1.66 - 1.47 (m, 1H), 1.44 - 1.31 (m, 1H), 0.99 (t, *J* = 7.1 Hz, 3H).

Example 3: 3-(5-(((R)-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-7)




Compound **I-7** was made according to General Method X starting from 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (61 mg, 0.18 mmol) and isobutanal (0.024 mL, 0.27 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((R)-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-7** as a white solid. LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.54 (d, *J* = 8.3 Hz, 1H), 7.11 (d, *J* = 2.2 Hz, 1H), 6.97 (dd, *J* = 8.3, 2.2 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.2 Hz, 1H), 4.48 - 4.37 (m, 1H), 4.31 (d, *J* = 17.1 Hz, 1H), 4.18 (d, *J* = 17.2 Hz, 1H), 2.89 - 2.78 (m, 2H), 2.58 - 2.48 (m, 2H), 2.37 - 2.25 (m, 1H), 2.06 - 1.86 (m, 6H), 1.72 - 1.60 (m, 2H), 1.55 - 1.41 (m, 1H), 1.35 - 1.24 (m, 1H), 0.77 (t, *J* = 5.9 Hz, 6H).

Example 4: 3-(5-(((R)-1-(oxetan-3-ylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-8)



Compound **I-8** was made according to General Method III starting from 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (72 mg, 0.21 mmol) and oxetane-3-carbaldehyde (27 mg, 0.32 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((R)-1-(oxetan-3-ylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-8** as a white solid. LCMS [M+H]⁺: 414.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.53 (d, *J* = 8.4 Hz, 1H), 7.11 (d, *J* = 2.2 Hz, 1H), 6.97 (dd, *J* = 8.4, 2.1 Hz, 1H), 5.00 (dd, *J* = 13.4, 5.1 Hz, 1H), 4.60 - 4.49 (m, 2H), 4.44 - 4.28 (m, 2H), 4.23 - 4.13 (m, 3H), 3.23 - 3.21 (m, 1H), 3.15 - 3.04 (m, 1H), 2.90 - 2.78 (m, 2H), 2.62 - 2.56 (m, 2H), 2.55 - 2.49 (m, 1H), 2.36 - 2.28 (m, 1H), 2.10 - 2.02 (m, 1H), 2.00 - 1.87 (m, 3H), 1.68 - 1.60 (m, 1H), 1.51 - 1.38 (m, 1H), 1.34 - 1.23 (m, 1H).

Example 5: 3-(5-(((R)-1-((4,4-difluorocyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-9)




Compound **I-9** was made according to General Method III starting from 1-

- 5 (hydroxymethyl)-3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (60 mg, 0.18 mmol) and 4,4-difluorocyclohexane-1-carbaldehyde (39 mg, 0.26 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((R)-1-((4,4-difluorocyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-9** as a white solid. LCMS [M+H]⁺: 476.4. ¹H NMR (400
- 10 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.61 (d, *J* = 8.3 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.05 (dt, *J* = 8.3, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.56 - 4.46 (m, 1H), 4.39 (dd, *J* = 17.5, 2.4 Hz, 1H), 4.26 (d, *J* = 17.1 Hz, 1H), 2.98 - 2.86 (m, 2H), 2.66 - 2.55 (m, 2H), 2.45 - 2.34 (m, 1H), 2.20 - 1.92 (m, 8H), 1.84 - 1.50 (m, 7H), 1.44 - 1.33 (m, 1H), 1.15 - 1.02 (m, 2H).

Example 6: 3-(5-(((R)-1-(cyclohexylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-


- 15 **yl)piperidine-2,6-dione (I-10)**



Compound **I-10** was made according to General Method III starting from 1-

- (hydroxymethyl)-3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (60 mg, 0.18 mmol) and cyclohexanecarboxaldehyde (0.032 mL, 0.26 mmol). The crude
- 20 material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((R)-1-(cyclohexylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-10** as a white solid. LCMS [M+H]⁺: 440.2. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.53 (d, *J* = 8.3 Hz, 1H), 7.11 (d, *J* = 2.2 Hz, 1H), 6.97 (dt, *J* = 8.5, 1.6 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.2 Hz, 1H), 4.49 - 4.39 (m, 1H), 4.31 (dd, *J* = 17.1, 3.4 Hz, 1H), 4.18
- 25 (dd, *J* = 17.1, 3.0 Hz, 1H), 2.90 - 2.78 (m, 2H), 2.58 - 2.48 (m, 2H), 2.38 - 2.24 (m, 1H), 2.06 - 1.87 (m, 6H), 1.69 - 1.25 (m, 9H), 1.17 - 1.00 (m, 3H), 0.79 - 0.65 (m, 2H).


Example 7: 3-(5-(((R)-1-(cyclobutylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-11)



Compound I-9 was made according to General Method III starting from 1-


- 5 (hydroxymethyl)-3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 (68 mg, 0.20 mmol) and cyclobutanecarbaldehyde (25 mg, 0.30 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford the product. The material was further purified by basic reverse phase HPLC (25-50% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior
- 10 to sample collection. Fractions containing desired product were combined and lyophilized to afford formate salt of 3-(5-(((R)-1-(cyclobutylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-11 as a white solid. LCMS [M+H]⁺: 412.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 8.14 (s, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.11 (d, J = 2.2 Hz, 1H), 6.97 (dd, J = 8.3, 2.3 Hz, 1H), 5.00 (dd, J = 13.3, 5.1 Hz, 1H), 4.45 - 4.35 (m, 1H), 4.31 (d, J = 17.4 Hz, 1H),
- 15 4.18 (d, J = 17.1 Hz, 1H), 2.90 - 2.77 (m, 2H), 2.58 - 2.47 (m, 2H), 2.41 - 2.34 (m, 1H), 2.34 - 2.24 (m, 3H), 2.05 - 1.84 (m, 6H), 1.82 - 1.39 (m, 6H), 1.34 - 1.20 (m, 1H).

Example 8: 3-(1-oxo-5-(((R)-1-propylpiperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione (I-12)




- 20 Compound I-12 was made according to General Method III starting from 1-(hydroxymethyl)-3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 (68 mg, 0.20 mmol) and propanal (0.021 mL, 0.30 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(1-oxo-5-(((R)-1-propylpiperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione I-12 as a white solid.
- 25 LCMS [M+H]⁺: 386.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 2.2 Hz, 1H), 6.97 (dd, J = 8.3, 2.2 Hz, 1H), 5.00 (dd, J = 13.3, 5.2 Hz, 1H), 4.47 - 4.36 (m, 1H), 4.31 (d, J = 17.4 Hz, 1H), 4.18 (d, J = 17.2 Hz, 1H), 2.93 - 2.78 (m, 2H), 2.59 - 2.48 (m, 2H), 2.37 - 2.16 (m, 3H), 2.07 - 1.87 (m, 4H), 1.70 - 1.61 (m, 1H), 1.54 - 1.42 (m, 1H), 1.41 - 1.25 (m, 3H), 0.76 (t, J = 7.3 Hz, 3H).

Example 9: 3-(5-(((R)-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-13)



3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol) was suspended in DMA (1.75 mL). K₂CO₃ (36 mg, 0.26 mmol) was added and the reaction was evacuated and backfilled with nitrogen three times. 2-iodopropane (0.087 mL, 0.87 mmol) was added and the reaction stirred at 60 °C for 1 hr under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford product 3-(5-(((R)-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-13 as a white solid. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.20 (d, *J* = 2.3 Hz, 1H), 7.05 (dd, *J* = 8.4, 2.3 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.0 Hz, 1H), 4.56 - 4.44 (m, 1H), 4.39 (d, *J* = 17.1 Hz, 1H), 4.26 (d, *J* = 17.1 Hz, 1H), 3.31 - 3.27 (m, 1H), 3.01 - 2.84 (m, 2H), 2.65 - 2.56 (m, 1H), 2.44 - 2.35 (m, 1H), 2.31 - 2.24 (m, 2H), 2.18 - 1.94 (m, 4H), 1.79 - 1.71 (m, 1H), 1.62 - 1.52 (m, 1H), 1.49 - 1.32 (m, 3H), 0.84 (t, *J* = 7.3 Hz, 3H).


Example 10: 3-(1-oxo-5-(((R)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione (I-14)



3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol) and 4-iodotetrahydro-2H-pyran (0.105 mL, 0.874 mmol) were suspended in DMA (1.75 mL). K₂CO₃ (36 mg, 0.26 mmol) was added and the reaction was evacuated and backfilled with nitrogen 3 times. The reaction stirred at 100 °C for 4 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(1-oxo-5-(((R)-1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione I-14 as a white solid. LCMS [M+H]⁺: 428.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.61 (d, *J* = 8.3 Hz, 1H), 7.19 (d, *J* = 2.4


Hz, 1H), 7.05 (dd, $J = 8.4, 2.2$ Hz, 1H), 5.07 (dd, $J = 13.3, 5.0$ Hz, 1H), 4.53 - 4.36 (m, 2H), 4.26 (d, $J = 17.5$ Hz, 1H), 3.87 (dd, $J = 11.8, 3.8$ Hz, 2H), 3.30 - 3.21 (m, 3H), 3.14 - 3.02 (m, 1H), 2.97 - 2.84 (m, 1H), 2.77 - 2.71 (m, 1H), 2.64 - 2.56 (m, 1H), 2.44 - 2.36 (m, 1H), 2.31 - 2.17 (m, 2H), 2.10 - 1.95 (m, 2H), 1.79 - 1.70 (m, 1H), 1.68 - 1.59 (m, 2H), 1.56 - 1.31 (m, 4H).

5 Example 11: 3-(5-(((*R*)-1-(2-oxaspiro[3.3]heptan-6-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-15)



3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol) and 6-iodo-2-oxaspiro[3.3]heptane (196 mg, 0.87 mmol) were suspended in DMA (1.75 mL). K₂CO₃ (36 mg, 0.26 mmol) was added and the reaction was evacuated and backfilled with nitrogen 3 times. The reaction stirred at 60 °C for 1 hr then at 100 °C for 2 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford the product. Material was further purified by reverse phase basic HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined, concentrated and lyophilized to afford formate salt of 3-(5-(((*R*)-1-(2-oxaspiro[3.3]heptan-6-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-15 as a white solid. LCMS [M+H]⁺: 440.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.25 (s, 2H), 7.54 (d, $J = 8.4$ Hz, 1H), 7.11 (d, $J = 2.2$ Hz, 1H), 6.97 (dd, $J = 8.4, 2.2$ Hz, 1H), 5.00 (dd, $J = 13.3, 5.1$ Hz, 1H), 4.48 (s, 2H), 4.45 - 4.27 (m, 5H), 4.18 (d, $J = 17.1$ Hz, 1H), 2.89 - 2.72 (m, 2H), 2.56 - 2.46 (m, 2H), 2.36 - 2.17 (m, 3H), 1.99 - 1.74 (m, 6H), 1.68 - 1.61 (m, 1H), 1.48 - 1.38 (m, 1H), 1.36 - 1.25 (m, 1H).


25 Example 12: 3-(5-(((*R*)-1-(oxetan-3-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-16)



3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol) and 3-iodooxetane (0.077 mL, 0.87 mmol) were suspended in DMA (1.75 mL). K₂CO₃ (36 mg, 0.26 mmol) was added and the reaction was evacuated and backfilled with nitrogen 3 times. The reaction stirred at 100 °C for a total of 6 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with


4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined, concentrated, and further purified by reverse phase basic HPLC (10-30 % ACN in H₂O with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt of 3-(5-(((R)-1-(oxetan-3-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-16** as a white solid. LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.78 (s, 1H), 8.25 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.15 (d, *J* = 2.3 Hz, 1H), 6.99 (dd, *J* = 8.7, 2.2 Hz, 1H), 5.00 (dd, *J* = 13.4, 5.1 Hz, 1H), 4.51 - 4.42 (m, 3H), 4.39 (td, *J* = 6.0, 2.2 Hz, 1H), 4.36 - 4.27 (m, 2H), 4.19 (dd, *J* = 17.5, 2.1 Hz, 1H), 3.39 (p, *J* = 6.3 Hz, 2H), 2.90 - 2.71 (m, 2H), 2.56 - 2.45 (m, 1H), 2.37 - 2.23 (m, 1H), 2.02 - 1.84 (m, 4H), 1.72 - 1.62 (m, 1H), 1.56 - 1.44 (m, 1H), 1.41 - 1.29 (m, 1H).

Example 13: 3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-17**)**




To a solution of 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (100 mg, 0.29 mmol) in EtOH (1.5 mL), sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added followed by cyclopropanecarbaldehyde (0.031 mg, 0.44 mmol). The reaction stirred at r.t. for 1 hr. ISOLUTE® (HM-N Part No. 9800-5000) was added to the reaction and concentrated. The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) and concentrated. The product was diluted with 1:1 MeCN:water and lyophilized to afford 3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-17**. LCMS [M+H]⁺: 398.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.05 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.57 - 4.44 (m, 1H), 4.43 - 4.18 (m, 2H), 3.08 (d, *J* = 11.0 Hz, 1H), 2.90 (ddd, *J* = 17.3, 13.6, 5.4 Hz, 1H), 2.76 (d, *J* = 11.2 Hz, 1H), 2.63 - 2.54 (m, 1H), 2.44 - 2.29 (m, 1H), 2.23 (d, *J* = 6.5 Hz, 2H), 2.19 - 1.92 (m, 3H), 1.77 - 1.67 (m, 1H), 1.64 - 1.48 (m, 1H), 1.36 (q, *J* = 11.6, 11.0 Hz, 1H), 0.95 (m, 1H), 0.88 - 0.75 (m, 1H), 0.48 - 0.38 (m, 2H), 0.05 (d, *J* = 4.9 Hz, 2H).

Example 14: 3-(5-(((R)-1-((1-ethyl-1H-pyrazol-4-yl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-18)



To a solution of 3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isobenzofuran-1(3H)-one INT-2 (100 mg, 0.29 mmol) in EtOH (1.5 mL), sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added followed by the addition of 1-ethyl-1H-pyrazole-4-carbaldehyde (54.2 mg, 0.44 mmol) in EtOH (0.5 mL). The reaction stirred at r.t. for a total of 48 hrs. ISOLUTE® (HM-N Part No. 9800-5000) was added to the reaction and the reaction was concentrated. The dry loaded crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford 3-(5-(((R)-1-((1-ethyl-1H-pyrazol-4-yl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-18 as a colorless oil. LCMS [M+H]⁺: 452.5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.65 - 7.54 (m, 2H), 7.29 (d, *J* = 1.5 Hz, 1H), 7.17 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.3, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.50 (dt, *J* = 8.8, 4.6 Hz, 1H), 4.43 - 4.18 (m, 2H), 4.06 (q, *J* = 7.3 Hz, 2H), 3.40 (s, 2H), 2.91 (ddd, *J* = 17.2, 13.6, 5.2 Hz, 2H), 2.67 - 2.55 (m, 2H), 2.46 - 2.29 (m, 1H), 2.15 - 1.92 (m, 4H), 1.72 (dt, *J* = 8.5, 4.3 Hz, 1H), 1.55 (ddt, *J* = 13.5, 6.8, 3.6 Hz, 1H), 1.32 (m, 4H).

Example 15: 3-(5-(((R)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-23)



20 Step 1: (R)-5-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one (21)

To a solution of (R)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one INT-20 (164 mg, 0.63 mmol) in DMF (4.2 mL) was added sodium triacetoxyborohydride (269 mg, 1.3 mmol). Acetaldehyde (54 μL, 0.951 mmol) was added. The reaction was stirred at r.t. for 1 hr. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted

with 4:1 DCM: iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford (*R*)-5-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **21** as a light yellow oil. LCMS

5 [M+H]⁺: 288.1. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 8.5 Hz, 1H), 6.96 (dd, *J* = 8.5, 2.2 Hz, 1H), 6.88 (d, *J* = 2.0 Hz, 1H), 5.15 (s, 2H), 4.13 (s, 1H), 2.75 - 2.66 (m, 1H), 2.58 - 2.34 (m, 5H), 1.72 - 1.43 (m, 2H), 0.99 (t, *J* = 7.2 Hz, 3H), 0.68 - 0.60 (m, 1H), 0.52 - 0.43 (m, 1H), 0.33 - 0.24 (m, 2H).


Step 2: Ethyl (*R*)-2-(chloromethyl)-4-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate (22**)**

10 To a solution of (*R*)-5-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **21** (163 mg, 0.57 mmol) in dichloroethane (2.8 mL) and ethanol (2.8 mL) in a 25 mL 2 neck round bottom flask stirred at 70 °C was added thionyl chloride (0.50 mL, 6.8 mmol) dropwise. The reaction stirred at 70 °C overnight. The reaction mixture was cooled to r.t., diluted with water, and quenched with saturated sodium bicarbonate. The reaction mixture was extracted
15 with ethyl acetate three times. The organic layers were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl (*R*)-2-(chloromethyl)-4-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate **22** as a light yellow oil. LCMS [M+H]⁺: 352.2.

Step 3: 3-(5-(((*R*)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (1-23**).**

In a microwave vial, 3-aminopiperidine-2,6-dione hydrochloride (77 mg, 0.47 mmol) was dissolved in DMF (0.94 mL). DIPEA (0.21 mL, 1.2 mmol) was added and the reaction was evacuated and backfilled with nitrogen three times. The reaction stirred at r.t. for 15 minutes. Then ethyl (*R*)-2-(chloromethyl)-4-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate **22** (82.4 mg,
25 0.23 mmol) dissolved in DMF (1.4 mL) was added and the reaction was evacuated and backfilled with nitrogen three times. The reaction stirred at 85 °C overnight then microwaved at 150 °C for 2 hrs. The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined,
30 concentrated and lyophilized to afford 3-(5-(((*R*)-6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **1-23** as a cream solid. LCMS [M+H]⁺: 398.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 7.52 (d, *J* = 8.5 Hz, 1H), 7.09 (d, *J* = 2.2 Hz, 1H), 6.96 (dd, *J* = 8.4, 2.3 Hz, 1H), 4.99 (dd, *J* = 13.3, 5.0 Hz, 1H), 4.30 (dd, *J* = 17.2, 6.8 Hz, 1H), 4.17 (dd, *J* = 17.1, 6.8 Hz, 1H), 4.06 (s, 1H), 2.83 (ddd, *J* = 17.2, 13.6, 5.4 Hz, 1H), 2.68 - 2.45 (m, 4H), 2.37 - 2.23 (m, 4H), 1.96 - 1.86 (m, 1H), 1.84 - 1.68 (m, 1H), 1.25 - 1.12 (m, 1H), 0.87 (td, *J* = 7.2, 1.7 Hz, 3H), 0.57 - 0.48 (m, 1H), 0.48 - 0.38 (m, 1H), 0.31 - 0.20 (m, 2H).

Example 16: 3-(5-(((*R*)-6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-26)



Step 1: (*R*)-5-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one (24)

Compound **24** was made according to General Method III starting from (*R*)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **INT-20** (90 mg, 0.35 mmol) and isobutanal (48 μ L, 0.52 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford (*R*)-5-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **24** as a clear oil. LCMS [M+H]⁺: 316.2.

Step 2: Ethyl (*R*)-2-(chloromethyl)-4-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate (25)


Compound **25** was made according to General Method IV starting from (*R*)-5-((6-ethyl-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **24** (114 mg, 0.36 mmol). Crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford (*R*)-2-(chloromethyl)-4-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate **25** as a light brown oil. LCMS [M+H]⁺: 380.3.

Step 3: 3-(5-(((*R*)-6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-26)

Compound **I-26** was made according to General Method V starting from ethyl (*R*)-2-(chloromethyl)-4-((6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)benzoate **25** (57.5 mg, 0.15 mmol). The reaction was concentrated and purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford the product. Material was further purified by a second silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-6-isobutyl-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-26** as a white solid. LCMS [M+H]⁺: 426.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.60 (d, *J* = 8.3 Hz, 1H), 7.15 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.7, 2.1 Hz, 1H), 5.07 (dd, *J* = 13.1, 5.1 Hz, 1H), 4.37 (dd, *J* = 17.2, 8.9 Hz, 1H),

4.25 (dd, $J = 17.2, 9.1$ Hz, 1H), 4.14 - 4.00 (m, 1H), 2.91 (ddd, $J = 17.4, 13.6, 5.4$ Hz, 1H), 2.73 - 2.68 (m, 1H), 2.64 - 2.56 (m, 1H), 2.49 - 2.29 (m, 4H), 2.10 - 1.85 (m, 4H), 1.72 - 1.59 (m, 1H), 1.27 - 1.15 (m, 1H), 0.84 - 0.74 (m, 6H), 0.64 - 0.57 (m, 1H), 0.54 - 0.48 (m, 1H), 0.39 - 0.29 (m, 2H).

5 **Example 17: 3-(5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisobenzofuran-2-yl)piperidine-2,6-dione**



Step 1: 5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one (28)

- 10 Compound **28** was made according to General Method IX starting from (*R*)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **INT-20** (218 mg, 0.84 mmol) and (*R*)-sec-butyl methanesulfonate **INT-27** (192 mg, 1.26 mmol). Additional (*R*)-sec-butyl methanesulfonate **INT-27** (192 mg, 1.26 mmol) and DIPEA (293 μ L, 1.68 mmol) were added. The reaction was evacuated and backfilled with nitrogen three times. The reaction stirred at 140 °C for 6 hrs
- 15 under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one **28** as light orange oil and recovered starting material (*R*)-5-((6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3H)-one as a light orange oil. LCMS $[M+H]^+$: 316.2. ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, $J = 8.5$ Hz, 1H), 7.03 (d, $J = 8.7$ Hz, 1H), 6.94 (s, 1H), 5.24 (s, 2H), 4.26 - 4.14 (m, 1H), 2.91 - 2.76 (m, 1H), 2.72 - 2.48 (m, 3H), 1.74 - 1.43 (m, 4H), 1.28 (s, 1H), 0.97 (d, $J = 6.5$ Hz, 3H), 0.89 (dt, $J = 14.1, 7.4$ Hz, 3H), 0.77 - 0.72 (m, 1H), 0.58 - 0.52 (m, 1H), 0.40 - 0.30 (m, 2H).
- 25


Step 2: Ethyl 4-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-2-(chloromethyl)benzoate (29)

Compound **29** was made according to General Method IV starting from 5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)isobenzofuran-1(3*H*)-one **28** (98.8 mg, 0.31 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl 4-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-2-(chloromethyl)benzoate **29** as a light orange oil. LCMS $[M+H]^+$: 380.3.

Step 3: 3-(5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-30)

Compound **I-30** was made according to General Method V starting from ethyl 4-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-2-(chloromethyl)benzoate **29** (88.3 mg, 0.23 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrated. The material was further purified by basic reverse phase HPLC (35-60% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt 3-(5-(((*R*)-6-((*S*)-sec-butyl)-6-azaspiro[2.5]octan-4-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-30** as a white solid. LCMS $[M+H]^+$: 426.5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 8.10 (s, 1H), 7.52 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.06 (d, *J* = 2.2 Hz, 1H), 6.94 (dd, *J* = 8.5, 2.2 Hz, 1H), 4.99 (dd, *J* = 13.4, 5.2 Hz, 1H), 4.35 - 4.24 (m, 1H), 4.24 - 4.12 (m, 1H), 4.09 - 3.98 (m, 1H), 3.25 (s, 3H), 2.90 - 2.74 (m, 1H), 2.70 - 2.58 (m, 1H), 2.56 - 2.48 (m, 2H), 2.39 - 2.23 (m, 2H), 1.95 - 1.85 (m, 1H), 1.81 - 1.61 (m, 1H), 1.29 - 1.08 (m, 2H), 0.84 - 0.72 (m, 4H), 0.69 (td, *J* = 7.4, 3.5 Hz, 2H), 0.56 - 0.48 (m, 1H), 0.46 - 0.38 (m, 1H), 0.30 - 0.20 (m, 2H).

Example 18: Diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-35)



Step 1: Single Enantiomer of Ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate (34)


Compound **34** was made according to General Method IV starting from 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3*H*)-one **INT-33 peak 1** (20.88 mg, 0.073 mmol).

Crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate **34** as an orange oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 352.4.

Step 2: Diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-35)

Compound **I-35** was made according to General Method V starting from single enantiomer of ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate **34** (25.7 mg, 0.073 mmol). The reaction was concentrated and purified by reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior to sample collection. Fractions containing desired product were lyophilized to afford formate salt of diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-35** as a blueish solid. LCMS [M+H]⁺: 398.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.97 (s, 1H), 8.26 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.0 Hz, 1H), 4.67 - 4.53 (m, 1H), 4.39 (d, *J* = 17.1 Hz, 1H), 4.26 (d, *J* = 17.1 Hz, 1H), 3.12 (d, *J* = 10.7 Hz, 1H), 2.91 (ddd, *J* = 17.4, 13.6, 5.4 Hz, 1H), 2.64 - 2.55 (m, 1H), 2.43 - 2.33 (m, 3H), 2.24 (d, *J* = 11.1 Hz, 1H), 2.12 - 1.93 (m, 3H), 1.69 (dd, *J* = 12.4, 9.6 Hz, 1H), 1.57 - 1.48 (m, 1H), 0.98 (t, *J* = 7.1 Hz, 3H), 0.49 - 0.28 (m, 4H).

Example 19: Diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-37)




Step 1: Single Enantiomer of Ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate (36)

Compound **36** was made according to General Method IV starting from 5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)isobenzofuran-1(3H)-one **INT-33 peak 2** (18.93 mg, 0.066 mmol) to afford single enantiomer of ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate **36** as an orange oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 352.3.

Step 2: Diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-37)

Compound **I-37** was made according to General Method V starting from single enantiomer of ethyl 2-(chloromethyl)-4-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)benzoate **36** (23.2 mg, 0.066 mmol). The reaction was concentrated and purified by reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior to sample collection. Fractions containing desired product were lyophilized to afford formate salt of diastereomers 3-(5-((5-ethyl-5-azaspiro[2.5]octan-7-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-37** as a blueish solid. LCMS [M+H]⁺: 398.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.00 (s, 1H), 8.32 (s, 3H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.4, 2.3 Hz, 1H), 5.07 (dd, *J* = 13.2, 5.1 Hz, 1H), 4.66 - 4.53 (m, 1H), 4.39 (d, *J* = 17.1 Hz, 1H), 4.26 (d, *J* = 17.2 Hz, 1H), 3.15 - 3.10 (m, 1H), 2.96 - 2.85 (m, 1H), 2.63 - 2.56 (m, 1H), 2.41 - 2.32 (m, 3H), 2.24 (d, *J* = 11.2 Hz, 1H), 2.11 - 1.94 (m, 3H), 1.69 (dd, *J* = 12.4, 9.6 Hz, 1H), 1.56 - 1.46 (m, 1H), 0.98 (t, *J* = 7.3 Hz, 3H), 0.48 - 0.25 (m, 4H).

Example 20: 3-(5-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-42**)**



Step 1: Ethyl 2-(chloromethyl)-4-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate (41**)**


Compound **41** was made according to General Method IV starting from 5-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-40 Peak 1** (86.4 mg, 0.32 mmol) to afford ethyl 2-(chloromethyl)-4-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **41** as a brown oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 338.2.

Step 2: 3-(5-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-42**)**

Compound **I-42** was made according to General Method V starting from ethyl 2-(chloromethyl)-4-(((1S*,5S*,6R*)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **41** (107 mg, 0.32 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined,

concentrated and lyophilized to afford 3-(5-(((1*S**,5*S**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-42** as a light blue solid. LCMS [M+H]⁺: 384.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.90 (s, 1H), 7.58 (d, *J* = 8.4 Hz, 1H), 7.13 (s, 1H), 7.06 - 6.96 (m, 1H), 5.01 (dd, *J* = 13.2, 5.0 Hz, 1H), 4.51 (s, 1H), 4.33 (dd, *J* = 17.2, 2.9 Hz, 1H), 4.20 (d, *J* = 17.3 Hz, 1H), 2.90 - 2.70 (m, 3H), 2.56 - 2.48 (m, 1H), 2.39 - 2.19 (m, 3H), 2.00 - 1.85 (m, 2H), 1.21 - 0.83 (m, 6H), 0.59 (s, 1H), 0.39 (s, 1H).

Example 21: 3-(5-(((1*R,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-44**)**



10 Step 1: Ethyl 2-(chloromethyl)-4-(((1*R,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate (**43**)**

Compound **43** was made according to General Method IV starting from 5-(((1*R**,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-40 Peak 2** (50.7 mg, 0.19 mmol) to afford ethyl 2-(chloromethyl)-4-(((1*R**,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **43** as a brown oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 338.2.


Step 2: 3-(5-(((1*R,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-44**)**

Compound **I-26** was made according to General Method V starting from ethyl 2-(chloromethyl)-4-(((1*R**,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **43** (62.5 mg, 0.19 mmol). The reaction was concentrated and purified by silica gel chromatography with the crude material passing through a plug of charcoal before going on the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated, lyophilized and further purified by reverse phase HPLC (15-40% ACN in H₂O with 5 mM NH₄OH as modifier) Test tubes contained 3 drops of formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford formate salt of 3-(5-(((1*R**,5*R**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-44**. LCMS [M+H]⁺: 384.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.66 (s, 1H), 8.22 (s, 1H), 7.57 (d, *J* = 8.5 Hz, 1H), 7.12 (d, *J* = 2.1 Hz, 1H), 7.01 (dd, *J* = 8.7, 2.2 Hz, 1H), 5.00 (dd, *J* =

13.4, 5.1 Hz, 1H), 4.55 - 4.45 (m, 1H), 4.33 (dd, $J = 17.1, 2.7$ Hz, 1H), 4.20 (d, $J = 17.2$ Hz, 1H), 2.91 - 2.70 (m, 3H), 2.57 - 2.48 (m, 1H), 2.41 - 2.14 (m, 4H), 2.00 - 1.87 (m, 2H), 1.16 - 1.07 (m, 1H), 0.99 - 0.84 (m, 4H), 0.63 - 0.53 (m, 1H), 0.38 (q, $J = 5.0$ Hz, 1H).

Example 22 3-(5-(((1*S,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-**

5 oxoisoindolin-2-yl)piperidine-2,6-dione (I-49)



Step 1: Ethyl 2-(chloromethyl)-4-(((1*S,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate (48)**


Compound **48** was made according to General Method IV starting from 5-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3*H*)-one **INT-47 Peak 1** (47.2 mg, 0.17 mmol) to afford ethyl 2-(chloromethyl)-4-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **48** as a brown oil. Material was taken through to the next step without purification. LCMS $[M+H]^+$: 338.2.

Step 2: 3-(5-(((1*S,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (I-49)**

Compound **I-49** was made according to General Method V starting from ethyl 2-(chloromethyl)-4-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **48** (58.4 mg, 0.17 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated, lyophilized and further purified by reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford 3-(5-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione **I-49** as a white solid. LCMS $[M+H]^+$: 384.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.49 (s, 1H), 8.23 (s, 1H), 7.53 (d, $J = 8.5$ Hz, 1H), 7.15 (d, $J = 2.2$ Hz, 1H), 7.01 (dd, $J = 8.3, 2.3$ Hz, 1H), 5.00 (dd, $J = 13.3, 5.1$ Hz, 1H), 4.93 - 4.83 (m, 1H), 4.31 (d, $J = 17.1$ Hz, 1H), 4.18 (d, $J = 17.1$ Hz, 1H), 2.91 - 2.77 (m, 1H), 2.63 (d, $J = 11.0$ Hz, 1H), 2.56 - 2.46 (m, 1H), 2.40 - 2.18 (m, 6H), 1.95 - 1.85 (m, 1H),

1.51 - 1.36 (m, 1H), 1.28 - 1.13 (m, 1H), 0.89 (t, $J = 7.1$ Hz, 3H), 0.64 - 0.53 (m, 1H), 0.41 - 0.33 (m, 1H).

Example 23: 3-(5-(((3*R*,6*R*)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-52)



Step 1: Tert-butyl (2*R*,5*R*)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate (50)

Compound **50** was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (500 mg, 1.10 mmol) and tert-butyl (2*R*,5*R*)-5-hydroxy-2-methylpiperidine-1-carboxylate (237 mg, 1.10 mmol). The crude material was purified by silica gel chromatography (0 to 100% EtOAc in Heptane). Fractions containing desired product were combined and concentrated to afford tert-butyl (2*R*,5*R*)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **50** as an off-white solid. LCMS $[M-H]^-$: 586.3.

Step 2: 3-(5-(((3*R*,6*R*)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (51)


Compound **51** was made according to General Method VII starting from tert-butyl (2*R*,5*R*)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **50** (251 mg, 0.43 mmol). The reaction mixture was diluted with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:TFE three times. The organic layers were combined and concentrated. The crude material was purified by silica gel chromatography (0 to 100% EtOH:Et₃N (v/v = 100:1) in EtOAc). Fractions containing desired product were combined and concentrated to afford 3-(5-(((3*R*,6*R*)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **51** as a white solid. LCMS $[M+H]^+$: 358.1.

Step 3: 3-(5-(((3*R*,6*R*)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-52)

To a solution of 3-(5-(((3*R*,6*R*)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **51** (62 mg, 0.17 mmol) and sodium triacetoxyborohydride (55.1 mg, 0.26 mmol) in EtOH (1 mL) was added acetaldehyde (0.015 mL, 0.260 mmol) at 0 °C. The reaction stirred at r.t. overnight. The reaction was concentrated and purified by silica gel chromatography


(0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrated to afford 3-(5-(((3*R*,6*R*)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-52** as an off-white solid. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, CD₂Cl₂) δ 8.19 - 8.05 (m, 1H), 7.70 (d, *J* = 8.3 Hz, 1H), 7.10 - 6.95 (m, 2H), 5.12 (dd, *J* = 13.4, 5.2 Hz, 1H), 4.49 (s, 1H), 4.39 - 4.26 (m, 2H), 3.25 - 3.18 (m, 1H), 2.92 - 2.75 (m, 3H), 2.61 (dq, *J* = 13.8, 7.0 Hz, 1H), 2.40 - 2.12 (m, 5H), 1.81 - 1.75 (m, 1H), 1.52 - 1.38 (m, 2H), 1.11 (d, *J* = 6.2 Hz, 3H), 1.00 (t, *J* = 7.1 Hz, 3H).

Example 24: 3-(5-(((*R*)-1-(but-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-53**)**



In a 2 mL microwave vial, DIPEA (51 uL, 0.291 mmol) and 1-bromo-2-butyne (17 uL, 0.189 mmol) were added to a solution of 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (50 mg, 0.15 mmol) in ACN (1 mL). The reaction stirred at 120 °C for 2 hrs under microwave radiation. The reaction was diluted with acetone and concentrated onto ISOLUTE® (HM-N Part No. 9800-5000). The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product that was a colorless oil that turned to a foam under high vac. The product was lyophilized to afford 3-(5-(((*R*)-1-(but-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-53**. LCMS [M+H]⁺: 396.5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.19 (s, 1H), 7.05 (d, *J* = 8.4 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.53 (s, 1H), 4.42 - 4.17 (m, 2H), 3.25 (s, 2H), 3.18 - 2.83 (m, 2H), 2.68 - 2.53 (m, 2H), 2.43 - 2.15 (m, 3H), 1.98 (d, *J* = 5.0 Hz, 2H), 1.79 (d, *J* = 2.3 Hz, 4H), 1.56 (s, 1H), 1.38 (d, *J* = 10.2 Hz, 1H).


Example 25: 3-(5-(((*R*)-1-(3-cyclopropylprop-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-54**)**



3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (73 mg, 0.21 mmol) was added to a 5 mL microwave vial, followed by the addition of (3-bromoprop-1-yn-1-yl)cyclopropane (44 mg, 0.28 mmol) in ACN (2.1 mL) and DIPEA (74 uL, 0.425 mmol). The reaction stirred at 120 °C for 2 hrs under microwave radiation. The reaction was diluted with DCM and concentrated onto ISOLUTE® (HM-N Part No. 9800-5000). The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product. The product material was lyophilized to afford 3-(5-(((*R*)-1-(3-cyclopropylprop-2-yn-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-54** as a fluffy white solid.


LCMS $[M+H]^+$: 422.4. ^1H NMR (400 MHz, DMSO- d_6) δ 10.97 (s, 1H), 7.61 (dt, J = 8.4, 3.0 Hz, 1H), 7.20 (d, J = 3.8 Hz, 1H), 7.11 - 6.96 (m, 1H), 5.07 (d, J = 13.5 Hz, 1H), 4.53 (s, 1H), 4.45 - 4.15 (m, 2H), 3.23 (s, 2H), 2.91 (m, 2H), 2.59 (d, J = 18.7 Hz, 2H), 2.47 - 2.13 (m, 3H), 1.97 (d, J = 11.1 Hz, 2H), 1.74 (m, 1H), 1.55 (m, 1H), 1.34 (d, J = 41.6 Hz, 2H), 0.74 (dt, J = 8.4, 3.0 Hz, 2H), 0.54 (dq, J = 5.8, 2.9 Hz, 2H).

Example 26: 3-(5-(((*R*)-1-((1*S*,3*S*)-3-ethoxycyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-56)



A 5 mL microwave vial was charged with 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol), (1*r*,3*r*)-3-ethoxycyclobutyl methanesulfonate INT-55 (80 mg, 0.35 mmol), DIPEA (0.06 mL, 0.35 mmol) and ACN (0.5 mL). The reaction stirred at 140 °C for a total of 4 hrs under microwave radiation. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrated to afford 3-((*R*)-1-((1*S*,3*S*)-3-ethoxycyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-56 as a white solid. LCMS $[M+H]^+$: 442.3. ^1H NMR (400 MHz, CD₂Cl₂) δ 8.04 (s, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.12 - 6.95 (m, 2H), 5.19 - 5.07 (m, 1H), 4.71 - 4.43 (m, 1H), 4.43 - 4.25 (m, 2H), 3.74 - 3.62 (m, 1H), 3.37 (q, J = 7.0 Hz, 2H), 3.07 (s, 1H), 2.94 - 2.66 (m, 3H), 2.53 - 2.28 (m, 4H), 2.24 - 2.15 (m, 1H), 2.13 - 1.94 (m, 3H), 1.91 - 1.74 (m, 3H), 1.14 (t, J = 7.0 Hz, 3H).


Example 27: 3-(5-(((*R*)-1-(((1*r*,3*R*)-3-methoxycyclobutyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-59)



Compound I-59 was made according to General Method IX starting from 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione INT-2 (60 mg, 0.18 mmol) and ((1*r*,3*r*)-3-methoxycyclobutyl)methyl methanesulfonate INT-58 (51 mg, 0.26 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-1-(((1*r*,3*R*)-3-methoxycyclobutyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-


dione **I-59** as a white solid. LCMS $[M+H]^+$: 442.5. ^1H NMR (400 MHz, DMSO- d_6) δ 10.97 (s, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 2.2 Hz, 1H), 7.05 (dd, J = 8.4, 2.3 Hz, 1H), 5.08 (dd, J = 13.2, 5.1 Hz, 1H), 4.53 - 4.35 (m, 2H), 4.26 (d, J = 17.0 Hz, 1H), 3.89 (p, J = 6.2 Hz, 1H), 3.30 (s, 1H), 3.09 (s, 3H), 2.97 - 2.85 (m, 2H), 2.65 - 2.56 (m, 2H), 2.38 (q, J = 4.3 Hz, 3H), 2.14 - 1.85 (m, 8H), 1.76 - 1.65 (m, 1H), 1.60 - 1.46 (m, 1H), 1.42 - 1.30 (m, 1H).

Example 28: 3-(5-(((*R*)-1-(7-oxaspiro[3.5]nonan-2-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-61**)**



Compound **I-61** was made according to General Method IX starting from 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (70 mg, 0.20 mmol) and 7-oxaspiro[3.5]nonan-2-yl methanesulfonate **INT-60** (79 mg, 0.36 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-1-(7-oxaspiro[3.5]nonan-2-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-61** as a white solid. LCMS $[M+H]^+$: 468.5. ^1H NMR (400 MHz, DMSO- d_6) δ 10.89 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.98 (dd, J = 8.3, 2.3 Hz, 1H), 5.00 (dd, J = 13.4, 5.2 Hz, 1H), 4.49 - 4.37 (m, 1H), 4.31 (dd, J = 17.2, 2.4 Hz, 1H), 4.25 - 4.13 (m, 1H), 3.46 - 3.39 (m, 2H), 3.39 - 3.32 (m, 2H), 3.23 - 3.21 (m, 1H), 2.89 - 2.76 (m, 2H), 2.69 - 2.62 (m, 1H), 2.56 - 2.48 (m, 2H), 2.37 - 2.28 (m, 1H), 2.01 - 1.74 (m, 6H), 1.70 - 1.62 (m, 1H), 1.52 - 1.28 (m, 7H).


Example 29: 3-(5-(((*R*)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-63**)**



3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (50 mg, 0.15 mmol) and 3,3-difluorocyclobutyl methanesulfonate **INT-62** (54 mg, 0.29 mmol) were added to a 2 mL microwave vial and suspended in ACN (0.73 mL). DIPEA (0.06 mL, 0.34 mmol) was added and the reaction was evacuated and backfilled with nitrogen three times. The reaction was stirred at 140 °C for a total of 14 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-

100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-1-(3,3-difluorocyclobutyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-63** as a white solid. LCMS [M+H]⁺: 434.2. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.14 (d, *J* = 2.1 Hz, 1H), 6.99 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.0 Hz, 1H), 4.50 - 4.37 (m, 1H), 4.31 (dd, *J* = 17.2, 2.6 Hz, 1H), 4.19 (dd, *J* = 17.4, 2.5 Hz, 1H), 2.90 - 2.77 (m, 2H), 2.70 - 2.48 (m, 5H), 2.39 - 2.27 (m, 3H), 2.02 - 1.85 (m, 4H), 1.75 - 1.63 (m, 1H), 1.57 - 1.26 (m, 2H).

Example 30: 3-(5-(((*R*)-1-(((1*r*,4*r*)-4-methoxycyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-65**)**




10

Compound **I-65** was made according to General Method IX starting from 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (60 mg, 0.18 mmol) and ((1*r*,4*r*)-4-methoxycyclohexyl)methyl methanesulfonate **INT-64** (58 mg, 0.26 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-1-(((1*r*,4*r*)-4-methoxycyclohexyl)methyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-65** as a white solid. LCMS [M+H]⁺: 470.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.62 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 2.2 Hz, 1H), 7.05 (dd, *J* = 8.6, 2.2 Hz, 1H), 5.08 (dd, *J* = 13.2, 5.0 Hz, 1H), 4.54 - 4.46 (m, 1H), 4.39 (dd, *J* = 17.2, 3.4 Hz, 1H), 4.26 (dd, *J* = 17.2, 3.2 Hz, 1H), 3.22 (s, 3H), 3.07 - 2.96 (m, 1H), 2.96 - 2.84 (m, 2H), 2.67 - 2.56 (m, 2H), 2.45 - 2.33 (m, 1H), 2.16 - 1.93 (m, 8H), 1.82 - 1.67 (m, 3H), 1.61 - 1.33 (m, 3H), 1.13 - 0.96 (m, 2H), 0.90 - 0.78 (m, 2H).

20

Example 31: 3-(5-(((*R*)-1-(but-3-en-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-67**)**




25

3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (100 mg, 0.29 mmol) and cyclobutyl methanesulfonate **INT-66** (66 mg, 0.44 mmol) were added to a 2 mL

microwave vial and suspended in ACN (1.5 mL). DIPEA (0.10 mL, 0.58 mmol) was added and the reaction was evacuated and backfilled with nitrogen three times. The reaction stirred at 140 °C for 2 hrs under microwave radiation. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted three times with 4:1 DCM:iPrOH. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((R)-1-(but-3-en-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-67** as a white solid and 3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-17** as a white solid.


3-(5-(((R)-1-(but-3-en-1-yl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-67): LCMS [M+H]⁺: 398.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.12 (d, *J* = 2.3 Hz, 1H), 6.97 (dd, *J* = 8.4, 2.3 Hz, 1H), 5.81 - 5.63 (m, 1H), 5.08 - 4.93 (m, 2H), 4.89 (dd, *J* = 10.2, 2.0 Hz, 1H), 4.47 - 4.35 (m, 1H), 4.31 (d, *J* = 17.2 Hz, 1H), 4.19 (d, *J* = 17.2 Hz, 1H), 2.98 - 2.78 (m, 2H), 2.64 - 2.56 (m, 1H), 2.56 - 2.47 (m, 1H), 2.38 - 2.24 (m, 3H), 2.20 - 1.85 (m, 6H), 1.71 - 1.59 (m, 1H), 1.58 - 1.40 (m, 1H), 1.37 - 1.23 (m, 1H).

Example 32: 3-(5-(((R)-1-((R)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-69)




Compound **I-69** was made according to General Method IX starting from 1-(hydroxymethyl)-3-(1-oxo-5-(((R)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (100 mg, 0.29 mmol) and (S)-sec-butyl methanesulfonate **INT-68** (66 mg, 0.44 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((R)-1-((R)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-69** as a white solid. LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.54 (d, *J* = 8.3 Hz, 1H), 7.10 (dd, *J* = 4.6, 2.2 Hz, 1H), 6.96 (dd, *J* = 8.4, 2.3 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.2 Hz, 1H), 4.46 - 4.25 (m, 2H), 4.18 (d, *J* = 17.1 Hz, 1H), 2.93 - 2.74 (m, 2H), 2.58 - 2.47 (m, 2H), 2.40 - 2.19 (m, 3H), 2.15 - 1.85 (m, 3H), 1.70 - 1.59 (m, 1H), 1.55 - 1.11 (m, 4H), 0.86 - 0.71 (m, 6H).

Example 33: 3-(5-(((R)-1-((S)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-70)



Compound **I-70** was made according to General Method IX starting from 1-(hydroxymethyl)-3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **INT-2** (100 mg, 0.29 mmol) and (*R*)-sec-butyl methanesulfonate **INT-27** (66 mg, 0.44 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated and lyophilized to afford 3-(5-(((*R*)-1-((*S*)-sec-butyl)piperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione **I-70** as a white solid. LCMS [M+H]⁺: 400.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 7.53 (d, *J* = 8.3 Hz, 1H), 7.10 (dd, *J* = 4.6, 2.2 Hz, 1H), 6.96 (dd, *J* = 8.3, 2.1 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.0 Hz, 1H), 4.45 - 4.24 (m, 2H), 4.18 (d, *J* = 17.1 Hz, 1H), 2.92 - 2.79 (m, 2H), 2.58 - 2.47 (m, 2H), 2.40 - 2.19 (m, 3H), 2.14 - 1.86 (m, 3H), 1.71 - 1.59 (m, 1H), 1.49 - 1.10 (m, 4H), 0.87 - 0.73 (m, 6H).

Example 34: *rac*-3-(5-(((3*R*,5*R*)-1-Ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (I-73**)**



Step 1: *rac*-Tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate (71**)**

71 was made according to General Method VI starting from 3-(5-bromo-1-oxoisoindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (850 mg, 1.88 mmol) *rac*-tert-butyl (3*R*,5*R*)-3,5-dihydroxypiperidine-1-carboxylate (489 mg, 2.25 mmol). The crude material was purified by silica gel chromatography (0 to 50% Acetone in Heptane). Fractions containing desired product were combined and concentrated to afford *rac*-tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate **71** as a pale yellow solid. LCMS [M-H]⁻: 588.3.

Step 2: *rac*-3-(5-(((3*R*,5*R*)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (72**)**

72 was made according to General Method VII starting from **71** (453 mg, 0.77 mmol). The reaction was quenched with saturated aqueous NaHCO₃ and extracted with 4:1 DCM:EtOH three times. The organic layers were combined and concentrated to afford *rac*-3-(5-(((3*R*,5*R*)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **72** (276 mg, 0.768 mmol).


5 Material was used directly in the next reaction. LCMS [M+H]⁺: 360.2.

Step 3: *rac*-3-(5-(((3*R*,5*R*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-73)

To a solution of *rac*-3-(5-(((3*R*,5*R*)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **72** (276 mg, 0.77 mmol) and sodium triacetoxymethylborohydride (1.30 g, 6.14 mmol) in EtOH (5.0 mL) was added acetaldehyde (0.34 mL, 6.14 mmol) at 0 °C. The reaction was stirred at r.t. for 1 hr. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in Heptane). Fractions containing desired product were combined and concentrated to afford *rac*-3-(5-(((3*R*,5*R*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-73** as a white solid.

15 LCMS [M+H]⁺: 388.4. ¹H NMR (400 MHz, Deuterium Oxide) δ 8.43 (s, 1H), 7.74 (d, *J* = 8.5 Hz, 1H), 7.23 - 7.20 (m, 1H), 7.15 (dd, *J* = 8.5, 2.3 Hz, 1H), 5.17 (s, 1H), 5.10 (dd, *J* = 13.3, 5.2 Hz, 1H), 4.56 - 4.41 (m, 2H), 4.32 (s, 1H), 3.92 - 3.44 (m, 2H), 3.32 (q, *J* = 7.3 Hz, 2H), 2.98 - 2.79 (m, 3H), 2.49 (qd, *J* = 12.9, 5.5 Hz, 2H), 2.23 (dtd, *J* = 13.0, 5.2, 2.7 Hz, 1H), 1.78 (s, 1H), 1.34 (t, *J* = 7.3 Hz, 3H).

20 **Example 34a: *tert*-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate (71a)**




Example **34a** was synthesized by analogy to the previous **Example 34** starting with *tert*-butyl (3*R*,5*R*)-3,5-dihydroxypiperidine-1-carboxylate. LCMS [M-H]⁻: 588.3.

25

Example 35: *rac*-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-76); (*R*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*S*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*R*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, and (*S*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

30



Step 1: *rac*-tert-butyl (3*R*,4*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate (74)

74 was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (1.85 g, 4.08 mmol) and *rac*-tert-butyl (3*R*,4*S*)-3-hydroxy-4-methylpiperidine-1-carboxylate (966 mg, 4.49 mmol). The reaction mixture was filtered and concentrated to afford *rac*-tert-butyl (3*R*,4*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate 74 as a yellow oil. Material was taken through to the next step without purification.

LCMS [M-H]⁻: 586.7

Step 2: *rac*-3-(5-(((3*R*,4*S*)-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (75)

75 was made according to General Method VII starting from *rac*-tert-butyl (3*R*,4*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate 74 (2.4 g, 4.08 mmol). The reaction was quenched with saturated aqueous NaHCO₃ and extracted with 4:1 DCM:TFE three times. The organic layers were combined, concentrated and the crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1 in heptane). Fractions containing desired product were combined and concentrated to afford *rac*-3-(5-(((3*R*,4*S*)-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione 75 as white solid. LCMS [M+H]⁺: 358.4.

Step 3: *rac*-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-76), (*R*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-

oxoisindolin-2-yl)piperidine-2,6-dione, (S)-3-(5-(((3R,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione, (R)-3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione, and (S)-3-(5-(((3S,4R)-1-ethyl-4-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione

- 5 To a solution of *rac*-3-(5-(((3R,4S)-4-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **75** (350 mg, 0.979 mmol) and sodium triacetoxyborohydride (311 mg, 1.469 mmol) in EtOH (5 mL) at 0 °C was added acetaldehyde (64.7 mg, 1.469 mmol). The reaction stirred at r.t. for 2 hrs. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in Heptane). Fractions
- 10 containing desired product were combined and concentrated to afford *rac*-3-(5-(((3R,4S)-1-ethyl-4-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-76** as a white solid. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, CD₂Cl₂) δ 7.69 (d, *J* = 8.4 Hz, 1H), 7.10 (s, 1H), 7.03 (ddd, *J* = 8.5, 3.9, 2.2 Hz, 1H), 5.12 (ddd, *J* = 13.4, 5.2, 3.5 Hz, 1H), 4.41 - 4.19 (m, 2H), 4.07 (qd, *J* = 9.4, 4.2 Hz, 1H), 3.31 - 3.12 (m, 1H), 2.98 - 2.73 (m, 3H), 2.53 - 2.37 (m, 2H), 2.37 -
- 15 2.23 (m, 1H), 2.20 - 2.10 (m, 1H), 2.07 - 1.87 (m, 2H), 1.84 - 1.75 (m, 1H), 1.73 - 1.61 (m, 1H), 1.47 - 1.36 (m, 1H), 1.09 - 0.96 (m, 6H).

The diastereomeric mixture of isomers was separated via chiral SFC [Column 20 x 250 mm ChromegaChiral CC4 from ES; CO₂ Co-solvent 55% Ethanol/ACN (1:3) with 0.25% triethylamine; at 80 g/min at 100 bar, at 25 °C] to afford four stereoisomers: **Peak 1 (Ex. 35A)**, **Peak 2 (Ex. 35B)**, **Peak 3 (Ex. 35C)**, **Peak 4 (Ex. 35D)**, **Peak 5 (Ex. 35E)**, **Peak 6 (Ex. 35F)**, **Peak 7 (Ex. 35G)**, **Peak 8 (Ex. 35H)**, **Peak 9 (Ex. 35I)**, **Peak 10 (Ex. 35J)**, **Peak 11 (Ex. 35K)**, **Peak 12 (Ex. 35L)**, **Peak 13 (Ex. 35M)**, **Peak 14 (Ex. 35N)**, **Peak 15 (Ex. 35O)**, **Peak 16 (Ex. 35P)**, **Peak 17 (Ex. 35Q)**, **Peak 18 (Ex. 35R)**, **Peak 19 (Ex. 35S)**, **Peak 20 (Ex. 35T)**, **Peak 21 (Ex. 35U)**, **Peak 22 (Ex. 35V)**, **Peak 23 (Ex. 35W)**, **Peak 24 (Ex. 35X)**, **Peak 25 (Ex. 35Y)**, **Peak 26 (Ex. 35Z)**, **Peak 27 (Ex. 35AA)**, **Peak 28 (Ex. 35AB)**, **Peak 29 (Ex. 35AC)**, **Peak 30 (Ex. 35AD)**, **Peak 31 (Ex. 35AE)**, **Peak 32 (Ex. 35AF)**, **Peak 33 (Ex. 35AG)**, **Peak 34 (Ex. 35AH)**, **Peak 35 (Ex. 35AI)**, **Peak 36 (Ex. 35AJ)**, **Peak 37 (Ex. 35AK)**, **Peak 38 (Ex. 35AL)**, **Peak 39 (Ex. 35AM)**, **Peak 40 (Ex. 35AN)**, **Peak 41 (Ex. 35AO)**, **Peak 42 (Ex. 35AP)**, **Peak 43 (Ex. 35AQ)**, **Peak 44 (Ex. 35AR)**, **Peak 45 (Ex. 35AS)**, **Peak 46 (Ex. 35AT)**, **Peak 47 (Ex. 35AU)**, **Peak 48 (Ex. 35AV)**, **Peak 49 (Ex. 35AW)**, **Peak 50 (Ex. 35AX)**, **Peak 51 (Ex. 35AY)**, **Peak 52 (Ex. 35AZ)**, **Peak 53 (Ex. 35BA)**, **Peak 54 (Ex. 35BB)**, **Peak 55 (Ex. 35BC)**, **Peak 56 (Ex. 35BD)**, **Peak 57 (Ex. 35BE)**, **Peak 58 (Ex. 35BF)**, **Peak 59 (Ex. 35BG)**, **Peak 60 (Ex. 35BH)**, **Peak 61 (Ex. 35BI)**, **Peak 62 (Ex. 35BJ)**, **Peak 63 (Ex. 35BK)**, **Peak 64 (Ex. 35BL)**, **Peak 65 (Ex. 35BM)**, **Peak 66 (Ex. 35BN)**, **Peak 67 (Ex. 35BO)**, **Peak 68 (Ex. 35BP)**, **Peak 69 (Ex. 35BQ)**, **Peak 70 (Ex. 35BR)**, **Peak 71 (Ex. 35BS)**, **Peak 72 (Ex. 35BT)**, **Peak 73 (Ex. 35BU)**, **Peak 74 (Ex. 35BV)**, **Peak 75 (Ex. 35BW)**, **Peak 76 (Ex. 35BX)**, **Peak 77 (Ex. 35BY)**, **Peak 78 (Ex. 35BZ)**, **Peak 79 (Ex. 35CA)**, **Peak 80 (Ex. 35CB)**, **Peak 81 (Ex. 35CC)**, **Peak 82 (Ex. 35CD)**, **Peak 83 (Ex. 35CE)**, **Peak 84 (Ex. 35CF)**, **Peak 85 (Ex. 35CG)**, **Peak 86 (Ex. 35CH)**, **Peak 87 (Ex. 35CI)**, **Peak 88 (Ex. 35CJ)**, **Peak 89 (Ex. 35CK)**, **Peak 90 (Ex. 35CL)**, **Peak 91 (Ex. 35CM)**, **Peak 92 (Ex. 35CN)**, **Peak 93 (Ex. 35CO)**, **Peak 94 (Ex. 35CP)**, **Peak 95 (Ex. 35CQ)**, **Peak 96 (Ex. 35CR)**, **Peak 97 (Ex. 35CS)**, **Peak 98 (Ex. 35CT)**, **Peak 99 (Ex. 35CU)**, **Peak 100 (Ex. 35CV)**, **Peak 101 (Ex. 35CW)**, **Peak 102 (Ex. 35CX)**, **Peak 103 (Ex. 35CY)**, **Peak 104 (Ex. 35CZ)**, **Peak 105 (Ex. 35DA)**, **Peak 106 (Ex. 35DB)**, **Peak 107 (Ex. 35DC)**, **Peak 108 (Ex. 35DD)**, **Peak 109 (Ex. 35DE)**, **Peak 110 (Ex. 35DF)**, **Peak 111 (Ex. 35DG)**, **Peak 112 (Ex. 35DH)**, **Peak 113 (Ex. 35DI)**, **Peak 114 (Ex. 35DJ)**, **Peak 115 (Ex. 35DK)**, **Peak 116 (Ex. 35DL)**, **Peak 117 (Ex. 35DM)**, **Peak 118 (Ex. 35DN)**, **Peak 119 (Ex. 35DO)**, **Peak 120 (Ex. 35DP)**, **Peak 121 (Ex. 35DQ)**, **Peak 122 (Ex. 35DR)**, **Peak 123 (Ex. 35DS)**, **Peak 124 (Ex. 35DT)**, **Peak 125 (Ex. 35DU)**, **Peak 126 (Ex. 35DV)**, **Peak 127 (Ex. 35DW)**, **Peak 128 (Ex. 35DX)**, **Peak 129 (Ex. 35DY)**, **Peak 130 (Ex. 35DZ)**, **Peak 131 (Ex. 35EA)**, **Peak 132 (Ex. 35EB)**, **Peak 133 (Ex. 35EC)**, **Peak 134 (Ex. 35ED)**, **Peak 135 (Ex. 35EE)**, **Peak 136 (Ex. 35EF)**, **Peak 137 (Ex. 35EG)**, **Peak 138 (Ex. 35EH)**, **Peak 139 (Ex. 35EI)**, **Peak 140 (Ex. 35EJ)**, **Peak 141 (Ex. 35EK)**, **Peak 142 (Ex. 35EL)**, **Peak 143 (Ex. 35EM)**, **Peak 144 (Ex. 35EN)**, **Peak 145 (Ex. 35EO)**, **Peak 146 (Ex. 35EP)**, **Peak 147 (Ex. 35EQ)**, **Peak 148 (Ex. 35ER)**, **Peak 149 (Ex. 35ES)**, **Peak 150 (Ex. 35ET)**, **Peak 151 (Ex. 35EU)**, **Peak 152 (Ex. 35EV)**, **Peak 153 (Ex. 35EW)**, **Peak 154 (Ex. 35EX)**, **Peak 155 (Ex. 35EY)**, **Peak 156 (Ex. 35EZ)**, **Peak 157 (Ex. 35FA)**, **Peak 158 (Ex. 35FB)**, **Peak 159 (Ex. 35FC)**, **Peak 160 (Ex. 35FD)**, **Peak 161 (Ex. 35FE)**, **Peak 162 (Ex. 35FF)**, **Peak 163 (Ex. 35FG)**, **Peak 164 (Ex. 35FH)**, **Peak 165 (Ex. 35FI)**, **Peak 166 (Ex. 35FJ)**, **Peak 167 (Ex. 35FK)**, **Peak 168 (Ex. 35FL)**, **Peak 169 (Ex. 35FM)**, **Peak 170 (Ex. 35FN)**, **Peak 171 (Ex. 35FO)**, **Peak 172 (Ex. 35FP)**, **Peak 173 (Ex. 35FQ)**, **Peak 174 (Ex. 35FR)**, **Peak 175 (Ex. 35FS)**, **Peak 176 (Ex. 35FT)**, **Peak 177 (Ex. 35FU)**, **Peak 178 (Ex. 35FV)**, **Peak 179 (Ex. 35FW)**, **Peak 180 (Ex. 35FX)**, **Peak 181 (Ex. 35FY)**, **Peak 182 (Ex. 35FZ)**, **Peak 183 (Ex. 35GA)**, **Peak 184 (Ex. 35GB)**, **Peak 185 (Ex. 35GC)**, **Peak 186 (Ex. 35GD)**, **Peak 187 (Ex. 35GE)**, **Peak 188 (Ex. 35GF)**, **Peak 189 (Ex. 35GG)**, **Peak 190 (Ex. 35GH)**, **Peak 191 (Ex. 35GI)**, **Peak 192 (Ex. 35GJ)**, **Peak 193 (Ex. 35GK)**, **Peak 194 (Ex. 35GL)**, **Peak 195 (Ex. 35GM)**, **Peak 196 (Ex. 35GN)**, **Peak 197 (Ex. 35GO)**, **Peak 198 (Ex. 35GP)**, **Peak 199 (Ex. 35GQ)**, **Peak 200 (Ex. 35GR)**, **Peak 201 (Ex. 35GS)**, **Peak 202 (Ex. 35GT)**, **Peak 203 (Ex. 35GU)**, **Peak 204 (Ex. 35GV)**, **Peak 205 (Ex. 35GW)**, **Peak 206 (Ex. 35GX)**, **Peak 207 (Ex. 35GY)**, **Peak 208 (Ex. 35GZ)**, **Peak 209 (Ex. 35HA)**, **Peak 210 (Ex. 35HB)**, **Peak 211 (Ex. 35HC)**, **Peak 212 (Ex. 35HD)**, **Peak 213 (Ex. 35HE)**, **Peak 214 (Ex. 35HF)**, **Peak 215 (Ex. 35HG)**, **Peak 216 (Ex. 35HH)**, **Peak 217 (Ex. 35HI)**, **Peak 218 (Ex. 35HJ)**, **Peak 219 (Ex. 35HK)**, **Peak 220 (Ex. 35HL)**, **Peak 221 (Ex. 35HM)**, **Peak 222 (Ex. 35HN)**, **Peak 223 (Ex. 35HO)**, **Peak 224 (Ex. 35HP)**, **Peak 225 (Ex. 35HQ)**, **Peak 226 (Ex. 35HR)**, **Peak 227 (Ex. 35HS)**, **Peak 228 (Ex. 35HT)**, **Peak 229 (Ex. 35HU)**, **Peak 230 (Ex. 35HV)**, **Peak 231 (Ex. 35HW)**, **Peak 232 (Ex. 35HX)**, **Peak 233 (Ex. 35HY)**, **Peak 234 (Ex. 35HZ)**, **Peak 235 (Ex. 35IA)**, **Peak 236 (Ex. 35IB)**, **Peak 237 (Ex. 35IC)**, **Peak 238 (Ex. 35ID)**, **Peak 239 (Ex. 35IE)**, **Peak 240 (Ex. 35IF)**, **Peak 241 (Ex. 35IG)**, **Peak 242 (Ex. 35IH)**, **Peak 243 (Ex. 35II)**, **Peak 244 (Ex. 35IJ)**, **Peak 245 (Ex. 35IK)**, **Peak 246 (Ex. 35IL)**, **Peak 247 (Ex. 35IM)**, **Peak 248 (Ex. 35IN)**, **Peak 249 (Ex. 35IO)**, **Peak 250 (Ex. 35IP)**, **Peak 251 (Ex. 35IQ)**, **Peak 252 (Ex. 35IR)**, **Peak 253 (Ex. 35IS)**, **Peak 254 (Ex. 35IT)**, **Peak 255 (Ex. 35IU)**, **Peak 256 (Ex. 35IV)**, **Peak 257 (Ex. 35IW)**, **Peak 258 (Ex. 35IX)**, **Peak 259 (Ex. 35IY)**, **Peak 260 (Ex. 35IZ)**, **Peak 261 (Ex. 35JA)**, **Peak 262 (Ex. 35JB)**, **Peak 263 (Ex. 35JC)**, **Peak 264 (Ex. 35JD)**, **Peak 265 (Ex. 35JE)**, **Peak 266 (Ex. 35JF)**, **Peak 267 (Ex. 35JG)**, **Peak 268 (Ex. 35JH)**, **Peak 269 (Ex. 35JI)**, **Peak 270 (Ex. 35JJ)**, **Peak 271 (Ex. 35JK)**, **Peak 272 (Ex. 35JL)**, **Peak 273 (Ex. 35JM)**, **Peak 274 (Ex. 35JN)**, **Peak 275 (Ex. 35JO)**, **Peak 276 (Ex. 35JP)**, **Peak 277 (Ex. 35JQ)**, **Peak 278 (Ex. 35JR)**, **Peak 279 (Ex. 35JS)**, **Peak 280 (Ex. 35JT)**, **Peak 281 (Ex. 35JU)**, **Peak 282 (Ex. 35JV)**, **Peak 283 (Ex. 35JW)**, **Peak 284 (Ex. 35JX)**, **Peak 285 (Ex. 35JY)**, **Peak 286 (Ex. 35JZ)**, **Peak 287 (Ex. 35KA)**, **Peak 288 (Ex. 35KB)**, **Peak 289 (Ex. 35KC)**, **Peak 290 (Ex. 35KD)**, **Peak 291 (Ex. 35KE)**, **Peak 292 (Ex. 35KF)**, **Peak 293 (Ex. 35KG)**, **Peak 294 (Ex. 35KH)**, **Peak 295 (Ex. 35KI)**, **Peak 296 (Ex. 35KJ)**, **Peak 297 (Ex. 35KK)**, **Peak 298 (Ex. 35KL)**, **Peak 299 (Ex. 35KM)**, **Peak 300 (Ex. 35KN)**, **Peak 301 (Ex. 35KO)**, **Peak 302 (Ex. 35KP)**, **Peak 303 (Ex. 35KQ)**, **Peak 304 (Ex. 35KR)**, **Peak 305 (Ex. 35KS)**, **Peak 306 (Ex. 35KT)**, **Peak 307 (Ex. 35KU)**, **Peak 308 (Ex. 35KV)**, **Peak 309 (Ex. 35KW)**, **Peak 310 (Ex. 35KX)**, **Peak 311 (Ex. 35KY)**, **Peak 312 (Ex. 35KZ)**, **Peak 313 (Ex. 35LA)**, **Peak 314 (Ex. 35LB)**, **Peak 315 (Ex. 35LC)**, **Peak 316 (Ex. 35LD)**, **Peak 317 (Ex. 35LE)**, **Peak 318 (Ex. 35LF)**, **Peak 319 (Ex. 35LG)**, **Peak 320 (Ex. 35LH)**, **Peak 321 (Ex. 35LI)**, **Peak 322 (Ex. 35LJ)**, **Peak 323 (Ex. 35LK)**, **Peak 324 (Ex. 35LL)**, **Peak 325 (Ex. 35LM)**, **Peak 326 (Ex. 35LN)**, **Peak 327 (Ex. 35LO)**, **Peak 328 (Ex. 35LP)**, **Peak 329 (Ex. 35LQ)**, **Peak 330 (Ex. 35LR)**, **Peak 331 (Ex. 35LS)**, **Peak 332 (Ex. 35LT)**, **Peak 333 (Ex. 35LU)**, **Peak 334 (Ex. 35LV)**, **Peak 335 (Ex. 35LW)**, **Peak 336 (Ex. 35LX)**, **Peak 337 (Ex. 35LY)**, **Peak 338 (Ex. 35LZ)**, **Peak 339 (Ex. 35MA)**, **Peak 340 (Ex. 35MB)**, **Peak 341 (Ex. 35MC)**, **Peak 342 (Ex. 35MD)**, **Peak 343 (Ex. 35ME)**, **Peak 344 (Ex. 35MF)**, **Peak 345 (Ex. 35MG)**, **Peak 346 (Ex. 35MH)**, **Peak 347 (Ex. 35MI)**, **Peak 348 (Ex. 35MJ)**, **Peak 349 (Ex. 35MK)**, **Peak 350 (Ex. 35ML)**, **Peak 351 (Ex. 35MN)**, **Peak 352 (Ex. 35MO)**, **Peak 353 (Ex. 35MP)**, **Peak 354 (Ex. 35MQ)**, **Peak 355 (Ex. 35MR)**, **Peak 356 (Ex. 35MS)**, **Peak 357 (Ex. 35MT)**, **Peak 358 (Ex. 35MU)**, **Peak 359 (Ex. 35MV)**, **Peak 360 (Ex. 35MW)**, **Peak 361 (Ex. 35MX)**, **Peak 362 (Ex. 35MY)**, **Peak 363 (Ex. 35MZ)**, **Peak 364 (Ex. 35NA)**, **Peak 365 (Ex. 35NB)**, **Peak 366 (Ex. 35NC)**, **Peak 367 (Ex. 35ND)**, **Peak 368 (Ex. 35NE)**, **Peak 369 (Ex. 35NF)**, **Peak 370 (Ex. 35NG)**, **Peak 371 (Ex. 35NH)**, **Peak 372 (Ex. 35NI)**, **Peak 373 (Ex. 35NJ)**, **Peak 374 (Ex. 35NK)**, **Peak 375 (Ex. 35NL)**, **Peak 376 (Ex. 35NM)**, **Peak 377 (Ex. 35NO)**, **Peak 378 (Ex. 35NP)**, **Peak 379 (Ex. 35NQ)**, **Peak 380 (Ex. 35NR)**, **Peak 381 (Ex. 35NS)**, **Peak 382 (Ex. 35NT)**, **Peak 383 (Ex. 35NU)**, **Peak 384 (Ex. 35NV)**, **Peak 385 (Ex. 35NW)**, **Peak 386 (Ex. 35NX)**, **Peak 387 (Ex. 35NY)**, **Peak 388 (Ex. 35NZ)**, **Peak 389 (Ex. 35OA)**, **Peak 390 (Ex. 35OB)**, **Peak 391 (Ex. 35OC)**, **Peak 392 (Ex. 35OD)**, **Peak 393 (Ex. 35OE)**, **Peak 394 (Ex. 35OF)**, **Peak 395 (Ex. 35OG)**, **Peak 396 (Ex. 35OH)**, **Peak 397 (Ex. 35OI)**, **Peak 398 (Ex. 35OJ)**, **Peak 399 (Ex. 35OK)**, **Peak 400 (Ex. 35OL)**, **Peak 401 (Ex. 35OM)**, **Peak 402 (Ex. 35ON)**, **Peak 403 (Ex. 35OO)**, **Peak 404 (Ex. 35OP)**, **Peak 405 (Ex. 35OQ)**, **Peak 406 (Ex. 35OR)**, **Peak 407 (Ex. 35OS)**, **Peak 408 (Ex. 35OT)**, **Peak 409 (Ex. 35OU)**, **Peak 410 (Ex. 35OV)**, **Peak 411 (Ex. 35OW)**, **Peak 412 (Ex. 35OX)**, **Peak 413 (Ex. 35OY)**, **Peak 414 (Ex. 35OZ)**, **Peak 415 (Ex. 35PA)**, **Peak 416 (Ex. 35PB)**, **Peak 417 (Ex. 35PC)**, **Peak 418 (Ex. 35PD)**, **Peak 419 (Ex. 35PE)**, **Peak 420 (Ex. 35PF)**, **Peak 421 (Ex. 35PG)**, **Peak 422 (Ex. 35PH)**, **Peak 423 (Ex. 35PI)**, **Peak 424 (Ex. 35PJ)**, **Peak 425 (Ex. 35PK)**, **Peak 426 (Ex. 35PL)**, **Peak 427 (Ex. 35PM)**, **Peak 428 (Ex. 35PN)**, **Peak 429 (Ex. 35PO)**, **Peak 430 (Ex. 35PP)**, **Peak 431 (Ex. 35PQ)**, **Peak 432 (Ex. 35PR)**, **Peak 433 (Ex. 35PS)**, **Peak 434 (Ex. 35PT)**, **Peak 435 (Ex. 35PU)**, **Peak 436 (Ex. 35PV)**, **Peak 437 (Ex. 35PW)**, **Peak 438 (Ex. 35PX)**, **Peak 439 (Ex. 35PY)**, **Peak 440 (Ex. 35PZ)**, **Peak 441 (Ex. 35QA)**, **Peak 442 (Ex. 35QB)**, **Peak 443 (Ex. 35QC)**, **Peak 444 (Ex. 35QD)**, **Peak 445 (Ex. 35QE)**, **Peak 446 (Ex. 35QF)**, **Peak 447 (Ex. 35QG)**, **Peak 448 (Ex. 35QH)**, **Peak 449 (Ex. 35QI)**, **Peak 450 (Ex. 35QJ)**, **Peak 451 (Ex. 35QK)**, **Peak 452 (Ex. 35QL)**, **Peak 453 (Ex. 35QM)**, **Peak 454 (Ex. 35QN)**, **Peak 455 (Ex. 35QO)**, **Peak 456 (Ex. 35QP)**, **Peak 457 (Ex. 35QQ)**, **Peak 458 (Ex. 35QR)**, **Peak 459 (Ex. 35QS)**, **Peak 460 (Ex. 35QT)**, **Peak 461 (Ex. 35QU)**, **Peak 462 (Ex. 35QV)**, **Peak 463 (Ex. 35QW)**, **Peak 464 (Ex. 35QX)**, **Peak 465 (Ex. 35QY)**, **Peak 466 (Ex. 35QZ)**, **Peak 467 (Ex. 35RA)**, **Peak 468 (Ex. 35RB)**, **Peak 469 (Ex. 35RC)**, **Peak 470 (Ex. 35RD)**, **Peak 471 (Ex. 35RE)**, **Peak 472 (Ex. 35RF)**, **Peak 473 (Ex. 35RG)**, **Peak 474 (Ex. 35RH)**, **Peak 475 (Ex. 35RI)**, **Peak 476 (Ex. 35RJ)**, **Peak 477 (Ex. 35RK)**, **Peak 478 (Ex. 35RL)**, **Peak 479 (Ex. 35RM)**, **Peak 480 (Ex. 35RN)**, **Peak 481 (Ex. 35RO)**, **Peak 482 (Ex. 35RP)**, **Peak 483 (Ex. 35RQ)**, **Peak 484 (Ex. 35RR)**, **Peak 485 (Ex. 35RS)**, **Peak 486 (Ex. 35RT)**, **Peak 487 (Ex. 35RU)**, **Peak 488 (Ex. 35RV)**, **Peak 489 (Ex. 35RW)**, **Peak 490 (Ex. 35RX)**, **Peak 491 (Ex. 35RY)**, **Peak 492 (Ex. 35RZ)**, **Peak 493 (Ex. 35SA)**, **Peak 494 (Ex. 35SB)**, **Peak 495 (Ex. 35SC)**, **Peak 496 (Ex. 35SD)**, **Peak 497 (Ex. 35SE)**, **Peak 498 (Ex. 35SF)**, **Peak 499 (Ex. 35SG)**, **Peak 500 (Ex. 35SH)**, **Peak 501 (Ex. 35SI)**, **Peak 502 (Ex. 35SJ)**, **Peak 503 (Ex. 35SK)**, **Peak 504 (Ex. 35SL)**, **Peak 505 (Ex. 35SM)**, **Peak 506 (Ex. 35SN)**, **Peak 507 (Ex. 35SO)**, **Peak 508 (Ex. 35SP)**, **Peak 509 (Ex. 35SQ)**, **Peak 510 (Ex. 35SR)**, **Peak 511 (Ex. 35SS)**, **Peak 512 (Ex. 35ST)**, **Peak 513 (Ex. 35SU)**, **Peak 514 (Ex. 35SV)**, **Peak 515 (Ex. 35SW)**, **Peak 516 (Ex. 35SX)**, **Peak 517 (Ex. 35SY)**, **Peak 518 (Ex. 35SZ)**, **Peak 519 (Ex. 35TA)**, **Peak 520 (Ex. 35TB)**, **Peak 521 (Ex. 35TC)**, **Peak 522 (Ex. 35TD)**, **Peak 523 (Ex. 35TE)**, **Peak 524 (Ex. 35TF)**, **Peak 525 (Ex. 35TG)**, **Peak 526 (Ex. 35TH)**, **Peak 527 (Ex. 35TI)**, **Peak 528 (Ex. 35TJ)**, **Peak 529 (Ex. 35TK)**, **Peak 530 (Ex. 35TL)**, **Peak 531 (Ex. 35TM)**, **Peak 532 (Ex. 35TN)**, **Peak 533 (Ex. 35TO)**, **Peak 534 (Ex. 35TP)**, **Peak 535 (Ex. 35TQ)**, **Peak 536 (Ex. 35TR)**, **Peak 537 (Ex. 35TS)**, **Peak 538 (Ex. 35TT)**, **Peak 539 (Ex. 35TU)**, **Peak 540 (Ex. 35TV)**, **Peak 541 (Ex. 35TW)**, **Peak 542 (Ex. 35TX)**, **Peak 543 (Ex. 35TY)**, **Peak 544 (Ex. 35TZ)**, **Peak 545 (Ex. 35UA)**, **Peak 546 (Ex. 35UB)**, **Peak 547 (Ex. 35UC)**, **Peak 548 (Ex. 35UD)**, **Peak 549 (Ex. 35UE)**, **Peak 550 (Ex. 35UF)**, **Peak 551 (Ex. 35UG)**, **Peak 552 (Ex. 35UH)**, **Peak 553 (Ex. 35UI)**, **Peak 554 (Ex. 35UJ)**, **Peak 555 (Ex. 35UK)**, **Peak 556 (Ex. 35UL)**, **Peak 557 (Ex. 35UM)**, **Peak 558 (Ex. 35UN)**, **Peak 559 (Ex. 35UO)**, **Peak 560 (Ex. 35UP)**, **Peak 561 (Ex. 35UQ)**, **Peak 562 (Ex. 35UR)**, **Peak 563 (Ex. 35US)**, **Peak 564 (Ex. 35UT)**, **Peak 565 (Ex. 35UU)**, **Peak 566 (Ex. 35UV)**, **Peak 567 (Ex. 35UW)**, **Peak 568 (Ex. 35UX)**, **Peak 569 (Ex. 35UY)**, **Peak 570 (Ex. 35UZ)**, **Peak 571 (Ex. 35VA)**, **Peak 572 (Ex. 35VB)**, **Peak 573 (Ex. 35VC)**, **Peak 574 (Ex. 35VD)**, **Peak 575 (Ex. 35VE)**, **Peak 576 (Ex. 35VF)**, **Peak 577 (Ex. 35VG)**, **Peak 578 (Ex. 35VH)**, **Peak 579 (Ex. 35VI)**, **Peak 580 (Ex. 35VJ)**, **Peak 581 (Ex. 35VK)**, **Peak 582 (Ex. 35VL)**, **Peak 583 (Ex. 35VM)**, **Peak 584 (Ex. 35VN)**, **Peak 585 (Ex. 35VO)**, **Peak 586 (Ex. 35VP)**, **Peak 587 (Ex. 35VQ)**, **Peak 588 (Ex. 35VR)**, **Peak 589 (Ex. 35VS)**, **Peak 590 (Ex. 35VT)**, **Peak 591 (Ex. 35VU)**, **Peak 592 (Ex. 35VV)**, **Peak 593 (Ex. 35VW)**, **Peak 594 (Ex. 35VX)**, **Peak 595 (Ex. 35VY)**, **Peak 596 (Ex. 35VZ)**, **Peak 597 (Ex. 35WA)**, **Peak 598 (Ex. 35WB)**, **Peak 599 (Ex. 35WC)**, **Peak 600 (Ex. 35WD)**, **Peak 601 (Ex. 35WE)**, **Peak 602 (Ex. 35WF)**, **Peak 603 (Ex. 35WG)**, **Peak 604 (Ex. 35WH)**, **Peak 605 (Ex. 35WI)**, **Peak 606 (Ex. 35WJ)**, **Peak 607 (Ex. 35WK)**, **Peak 608 (Ex. 35WL)**, **Peak 609 (Ex. 35WM)**, **Peak 610 (Ex. 35WN)**, **Peak 611 (Ex. 35WO)**, **Peak 612 (Ex. 35WP)**, **Peak 613 (Ex. 35WQ)**, **Peak 614 (Ex. 35WR)**, **Peak 615 (Ex. 35WS)**, **Peak 616 (Ex. 35WT)**, **Peak 617 (Ex. 35WU)**, **Peak 618 (Ex. 35WV)**, **Peak 619 (Ex. 35WW)**, **Peak 620 (Ex. 35WX)**, **Peak 621 (Ex. 35WY)**, **Peak 622 (Ex. 35WZ)**, **Peak 623 (Ex. 35XA)**, **Peak 624 (Ex. 35XB)**, **Peak 625 (Ex. 35XC)**, **Peak 626 (Ex. 35XD)**,

Step 1: Tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)azepane-1-carboxylate (77)

Compound **77** was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (200 mg, 0.44 mmol) and tert-butyl (3R)-3-hydroxyazepane-1-carboxylate (104 mg, 0.49 mmol). The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)azepane-1-carboxylate **77** as a yellow oil. LCMS [M+H]⁺: 432.4.


Step 2: 3-(5-(((R)-azepan-3-yl)oxy)-1-oxoisindolin-2-yl)-1-(hydroxymethyl)piperidine-2,6-dione (78)

To tert-butyl (3R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)azepane-1-carboxylate **77** (44.4 mg, 0.076 mmol) dissolved in ACN (1.0 mL) was added methanesulfonic acid (0.1 mL, 1.54 mmol). The reaction stirred at r.t. for 2 hrs. The reaction was cooled to 0 °C and triethylamine (0.43 mL, 3.1 mmol) followed by N1,N2-dimethylethane-1,2-diamine (0.016 mL, 0.15 mmol) were added. The reaction stirred at r.t. for 96 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated to afford 3-(5-(((R)-azepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **78** as a yellow solid. LCMS [M+H]⁺: 358.2.

Step 3: 3-(5-(((R)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-79)

To a solution of 3-(5-(((R)-azepan-3-yl)oxy)-1-oxoisindolin-2-yl)-1-(hydroxymethyl)piperidine-2,6-dione **78** (28 mg, 0.078 mmol) in DMF (0.522 mL), sodium triacetoxyborohydride (50 mg, 0.24 mmol) was added followed by acetaldehyde (0.01 mL, 0.18 mmol). The reaction stirred at r.t. for 18 hrs. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM: iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Product was further purified by reverse phase HPLC (25-50% ACN in H₂O with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing pure product were combined and lyophilized to afford formate salt 3-(5-(((R)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-79** as a white solid. LCMS [M+H]⁺: 386.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.88 (s, 1H), 8.17 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 2.2 Hz, 1H), 6.94 (dd, J = 8.4, 2.2 Hz, 1H), 5.00 (dd, J = 13.3, 5.1 Hz, 1H), 4.59 - 4.43 (m, 1H), 4.31 (dd, J = 17.1, 1.9 Hz, 1H), 4.18 (d, J = 17.1 Hz, 1H), 2.89 - 2.77 (m, 2H), 2.67 - 2.45 (m, 6H), 2.37 - 2.23 (m, 1H), 2.01 - 1.86 (m, 2H), 1.70 - 1.39 (m, 5H), 0.88 (td, J = 7.0, 1.7 Hz, 3H).

Example 37: 3-(5-(((S)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-84)



Step 1: Tert-butyl (S)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate (80)

To a 40 mL vial, 5-bromoisobenzofuranone (100 mg, 0.47 mmol), (S)-3-hydroxy-1-N-Boc-azepane (101 mg, 0.47 mmol), dtbbpy (12.6 mg, 0.047 mmol), $\text{NiCl}_2(\text{glyme})$ (10.3 mg, 0.047 mmol), and $\text{Ir}[(\text{dF}(\text{CF}_3)\text{ppy})_2\text{dtbbpy}]\text{PF}_6$ (13.1 mg, 0.012 mmol) were added. ACN (1.6 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (84 μL , 0.49 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% ethyl acetate in heptane) to afford tert-butyl (S)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate **80** as a yellow solid. LCMS $[\text{M}+\text{H}-\text{tert-butyl}]^+$: 292.1.

Step 2: (S)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one (81)

Tert-butyl (S)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate **80** (104 mg, 0.30 mmol) was suspended in dioxane (3.0 mL). 4 M HCl in dioxane (449 μL , 1.8 mmol) was added and the reaction stirred at r.t. for 5 hrs. The reaction was concentrated to afford (S)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one **81** as a brown semi-solid. Material was used directly in the next reaction. LCMS $[\text{M}+\text{H}]^+$: 248.2.

Step 3: (S)-5-((1-ethylazepan-3-yl)oxy)isobenzofuran-1(3H)-one (82)

Compound **82** was made according to General Method X starting from (S)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one **81** (74 mg, 0.30 mmol) and acetaldehyde (25 μL , 0.45 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v

= 75:25:1) in heptane) to afford (S)-5-((1-ethylazepan-3-yl)oxy)isobenzofuran-1(3H)-one **82** as a brown oil. LCMS [M+H]⁺: 276.2


Step 4: Ethyl (S)-2-(chloromethyl)-4-((1-ethylazepan-3-yl)oxy)benzoate (83)

Compound **83** was made according to General Method IV starting from (S)-5-((1-ethylazepan-3-yl)oxy)isobenzofuran-1(3H)-one **82** (7 mg, 0.025 mmol) to afford ethyl (S)-2-(chloromethyl)-4-((1-ethylazepan-3-yl)oxy)benzoate **83** as a brown oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 340.4.

Step 5: 3-(5-(((S)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-84)

Compound **I-84** was made according to General Method V starting from ethyl (S)-2-(chloromethyl)-4-((1-ethylazepan-3-yl)oxy)benzoate **83** (20 mg, 0.059 mmol). The reaction was concentrated and purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior to sample collection. Fractions containing desired product were combined and concentrated to afford product as an indigo-coloured solid. The material was further purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior to sample collection. Fractions containing desired product were combined and concentrated to afford 3-(5-(((S)-1-ethylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-84** as a clear oil. LCMS [M+H]⁺: 386.4. ¹H NMR (400 MHz, Acetonitrile-d₃) δ 8.84 (s, 1H), 7.69 (d, *J* = 8.3 Hz, 1H), 7.20 (d, *J* = 6.6 Hz, 1H), 7.11 (dt, *J* = 8.4, 2.3 Hz, 1H), 5.07 (dd, *J* = 13.4, 5.1 Hz, 1H), 4.92 (dd, *J* = 7.0, 3.6 Hz, 1H), 4.44 - 4.27 (m, 2H), 3.89 (p, *J* = 6.1 Hz, 3H), 3.32 (dd, *J* = 13.8, 3.0 Hz, 2H), 3.26 - 3.19 (m, 2H), 3.11 (t, *J* = 6.0 Hz, 2H), 2.99 (q, *J* = 7.2 Hz, 2H), 2.86 - 2.79 (m, 1H), 2.74 (ddd, *J* = 17.6, 4.8, 2.6 Hz, 1H), 2.43 (qd, *J* = 13.2, 4.9 Hz, 1H), 2.18 - 2.06 (m, 2H), 1.21 (td, *J* = 7.2, 1.2 Hz, 3H).

Example 38: 3-(5-(((R)-1-isobutylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-89)



Step 1: Tert-butyl (R)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate (85)

Compound **85** was made according to General Method I starting from 5-bromoisobenzofuran-1(3H)-one (250 mg, 1.17 mmol) and tert-butyl (3R)-3-hydroxyazepane-1-carboxylate (278 mg, 1.29 mmol). The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl (R)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate **85** as a clear oil. LCMS $[\text{M}+\text{H}-\text{tert-butyl}]^+$: 292.3.

Step 2: (R)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one (86)

Tert-butyl (R)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)azepane-1-carboxylate **85** (305 mg, 0.88 mmol) was suspended in dioxane (4.4 mL). 4M HCl in dioxane (1.3 mL, 5.3 mmol) was added and the reaction stirred at r.t. for 72 hrs. The reaction was concentrated to afford (R)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one **86** as a clear oil. Material was used directly in the next reaction. LCMS $[\text{M}+\text{H}]^+$: 248.3.

Step 3: (R)-5-((1-isobutylazepan-3-yl)oxy)isobenzofuran-1(3H)-one (87)

Compound **87** was made according to General Method III starting from (R)-5-(azepan-3-yloxy)isobenzofuran-1(3H)-one **86** (64 mg, 0.26 mmol) and isobutanal (0.04 mL, 0.44 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford (R)-5-((1-isobutylazepan-3-yl)oxy)isobenzofuran-1(3H)-one **87** as a clear oil. LCMS $[\text{M}+\text{H}]^+$: 304.2.


Step 4: Ethyl (R)-2-(chloromethyl)-4-((1-isobutylazepan-3-yl)oxy)benzoate (88)

Compound **88** was made according to General Method IV starting from (*R*)-5-((1-isobutylazepan-3-yl)oxy)isobenzofuran-1(3H)-one **87** (30.3 mg, 0.10 mmol) to afford ethyl (*R*)-2-(chloromethyl)-4-((1-isobutylazepan-3-yl)oxy)benzoate **88** as a brown oil. Material was taken through to the next step without purification. LCMS $[M+H]^+$: 368.5.

5 Step 5: 3-(5-(((*R*)-1-isobutylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-89)

Compound **I-89** was made according to General Method V starting from ethyl (*R*)-2-(chloromethyl)-4-((1-isobutylazepan-3-yl)oxy)benzoate **88** (36.8 mg, 0.10 mmol). The reaction was concentrated onto CELITE®. The dry loading tube was first filled with 1/2 inch of activated charcoal, then a filter pad, the CELITE® residue, and a second filter pad. The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((*R*)-1-isobutylazepan-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-89** as a white solid. LCMS $[M+H]^+$: 414.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.12 (d, *J* = 2.3 Hz, 1H), 7.00 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.2, 5.0 Hz, 1H), 4.68 - 4.51 (m, 1H), 4.38 (dd, *J* = 17.2, 3.3 Hz, 1H), 4.26 (dd, *J* = 17.1, 2.0 Hz, 1H), 2.96 - 2.85 (m, 2H), 2.75 (dd, *J* = 13.9, 6.6 Hz, 1H), 2.66 - 2.56 (m, 3H), 2.45 - 2.36 (m, 1H), 2.24 (d, *J* = 7.2 Hz, 2H), 2.12 - 1.94 (m, 2H), 1.81 - 1.48 (m, 6H), 0.86 (dd, *J* = 6.4, 2.8 Hz, 6H).

Example 39: 3-(5-(((*R*)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-94)



Step 1: Tert-butyl (*R*)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)pyrrolidine-1-carboxylate (90)

Compound **90** was made according to General Method I starting from 5-bromoisobenzofuran-1(3H)-one (100 mg, 0.47 mmol) and (*R*)-1-N-Boc-3-hydroxy-pyrrolidine (97 mg, 0.52 mmol). The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford tert-butyl (*R*)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)pyrrolidine-1-carboxylate **90** as a yellow oil. LCMS [M+H]⁺: 264.1.

Step 2: (*R*)-5-(pyrrolidin-3-yloxy)isobenzofuran-1(3H)-one (91)

Tert-butyl (*R*)-3-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)pyrrolidine-1-carboxylate **90** (98 mg, 0.31 mmol) was suspended in dioxane (3.1 mL). 4M HCl in dioxane (0.46 mL, 1.84 mmol) was added and the reaction stirred at r.t. for 2 hrs. Trifluoroethanol (1 mL) was added followed by additional 4M HCl in dioxane (0.46 mL, 1.84 mmol). The reaction stirred at r.t. for 72 hrs. The reaction was concentrated to afford (*R*)-5-(pyrrolidin-3-yloxy)isobenzofuran-1(3H)-one **91** as a white solid. Material was used directly in the next reaction. LCMS [M+H]⁺: 220.1.

Step 3: (*R*)-5-((1-ethylpyrrolidin-3-yl)oxy)isobenzofuran-1(3H)-one (92)

Compound **92** was made according to General Method X starting from (*R*)-5-(pyrrolidin-3-yloxy)isobenzofuran-1(3H)-one **91** (67.3 mg, 0.31 mmol) and acetaldehyde (26 µL, 0.46 mmol). The crude material was purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford (*R*)-5-((1-ethylpyrrolidin-3-yl)oxy)isobenzofuran-1(3H)-one **92** as a brown oil. LCMS [M+H]⁺: 248.2. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.5 Hz, 1H), 6.92 (dd, *J* = 8.5, 2.1 Hz, 1H), 6.78 (d, *J* = 2.1 Hz, 1H), 5.17 (s, 2H), 4.87 - 4.78 (m, 1H), 2.84 - 2.76 (m, 3H), 2.53 - 2.43 (m, 2H), 2.35 - 2.26 (m, 1H), 2.00 - 1.90 (m, 1H), 1.74 - 1.65 (m, 1H), 1.08 (t, *J* = 7.2 Hz, 3H).


Step 4: Ethyl (*R*)-2-(chloromethyl)-4-((1-ethylpyrrolidin-3-yl)oxy)benzoate (93)

Compound **93** was made according to General Method IV starting from (*R*)-5-((1-ethylpyrrolidin-3-yl)oxy)isobenzofuran-1(3H)-one **92** (17.5 mg, 0.071 mmol) to afford ethyl (*R*)-2-(chloromethyl)-4-((1-ethylpyrrolidin-3-yl)oxy)benzoate **93** as a brown oil. Material was taken through to the next step without purification. LCMS [M+H]⁺: 312.3.

Step 5: 3-(5-(((*R*)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-94)


Compound **I-94** was made according to General Method V starting from ethyl (*R*)-2-(chloromethyl)-4-((1-ethylpyrrolidin-3-yl)oxy)benzoate **93** (22 mg, 0.071 mmol). The reaction was concentrated and purified by reverse phase HPLC (10-30% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops of formic acid prior to sample collections. Fractions containing desired product were combined and lyophilized to afford formate salt of 3-(5-(((*R*)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-94** as a white solid. LCMS [M+H]⁺: 358.2. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.89 (s, 1H), 8.17 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 2.2 Hz, 1H), 6.93 (dd, *J* = 8.3, 2.4 Hz, 1H), 5.00 (dd, *J* = 13.4, 5.1 Hz, 1H), 4.93 - 4.85 (m, 1H), 4.32 (d, *J* = 17.1 Hz, 1H), 4.19 (d, *J* = 17.2 Hz, 1H), 2.89 - 2.72 (m, 2H), 2.68 - 2.58 (m, 1H), 2.56 - 2.49 (m, 1H), 2.39 - 2.20 (m, 6H), 1.95 - 1.86 (m, 1H), 1.75 - 1.62 (m, 1H), 0.96 (t, *J* = 7.2 Hz, 3H).

Example 40: 3-(5-(((S)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-99)



Compound **I-99** was made according to the previous **Example 39**, except that step 1 employed (S)-1-N-boc-3-hydroxy-pyrrolidine. In the final step 5, the reaction was concentrated and purified by silica gel chromatography (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane) to afford 3-(5-(((S)-1-ethylpyrrolidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-99** as a black solid. LCMS [M+H]⁺: 358.1. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 8.5 Hz, 1H), 6.89 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.82 (d, *J* = 2.2 Hz, 1H), 5.13 (dd, *J* = 13.2, 5.2 Hz, 1H), 4.86 (q, *J* = 4.8, 3.0 Hz, 1H), 4.36 (dd, *J* = 15.9, 4.7 Hz, 1H), 4.21 (d, *J* = 15.9 Hz, 1H), 3.38 (q, *J* = 7.3 Hz, 1H), 3.04 (dt, *J* = 14.1, 7.1 Hz, 1H), 2.84 - 2.74 (m, 5H), 2.58 (ddt, *J* = 11.4, 8.1, 3.5 Hz, 3H), 2.34 - 2.24 (m, 2H), 1.11 (t, *J* = 7.2 Hz, 3H).

Example 41: 3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-102)



Step 1: Tert-butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate (100)

To a 40 mL vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (527 mg, 1.16 mmol), dtbbpy (16 mg, 0.058 mmol), NiCl₂(glyme) (13 mg, 0.058 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (13 mg, 0.012 mmol) were added. Tert-butyl (2S,5R)-5-hydroxy-2-methylpiperidine-1-carboxylate (250 mg, 1.16 mmol) in ACN (6.0 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.206 mL, 1.2 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 72 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptanes) to afford tert-butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-

(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **100** as a yellow foam. LCMS [M-H]⁻: 586.1.


Step 2: 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (101)

5 Compound **101** was made according to General Method VII starting from *tert*-butyl (2*S*,5*R*)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **100** (525 mg, 0.89 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated
10 to remove DCM. A white solid crashed out of solution with remaining iPrOH. The solid was filtered to afford 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** as a white powder. LCMS [M+H]⁺: 358.1. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.17 (d, *J* = 2.2 Hz, 1H), 7.07 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.59 - 4.17 (m, 4H), 3.32 (s, 3H), 3.09 (d, *J* = 13.7 Hz, 1H), 2.95 - 2.72 (m,
15 2H), 2.65 - 2.54 (m, 2H), 2.43 - 2.26 (m, 1H), 2.01 - 1.89 (m, 2H), 1.70 (t, *J* = 13.9 Hz, 1H), 1.46 - 1.22 (m, 2H).

Step 3: 3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-102)


To a vial containing 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (200 mg, 0.56 mmol) and ACN (4.0 mL) was added sodium triacetoxyborohydride (356 mg, 1.68 mmol) followed by acetaldehyde (63 uL, 1.12 mmol). The reaction was stirred at r.t. overnight. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organics layers were combined, passed through a phase separator, and concentrated. The crude material was
25 purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,6S)-1-ethyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-102** as a white solid. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 8.21 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.18 (d, *J* = 2.2 Hz, 1H), 7.05 (dd, *J* = 8.5, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.61 - 4.48 (m, 1H), 4.45 - 4.15 (m, 2H), 2.90 (ddd, *J* = 17.3, 13.6, 5.4 Hz, 1H), 2.77 - 2.58 (m, 4H), 2.58 - 2.51 (m, 2H), 2.37 (qd, *J* = 13.2, 4.4 Hz, 1H), 2.02 - 1.91 (m, 1H), 1.82 - 1.67 (m, 2H), 1.67 - 1.47 (m, 2H), 0.99 (d, *J* = 6.4 Hz, 3H), 0.95 (s, 3H).

Example 42: 3-(5-(((*R*)-1-cyclopentylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-103)




To a suspension of 3-(1-oxo-5-(((*R*)-piperidin-3-yl)oxy)isindolin-2-yl)piperidine-2,6-dione **INT-2** (109 mg, 0.32 mmol), MgSO_4 (76 mg, 0.64 mmol), sodium triacetoxyborohydride (101 mg, 0.48 mmol) in DMF (1.5 mL) was added cyclopentanone (0.28 mL, 3.2 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was diluted with 4:1 DCM:iPrOH and washed with saturated aqueous sodium bicarbonate. The organic layer was passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM). Material was diluted with 1:3 ACN:water and lyophilized to afford 3-(5-(((*R*)-1-cyclopentylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-103** as a white solid. LCMS $[\text{M}+\text{H}]^+$: 412.9. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.18 (s, 1H), 7.04 (d, *J* = 8.4 Hz, 1H), 5.06 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.47 (s, 1H), 4.43 - 4.16 (m, 2H), 3.03 (d, *J* = 10.7 Hz, 1H), 2.96 - 2.81 (m, 1H), 2.71 (m, 1H), 2.53 (m, 3H), 2.35 (dd, *J* = 16.2, 11.7 Hz, 1H), 2.15 - 1.91 (m, 3H), 1.73 (m, 3H), 1.62 - 1.23 (m, 8H).

Example 43: 3-(5-(((*R*)-1-cyclohexylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-104)



Compound **I-104** was prepared in an analogous manner to previous **Example 42 (I-103)**. The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product. Material was diluted with 1:3 ACN:water and lyophilized to afford 3-(5-(((*R*)-1-cyclohexylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-104** as a white solid. LCMS $[\text{M}+\text{H}]^+$: 426.5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.18 (s, 1H), 7.04 (d, *J* = 8.5 Hz, 1H), 5.08 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.55 - 4.13 (m, 3H), 3.02 (s, 1H), 2.91 (ddd, *J* = 18.0, 13.5, 5.4 Hz, 1H), 2.55 (s, 2H), 2.32 (dp, *J* = 34.3, 12.5, 12.0 Hz, 5H), 2.12 - 1.91 (m, 2H), 1.72 (d, *J* = 8.7 Hz, 4H), 1.54 (t, *J* = 14.9 Hz, 2H), 1.34 (d, *J* = 11.5 Hz, 1H), 1.19 (s, 4H), 1.06 (s, 1H).

Example 44: *rac*-3-(5-(((2*R*,3*R*)-1-ethyl-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-107)



Step 1: *rac*-Tert-butyl (2*R*,3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate (105)

To a 40 mL vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (500 mg, 1.1 mmol), dtbbpy (15 mg, 0.055 mmol), NiCl₂(glyme) (12 mg, 0.055 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (12 mg, 0.011 mmol) were added. *rac*-Tert-butyl (2*R*,3*R*)-3-hydroxy-2-methylpiperidine-1-carboxylate (237 mg, 1.1 mmol) in ACN (5.0 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.20 mL, 1.2 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 24 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford *rac*-tert-butyl (2*R*,3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **105** as a yellow foam. LCMS [M-H]⁻: 586.5.


Step 2: *rac*-3-(5-(((2*R*,3*R*)-2-Methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (106)

Compound **106** was made according to General Method VII starting from *rac*-tert-butyl (2*R*,3*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **105** (588 mg, 1.0 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0-100% EtOH:Et₃N (v/v = 100:1) in dichloromethane) to afford *rac*-3-(5-(((2*R*,3*R*)-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **106** as a white cream solid. LCMS [M+H]⁺: 358.2.

Step 3: *rac*-3-(5-(((2*R*,3*R*)-1-Ethyl-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-107)

To a vial containing *rac*-3-(5-(((2*R*,3*R*)-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **106** (177 mg, 0.50 mmol) and ACN (4.0 mL) was added sodium triacetoxymethylborohydride (315 mg, 1.5 mmol) followed by acetaldehyde (60 μ L, 0.99 mmol). The reaction stirred at r.t. for 1 hr. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product. Material was diluted with 1:3 ACN:water, lyophilized and further purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford the formate salt of *rac*-3-(5-(((2*R*,3*R*)-1-ethyl-2-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-107** as a white solid. LCMS [M+H]⁺: 386.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 8.26 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.20 (d, *J* = 2.1 Hz, 1H), 7.06 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.53 (dt, *J* = 8.5, 4.1 Hz, 1H), 4.46 - 4.19 (m, 2H), 3.14 (dd, *J* = 6.8, 4.4 Hz, 1H), 2.91 (ddd, *J* = 17.9, 13.5, 5.4 Hz, 1H), 2.65 - 2.52 (m, 2H), 2.45 - 2.29 (m, 4H), 2.06 - 1.91 (m, 1H), 1.70 (dd, *J* = 22.3, 8.7 Hz, 3H), 1.54 (s, 1H), 1.04 - 0.87 (m, 6H).

Example 45: *rac*-3-(5-(((3*R*,5*S*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-111**); (*R*)-3-(5-(((3*R*,5*S*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*S*)-3-(5-(((3*R*,5*S*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*R*)-3-(5-(((3*S*,5*R*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, and (*S*)-3-(5-(((3*S*,5*R*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione



Step 1: *rac*-Tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate (109)

Compound **109** was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (750 mg, 1.65 mmol) and *rac*-tert-butyl (3*R*,5*S*)-3-hydroxy-5-methylpiperidine-1-carboxylate (356 mg, 1.65 mmol). The reaction was concentrated to afford *rac*-tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate **109** as a pale yellow solid. Material was taken through to the next step without purification. LCMS [M-H]⁻: 586.8.

Step 2: *rac*-3-(5-(((3*R*,5*S*)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (110)

Compound **110** was made according to General Method VII starting from *rac*-tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate **109** (970 mg, 1.65 mmol). The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:TFE three times. The organic layers were combined and concentrated to afford *rac*-3-(5-(((3*R*,5*S*)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **110**. Material was taken through to the next step without purification. LCMS [M+H]⁺: 358.3.


Step 3: *rac*-3-(5-(((3*R*,5*S*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-111); (R)-3-(5-(((3*R*,5*S*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-

oxoisoindolin-2-yl)piperidine-2,6-dione, (S)-3-(5-(((3R,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy))-1-oxoisoindolin-2-yl)piperidine-2,6-dione, (R)-3-(5-(((3S,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy))-1-oxoisoindolin-2-yl)piperidine-2,6-dione, and (S)-3-(5-(((3S,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy))-1-oxoisoindolin-2-yl)piperidine-2,6-dione

5 To a solution of *rac*-3-(5-(((3R,5S)-5-methylpiperidin-3-yl)oxy))-1-oxoisoindolin-2-yl)piperidine-2,6-dione **110** (590 mg, 1.65 mmol) and sodium triacetoxymethylborohydride (2.8 g, 13.2 mmol) in EtOH (5.0 mL) was added acetaldehyde (0.74 mL, 13.2 mmol) at 0 °C. The reaction stirred at r.t. overnight. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in Heptane). Fractions containing desired
10 product were combined and concentrated to afford *rac*-3-(5-(((3R,5S)-1-ethyl-5-methylpiperidin-3-yl)oxy))-1-oxoisoindolin-2-yl)piperidine-2,6-dione **I-111** as a white solid. LCMS [M+H]⁺: 386.4. ¹H NMR (400 MHz, CD₂Cl₂) δ 8.40 (s, 1H), 7.70 (d, *J* = 8.4 Hz, 1H), 7.20 (dd, *J* = 10.8, 2.2 Hz, 1H), 7.04 (ddd, *J* = 8.1, 5.4, 2.2 Hz, 1H), 5.11 (dd, *J* = 13.4, 5.1 Hz, 1H), 4.89 – 4.74 (m, 1H), 4.43 – 4.25 (m, 2H), 3.73 – 3.55 (m, 1H), 3.28 – 3.13 (m, 1H), 2.93 – 2.71 (m, 4H), 2.40 – 2.03
15 (m, 5H), 1.96 (t, *J* = 11.5 Hz, 1H), 1.30 – 1.10 (m, 4H), 1.00 (d, *J* = 6.5 Hz, 3H).

The diastereomeric mixture of isomers was further separated via a first chiral SFC [Column 20 x 250 mm ChromegaChiral CC4 from ES Industries; CO₂ Co-solvent 60% Ethanol with 0.25% triethylamine; at 60 g/min at 100 bar, at 25 °C] then a second chiral SFC [Column 21 x 250 mm Chiralpak AD-H from Chiral Technologies; CO₂ Co-solvent 50% Ethanol with 0.25%
20 triethylamine; at 60 g/min at 100 bar, at 25 °C] to afford four stereoisomers: **Peak 1 (Ex. 45A)**, *Rt* = 9.87 min, as a white solid; **Peak 2 (Ex. 45B)**, *Rt* = 8.80 min, as a white solid; **Peak 3 (Ex. 45C)**, *Rt* = 4.54 min, as a white solid; **Peak 4 (Ex. 45D)**, *Rt* = 6.53 min, as a white solid. The absolute stereochemistry of the four stereoisomers corresponding to the four product peaks was not determined.

Example 46: *rac*-3-(5-(((3*R*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-114); (*R*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*S*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*R*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*S*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione



Step 1: *rac*-Tert-butyl (3*R*,4*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate (112)

To a 40 mL vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (527 mg, 1.16 mmol), dtbbpy (16 mg, 0.058 mmol), NiCl₂(glyme) (13 mg, 0.058 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (13 mg, 0.012 mmol) were added. Tert-butyl (3*R**,4*R**)-3-hydroxy-4-methylpiperidine-1-carboxylate (250 mg, 1.16 mmol) in ACN (6.0 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.21 mL, 1.2 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 24 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc/heptane) to afford *rac*-tert-butyl (3*R*,4*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate 112 (448 mg, 0.762 mmol) as a yellow oily foam. LCMS [M-H]⁻: 586.4

Step 2: *rac*-3-(5-(((3*R*,4*R*)-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**113**)

Compound **113** was made according to General Method VII starting from *rac*-tert-butyl (3*R*,4*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-methylpiperidine-1-carboxylate **112** (448 mg, 0.76 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated to afford crude *rac*-3-(5-(((3*R*,4*R*)-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **113** (418 mg, 1.17 mmol). Material was taken through to the next step without purification.

LCMS [M+H]⁺: 358.3.


Step 3: *rac*-3-(5-(((3*R*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-114**); (*R*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*S*)-3-(5-(((3*R*,4*S*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, (*R*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, and (*S*)-3-(5-(((3*S*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione

To a vial containing *rac*-3-(5-(((3*R*,4*R*)-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **113** (418 mg, 1.17 mmol) and ACN (6.0 mL) was added sodium triacetoxyborohydride (744 mg, 3.51 mmol) followed by acetaldehyde (132 μ L, 2.4 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM). Fractions containing desired product were combined, concentrated diluted with DMSO:H₂O:ACN (1:1:1). The precipitate was filtered and washed with acetone to afford *rac*-3-(5-(((3*R*,4*R*)-1-ethyl-4-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-114** as a white solid. LCMS [M+H]⁺: 386.5. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.18 (s, 1H), 7.06 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.51 (s, 1H), 4.43 - 4.15 (m, 2H), 2.90 (ddd, *J* = 17.7, 13.6, 5.3 Hz, 2H), 2.55 (d, *J* = 9.4 Hz, 2H), 2.37 (dd, *J* = 13.1, 4.4 Hz, 1H), 2.30 (q, *J* = 7.0 Hz, 3H), 2.11 (m, 1H), 1.99 - 1.82 (m, 2H), 1.72 - 1.47 (m, 2H), 0.93 (ddd, *J* = 13.2, 7.3, 3.9 Hz, 6H). The filtrate was purified by acidic reverse phase HPLC (2-12% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined, lyophilized.

The diastereomeric mixture of isomers was separated via chiral SFC [Column 2 x 25 mm ChromegaChiral CC4 from ES; CO₂ Co-solvent 70% Ethanol with 0.25% triethylamine; at 60 g/min at 100 bar, at 25 °C] to afford four stereoisomers: **Peak 1 (Ex. 46A)**, Rt = 3.2 min, as a white solid; **Peak 2 (Ex. 46B)**, Rt = 3.1 min, as a white solid. Two stereoisomers required additional separation via chiral SFC [Column 2.1 x 25 cm Chiralpak AD-H from Chiral Technologies; CO₂ Co-solvent 50% ethanol with 0.25% triethylamine; at 70 g/min at 100 bar, at 25 °C] to afford two single stereoisomers: **Peak 3 (Ex. 46C)**, Rt = 3.5 mins, obtained as a white

solid; **Peak 4 (Ex. 46D)**, $R_t = 3.7$ mins, obtained as a white solid. The absolute stereochemistry of the four stereoisomers corresponding to the four product peaks was not determined.

Example 47: *rac*-3-(5-(((3*R*,5*S*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-117)



Step 1: *rac*-Tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate (115)

To a 40 mL capped vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (500 mg, 1.1 mmol), dtbbpy (15 mg, 0.055 mmol), $\text{NiCl}_2(\text{glyme})$ (12 mg, 0.055 mmol), and $\text{Ir}[(\text{dF}(\text{CF}_3)\text{ppy})_2\text{dtbbpy}]\text{PF}_6$ (12 mg, 0.011 mmol) were added. *rac*-Tert-butyl (3*R*,5*S*)-3,5-dihydroxypiperidine-1-carboxylate (240 mg, 1.1 mmol) in ACN (5.0 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.20 mL, 1.2 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto ISOLUTE® (HM-N Part No. 9800-5000) and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford *rac*-tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate **115** as a colorless foam. LCMS $[\text{M}+\text{H}-156.34]^+$: 434.2.

Step 2: *rac*-3-(5-(((3*R*,5*S*)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (116)


Compound **116** was made according to General Method VII starting from *rac*-tert-butyl (3*R*,5*S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate **115** (550 mg, 0.93 mmol). The reaction was quenched with a 50% saturated sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated. Crude material was purified by silica gel chromatography (0-100% EtOH:Et₃N (v/v = 100:1) in dichloromethane). Fractions containing desired product were combined, concentrated, suspended in 2:1 water:ACN and lyophilized to afford *rac*-3-(5-(((3*R*,5*S*)-5-hydroxypiperidin-3-

yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **116** as a white solid. LCMS $[M+H]^+$: 360.2. ^1H NMR (400 MHz, DMSO- d_6) δ 10.98 (s, 1H), 7.65 (t, J = 9.0 Hz, 1H), 7.24 (d, J = 11.1 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 5.16 (d, J = 39.1 Hz, 1H), 4.73 - 4.15 (m, 4H), 3.77 (s, 1H), 3.22 - 2.66 (m, 5H), 2.38 - 2.27 (m, 3H), 1.96 (d, J = 34.9 Hz, 2H), 1.57 (d, J = 11.2 Hz, 1H).

5 Step 3: *rac*-3-(5-(((3*R*,5*S*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-117)

To a vial containing *rac*-3-(5-(((3*R*,5*S*)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **116** (34 mg, 0.095 mmol) and ACN (2.0 mL) was added sodium triacetoxyborohydride (60 mg, 0.28 mmol) followed by acetaldehyde (11 μ L, 0.19 mmol). The reaction stirred at r.t. for 1 hr. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM). The material was further purified by basic reverse phase HPLC (10-30% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford *rac*-3-(5-(((3*R*,5*S*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-117** as a white solid. LCMS $[M+H]^+$: 388.5. ^1H NMR (400 MHz, DMSO- d_6) δ 10.94 (s, 1H), 8.23 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 2.2 Hz, 1H), 7.10 – 6.97 (m, 1H), 5.06 (dd, J = 13.3, 5.0 Hz, 1H), 4.48 (dt, J = 10.3, 5.3 Hz, 1H), 4.42 – 4.18 (m, 2H), 3.62 (tt, J = 9.7, 4.4 Hz, 1H), 3.10 (d, J = 10.3 Hz, 1H), 2.90 (ddd, J = 18.8, 11.8, 5.2 Hz, 2H), 2.69 – 2.53 (m, 1H), 2.46 – 2.28 (m, 4H), 2.04 – 1.91 (m, 1H), 1.84 (td, J = 10.1, 2.8 Hz, 1H), 1.68 (t, J = 10.2 Hz, 1H), 1.17 (qd, J = 11.1, 2.8 Hz, 1H), 0.99 (td, J = 7.1, 5.0 Hz, 4H).

Example 48: 3-(5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-123)



25 Step 1: 5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (121)

Compound **121** was made according to General Method X starting from single enantiomer 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **INT-119** (0.1 g, 0.336 mmol) and acetaldehyde (0.028 mL, 0.504 mmol). The crude material was purified by silica gel

chromatography (0-100% 3:1 EtOAc:EtOH with 1% TEA in heptane) to afford 5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **121** as a yellow oil. LCMS [M+H]⁺: 290.1.


Step 2: Ethyl 2-(chloromethyl)-4-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)benzoate (122**)**

To a solution of 5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **121** (0.033 g, 0.114 mmol) in dichloroethane (1.0 mL) and ethanol (1.0 mL) in a 25 mL 2 neck round bottom flask stirred at 70 °C was added thionyl chloride (0.10 mL, 1.368 mmol) dropwise. The reaction stirred at 70 °C overnight. The reaction mixture was cooled to r.t., diluted with water, and quenched with saturated sodium bicarbonate. The reaction mixture was extracted with ethyl acetate three times. The organic layers were combined, passed through a phase separator and concentrated. The crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl 2-(chloromethyl)-4-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)benzoate **122** as a light orange oil. LCMS [M+H]⁺: 354.3.

Step 3: 3-(5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-123**)**

Compound **I-123** was made according to General Method V starting from ethyl 2-(chloromethyl)-4-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)benzoate **122** (22.9 mg, 0.065 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% 3:1 ethyl acetate:ethanol with 1% triethylamine in heptane). Fractions containing desired product were combined and concentrated. The material was further purified by basic reverse phase HPLC (25-50% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt 3-(5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-123** as a cream solid. LCMS [M+H]⁺: 400.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.76 (s, 1H), 8.19 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.13 (d, J = 2.1 Hz, 1H), 6.99 (dd, J = 8.3, 2.2 Hz, 1H), 5.00 (dd, J = 13.3, 5.0 Hz, 1H), 4.32 (dd, J = 17.2, 6.1 Hz, 1H), 4.25 - 4.06 (m, 2H), 2.89 - 2.69 (m, 2H), 2.56 - 2.47 (m, 2H), 2.36 - 2.22 (m, 3H), 2.16 - 2.05 (m, 2H), 1.96 - 1.87 (m, 1H), 1.47 - 1.40 (m, 2H), 0.96 - 0.87 (m, 9H). Absolute stereochemistry at 3-position of the piperidine ring of **I-123** was not determined.

Example 49: 3-(5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-126**)**




Example 49 (I-126) was synthesized by analogy to the previous **Example 48** starting with single enantiomer **INT-120**. Absolute stereochemistry at 3-position of the piperidine ring of **I-126** was not determined.

Step 1: 5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (124) LCMS [M+H]⁺: 290.1.

Step 2: 5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (125) Material was used directly in the next reaction without purification. LCMS [M+H]⁺: 354.3.

5 In the final step 3, the reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% 3:1 ethyl acetate:ethanol with 1% triethylamine in heptane). Fractions containing desired product were combined and concentrated. The material was further purified by basic reverse phase HPLC (25-50% ACN in water with 5 mM NH₄OH as modifier). Test
10 tubes contained 3 drops of formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt 3-(5-((1-ethyl-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-126** as a white solid. LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.21 (s, 2H), 7.55 (d, *J* = 8.5 Hz, 1H), 7.14 (d, *J* = 2.1 Hz, 1H), 6.99 (dd, *J* = 8.3, 2.3 Hz, 1H), 5.00 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.32 (dd, *J* = 17.2, 6.2 Hz, 1H), 4.25 - 4.10 (m, 2H), 2.89 - 2.72 (m, 2H), 2.56 - 2.45 (m, 2H), 2.37 - 2.23 (m, 3H), 2.17 - 2.06 (m, 2H), 1.95 - 1.85 (m, 1H), 1.49 - 1.36 (m, 2H), 0.98 - 0.85 (m, 9H).

Example 50: 3-(5-((1-((*S*)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-129)



20 **Step 1: 5-((1-((*S*)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (127)**

Compound **127** was made according to [General Method IX](#) starting from single enantiomer 5-((4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **INT-119** (0.1 g, 0.383 mmol) and (*R*)-sec-butyl methanesulfonate **INT-27** (0.2 g, 1.314 mmol). The crude material was purified by silica gel chromatography (0-100% 3:1 ethyl acetate:ethanol with 1% triethylamine in
25 heptane). Fractions containing product were combined and concentrated to afford 5-((1-((*S*)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **127** as light orange oil. LCMS [M+H]⁺: 318.3. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.5 Hz, 1H), 7.02 - 6.94 (m, 1H),

6.95 - 6.86 (m, 1H), 5.16 (s, 2H), 4.21 - 3.98 (m, 1H), 2.78 - 2.71 (m, 1H), 2.54 - 2.26 (m, 4H), 1.60 - 1.43 (m, 3H), 1.27 - 1.12 (m, 1H), 0.99 (s, 3H), 0.97 - 0.86 (m, 6H), 0.85 - 0.79 (m, 3H).


Step 2: Ethyl 4-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-2-(chloromethyl)benzoate (128)

5 Compound **128** was made according to General Method IV starting from 5-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one **127** (0.0408 g, 0.129 mmol). Crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl 4-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-2-(chloromethyl)benzoate **128** as a brown orange oil. Material was used directly in the next reaction. LCMS [M+H]⁺: 382.2.

10 **Step 3: 3-(5-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-129)**

Compound **I-129** was made according to General Method V starting from ethyl 4-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-2-(chloromethyl)benzoate **128** (49.3 mg, 0.129 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% 3:1 ethyl acetate:ethanol with 1% triethylamine in heptane). Fractions containing desired product were combined and concentrated. The material was further purified by basic reverse phase HPLC (35-60% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt 3-(5-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-129** as a white solid. LCMS [M+H]⁺: 428.4. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 8.16 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.13 - 7.07 (m, 1H), 6.99 - 6.94 (m, 1H), 5.00 (dd, J = 13.3, 5.1 Hz, 1H), 4.32 (dd, J = 17.2, 4.3 Hz, 1H), 4.19 (dd, J = 17.3, 3.9 Hz, 1H), 4.14 - 4.03 (m, 1H), 2.83 (ddd, J = 17.3, 13.5, 5.4 Hz, 1H), 2.72 - 2.58 (m, 1H), 2.56 - 2.48 (m, 1H), 2.40 - 2.17 (m, 5H), 1.95 - 1.81 (m, 1H), 1.49 - 1.30 (m, 3H), 1.21 - 1.07 (m, 1H), 0.97 - 0.88 (m, 6H), 0.83 (d, J = 6.7 Hz, 3H), 0.81 - 0.68 (m, 3H). Absolute stereochemistry at 3-position of the piperidine ring of **I-129** was not determined.

Example 51: 3-(5-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-132)



30

Example 51 (I-132) was synthesized by analogy to the previous **Example 50** starting with single enantiomer **INT-120**. Absolute stereochemistry at 3-position of the piperidine ring of **I-132** was not determined.

Step 1: 5-((1-((S)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)isobenzofuran-1(3H)-one (130)

LCMS [M+H]⁺: 318.4. ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 8.5 Hz, 1H), 7.10 - 7.03 (m, 1H), 7.00 - 6.94 (m, 1H), 5.24 (s, 2H), 4.24 - 4.10 (m, 1H), 2.85 - 2.76 (m, 1H), 2.60 - 2.33 (m, 4H), 1.64 - 1.47 (m, 3H), 1.35 - 1.21 (m, 1H), 1.07 (s, 3H), 1.03 (s, 3H), 1.00 - 0.95 (m, 3H), 0.94 - 0.87 (m, 3H).


5 **Step 2: Ethyl 4-((1-((*S*)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-2-(chloromethyl)benzoate (131)**

Material was used directly in the next reaction. LCMS [M+H]⁺: 382.3.

In the final step 3, the material was further purified by basic reverse phase HPLC (35-60% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt 3-(5-((1-((*S*)-sec-butyl)-4,4-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione I-132 as a white solid. LCMS [M+H]⁺: 428.5. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 8.29 (s, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.10 (dd, *J* = 8.1, 2.2 Hz, 1H), 7.01 - 6.95 (m, 1H), 5.00 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.32 (dd, *J* = 17.3, 5.1 Hz, 1H), 4.19 (dd, *J* = 17.3, 5.9 Hz, 1H), 4.14 - 4.05 (m, 1H), 2.83 (ddd, *J* = 17.1, 13.5, 5.4 Hz, 1H), 2.70 - 2.62 (m, 1H), 2.56 - 2.49 (m, 1H), 2.36 - 2.19 (m, 5H), 1.96 - 1.86 (m, 1H), 1.49 - 1.31 (m, 3H), 1.22 - 1.07 (m, 1H), 0.96 - 0.89 (m, 6H), 0.83 (d, *J* = 6.4 Hz, 3H), 0.80 - 0.71 (m, 3H).

Example 52: rac-3-(5-(((3*R*,5*R*)-1-Ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-136)

20



Step 1: *rac*-Tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate (134)

To a 40 mL capped vial, 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (988 mg, 2.2 mmol), dtbbpy (29.2 mg, 0.11 mmol), NiCl₂(glyme) (24 mg, 0.11 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (24 mg, 0.022 mmol) were added. *rac*-Tert-butyl (3*R*,5*R*)-3-hydroxy-5-methylpiperidine-1-carboxylate INT-133 (469 mg, 2.2 mmol) in ACN (10.0 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (0.39 mL, 2.3

mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 24 hrs and 48 hrs with no LED. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford *rac*-tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-

5 oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate **134**. LCMS [M-H]⁻: 586.3.


Step 2: *rac*-3-(5-(((3*R*,5*R*)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (135)

Compound **135** was made according to General Method VII starting from *rac*-tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate **134** (1.11 g, 1.89 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated to afford *rac*-3-(5-(((3*R*,5*R*)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **135**. Material was used directly in the next reaction without purification. LCMS [M+H]⁺: 358.2.

15 **Step 3: *rac*-3-(5-(((3*R*,5*R*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-136)**

To a vial containing *rac*-3-(5-(((3*R*,5*R*)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **135** (629 mg, 1.76 mmol) and ACN (10.0 mL) was added sodium triacetoxyborohydride (1.12 g, 5.28 mmol) followed by acetaldehyde (200 µL, 3.5 mmol). The reaction stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organics layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product. Material was dissolved in 1:1:1 DMSO:water:ACN (v/v/v = 1:1:1) and further purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford *rac*-3-(5-(((3*R*,5*R*)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-136**. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, DMSO-d₆) δ 10.95 (s, 1H), 8.24 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 2.2 Hz, 1H), 7.04 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.77 - 4.64 (m, 1H), 4.46 - 4.15 (m, 2H), 2.94 - 2.84 (m, 2H), 2.71 (d, *J* = 10.8 Hz, 1H), 2.59 (ddd, *J* = 17.3, 4.5, 2.4 Hz, 1H), 2.39 - 2.29 (m, 3H), 2.23 (d, *J* = 12.2 Hz, 1H), 1.98 (ddd, *J* = 9.9, 5.4, 2.7 Hz, 2H), 1.86 (d, *J* = 13.9 Hz, 1H), 1.72 (t, *J* = 10.1 Hz, 1H), 1.29 (t, *J* = 12.2 Hz, 1H), 0.95 (td, *J* = 7.2, 1.6 Hz, 3H), 0.87 (dd, *J* = 6.8, 1.2 Hz, 3H).

35 **Example 53: 3-(5-(((1*S**,5*R**,6*R**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-138)**




Step 1: Ethyl 2-(chloromethyl)-4-(((1*R,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate (137)**

Compound **137** was made according to General Method IV starting from 5-(((1*R**,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)isobenzofuran-1(3H)-one **INT-47 Peak 2** (77.8 mg, 0.29 mmol). Crude material was purified by silica gel chromatography (0-100% EtOAc in heptane) to afford ethyl 2-(chloromethyl)-4-(((1*R**,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **137** as a brown oil. LCMS [M+H]⁺: 338.2.

Step 2: 3-(5-(((1*R,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-138)**

Compound **I-138** was made according to General Method V starting from ethyl 2-(chloromethyl)-4-(((1*R**,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)benzoate **137** (70 mg, 0.21 mmol). The reaction was concentrated and purified by silica gel chromatography pushing the crude material through a plug of charcoal before reaching the silica column (0-100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Pure fractions were combined, concentrated, and further purified by reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt of 3-(5-(((1*R**,5*S**,6*S**)-3-ethyl-3-azabicyclo[4.1.0]heptan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-138** as a white solid. LCMS [M+H]⁺: 384.2. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.30 (s, 2H), 7.60 (d, *J* = 8.3 Hz, 1H), 7.23 (d, *J* = 2.0 Hz, 1H), 7.08 (dd, *J* = 8.7, 2.4 Hz, 1H), 5.08 (dd, *J* = 13.3, 5.0 Hz, 1H), 5.02 - 4.91 (m, 1H), 4.39 (d, *J* = 17.1 Hz, 1H), 4.26 (d, *J* = 17.0 Hz, 1H), 2.92 (ddd, *J* = 18.0, 13.5, 5.4 Hz, 1H), 2.71 (d, *J* = 11.0 Hz, 1H), 2.65 - 2.56 (m, 1H), 2.47 - 2.36 (m, 3H), 2.35 - 2.25 (m, 3H), 2.04 - 1.93 (m, 1H), 1.57 - 1.46 (m, 1H), 1.33 - 1.20 (m, 1H), 0.97 (t, *J* = 7.1 Hz, 3H), 0.73 - 0.65 (m, 1H), 0.48 - 0.39 (m, 1H). The absolute stereochemistry of **I-138** was not determined.

Example 54: rac-3-(5-((-7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-144)



Step 1: *rac*-Tert-butyl 5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-7-azaspiro[3.5]nonane-7-carboxylate (140)

To a 40 mL capped vial, 5-bromoisobenzofuran-1(3H)-one (45 mg, 0.21 mmol), *rac*-tert-butyl 5-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate (52 mg, 0.22 mmol), dtbbpy (5.7 mg, 0.021 mmol), NiCl₂(glyme) (4.6 mg, 0.021 mmol), and Ir[(dF(CF₃)ppy)₂dtbbpy]PF₆ (4.7 mg, 4.2 μmol) were added. ACN (0.9 mL) was added and the reaction was purged with nitrogen for 5-10 minutes ensuring reaction turns green. Then 2,2,6,6-tetramethylpiperidine (37 μL, 0.22 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 18 hrs. The reaction was concentrated onto CELITE® and purified by silica gel chromatography (0-100% EtOAc in heptane) to afford *rac*-tert-butyl 5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-7-azaspiro[3.5]nonane-7-carboxylate **140** as a light yellow solid. LCMS [M+H-tert-butyl]⁺: 318.3.

Step 2: *rac*-5-((7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one (141)

Compound **141** was made according to General Method II starting from *rac*-tert-butyl 5-((1-oxo-1,3-dihydroisobenzofuran-5-yl)oxy)-7-azaspiro[3.5]nonane-7-carboxylate **140** (23 mg, 0.062 mmol). The reaction was concentrated to afford *rac*-5-((7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one **141** as a light yellow oil. Material was used directly in the next step. LCMS [M+H]⁺: 274.1.

Step 3: *rac*-5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one (142)

Compound **142** was made according to General Method X starting from *rac*-5-((7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one **141** (17 mg, 0.062 mmol) and acetaldehyde (5.3 μ L, 0.093 mmol). The crude material was purified by silica gel chromatography (0-20% methanol in DCM) to afford *rac*-5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one **142** as a light orange solid. LCMS $[M+H]^+$: 302.2.


Step 4: *rac*-Ethyl 2-(chloromethyl)-4-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)benzoate (143)

Compound **143** was made according to General Method IV starting from *rac*-5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)isobenzofuran-1(3H)-one **142** (12.5 mg, 0.041 mmol) to afford *rac*-ethyl 2-(chloromethyl)-4-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)benzoate **143** as a brown orange oil. Material was taken through to the next step without purification. LCMS $[M+H]^+$: 366.3.

Step 5: *rac*-3-(5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-144)

Compound **I-144** was made according to General Method V starting from *rac*-ethyl 2-(chloromethyl)-4-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)benzoate **143** (15 mg, 0.041 mmol). The reaction was concentrated and purified by basic reverse phase HPLC (25-50% ACN in water with 5 mM NH_4OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Pure fractions were combined and lyophilized to afford formate salt of *rac*-3-(5-((7-ethyl-7-azaspiro[3.5]nonan-5-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-144** as a light blue solid. LCMS $[M+H]^+$: 412.2. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.88 (s, 1H), 8.24 (s, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.03 (dd, J = 8.4, 2.2 Hz, 1H), 5.00 (dd, J = 13.3, 5.0 Hz, 1H), 4.32 (dd, J = 17.2, 7.3 Hz, 1H), 4.26 - 4.13 (m, 2H), 3.00 - 2.90 (m, 1H), 2.84 (ddd, J = 17.3, 13.7, 5.4 Hz, 1H), 2.52 (ddd, J = 17.4, 4.5, 2.4 Hz, 1H), 2.33 (td, J = 13.2, 4.5 Hz, 1H), 2.27 - 2.17 (m, 2H), 2.11 (d, J = 14.1 Hz, 2H), 1.95 - 1.70 (m, 4H), 1.55 (dtd, J = 26.1, 9.6, 4.1 Hz, 2H), 0.91 (d, J = 6.7 Hz, 4H), 0.86 (t, J = 7.2 Hz, 3H).

Example 55: 3-(5-(((3*S,4*S**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-150)**



Step 1: Tert-butyl (3S*,4S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate (147)

To a solution of benzyl (3S*,4S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate INT-146 Peak 1 (absolute stereochemistry unknown) (230 mg, 0.91 mmol) in MeOH (2 mL) was added Boc_2O (218 mg, 0.23 mL, 1.0 mmol) and 10% Pd/C (50 mg, 0.047 mmol). The mixture stirred under an atmosphere of hydrogen gas at r.t. for 16 hrs. The suspension was filtered through a pad of CELITE®, the pad was washed with MeOH (3 x 5 mL), and the combined filtrates were concentrated. The crude material was purified by silica gel chromatography (30-55% ethyl acetate in petroleum ether) and the fractions with pure product were concentrated to afford tert-butyl (3S*,4S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate **147** as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 4.60 - 4.41 (m, 1H), 4.00 - 3.72 (m, 3H), 3.11 (br s, 2H), 2.69 - 2.38 (m, 1H), 2.16 - 2.06 (m, 1H), 1.72 (br s, 1H), 1.48 (s, 9H).

Step 2: Tert-butyl (3S*,4S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate (148)

A mixture of 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (100 mg, 0.22 mmol), tert-butyl (3S*,4S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate (97 mg, 0.44 mmol), $\text{Ir}[\text{dF}(\text{CF}_3)\text{ppy}]_2(\text{dtbbpy})(\text{PF}_6)$ (3 mg, 0.002 mmol) and $\text{NiCl}_2\cdot\text{dtbbpy}$ (4 mg, 0.011 mmol), quinuclidine (3 mg, 0.022 mmol), TMP (62 mg, 0.44 mmol) in ACN (2.0 mL) was degassed with nitrogen gas three times. The reaction vial was sealed with parafilm, placed 2 cm away from a blue LED, and irradiated at r.t. for 16 hrs. The reaction

mixture was filtered and the filter cake was washed with ACN (3 x 5 mL). The combined filtrates were concentrated. The crude material was purified by silica gel chromatography (20-60% EtOAc in petroleum ether) and the fractions containing pure product were concentrated to afford

5 tert-butyl (3S*,4S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **148** as bright yellow oil. LCMS [M-27]⁺: 564.4. ¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J = 8.4 Hz, 1H), 7.27 (br s, 1H), 7.19 - 7.07 (m, 1H), 5.20 - 5.12 (m, 1H), 5.11 - 4.79 (m, 3H), 4.68 - 4.52 (m, 1H), 4.47 - 4.18 (m, 2H), 3.58 - 3.46 (m, 3H), 3.12 - 2.98 (m, 1H), 2.86 - 2.73 (m, 1H), 2.38 - 2.30 (m, 1H), 2.07 (s, 9H), 1.75 (d, J = 9.6 Hz, 1H), 1.26 (br s, 5H), 0.89 - 0.77 (m, 2H), -0.02 (s, 9H).

10 **Step 3: 3-(5-(((3S*,4S*)-4-fluoropiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (149)**


To a mixture of tert-butyl (3S*,4S*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **148** (80 mg, 0.13 mmol) in ACN (1.0 mL) was added MsOH (130 mg, 0.09 mL, 1.35 mmol). The reaction stirred at r.t. for 12 hrs. Then Et₃N (178 mg, 0.24 mL, 1.76 mmol) and DMEDA (20 mg, 0.02 mL, 0.23 mmol) were added and the reaction mixture stirred at r.t. for 8 hrs. The reaction mixture was concentrated, dissolved in DMSO and purified by reverse phase column chromatography (Solid phase: XB-C18, 20-35 μm, 100 Å, 0-18% acetonitrile in water with 0.1% formic acid). Fractions containing pure product were concentrated to remove ACN and then lyophilized to afford 3-(5-(((3S*,4S*)-4-fluoropiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **149** as a yellow solid. LCMS [M+H]⁺: 362.1.

20 **Step 4: 3-(5-(((3S*,4S*)-1-ethyl-4-fluoropiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-150)**

To a mixture of 3-(5-(((3S*,4S*)-4-fluoropiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **149** (20 mg, 0.06 mmol) and acetaldehyde (49 mg, 0.44 mmol, 40%) in THF:EtOH (1:1, 0.5 mL) was added 2M ZnCl₂ in THF (0.08 mL, 0.17 mmol) and stirred at r.t. for 1 hr. NaBH₃CN (10 mg, 0.17 mmol) was added to the reaction mixture and the reaction mixture stirred at r.t. for 15 hrs. Additional acetaldehyde (30 mg, 0.26 mmol 40%) was added to the reaction mixture and stirred at r.t. for 16 hrs. The suspension was filtered and the filter cake was washed with ACN (3 x 5 mL). The combined filtrates were concentrated. The crude material was dissolved in DMSO and purified by reverse phase HPLC (1-25% ACN in water with 0.225% formic acid as modifier). The fractions containing pure product were concentrated to remove the ACN and lyophilized to afford formate salt 3-(5-(((3S*,4S*)-1-ethyl-4-fluoropiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-150** as an off-white solid. LCMS [M+H]⁺: 390.1. ¹H NMR(400 MHz, ACETONITRILE-d₃) δ 9.04 (br s, 1H), 8.19 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.20 (s, 1H), 7.11 - 7.00(m, 1H), 5.04 - 5.95 (m, 1H), 4.82 - 4.59 (m, 2H), 4.40 - 4.23 (m, 2H), 3.32 - 3.22 (m, 1H), 3.02 - 2.93 (m, 1H), 2.87 - 2.68 (m, 2H), 2.61 (q, J = 7.2 Hz, 2H), 2.48 - 2.32 (m, 3H), 2.28 - 2.16 (m, 1H), 2.10 - 1.98 (m, 1H), 1.93 (br s, 1H), 1.08 (t, J = 7.2 Hz,

3H). ^{19}F NMR(400 MHz, ACETONITRILE- d_3) δ -185.5. The absolute stereochemistry at the 3- and 4-position of the piperidine ring was not determined.

Example 56: 3-(5-(((3*R,4*R**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-154)**



Step 1: Tert-butyl (3*R,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate (151)**

To a mixture of benzyl (3*R**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate INT-146 peak 2 (absolute stereochemistry undetermined) (240 mg, 0.95 mmol) in MeOH (2.0 mL) was added Boc_2O (227 mg, 0.24 mL, 1.04 mmol) and 10% Pd/C (50 mg, 0.047 mmol). The mixture stirred under an atmosphere of hydrogen gas at r.t. for 16 hrs. The suspension was filtered through a pad of CELITE®, the pad was washed with MeOH (3 x 5 mL), and the combined filtrates were concentrated. The crude material was purified by silica gel chromatography (20-50% ethyl acetate in petroleum ether) and the fractions with pure product were concentrated to afford tert-butyl (3*R**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **151** as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 4.60 - 4.39 (m, 1H), 4.04 - 3.72 (m, 3H), 3.10 (d, J = 1.6 Hz, 2H), 2.54 - 2.30 (m, 1H), 2.16 - 2.03 (m, 1H), 1.82 - 1.68 (m, 1H), 1.48 (s, 9H).

Step 2: Tert-butyl (3*R,4*R**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate (152)**

A mixture of 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (100 mg, 0.22 mmol), tert-butyl (3*R**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **151** (73 mg, 0.33 mmol), $\text{Ir}[\text{dF}(\text{CF}_3)\text{ppy}]_2(\text{dtbbpy})(\text{PF}_6)_3$ (3 mg, 0.002 mmol) and $\text{NiCl}_2 \cdot \text{dtbbpy}$ (4 mg, 0.011 mmol), quinuclidine (2 mg, 0.022 mmol), TMP (62 mg, 0.44 mmol) in

ACN (2.0 mL) was degassed three times under N₂. The reaction vial was sealed with parafilm, placed 2 cm away from one blue LED, and irradiated at r.t. for 16 hrs. The reaction mixture was filtered and the filter cake was washed with ACN (3 x 5 mL) and the combined filtrates were concentrated. The crude material was purified by reverse phase column chromatography (Solid
5 phase: XB-C18, 20-35 µm, 100 Å, Mobile phase: 0-24% acetonitrile in water with 0.1% formic acid as modifier) and the fractions with pure product were concentrated to afford tert-butyl (3*R**,4*R**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **152** as a white solid. LCMS [M+H-28]⁺: 564.4.


*Step 3: 3-(5-(((3*R**,4*R**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-*
10 *dione (153).*

MsOH (57 mg, 0.04 mL, 0.59 mmol) was added to a mixture of tert-butyl (3*R**,4*R**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **152** (30 mg, 0.059 mmol) in ACN (0.5 mL). The reaction mixture stirred at r.t. for 12 hrs. Et₃N (79 mg, 0.1 mL, 0.77 mmol) and DMEDA (9 mg, 0.01 mL, 0.10
15 mmol) were added dropwise and the mixture stirred at r.t. for 8 hrs. The reaction was concentrated to afford crude 3-(5-(((3*R**,4*R**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **153**. Material was taken on to the next step without purification. LCMS [M+H]⁺: 362.1.

*Step 4: 3-(5-(((3*R**,4*R**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-*
20 *2,6-dione (I-154)*

2M ZnCl₂ in THF (0.2 mL, 0.42 mmol) was added to a mixture of 3-(5-(((3*R**,4*R**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **153** (50 mg, 0.12 mmol) and acetaldehyde (64 mg, 0.6 mmol, 40%) in THF:EtOH (1:1, 0.5 mL) at r.t. and stirred for 1 hr. NaBH₃CN (26 mg, 0.42 mmol) was added and the reaction stirred at r.t. for 15 hrs. Additional
25 acetaldehyde (64 mg, 0.6 mmol, 40%) was added and the reaction stirred at r.t. for 32 hrs. The reaction mixture was concentrated. The crude material was dissolved in DMSO and purified by reverse phase HPLC (1-25% ACN in water with 0.225% formic acid as modifier). Fractions with pure product were concentrated to afford formate salt 3-(5-(((3*R**,4*R**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-154** as a yellow solid. LCMS [M+H]⁺: 390.1
30 m/z. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (br s, 1H), 8.23 (s, 1H), 7.64 (d, *J* = 8.4 Hz, 1H), 7.29 (s, 1H), 7.13 - 6.50 (m, 1H), 5.09 - 4.95 (m, 1H), 4.81 - 4.58 (m, 2H), 4.46 - 4.25 (m, 2H), 3.15 - 3.09 (m, 1H), 2.97 - 2.88 (m, 1H), 2.87 - 2.80 (m, 1H), 2.65 - 2.60 (m, 1H), 2.42 - 2.35 (m, 3H), 2.17 - 2.05 (m, 3H), 2.04 - 1.97 (m, 1H), 1.86 - 1.74 (m, 1H), 1.00 (t, *J* = 7.2 Hz, 3H). ¹⁹F NMR (377 MHz, DMSO-*d*₆) δ -181.9. The absolute stereochemistry at the 3- and 4-position of
35 the piperidine ring was not determined.

Example 57: 3-(5-(((3*S,4*R**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-159)**



Step 1: Tert-butyl (3*S,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate (156)**

Boc₂O (371 mg, 0.39 mL, 1.7 mmol) and 10% Pd/C (100 mg, 0.094 mmol) were added to a solution of benzyl (3*S**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **INT-155 Peak 1** (absolute stereochemistry undetermined) (430 mg, 1.7 mmol) in MeOH (5.0 mL) at r.t. and stirred under an atmosphere of hydrogen gas for 16 hrs. The suspension was filtered through a pad of CELITE® and the filter cake was washed with MeOH (3 x 5 mL). The combined filtrates were concentrated. The crude material was purified by silica gel chromatography (40-60% EtOAc in petroleum ether) and the fractions containing pure product were collected and concentrated to afford tert-butyl (3*S**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **156** as colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ 5.17 (d, *J* = 4.8 Hz, 1H), 4.83 - 4.60 (m, 1H), 3.64 - 3.39 (m, 3H), 3.22 - 3.00 (m, 2H), 1.94 - 1.82 (m, 1H), 1.73 - 1.53 (m, 1H), 1.39 (s, 9H)

Step 2: Tert-butyl (3*S,4*R**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate (157)**

A mixture of 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (250 mg, 0.55 mmol), tert-butyl (3*S**,4*R**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **156** (242 mg, 1.1 mmol), Ir[dF(CF₃)ppy]₂(dtbbpy)(PF₆) (7 mg, 0.006 mmol), NiCl₂·dtbbpy (1 mg, 0.003 mmol), quinuclidine (7 mg, 0.06 mmol), TMP (155 mg, 1.1 mmol) in ACN (4.0 mL) was degassed three times under N₂. The reaction vial was sealed with parafilm, placed 2 cm away from one blue LED, and irradiated at r.t. for 16 hrs. The reaction mixture was filtered and the filter cake was washed with ACN (3 x 5 mL). The filtrates were combined and concentrated. The crude material was purified by silica gel chromatography (0-100% EtOAc in petroleum ether) and fractions containing pure product were concentrated to afford tert-butyl (3*S**,4*R**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **157** as a green oil. LCMS [M+H-28]⁺: 564.4 m/z. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.65 (d, *J* = 8.4 Hz, 1H), 7.28 - 7.22 (m, 1H), 7.17 - 7.06 (m, 1H), 5.19 - 5.17 (m, 1H), 5.11 - 4.94 (m, 3H), 4.86 - 4.73 (m, 1H), 4.43 - 4.41 (m, 1H), 4.23 - 4.20 (m,

1H), 3.55 - 3.53 (m, 1H), 3.52 - 3.50 (m, 3H), 3.13 - 2.98 (m, 2H), 2.78 - 2.76 (m, 2H), 2.38 - 2.30 (m, 1H), 2.03 - 1.79 (m, 3H), 1.40 - 1.10 (m, 9H), 0.83 - 0.81 (m, 2H), -0.02 (s, 9H).


Step 3: 3-(5-(((3S*,4R*)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (158)

5 MsOH (406 mg, 0.27 mL, 4.22 mmol) was added to a solution of tert-butyl (3S*,4R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **157** (250 mg, 0.42 mmol) in ACN (3.0 mL) and stirred at 40 °C for 2 hrs. Et₃N (556 mg, 0.76 mL, 5.5 mmol) and DMEDA (63 mg, 0.08 mL, 0.71 mmol) were added and the reaction mixture stirred at r.t. for 14 hrs. The reaction mixture was concentrated. The
10 crude material was dissolved in DMSO and purified by reverse phase column chromatography [Column: XB-C18 (20-35 µm, 100 Å); 0%-20% ACN in H₂O with 0.1% formic acid as modifier]. The fractions with pure product were concentrated to afford formate salt 3-(5-(((3S*,4R*)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **158** as a yellow solid. LCMS [M+H]⁺: 362.2 m/z. ¹H NMR (400 MHz, DMSO-d₆) δ 10.98 (br s, 1H), 8.21 (s, 1H), 7.64 (d, J =
15 8.4 Hz, 1H), 7.26 (s, 1H), 7.14 - 7.12 (m, 1H), 5.09 - 5.05 (m, 2H), 4.73 - 4.68 (m, 1H), 4.42 - 4.24 (m, 2H), 3.06 - 2.82 (m, 4H), 2.79 - 2.71 (m, 1H), 2.60 - 2.55 (m, 1H), 2.40 - 2.35 (m, 2H), 2.06 - 1.77 (m, 3H).

Step 4: 3-(5-(((3S*,4R*)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-159)

20 2M ZnCl₂ in THF (0.37 mL, 0.74 mmol) was added to a solution of 3-(5-(((3S*,4R*)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **158** (100 mg, 0.25 mmol) and acetaldehyde (270 mg, 2.45 mmol, 40%) in THF:EtOH (1:1, 1 mL) at r.t. and stirred for 1 hr. NaBH₃CN (46 mg, 0.74 mmol) was added and the reaction mixture stirred at r.t. for 15 hrs. The suspension was concentrated. The crude material was dissolved in DMSO and purified by
25 reverse phase HPLC (1-25% ACN in water with 0.225% formic acid as modifier). The fractions containing pure product were concentrated to afford formate salt 3-(5-(((3S*,4R*)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-159** as a white solid. LCMS [M+H]⁺: 390.1. ¹H NMR (400 MHz, ACETONITRILE-d₃) δ 9.02 (br s, 1H), 8.20 (s, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.18 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 5.11 - 4.91 (m, 2H), 4.84 - 4.71 (m, 1H),
30 4.39 - 4.25 (m, 2H), 3.05 (d, J = 10.4 Hz, 1H), 2.86 - 2.70 (m, 4H), 2.67 - 2.55 (m, 3H), 2.45 - 2.34 (m, 1H), 2.23 - 1.98 (m, 3H), 1.10 (t, J = 7.2 Hz, 3H). The absolute stereochemistry at the 3- and 4-position of the piperidine ring was not determined.

Example 58: 3-(5-(((3R*,4S*)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-163)



Step 1: Tert-butyl (3*R**,4*S**)-4-fluoro-3-hydroxypiperidine-1-carboxylate (160)

Boc₂O (389 mg, 0.41 mL, 1.78 mmol) and 10% Pd/C (100 mg, 0.094 mmol) were added to a solution of benzyl (3*R*,4*S*)-4-fluoro-3-hydroxypiperidine-1-carboxylate INT-155 Peak 2 (absolute stereochemistry undetermined) (430 mg, 1.7 mmol) in MeOH (5.0 mL) at 25 °C and stirred under an atmosphere of hydrogen gas for 16 hrs. The suspension was filtered through a pad of CELITE® and the filter cake was washed with MeOH (3 x 5 mL). The combined filtrates were concentrated. The crude material was purified by silica gel chromatography (40-60% EtOAc in petroleum ether) and the fractions containing pure product were collected and concentrated to afford tert-butyl (3*R**,4*S**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **160** as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ 5.17 (d, *J* = 5.2 Hz, 1H), 4.86 - 4.58 (m, 1H), 3.65 - 3.37 (m, 3H), 3.23 - 3.00 (m, 2H), 1.94 - 1.80 (m, 1H), 1.74 - 1.54 (m, 1H), 1.39 (s, 9H).

Step 2: Tert-butyl (3*R**,4*S**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate (161)

A mixture of 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (260 mg, 0.57 mmol), tert-butyl (3*R**,4*S**)-4-fluoro-3-hydroxypiperidine-1-carboxylate **160** (250 mg, 1.15 mmol), Ir[dF(CF₃)ppy]₂(dtbbpy)(PF₆) (7 mg, 0.006 mmol), NiCl₂·dtbbpy (1 mg, 0.003 mmol), quinuclidine (7 mg, 0.006 mmol), TMP (162 mg, 1.15 mmol) in ACN (4.0 mL) was degassed three times under N₂. The reaction vial was sealed with parafilm, placed 2 cm away from one blue LED, and irradiated at r.t. for 16 hrs. The reaction mixture was filtered and the filter cake was washed with ACN (3 x 5 mL). The filtrates were combined and concentrated. The crude material was purified by silica gel chromatography (0-100% EtOAc in petroleum ether) and fractions containing pure product were concentrated to afford tert-butyl (3*R**,4*S**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate as a green oil. LCMS [M-27]⁺: 564.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.66 (d, *J* = 8.4 Hz, 1H), 7.25 - 7.11 (m, 1H), 7.16 - 7.09 (m, 1H), 5.22 - 5.20 (m, 1H), 5.11 - 4.97 (m, 3H), 4.86 - 4.73 (m, 1H), 4.42 - 4.39 (m, 1H), 4.24 - 4.21 (m, 1H), 3.55 - 3.52 (m, 3H), 3.22 - 2.91 (m, 2H), 2.85 - 2.74 (m, 1H), 2.39 - 2.30 (m, 1H), 2.07 - 2.01 (m, 2H), 1.95

- 1.81 (m, 1H), 1.41 (br d, $J = 6.8$ Hz, 2H), 1.18 (t, $J = 7.2$ Hz, 9H), 0.84 - 0.80 (m, 2H), 0.01 - 0.04 (m, 9H).


Step 3: 3-(5-(((3*R,4*S**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (162)**

5 MsOH (422 mg, 0.29 mL, 4.4 mmol) was added to a solution of tert-butyl (3*R**,4*S**)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-4-fluoropiperidine-1-carboxylate **161** (260 mg, 0.44 mmol) in ACN (3.0 mL) and stirred at 40 °C for 2 hrs. Et₃N (578 mg, 0.79 mL, 5.7 mmol) and DMEDA (65 mg, 0.08 mL, 0.74 mmol) were added and the reaction mixture stirred at r.t. for 14 hrs. The reaction mixture was concentrated. The
10 crude material was dissolved in DMSO and purified by reverse phase column chromatography [Column: XB-C18 (20-35 μm, 100 Å); 0%-20% ACN in H₂O with 0.1% formic acid as modifier]. The fractions with pure product were concentrated to afford formate salt 3-(5-(((3*R**,4*S**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **162** as a yellow solid. LCMS [M+H]⁺: 362.2. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (br s, 1H), 8.21 (s, 1H), 7.64 (d, $J = 8.4$
15 Hz, 1H), 7.26 (s, 1H), 7.13 - 7.10 (m, 1H), 5.13 - 4.95 (m, 2H), 4.69 - 4.65 (m, 1H), 4.37 - 4.30 (m, 1H), 4.29 (d, $J = 4.0$ Hz, 1H), 3.06 - 2.65 (m, 5H), 2.63 - 2.55 (m, 1H), 2.39 - 2.30 (m, 2H), 2.06 - 1.78 (m, 3H).

Step 4: 3-(5-(((3*R,4*S**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-163)**

20 2M ZnCl₂ in THF (0.37 mL, 0.74 mmol) was added to a solution of 3-(5-(((3*R**,4*S**)-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **162** (100 mg, 0.25 mmol) and acetaldehyde (270 mg, 2.45 mmol, 40%) in THF:EtOH (1:1, 1 mL) at r.t. and stirred for 1 hr. NaBH₃CN (46 mg, 0.74 mmol) was added and the reaction mixture stirred at r.t. for 15 hrs. The suspension was concentrated. The crude material was dissolved in DMSO and purified by
25 reverse phase HPLC (1-25% ACN in water with 0.225% formic acid as modifier). The fractions containing pure product were concentrated to afford formate salt 3-(5-(((3*R**,4*S**)-1-ethyl-4-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-163** as a white solid. LCMS [M+H]⁺: 390.1. ¹H NMR (400 MHz, ACETONITRILE-*d*₃) δ 9.08 - 8.80 (m, 1H), 8.15 (br s, 1H), 7.66 (d, $J = 8.4$ Hz, 1H), 7.26 - 6.99 (m, 2H), 5.10 - 4.87 (m, 2H), 4.75 - 4.62 (m, 1H), 4.40 -
30 4.22 (m, 2H), 2.91 (d, $J = 9.6$ Hz, 1H), 2.82 - 2.60 (m, 4H), 2.56 - 2.49 (m, 3H), 2.17 - 2.06 (m, 2H), 2.02 - 1.95 (m, 1H), 1.92 - 1.82 (m, 1H), 1.06 (t, $J = 7.2$ Hz, 3H). The absolute stereochemistry at the 3- and 4-position of the piperidine ring was not determined.

Example 59: 3-(5-(((3*R*,5*S*)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-169)



Step 1: Tert-butyl (3S,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate (166)

Boc₂O (1.2 g, 5.5 mmol) and 10% Pd(OH)₂/C (300 mg, 0.21 mmol) were added to a solution of (3R,5S)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-164 (1.4 g, 4.5 mmol) in MeOH (20.0 mL) at r.t. The reaction mixture stirred at 60 °C for 16 hrs under hydrogen gas (50 psi). The suspension was filtered through a pad of CELITE®, the pad was washed with MeOH (3 x 10 mL), and the filtrate was concentrated. The crude material was purified by silica gel chromatography (30-60% EtOAc in petroleum ether) and the fractions containing pure compound were combined and concentrated to afford tert-butyl (3S,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate **166** as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 4.91 - 4.61 (m, 1H), 3.85 (br s, 2H), 3.65 (br d, *J* = 9.9 Hz, 1H), 3.54 - 3.27 (m, 2H), 2.41 - 2.23 (m, 1H), 2.16 - 1.99 (m, 2H), 1.48 (s, 9H). ¹⁹F NMR (377 MHz, CDCl₃) δ -181.4.

Step 2: Tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate (167)

A mixture of (3S,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate **166** (387 mg, 1.8 mmol), 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (400 mg, 0.88 mmol), Ir[dF(CF₃)ppy]₂(dtbbpy)(PF₆) (10 mg, 0.009 mmol) and NiCl₂·dtbbpy (18 mg, 0.044 mmol), quinuclidine (10 mg, 0.088 mmol), TMP (249 mg, 1.76 mmol) in ACN (8.0 mL) was degassed three times under N₂. The reaction vial was sealed with parafilm, placed 2 cm away from a blue LED, and irradiated at r.t. for 16 hr. The reaction mixture was filtered, the filter cake was washed with EtOAc (3 x 10 mL) and the combined filtrates were concentrated. The crude material was purified by silica gel chromatography (50-80% EtOAc in petroleum ether) and concentrated to afford tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate **167** as a bright yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, *J* = 8.4 Hz, 1H), 7.14 - 6.92 (m, 2H), 5.32 - 5.13 (m, 3H), 4.72 - 4.02 (m, 6H), 3.72 - 3.55 (m, 2H), 3.36 - 2.81 (m,

4H), 2.57 - 2.50 (m, 1H), 2.43 - 2.14 (m, 2H), 2.05 - 1.90 (m, 1H), 1.47 (br s, 9H), 1.00 - 0.90 (m, 2H), 0.01 (s, 9H). ¹⁹F NMR (377 MHz, CDCl₃) δ -182.6.


Step 3: 3-(5-(((3R,5S)-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (168)

5 MsOH (568 mg, 0.38 mL, 5.9 mmol) was added to a solution of tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate **167** (350 mg, 0.59 mmol) in ACN (2.1 mL) and stirred at 40 °C for 2 hrs. The reaction mixture was cooled to 0 °C, Et₃N (777 mg, 1.1 mL, 7.7 mmol) was added drop wise followed by DMEDA (104 mg, 0.13 mL, 1.2 mmol). The reaction mixture stirred at r.t.
10 for 14 hrs. The reaction mixture was concentrated and the crude material was purified by reverse phase HPLC (2-32% ACN in water with 10 mM NH₄HCO₃ as modifier). Fractions containing pure material were collected and concentrated to afford formate salt tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate **168** as a light yellow solid. ¹H NMR (400 MHz, DMSO-
15 d₆) δ 7.62 (d, J = 8.4 Hz, 1H), 7.21 (s, 1H), 7.08 - 7.05 (m, 1H), 5.10 - 5.04 (m, 1H), 4.77 - 4.34 (m, 6H), 4.33 - 4.20 (m, 1H), 3.12 - 3.09 (m, 2H), 2.95 - 2.85 (m, 1H), 2.65 - 2.56 (m, 2H), 2.44 - 2.29 (m, 2H), 2.01 - 1.95 (m, 1H), 1.70 - 1.62 (m, 1H).

Step 4: 3-(5-(((3R,5S)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-169)

20 A mixture of tert-butyl (3R,5S)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate **168** (80 mg, 0.22 mmol), iodoethane (41 mg, 0.27 mmol) and NaHCO₃ (56 mg, 0.68 mmol) in ACN (1.0 mL) stirred at 80 °C for 16 hrs. The reaction mixture was concentrated and the crude material was purified by reverse phase HPLC (15-48% ACN in water with 10 mM NH₄HCO₃ as modifier). Fractions
25 containing pure product were acidified with formic acid to pH 6 and concentrated to afford 3-(5-(((3R,5S)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-169** as an off-white solid. LCMS [M+H]⁺: 390.3. ¹H NMR (400 MHz, ACETONITRILE-d₃) δ 9.04 - 8.75 (m, 1H), 8.10 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 1.6 Hz, 1H), 7.05 - 7.02 (m, 1H), 5.06 - 5.01 (m, 1H), 4.84 - 4.60 (m, 1H), 4.53 - 4.49 (m, 1H), 4.41 - 4.23 (m, 2H), 3.13 - 3.01 (m, 2H),
30 2.87 - 2.77 (m, 1H), 2.73 - 2.72 (m, 1H), 2.59 - 2.53 (m, 3H), 2.45 - 2.34 (m, 1H), 2.32 - 2.20 (m, 2H), 2.10 - 2.09 (m, 1H), 1.74 - 1.60 (m, 1H), 1.06 - 1.03 (m, 3H). ¹⁹F NMR (377 MHz, ACETONITRILE-d₃) δ -183.1.

Example 60: 3-(5-(((3R,5R)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-173)



Step 1: Tert-butyl (3R,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate (170)

Boc₂O (1.3 g, 6.0 mmol) and 10% Pd(OH)₂/C (300 mg, 0.21 mmol) were added to a solution of (3R,5R)-1-benzyl-3-(benzyloxy)-5-fluoropiperidine INT-165 (1.5 g, 5.0 mmol) in MeOH (30.0 mL) at r.t. The reaction mixture stirred at 60 °C for 16 hrs under H₂ (50 psi). The suspension was filtered through a pad of CELITE® and the pad was washed with MeOH (3 x 20 mL). The filtrate was concentrated to afford tert-butyl (3R,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate as a white solid. Material was taken on crude to the next reaction without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ = 5.03 (s, 1H), 4.95 - 4.72 (m, 1H), 3.99 - 3.74 (m, 2H), 3.67 (s, 1H), 3.15 - 2.96 (m, 1H), 2.80 - 2.53 (m, 1H), 2.09 (s, 1H), 1.69 - 1.47 (m, 1H), 1.39 (s, 9H).

Step 2: tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate (171)

A mixture of tert-butyl (3R,5R)-3-fluoro-5-hydroxypiperidine-1-carboxylate 170 (289 mg, 1.32 mmol), 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione INT-1 (300 mg, 0.66 mmol), Ir[dF(CF₃)ppy]₂(dtbbpy)(PF₆) (7 mg, 0.006 mmol) and NiCl₂·dtbbpy (13 mg, 0.033 mmol), quinuclidine (7 mg, 0.066 mmol), TMP (186 mg, 1.3 mmol) in ACN (6.0 mL) was degassed three times under N₂. The reaction vial was sealed with parafilm, placed 2 cm away from a blue LED, and irradiated at r.t. for 16 hrs. The reaction mixture was filtered, the filter cake was washed with EtOAc (3 x 5 mL) and the filtrate was concentrated. The crude material was purified by silica gel chromatography (0-70% EtOAc in petroleum ether) and the fractions containing pure product were collected and concentrated to afford tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate 171 as a bright yellow solid. LCMS [M+H]⁺: 362.3 m/z. ¹H NMR (400 MHz, DMSO-d₆) δ 7.66 (d, J = 8.0 Hz, 1H), 7.20 (br s, 1H), 7.08 - 7.05 (m, 1H), 5.21 - 5.17 (m, 1H), 5.08 - 5.00 (m, 3H), 4.92 - 4.60 (m, 2H), 4.48 - 4.36 (m, 1H), 4.29 - 4.17 (m, 1H), 3.92 - 3.79 (m, 1H), 3.66 - 3.64 (m, 1H), 3.57 - 3.44 (m, 3H), 3.17 - 2.95 (m, 2H), 2.84 - 2.73 (m, 1H),

2.36 - 2.32 (m, 1H), 2.26 - 2.12 (m, 1H), 2.07 - 2.01 (m, 1H), 1.40 - 1.25 (m, 9H), 0.85 - 0.81 (m, 2H), -0.02 (s, 9H). δ 7.66 (d, J = 8.0 Hz, 1H), 7.20 (br s, 1H), 7.08 - 7.05 (m, 1H), 5.21 - 5.17 (m, 1H), 5.08 - 5.00 (m, 3H), 4.92 - 4.60 (m, 2H), 4.48 - 4.36 (m, 1H), 4.29 - 4.17 (m, 1H), 3.92 - 3.79 (m, 1H), 3.66 - 3.64 (m, 1H), 3.57 - 3.44 (m, 3H), 3.17 - 2.95 (m, 2H), 2.84 - 2.73 (m, 1H),
5 2.36 - 2.32 (m, 1H), 2.26 - 2.12 (m, 1H), 2.07 - 2.01 (m, 1H), 1.40 - 1.25 (m, 9H), 0.85 - 0.81 (m, 2H), -0.02 (s, 9H).


Step 3: 3-(5-(((3R,5R)-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (172)

MsOH (487 mg, 0.33 mL, 5.1 mmol) was added to a solution of tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-fluoropiperidine-1-carboxylate **171** (300 mg, 0.51 mmol) in ACN (3.0 mL). The reaction stirred at 40 °C for 2 hrs. The reaction mixture was cooled to 0 °C, Et₃N (667 mg, 0.92 mL, 6.6 mmol) was added dropwise followed by DMEDA (89 mg, 0.11 mL, 1.0 mmol). The reaction mixture stirred at r.t. for 14 hrs. The reaction mixture was concentrated and the crude material was
15 purified by reverse phase HPLC (10-40% ACN in water with 10 mM NH₄HCO₃ as modifier). Fractions with pure product were collected and concentrated to afford 3-(5-(((3R,5R)-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **172** as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.19 (s, 1H), 7.07 - 7.04 (s, 1H), 5.08 - 5.04 (m, 1H), 4.94 - 4.73 (m, 1H), 4.70 - 4.58 (m, 1H), 4.44 - 4.34 (m, 1H), 4.33 - 4.20 (m,
20 1H), 3.11 - 3.03 (m, 1H), 2.95 - 2.71 (m, 3H), 2.62 - 2.55 (m, 2H), 2.40 - 2.36 (m, 1H), 2.28 - 2.20 (m, 1H), 2.02 - 1.86 (m, 2H). ¹⁹F NMR (400 MHz, DMSO-*d*₆) δ 182.6.

Step 4: 3-(5-(((3R,5R)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-173)

Acetaldehyde (107 mg, 0.97 mmol, 40%) and 2M ZnCl₂ in THF (132 mg, 0.48 mL, 0.97
25 mmol) were added to a solution of 3-(5-(((3R,5R)-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **172** (70 mg, 0.19 mmol) in 1:1 THF/EtOH (1.0 mL) at r.t. and stirred for 1 hr. NaBH₃CN (37 mg, 0.58 mmol) was added and the mixture stirred at r.t. for 15 hrs. The reaction mixture was concentrated and the resulting crude material was purified by reverse phase HPLC (0-20% ACN in water with 0.225% formic acid as modifier). Fractions containing
30 pure product were collected and concentrated to afford formate salt 3-(5-(((3R,5R)-1-ethyl-5-fluoropiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-173** as an off-white solid. LCMS [M+H]⁺: 390.2. ¹H NMR (400 MHz, ACETONITRILE-*d*₃+D₂O) δ 8.35 - 8.27 (m, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.13 (br s, 1H), 7.06 (d, J = 8.4 Hz, 1H), 5.13 - 4.92 (m, 2H), 4.89 - 4.80 (m, 1H), 4.44 - 4.27 (m, 2H), 3.15 - 3.12 (m, 1H), 3.07 - 2.96 (m, 1H), 2.84 - 2.66 (m, 5H), 2.55 -
35 2.54 (m, 1H), 2.44 - 2.29 (m, 2H), 2.15 - 2.06 (m, 1H), 2.02 - 1.96 (m, 0.5H), 1.91 - 1.83 (m, 0.5H), 1.14 - 1.04 (m, 3H). ¹⁹F NMR (400 MHz, ACETONITRILE-*d*₃) δ 182.5.

Example 61: 3-(5-((2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-176)




Step 1: *rac*-Tert-butyl 6-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (175)

A racemic mixture of regioisomers tert-butyl 5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate **INT-174A** and **INT-174B** (941 mg, 4.41 mmol), 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (2.00 g, 4.41 mmol), $\text{Ir}[\text{dF}(\text{CF}_3)\text{ppy}]_2(\text{dtbbpy})(\text{PF}_6)$ (0.050 g, 0.044 mmol) and $\text{NiCl}_2(\text{glyme})$ (48 mg, 0.22 mmol), dtbbpy (59 mg, 0.221 mmol) in ACN (20 mL) was purged with nitrogen for 10 min. Then, TMP (0.78 mL, 4.6 mmol) was added. The reaction was placed in a PennOC m1 450nm Photoreactor under blue LED light at r.t. for 24 hrs. The reaction mixture was concentrated onto CELITE®, and purified by silica gel chromatography (0-100% EtOAc in heptanes) to afford **175** (1.8 g) that was used in the next step without further purification. LCMS $[\text{M}-\text{H}]^-$: 584.4

Step 2: *rac*-3-(5-((2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-176)).


Compound **I-176** was made according to General Method VII starting from **175** (1.0 g, 1.7 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated, and purified by silica gel chromatography (0-100% EtOAc:EtOH:Et3N (v/v/v = 75:25:1) in DCM), then eluent was changed to (0-100% EtOH/DCM with 1% triethylamine) to afford **I-176**. LCMS $[\text{M}+\text{H}]^+$: 356.2.

Example 62: *rac*-3-(5-((2-ethyl-2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione



To a vial containing 3-(5-((2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-176** (140 mg, 0.394 mmol) and ACN (4.0 mL) was added sodium triacetoxyborohydride (250 mg, 1.2 mmol) followed by acetaldehyde (45 μ L, 0.79 mmol). The reaction stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organics layers were combined, passed through a phase separator, and concentrated. The crude material was purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH_4OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford **I-177** *rac*-3-(5-((2-ethyl-2-azabicyclo[2.2.1]heptan-6-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione LCMS $[\text{M}+\text{H}]^+$: 384.3. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.97 (s, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 2.2 Hz, 1H), 7.04 - 6.92 (m, 1H), 5.07 (dd, J = 13.2, 5.1 Hz, 1H), 4.52 (d, J = 6.5 Hz, 1H), 4.46 - 4.11 (m, 2H), 2.98 - 2.78 (m, 1H), 2.70 - 2.59 (m, 2H), 2.55 (d, J = 4.3 Hz, 2H), 2.46 - 2.25 (m, 4H), 1.95 (d, J = 17.0 Hz, 2H), 1.52 (s, 2H), 1.42 (d, J = 13.4 Hz, 1H), 1.00 (t, J = 7.1 Hz, 3H).

Example 63: 3-(5-(((3*R*,5*R*)-5-ethoxy-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-181**)**



Step 1: tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate (179**)**

To a stirred solution of $\text{N}^1, \text{N}^1, \text{N}^8, \text{N}^8$ -tetramethylnaphthalene-1,8-diamine (155 mg, 0.725 mmol) and tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate **71a** (Example 34a) (225 mg, 0.382 mmol) in ACN (2 mL) was added dropwise triethyloxonium tetrafluoroborate as a 1 M solution in DCM (650 μ L, 0.650 mmol) at 0°C under positive pressure of nitrogen. After the addition was complete, the reaction was warmed to r.t. and stirred for 5 days. The reaction was filtered over CELITE® with acetone and the solvents removed under reduced pressure. This crude material **179** was taken on as is without further purification. LCMS $[\text{M}+\text{NH}_4]^+$: 634.4

Step 2: 3-(5-(((3*R*,5*R*)-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (180**)**


Compound **180** was made according to General Method VII starting from tert-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate **179** (236 mg, 0.382 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1

DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated. Material was used directly in the next reaction without purification. LCMS [M+H]⁺: 388.3.

Step 3: 3-(5-(((3*R*,5*R*)-5-ethoxy-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-181**)**

To a vial containing 3-(5-(((3*R*,5*R*)-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (148 mg, 0.382 mmol) and ACN (2.0 mL) was added sodium triacetoxyborohydride (243 mg, 1.2 mmol) followed by acetaldehyde (43 μ L, 0.764 mmol). The reaction was stirred at r.t. for 5 days. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organic layers were combined, passed through a phase separator, and concentrated onto CELITE®. The crude material was purified by silica gel chromatography (0- 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM), then by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3*R*,5*R*)-5-ethoxy-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-181**. LCMS [M+H]⁺: 416.3. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 - 8.27 (m, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.75 (dd, J = 6.6, 3.5 Hz, 1H), 4.42 - 4.21 (m, 2H), 3.67 (d, J = 5.4 Hz, 1H), 3.56 - 3.36 (m, 2H), 2.91 (ddd, J = 17.3, 13.6, 5.4 Hz, 1H), 2.73 - 2.54 (m, 4H), 2.42 - 2.32 (m, 3H), 2.22 (dd, J = 11.0, 7.1 Hz, 1H), 1.97 (ddd, J = 11.3, 5.7, 3.0 Hz, 2H), 1.73 (t, J = 10.1 Hz, 1H), 1.09 (td, J = 6.9, 1.3 Hz, 3H), 0.96 (td, J = 7.2, 1.5 Hz, 3H).

Example 64: 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-184**)**



Step 1: *tert*-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methoxypiperidine-1-carboxylate (182)

To a stirred solution of *N*¹,*N*¹,*N*⁸,*N*⁸-tetramethylnaphthalene-1,8-diamine (155 mg, 0.725 mmol) and *tert*-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-hydroxypiperidine-1-carboxylate **71a** (Example 34a) (225 mg, 0.382 mmol) in DCM (3 mL) was added trimethyloxonium tetrafluoroborate (96 mg, 0.649 mmol), at 0 °C under positive pressure of nitrogen. After the addition was complete, the reaction was warmed to r.t. and stirred 24 hrs. The reaction was filtered over CELITE® with acetone and the solvents removed under reduced pressure. This crude material **182** was taken on as is without further purification. LCMS [M-H]⁻: 602.2


Step 2: 3-(5-(((3*R*,5*R*)-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (183)

Compound **183** was made according to General Method VII starting from *tert*-butyl (3*R*,5*R*)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methoxypiperidine-1-carboxylate **182** (230 mg, 0.381 mmol). The reaction was quenched with a 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:iPrOH three times. The organic layers were combined, passed through a phase separator and concentrated. Material was used directly in the next reaction without purification. LCMS [M+H]⁺: 374.3.

Step 3: 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-184)


To a vial containing 3-(5-(((3*R*,5*R*)-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **183** (142 mg, 0.380 mmol) and ACN (2.0 mL) was added sodium triacetoxyborohydride (242 mg, 1.1 mmol) followed by acetaldehyde (43 µL, 0.761 mmol). The reaction was stirred at r.t. for 5 days. The reaction was concentrated, diluted into DMSO/water/MeCN (v/v/v = 1:1:1) and purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-184**. LCMS [M+H]⁺: 402.3. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 - 8.24 (m, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.02 (dd, J = 8.4, 2.2 Hz, 1H), 5.06 (dd, J = 13.2, 5.1 Hz, 1H), 4.72 (dd, J = 6.3, 3.2 Hz, 1H), 4.46 - 4.17 (m, 2H), 3.55 (q, J = 3.6 Hz, 1H), 3.24 (d, J = 1.2 Hz, 3H), 2.98 - 2.81 (m, 1H), 2.62 - 2.51 (m, 3H), 2.44 - 2.25 (m, 5H), 2.03 - 1.84 (m, 2H), 1.84 - 1.72 (m, 1H), 0.96 (td, J = 7.2, 1.5 Hz, 3H).

Alternatively, **Example 64** can be synthesised according to the scheme below, whereby the ethoxyl group is replaced by the methoxyl group (e.g., using iodomethane):



The synthesis can be carried out according to literature procedures, e.g., according to Cossy, J. et al. *Eur. J. Org. Chem.* **1999**, 1693-1699. Intermediate compound **64-6** is then coupled with INT-1, e.g., according to the procedure in General Method VI. The remaining steps outlined in **Example 64** can then be employed to afford 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.

Example 65-1 and 65-2: 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, Peak 1 and Peak 2




The diastereomeric mixture of **I-184** (0.22 g, 0.53 mmol) was separated via chiral SFC [Column 21 x 250 mm: (S,S) Whelk-O1; CO₂ Co-solvent 35% ACN:IPA with 0.1% triethylamine; at 80 g/min at 125 bar at 25 °C] to afford two diastereomers. **Example 65-1, Peak 1:**

Diastereomer 1 of 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione as a white solid. Chiral SFC Rt 3.77 mins. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.78 – 4.67 (m, 1H), 4.39 (d, *J* = 17.2 Hz, 1H), 4.26 (d, *J* = 17.2 Hz, 1H), 3.75 – 3.48 (m, 1H), 3.25 (s, 3H), 2.90 (ddd, *J* = 18.1, 13.6, 5.4 Hz, 1H), 2.75 – 2.54 (m, 3H), 2.48 – 2.27 (m, 5H), 2.05 – 1.85 (m, 2H), 1.85 – 1.73 (m, 1H), 0.97 (t, *J* = 7.1 Hz, 3H).

Example 65-2, Peak 2: Diastereomer 2 of 3-(5-(((3*R*,5*R*)-1-ethyl-5-methoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione as a white solid. Chiral SFC Rt 5.29 mins. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.16 (d, *J* = 2.2 Hz, 1H), 7.03 (dd, *J* = 8.4, 2.2 Hz, 1H), 5.07 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.78 – 4.67 (m, 1H), 4.39 (d, *J* = 17.2 Hz, 1H), 4.26 (d, *J* = 17.2 Hz, 1H), 3.75 – 3.48 (m, 1H), 3.25 (s, 3H), 2.90 (ddd, *J* = 18.1, 13.6, 5.4 Hz, 1H), 2.75 – 2.54 (m, 3H), 2.48 – 2.27 (m, 5H), 2.05 – 1.85 (m, 2H), 1.85 – 1.73 (m, 1H), 0.97 (t, *J* = 7.1 Hz, 3H). The absolute stereochemistry at the glutarimide carbon of the two stereoisomers corresponding to the two product peaks was not determined.

Example 66: 3-(5-(((3*R*,5*R*)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-185**)**



Example 66 (I-185) was synthesized by analogy to **Example 34** starting with **Example 34a (71a)**


Step 1: 3-(5-(((3R,5R)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (186)

LCMS [M+H]⁺: 360.2.

Step 2: 3-(5-(((3R,5R)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (I-185)

To a solution of 3-(5-(((3R,5R)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione **186** (200 mg, 0.56 mmol) and sodium triacetoxyborohydride (354 mg, 1.67 mmol) in EtOH (2 mL) and MeCN (1 mL) was added acetaldehyde (0.063 mL, 1.1 mmol). The reaction was stirred for 1 hr. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:trifluoroethanol (3x). The reaction was concentrated and purified by reverse phase column chromatography (5-20% acetonitrile in water with 0.1% NH₄OH as modifier). Fractions containing desired product were combined and concentrated to afford 3-(5-(((3R,5R)-1-ethyl-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione **I-185** as a white solid. LCMS [M+H]⁺: 388.4. ¹H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 8.5, 2.2 Hz, 1H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.80 (s, 1H), 4.67 (s, 1H), 4.47 – 4.18 (m, 2H), 3.86 (br. s, 1H), 2.98 – 2.82 (m, 1H), 2.63 (d, J = 12.2 Hz, 3H), 2.45 – 2.35 (m, 4H), 2.10 (d, J = 9.1 Hz, 1H), 2.03 – 1.85 (m, 2H), 1.64 (t, J = 11.4 Hz, 1H), 0.99 – 0.96 (m, 3H).


Example 67: 3-(5-(((3R,5R)-5-hydroxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (I-187)



To a suspension of 3-(5-(((3R,5R)-5-hydroxypiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione **186** (Example 66, Step 1) (2.41 g, 6.71 mmol), in acetone (15 mL) and DMF (5 mL) was added sodium triacetoxyborohydride (2.84 g, 13.4 mmol) followed by acetic acid (0.77 mL, 13 mmol). The reaction was stirred for 4 hours. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:trifluoroethanol (3x). The crude material was purified by silica gel chromatography (silica saturated in Et₃N, 1 to 15 % EtOH in DCM). Fractions containing desired product were combined and concentrated to afford 3-(5-(((3R,5R)-5-hydroxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (**I-187**) as a white solid. LCMS [M+H]⁺: 402.4. ¹H NMR (400 MHz, MeOD) δ 7.72 (d, J = 8.5 Hz,


1H), 7.18 (s, 1H), 7.12 (dd, J = 8.5, 2.2 Hz, 1H), 5.13 (dd, J = 13.3, 5.2 Hz, 1H), 4.45 (d, J = 7.2 Hz, 2H), 4.08 (s, 1H), 3.87 (q, J = 9.2 Hz, 1H), 3.01 – 2.68 (m, 6H), 2.47 (td, J = 13.2, 4.8 Hz, 2H), 2.24 – 2.10 (m, 1H), 1.99 (s, 1H), 1.86 (s, 1H), 1.07 (d, J = 6.4 Hz, 6H).

Example 68: (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxy-N-methylpiperidine-1-carboxamide (I-188)



To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (100 mg, 0.258 mmol) and DBU (78 μ l, 0.516 mmol) in DMSO (1.0 mL) was added N-methyl-1-imidazolecarboxamide (58 mg, 0.464 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was purified by reverse phase HPLC (15-35% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined and lyophilized to afford (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxy-N-methylpiperidine-1-carboxamide **I-188**. LCMS $[M+H]^+$: 445.3. ^1H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.17 (s, 1H), 7.03 (d, J = 8.3 Hz, 1H), 6.43 (t, J = 3.9 Hz, 1H), 5.07 (dd, J = 13.2, 5.0 Hz, 1H), 4.65 (s, 1H), 4.49 – 4.17 (m, 2H), 3.67 – 3.47 (m, 4H), 3.42 (ddd, J = 9.3, 6.9, 2.2 Hz, 2H), 3.25 (dd, J = 15.7, 9.1 Hz, 1H), 3.00 – 2.79 (m, 1H), 2.54 (m, 4H), 2.38 (d, J = 13.1 Hz, 1H), 2.10 – 1.84 (m, 3H), 1.08 (td, J = 7.0, 0.9 Hz, 3H).

Example 69: ethyl (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate (I-189)



To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (130 mg, 0.336 mmol) and TEA (94 μ l, 0.67 mmol) in ACN (2.0 mL), cooled in an ice water bath was added ethyl chloroformate (65 mg, 0.60 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was poured into water and extracted with DCM three times. The organic layers were combined, passed through a phase separator, and concentrated. The crude material was purified by reverse phase HPLC (25-45% ACN in water with 0.1% formic acid as modifier, cyano 30x100 column). Fractions containing desired product were combined and lyophilized to afford ethyl (3R,5R)-3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-ethoxypiperidine-1-carboxylate **I-189**. LCMS $[M+H]^+$: 460.4. ^1H NMR


(400 MHz, DMSO) δ 10.96 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.69 (d, J = 32.1 Hz, 1H), 4.47 – 4.18 (m, 2H), 4.08 – 3.36 (m, 8H), 3.22 – 2.82 (m, 2H), 2.64 – 2.52 (m, 1H), 2.44 – 2.28 (m, 1H), 2.20 – 1.77 (m, 3H), 1.09 (t, J = 7.0 Hz, 5H), 0.93 (s, 1H).

5 Example 70: 3-(5-(((3R,5R)-1-acetyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-190)



To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (100 mg, 0.258 mmol) and DMAP (63 mg, 0.52 mmol) in ACN (3.0 mL), cooled in an ice water bath was added acetyl chloride (27 μ l, 0.39 mmol). After 1 hr, the reaction was purified by reverse phase HPLC (15-35% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-1-acetyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-190**. LCMS $[M+H]^+$: 430.4. ^1H NMR (400 MHz, MeOD) δ 7.72 (dd, J = 12.2, 8.3 Hz, 1H), 7.17 (d, J = 2.1 Hz, 1H), 7.09 (t, J = 9.4 Hz, 1H), 5.18 – 5.05 (m, 1H), 4.88 – 4.58 (m, 1H), 4.45 (dd, J = 7.3, 3.3 Hz, 2H), 4.33 – 4.15 (m, 1H), 3.89 – 3.74 (m, 1H), 3.74 – 3.42 (m, 4H), 3.19 – 3.07 (m, 1H), 2.96 – 2.71 (m, 2H), 2.47 (dd, J = 13.2, 4.7 Hz, 1H), 2.31 – 2.22 (m, 1H), 2.17 – 2.14 (m, 1H), 2.14 – 1.98 (m, 3H), 2.02 – 1.86 (m, 1H), 1.26 – 1.11 (m, 3H).


20 Example 71: 3-(5-(((3R,5R)-5-ethoxy-1-(methylsulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-191)



To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (100 mg, 0.258 mmol) and DMAP (63 mg, 0.52 mmol) in ACN (4.0 mL), cooled in an ice water bath was added methansulfonyl chloride (24 μ l, 0.31 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was poured into a saturated aqueous sodium bicarbonate solution and extracted with 4:1 DCM/iPrOH three times. The organic layers were combined, passed through a phase separator, and concentrated. The reaction was purified by reverse phase HPLC (5-95% ACN in water with 0.1% formic acid as modifier, 30x100 cyano column). Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-5-ethoxy-1-(methylsulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-191**. LCMS


[M+H]⁺: 466.3. ¹H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.21 (s, 1H), 7.08 (d, J = 8.5 Hz, 1H), 5.08 (dd, J = 13.3, 5.1 Hz, 1H), 4.84 (m, 1H), 4.50 – 4.20 (m, 2H), 3.75 (m, 1H), 3.61 – 3.42 (m, 3H), 3.38 (d, J = 4.2 Hz, 2H), 3.05 (dd, J = 12.2, 7.2 Hz, 1H), 2.94 (s, 3H), 2.93 – 2.85 (m, 1H), 2.62 (t, J = 20.5 Hz, 1H), 2.46 – 2.30 (m, 1H), 2.06 (d, J = 11.1 Hz, 1H), 2.03 – 1.93 (m, 1H), 1.87 (m, 1H), 1.11 (t, J = 7.0 Hz, 3H).

Example 72: 3-(5-(((3R,5R)-5-ethoxy-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-192)



To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (150 mg, 0.387 mmol) and EtOH (2.0 mL) was added sodium triacetoxyborohydride (164 mg, 0.774 mmol) followed by isobutyraldehyde (42 μ L, 0.58 mmol). After 15 min, an additional 1.5 eq (53 μ L, 0.58 mmol) of isobutyraldehyde was added. After 1 hr, an additional 1.5 eq (53 μ L, 0.58 mmol) of isobutyraldehyde was added. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organic layers were combined, passed through a phase separator, and concentrated. The crude material was purified by silica gel chromatography (0- 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM). Fractions containing desired product were concentrated. The crude oil was diluted into 2:1 water:MeCN and lyophilized to afford 3-(5-(((3R,5R)-5-ethoxy-1-isobutylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-192**. LCMS [M+H]⁺: 444.4. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.14 (d, J = 2.1 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.74 (m, 1H), 4.45 – 4.14 (m, 2H), 3.67 (m, 1H), 3.57 – 3.37 (m, 2H), 3.03 – 2.83 (m, 1H), 2.70 – 2.54 (m, 3H), 2.44 – 2.29 (m, 2H), 2.19 (t, J = 9.4 Hz, 1H), 2.06 (dd, J = 7.9, 2.0 Hz, 2H), 1.97 (d, J = 4.5 Hz, 2H), 1.69 (t, J = 10.1 Hz, 2H), 1.08 (t, J = 7.0 Hz, 3H), 0.79 (ddd, J = 9.9, 6.6, 2.3 Hz, 6H).

Example 73: 3-(5-(((3R,5R)-1-cyclobutyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-193)




To a vial containing 3-(5-((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (150 mg, 0.387 mmol), MgSO₄ (95.5 mg, 0.774 mmol) and

DMF (2.0 mL) was added sodium triacetoxyborohydride (123 mg, 0.581 mmol) followed by cyclobutanone (290 μ L, 3.87 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/TFE three times. The organic layers were combined, passed through a phase separator, and


concentrated. The crude material was purified by silica gel chromatography (0- 100% EtOAc:EtOH:Et3N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrate, then rediluted in 2:1 water/MeCN and lyophilized to afford 3-(5-(((3R,5R)-1-cyclobutyl-5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-193**. LCMS $[M+H]^+$: 442.4. ^1H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.03 (dd, J = 8.5, 2.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.72 (m, 1H), 4.45 – 4.18 (m, 2H), 3.65 (m, 1H), 3.54 – 3.37 (m, 2H), 2.98 – 2.55 (m, 3H), 2.46 – 2.27 (m, 3H), 2.19 – 1.50 (m, 11H), 1.09 (t, J = 7.0 Hz, 3H).

Example 74: 3-(5-(((3R,5R)-5-ethoxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-194)



To a vial containing 3-(5-(((5-ethoxypiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **180** (Example 63, Step 2) (150 mg, 0.387 mmol), $MgSO_4$ (95.5 mg, 0.774 mmol) and DMF (2.0 mL) was added sodium triacetoxyborohydride (123 mg, 0.581 mmol) followed by acetone (284 μ L, 3.87 mmol). The reaction was stirred at 40 $^\circ$ C for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/*i*PrOH three times. The organic layers were combined, passed through a phase separator, and concentrated. The crude material was purified by silica gel chromatography (0- 100% EtOAc:EtOH:Et3N (v/v/v = 75:25:1) in heptane), Fractions containing desired product were combined and concentrate, then rediluted in 2:1 water/MeCN and lyophilized to afford 3-(5-(((3R,5R)-5-ethoxy-1-isopropylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-194**. LCMS $[M+H]^+$: 430.2. ^1H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.02 (dd, J = 8.4, 2.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.71 (d, J = 5.5 Hz, 1H), 4.48 – 4.17 (m, 2H), 3.65 (m, 1H), 3.55 – 3.36 (m, 2H), 2.88 (q, J = 5.5 Hz, 1H), 2.78 – 2.54 (m, 5H), 2.41 – 2.29 (m, 2H), 1.96 (dt, J = 14.0, 5.0 Hz, 2H), 1.72 (ddd, J = 12.6, 8.0, 3.6 Hz, 1H), 1.09 (t, J = 7.0 Hz, 3H), 0.92 (ddd, J = 10.6, 6.6, 1.6 Hz, 6H).

Example 75-1 and 75-2: 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-202) and 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-203)



Step 1: tert-butyl (3R,5S)-3-methyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate (196**):**

To a solution of tert-butyl (3S,5R)-3-hydroxy-5-methylpiperidine-1-carboxylate (**195**) (4.03 g, 1 Eq, 18.7 mmol) in DCM (50 mL) at 0°C were added triethylamine (2.84 g, 3.91 mL, 1.5 Eq, 28.1 mmol) and methanesulfonyl chloride (3.00 g, 2.03 mL, 1.4 Eq, 26.2 mmol). The reaction was stirred at 0°C for 1 hr. The reaction mixture was poured into 150 ml of saturated aqueous sodium bicarbonate. The products were extracted 3x with DCM. The organic layers were passed through an isolate phase separator, and then the combined filtrate was concentrated to provide product tert-butyl (3R,5S)-3-methyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate **196** that was used directly into the next step without further purification. ^1H NMR (400 MHz, CDCl_3) δ 4.54 (tt, $J = 10.6, 4.7$ Hz, 1H), 4.36 (d, $J = 12.7$ Hz, 1H), 3.98 (s, 1H), 3.04 (s, 3H), 2.68 (t, $J = 11.6$ Hz, 1H), 2.27 (d, $J = 12.6$ Hz, 2H), 1.71 (q, $J = 5.3$ Hz, 1H), 1.46 (s, 9H), 1.31 (q, $J = 11.8$ Hz, 1H), 0.95 (d, $J = 6.6$ Hz, 3H).

Step 2: tert-butyl (3R,5R)-3-(formyloxy)-5-methylpiperidine-1-carboxylate (197**):**

To a solution of tert-butyl (3R,5S)-3-methyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate (**196**) (5.5 g, 1 Eq, 19 mmol) in Toluene (50 mL) were added potassium formate (3.2 g, 2 Eq, 37 mmol) and 1,4,7,10,13,16-hexaoxacyclooctadecane (9.9 g, 2 Eq, 37 mmol). The reaction was cooled to 23°C , then diluted with water. The products were extracted 2x with DCM. The organic layers were passed through an isolate phase separator, and the combined filtrate was concentrated. The residue was purified by flash column chromatography on silica gel (eluent: 0 – 50 % EtOAc in heptane) to afford tert-butyl (3R,5R)-3-(formyloxy)-5-methylpiperidine-1-carboxylate **197** (1.8 g, 7.4 mmol, 39 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.03 (s, 1H), 5.04 (s, 1H), 4.30 – 4.14 (m, 1H), 4.09 (s, 1H), 2.92 (dd, $J = 14.5,$

2.0 Hz, 1H), 2.35 (s, 1H), 1.95 (ddq, J = 13.2, 3.9, 1.9 Hz, 2H), 1.44 (s, 9H), 1.32 (ddd, J = 15.0, 12.3, 3.0 Hz, 1H), 0.89 (d, J = 6.5 Hz, 3H).

Step 3: tert-butyl (3R,5R)-3-(hydroxy)-5-methylpiperidine-1-carboxylate (198):

To a solution of tert-butyl (3R,5R)-3-(formyloxy)-5-methylpiperidine-1-carboxylate (197) (1.8 g, 1 Eq, 7.4 mmol) in MeOH (15 mL) at 23 °C was added Sodium methoxide (0.48 g, 18 mL, 0.5 molar in MeOH, 1.2 Eq, 8.9 mmol). The reaction mixture was poured into a flask containing water. The products were extracted 2x with DCM. The organic layers were passed through an isolate phase separator, and the combined filtrate was concentrated to provide tert-butyl (3R,5R)-3-hydroxy-5-methylpiperidine-1-carboxylate (198) (1.55 g, 7.1 mmol, 96 %). ¹H NMR (400 MHz, CDCl₃) δ 4.01 – 3.82 (m, 3H), 2.98 (dd, J = 13.6, 2.0 Hz, 1H), 2.45 (dd, J = 13.1, 10.2 Hz, 1H), 1.99 (dtd, J = 10.6, 6.8, 3.8 Hz, 1H), 1.93 – 1.78 (m, 2H), 1.45 (s, 9H), 1.25 (ddd, J = 13.8, 11.1, 2.9 Hz, 1H), 0.88 (d, J = 6.6 Hz, 3H).

Step 4: tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate (199)

tert-Butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate (199) was synthesized by analogy to **Example 52, Step 1**, starting with tert-butyl (3R,5R)-3-hydroxy-5-methylpiperidine-1-carboxylate (198). Purification by silica gel chromatography (0-100% acetone in heptane) afforded tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate 199. LCMS [M-H]⁻: 586.3.

Step 5: 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (200) and 1-(hydroxymethyl)-3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (201)

To a solution of tert-butyl (3R,5R)-3-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-5-methylpiperidine-1-carboxylate (199) (12.0 g, 1 Eq, 20.3 mmol) in MeCN (60mL) was added methanesulfonic acid (9.78 g, 6.61 mL, 5 Eq, 102 mmol) and the reaction mixture was stirred for 18 hr. The reaction was cooled to 0 °C and a stream of nitrogen gas was blown into the reaction flask while adding triethylamine (20.6 g, 28.4 mL, 10 Eq, 204 mmol) at 0 °C. N¹,N²-dimethylethane-1,2-diamine (DMEDA) (2.87 g, 3.49 mL, 1.6 Eq, 32.6 mmol) was rapidly added at 0 °C. The reaction was stirred for 1.5 hr at 0 °C. The reaction mixture was poured into saturated aqueous bicarbonate solution (400 ml) and was extracted with DCM (2x 200 mL). The combined extracts were passed through a phase separator and concentrated *in vacuo*. The resulting precipitate was suspended in diethyl ether and filtered. The filtrate was concentrated to afford a mixture of 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (200) and 1-(hydroxymethyl)-3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (201) as a beige solid (6.0 g). Material was taken through to the next step without further purification.


Step 6: 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-202) and 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-203)

To a vial containing a mixture of 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**200**) and 1-(hydroxymethyl)-3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**201**) (6.0 g) in EtOH (300 mL), cooled to 0 °C in an ice water bath, was added sodium triacetoxyborohydride (7.1 g, 34 mmol) followed by acetaldehyde (1.4 mL, 25.2 mmol) at 0 °C. The reaction was stirred at 0 °C for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with DCM three times. The organics layers were combined, and passed through a phase separator and the filtrate was concentrated. The crude material was purified by flash chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-202** (153 mg, 0.29 mmol) as a white solid and 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-203**. 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-203**) was dissolved in DMSO:water:ACN (v/v/v = 1:1:1) and further purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes containing product were collected and poured into a separatory flask containing saturated aqueous sodium bicarbonate solution, extracted with 4:1 DCM/TFE and passed through an isolate phase separator and the solvents were concentrated. The crude oil was rediluted in 2:1 water/MeCN and lyophilized to afford 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-203** (0.19 g, 0.51 mmol) as a white solid.

Example 75-1: 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-202); LCMS [M+H]⁺: 386.2. ¹H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 7.03 (d, J = 8.9 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.70 (s, 1H), 4.51 – 4.14 (m, 2H), 2.98 – 2.82 (m, 2H), 2.68 (d, J = 18.3 Hz, 1H), 2.63 – 2.53 (m, 1H), 2.40 – 2.25 (m, 3H), 2.21 (d, J = 11.9 Hz, 1H), 2.03 – 1.91 (m, 2H), 1.86 (d, J = 14.0 Hz, 1H), 1.70 (m, 1H), 1.28 (t, J = 12.0 Hz, 1H), 0.94 (t, J = 7.1 Hz, 3H), 0.89 – 0.83 (m, 3H).


Example 75-2: 3-(5-(((3R,5R)-1,5-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-203); LCMS [M+H]⁺: 372.4. ¹H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 7.03 (d, J = 8.8 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.71 (s, 1H), 4.47 – 4.13 (m, 2H), 2.98 – 2.73 (m, 2H), 2.61 (t, J = 20.5 Hz, 2H), 2.41 – 2.25 (m, 1H), 2.09 (d, J = 23.0 Hz, 4H), 1.97 (d, J = 12.3 Hz, 2H), 1.85 (d, J = 13.9 Hz, 1H), 1.66 (m, 1H), 1.24 (t, J = 12.3 Hz, 1H), 0.92 – 0.81 (m, 3H).

Example 76-1 and 76-2: 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione, Peak 1 and Peak 2



The diastereomeric mixture of 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**I-202**) (Example 75-1) was separated via chiral SFC [Column 21 x 250 mm Whelk-O1; CO₂ Co-solvent 35% IPA:ACN with 0.1% TEA; at 80 g/min at 125 bar at 25 °C] to afford the single diastereomers: **Example 76-1, Peak 1**: Diastereomer 1 of 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione as a white solid. Chiral SFC Rt 3.49 mins. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.71 (s, 1H), 4.44 – 4.21 (m, 2H), 2.97 – 2.81 (m, 2H), 2.75 – 2.65 (m, 1H), 2.63 – 2.56 (m, 1H), 2.41 – 2.28 (m, 3H), 2.23 (d, J = 11.9 Hz, 1H), 2.03 – 1.93 (m, 2H), 1.86 (d, J = 13.6 Hz, 1H), 1.71 (t, J = 10.2 Hz, 1H), 1.36 – 1.23 (m, 1H), 0.95 (t, J = 7.1 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H). **Example 76-1, Peak 2**: Diastereomer 2 of 3-(5-(((3R,5R)-1-ethyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione as a white solid. Chiral SFC Rt 5.04 mins. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.71 (s, 1H), 4.44 – 4.21 (m, 2H), 2.97 – 2.81 (m, 2H), 2.75 – 2.65 (m, 1H), 2.63 – 2.56 (m, 1H), 2.41 – 2.28 (m, 3H), 2.23 (d, J = 11.9 Hz, 1H), 2.03 – 1.93 (m, 2H), 1.86 (d, J = 13.6 Hz, 1H), 1.71 (t, J = 10.2 Hz, 1H), 1.36 – 1.23 (m, 1H), 0.95 (t, J = 7.1 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H). The absolute stereochemistry at the glutarimide carbon of the two stereoisomers corresponding to the two product peaks was not determined.

Example 77: 3-(5-(((3R,5R)-1-isopropyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt (I-204**)**




25

To a vial containing (**200**) (0.14 g, 0.38 mmol) and DMF (2 mL) was added sodium triacetoxyborohydride (0.12 g, 0.58 mmol) and MgSO₄ (95 mg, 0.77 mmol) followed by acetone (0.28 mL, 3.9 mmol). The reaction stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organics layers were combined, and passed through a phase separator and the combined filtrate was concentrated. The crude material was purified by flash chromatography (0 to 100% EtOAc:EtOH:Et3N (v/v/v = 75:25:1) in DCM) to afford product. Material was dissolved in DMSO:water:ACN (v/v/v = 1:1:1) and further purified by basic reverse phase HPLC (15-40%

30


ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-1-isopropyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt **I-204** as a white solid. LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO) δ 8.18 (s, 1H) (formate salt), 7.59 (d, J = 8.4 Hz, 1H), 7.14 (d, J = 2.2 Hz, 1H), 7.02 (dd, J = 8.4, 2.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.68 (br. s, 1H), 4.45 – 4.14 (m, 2H), 2.97 – 2.74 (m, 2H), 2.65 (td, J = 15.9, 8.4 Hz, 2H), 2.46 – 2.25 (m, 3H), 1.95 (t, J = 10.4 Hz, 3H), 1.83 (d, J = 13.1 Hz, 1H), 1.32 (m, 1H), 0.99 – 0.79 (m, 9H).

Example 78: 3-(5-(((3R,5R)-1-cyclobutyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt (I-205)




To a vial containing 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**200**) (0.1 g, 0.3 mmol) and DMF (1 mL) was added sodium triacetoxymethylborohydride (97 mg, 0.46 mmol) and MgSO₄ (75 mg, 0.61 mmol) followed by cyclobutanone (228 μL, 3.05 mmol). The reaction stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The organics layers were combined, and passed through a phase separator and the combined filtrate was concentrated. The crude material was purified by flash chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM) to afford product. Material was dissolved in DMSO:water:ACN (v/v/v = 1:1:1) and further purified by basic reverse phase HPLC (15-40% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-1-cyclobutyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt **I-205** as a white solid. LCMS [M+H]⁺: 412.4. ¹H NMR (400 MHz, DMSO) δ 10.95 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.16 (s, 1H), 7.04 (d, J = 8.7 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.68 (m, 1H), 4.50 – 4.15 (m, 2H), 2.97 – 2.54 (m, 5H), 2.40 – 2.28 (m, 1H), 2.09 – 1.72 (m, 7H), 1.56 (dd, J = 19.0, 9.3 Hz, 4H), 1.28 (t, J = 13.1 Hz, 1H), 0.86 (d, J = 6.7 Hz, 3H).

Example 79: 3-(5-(((3R,5R)-1-isobutyl-5-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt (I-206)



To a vial containing 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (**200**) (179 mg, 0.5 mmol) and EtOH (2 mL) and DMF (1 mL) was added sodium triacetoxyborohydride (212 mg, 1 mmol) followed by isobutyraldehyde (68 μ L, 0.75 mmol). The reaction stirred at r.t. for 1 hr. The reaction was poured into saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/TFE three times. The organics layers were combined, and passed through a phase separator and the combined filtrate was concentrated. The crude material was purified by flash chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptanes) to afford product. Material was dissolved in DMSO:water:ACN (v/v/v = 1:1:1) and further purified by basic reverse phase HPLC (35-60% ACN in water with 5 mM NH₄OH as modifier). Test tubes contained 3 drops formic acid prior to sample collection. Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-1-isobutyl-5-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione formate salt **I-206** as a white solid. LCMS [M+H]⁺: 414.4. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 7.03 (d, J = 8.3 Hz, 1H), 5.07 (dd, J = 13.2, 5.0 Hz, 1H), 4.70 (m, 1H), 4.47 – 4.13 (m, 2H), 2.97 – 2.77 (m, 2H), 2.71 – 2.54 (m, 2H), 2.36 (dd, J = 13.5, 9.1 Hz, 2H), 2.20 (d, J = 12.1 Hz, 1H), 2.00 (m, 3H), 1.90 – 1.62 (m, 3H), 1.33 (m, 1H), 0.89 (d, J = 6.7 Hz, 3H), 0.84 – 0.75 (m, 6H).


Example 80: 3-(5-(((3R,5R)-5-methyl-1-(methanesulfonyl)piperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-207**)**



To a vial containing 3-(5-(((3R,5R)-5-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (**200**) (200 mg, 0.56 mmol) and DMAP (137 mg, 1.12 mmol) in ACN (3.0 mL), cooled in an ice water bath was added methanesulfonyl chloride (65 μ L, 0.84 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was poured into water and extracted with DCM three times. The organic layers were combined, passed through a phase separator, and concentrated. The reaction was purified by reverse phase HPLC (10-30% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,5R)-5-methyl-1-(methanesulfonyl)piperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-207**. LCMS [M+H]⁺: 436.4. ¹H NMR (400 MHz, DMSO)


δ 10.95 (s, 1H), 7.62 (d, J = 8.3 Hz, 1H), 7.21 (t, J = 2.7 Hz, 1H), 7.07 (dt, J = 8.3, 2.6 Hz, 1H),
 5.06 (dd, J = 13.2, 5.0 Hz, 1H), 4.81 (t, J = 2.9 Hz, 1H), 4.48 – 4.22 (m, 2H), 3.79 – 3.65 (m,
 2H), 3.54 (dd, J = 11.8, 3.9 Hz, 1H), 3.05 (dd, J = 13.2, 2.0 Hz, 1H), 2.89 (m, 4H), 2.60 (t, J =
 3.7 Hz, 1H), 2.36 (td, J = 13.3, 4.6 Hz, 1H), 2.13 – 1.88 (m, 3H), 1.37 (td, J = 12.8, 2.7 Hz, 1H),
 0.88 (d, J = 6.5 Hz, 3H).

Example 81: 3-(5-(((3R,6S)-1-isopropyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-208)



To a suspension of 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (Example 41, Step 2) (98 mg, 0.27 mmol), MgSO_4 (66 mg, 0.55 mmol) in acetone (1.5 mL), was added sodium triacetoxyborohydride (99 mg, 0.47 mmol). The reaction was stirred at r.t. for 9 days. The reaction was diluted with 4:1 DCM:iPrOH and washed with saturated aqueous sodium bicarbonate. The organic layer was passed through a phase separator and concentrated onto Celite®. The crude material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM). Material was diluted with 1:3 ACN:water and lyophilized to afford 3-(5-(((3R,6S)-1-isopropyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-208** as a white solid. LCMS $[\text{M}+\text{H}]^+$: 400.5. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.16 (s, 1H), 7.04 (d, J = 9.1 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.55 (s, 1H), 4.38 (d, J = 16.9 Hz, 1H), 4.25 (d, J = 17.1 Hz, 1H), 3.10 – 2.98 (m, 1H), 2.98 – 2.77 (m, 2H), 2.75 – 2.63 (m, 1H), 2.59 (d, J = 17.1 Hz, 1H), 2.47 – 2.28 (m, 2H), 1.97 (d, J = 11.7 Hz, 1H), 1.82 – 1.68 (m, 2H), 1.55 (q, J = 5.5 Hz, 2H), 1.02 (d, J = 6.4 Hz, 3H), 0.90 (dd, J = 6.6, 3.2 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H).

Example 82: 3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione hydrochloride salt (I-209)




To a suspension of 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (Example 41, Step 2) (98 mg, 0.27 mmol), MgSO_4 (66 mg, 0.55 mmol) and 1-oxocyclobutane (0.5 mL, 7.1 mmol) in DMA (1.0 mL), was added sodium triacetoxyborohydride (0.23 g, 1.1 mmol). The reaction was stirred at r.t. for 9 days. The reaction was diluted with 4:1 DCM:iPrOH and washed with saturated aqueous sodium bicarbonate. The organic layer was passed through a phase separator and concentrated onto Celite®. The crude

material was purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in DCM).

3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione was suspended in acetonitrile/H₂O (3/1 mL). 1 M aqueous HCl (1 equivalent) was then added and solvent was concentrated in vacuo to afford 3-(5-(((3R,6S)-1-cyclobutyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione hydrochloride salt as a white solid (9.1 mg).


The solid was dissolved into aqueous HCl (1.0 M, 210 µl, 0.210 mmol) and the solution was lyophilized overnight to provide 3-(5-(((3R,6S)-1-isopropyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione hydrochloride salt **I-209** (93 mg, 0.21 mmol, 76%) as a white solid. LCMS [M+H]⁺: 412.5. ¹H NMR (400 MHz, DMSO) δ 11.19 – 11.04 (m) and 9.63 – 9.39 (m) (1H), 10.98 (d, J = 2.8 Hz, 1H), 7.68 (dd, J = 8.4, 6.9 Hz, 1H), 7.37 – 7.08 (m, 2H), 5.15 – 5.03 (m, 1H), 4.98 (bs) and 4.95 – 4.83 (m) (1H), 4.42 (d, J = 16.9 Hz, 1H), 4.29 (d, J = 17.1 Hz, 1H), 3.90 (dq, J = 38.2, 8.2 Hz, 1H), 3.70 – 3.56 (m) and 3.56 – 3.45 (m) (1H), 3.30 – 3.00 (m, 2H), 2.98 – 2.85 (m, 1H), 2.70 – 2.55 (m, 1H), 2.48 – 2.31 (m, 2H), 2.28 – 2.14 (m, 2H), 2.14 – 1.61 (m, 7H), 1.34 (d, J = 6.5 Hz, 2H), 1.24 (d, J = 6.8 Hz, 2H).

Example 83: ethyl (2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate (I-210**)**



To a vial containing 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (Example 41, Step 2) (130 mg, 0.36 mmol) and DIPEA (130 µl, 0.74 mmol) in ACN (2.0 mL), cooled in an ice water bath was added ethyl chloroformate (60 µl, 0.63 mmol). The reaction was stirred at r.t. for 1 hr. The reaction was quenched with 50% saturated aqueous sodium bicarbonate and extracted with 4:1 DCM/iPrOH three times. The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude material was purified by reverse phase HPLC (5-95% ACN in water with 0.1% formic acid as modifier, cyano 30x100 column). Fractions containing desired product were combined and lyophilized to afford ethyl (2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-methylpiperidine-1-carboxylate **I-210** as a white solid. LCMS [M+H]⁺: 430.3. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.22 (d, J = 1.9 Hz, 1H), 7.09 (dd, J = 8.3, 2.2 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.39 (dd, J = 16.5, 4.8 Hz, 2H), 4.35 – 4.22 (m, 2H), 4.15 (d, J = 12.2 Hz, 1H), 4.06 (qd, J = 7.1, 4.8 Hz, 2H), 3.00 – 2.79 (m, 2H), 2.59 (d, J = 17.0 Hz, 1H), 2.38 (qd, J = 13.5, 4.7 Hz, 1H), 2.00 (t, J = 15.2 Hz, 2H), 1.83 – 1.53 (m, 3H), 1.19 (t, J = 7.1 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H).


Example 84: (2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-N,2-dimethylpiperidine-1-carboxamide (I-211**)**



To a vial containing 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (Example 41, Step 2) (75 mg, 0.21 mmol) and DBU (59 μ l, 0.39 mmol) in DMSO (1.0 mL) was added N-methyl-1-imidazolecarboxamide (47 mg, 0.38 mmol).

- 5 The reaction was stirred at r.t. for 1 hr. The reaction was purified by reverse phase HPLC (15-35% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined and lyophilized to afford (2S,5R)-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-N,2-dimethylpiperidine-1-carboxamide **I-211** as a white solid. LCMS $[M+H]^+$: 415.3. ^1H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 2.2 Hz, 1H), 7.08 (dd, J = 8.4, 2.2 Hz, 1H), 6.57 – 6.41 (m, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.46 – 4.08 (m, 5H), 2.91 (ddd, J = 18.1, 13.6, 5.4 Hz, 1H), 2.76 – 2.66 (m, 1H), 2.63 – 2.53 (m, 4H), 2.46 – 2.27 (m, 1H), 2.06 – 1.92 (m, 2H), 1.89 – 1.49 (m, 3H), 1.10 (d, J = 6.8 Hz, 3H).

Example 85: 3-(5-(((3R,6S)-6-methyl-1-(methanesulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-212)



15


To a vial containing 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (100 mg, 0.28 mmol) and DMAP (68 mg, 0.56 mmol) in ACN (4.0 mL), cooled in an ice water bath was added methanesulfonyl chloride (25 μ l, 0.32 mmol). The reaction was stirred at 0-5 °C for 30 min and at r.t. for 30 min. The reaction was poured into a saturated aqueous sodium bicarbonate solution and extracted with 4:1 DCM/iPrOH three times. The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The reaction was purified by reverse phase HPLC (5-95% ACN in water with 0.1% formic acid as modifier, 30x100 cyano column). Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,6S)-6-methyl-1-

20

(methanesulfonyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-212** as a white solid. LCMS $[M+H]^+$: 436.4. ^1H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 7.09 (dd, J = 8.4, 2.2 Hz, 1H), 5.07 (dd, J = 13.3, 5.1 Hz, 1H), 4.48 (tt, J = 10.1, 4.4 Hz, 1H), 4.40 (dd, J = 17.3, 3.9 Hz, 1H), 4.27 (dd, J = 17.2, 5.1 Hz, 1H), 4.12 – 4.01 (m, 1H), 3.86 – 3.75 (m, 1H), 2.99 (s, 5H), 2.59 (d, J = 17.2 Hz, 1H), 2.39 (qd, J = 13.4, 4.8 Hz, 1H), 2.10 – 1.94 (m, 2H), 1.92 – 1.81 (m, 1H), 1.78 – 1.57 (m, 2H), 1.23 (d, J = 6.9 Hz, 3H).


30

Example 86: 3-(5-(((3R,6S)-1-acetyl-6-methylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-213)



To a vial containing 3-(5-(((3R,6S)-6-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **101** (Example 41, Step 2) (100 mg, 0.28 mmol) and DMAP (68 mg, 0.56 mmol) in ACN (3.0 mL), cooled in an ice water bath was added acetyl chloride (30 μ L, 0.42 mmol). The reaction was stirred at r.t. for 4 hr. The reaction was poured into a saturated aqueous sodium bicarbonate solution and extracted with 4:1 DCM/iPrOH three times. The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The reaction was purified by reverse phase HPLC (5-95% ACN in water with 0.1% formic acid as modifier). Fractions containing desired product were combined and lyophilized to afford 3-(5-(((3R,6S)-1-acetyl-6-methylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-213** as a white solid. LCMS $[\text{M}+\text{H}]^+$: 400.3. ^1H NMR (400 MHz, DMSO) δ of a 1.3:1 mixture of rotamers: 10.96 (s, 1H), 7.63 (d, $J = 8.4$ Hz, 1H), 7.27 (s) and 7.21 (s) (1H, rotamers), 7.10 (d, $J = 10.9$ Hz, 1H), 5.07 (dd, $J = 13.3, 5.1$ Hz, 1H), 4.75 – 4.67 (m) and 4.66 – 4.55 (m) (1H, rotamers), 4.56-4.45 (m) and 4.32-4.26 (m) (1H, rotamers), 4.39 (d, $J = 17.2$ Hz, 1H), 4.26 (d, $J = 17.1$ Hz, 1H), 4.19 – 4.08 (m) and 3.93 – 3.84 (m) (1H, rotamers), 3.47-3.40 (m) and 3.10 (t, $J = 11.9$ Hz) (1H, rotamers), 2.91 (ddd, $J = 18.1, 13.7, 5.4$ Hz, 1H), 2.59 (d, $J = 16.0$ Hz, 1H), 2.46 – 2.29 (m, 1H), 2.08 – 1.93 (m, 5H), 1.89 – 1.53 (m, 3H), 1.23 (d, $J = 6.7$ Hz) and 1.10 (d, $J = 7.0$ Hz) (3H, rotamers).

Example 87-1 and 87-2: 3-(1-oxo-5-(((3R,6S)-6-propylpiperidin-3-yl)oxy))isindolin-2-yl)piperidine-2,6-dione (I-221) and 3-(5-(((3R,6S)-1-ethyl-6-propylpiperidin-3-yl)oxy))-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-222)



Step 1: *tert*-butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-oxopentan-2-yl)carbamate

To CDI (15 g, 92 mmol) in acetonitrile (75 mL) was added (S)-2-((*tert*-butoxycarbonyl)amino)pentanoic acid (**214**) (20 g, 92 mmol) portion-wise over 15 minutes at 15 °C. After CO₂ evolution ceased, 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) (14 g, 97 mmol) was added at 15 °C and the reaction was stirred overnight at r.t. Reaction mixture was concentrated in vacuo and the crude was poured into a 1M solution of KH₂PO₄ (300 mL) and the aqueous phase was extracted 3x with EtOAc. Assembled organic fractions were washed with brine and dried with Na₂SO₄. After filtration and concentration in vacuo, *tert*-butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-oxopentan-2-yl)carbamate (36 g) was afforded as a yellow oil. [M-H]⁺: 342.2.

Step 2: *tert*-butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)pentan-2-yl)carbamate (215**)**

A solution of *tert*-butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-oxopentan-2-yl)carbamate (16.0 g, 46.6 mmol) in DCM (250 mL) and AcOH (600 mL) was cooled to -5 °C and sodium borohydride (3.53 g, 93.2 mmol) was added portion-wise over 15 minutes. The resulting solution was stirred for 3 hours at -5 °C. Brine (250 mL) was slowly added to the reaction at -5 °C then water (250 mL) was added at 5 °C. The two liquid phases were separated and the aqueous phase was extracted 2x with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. *tert*-Butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)pentan-2-yl)carbamate **215** (14.7 g) was afforded as a yellow oil. [M-H]⁺: 328.3.

Step 3: *tert*-butyl (S)-2-oxo-5-propylpyrrolidine-1-carboxylate (216**)**

tert-Butyl (S)-(1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)pentan-2-yl)carbamate (**215**) (14.7 g, 44.6 mmol) was stirred in toluene at reflux for 3 hours. Reaction mixture was concentrated *in vacuo* to afford *tert*-butyl (S)-2-oxo-5-propylpyrrolidine-1-carboxylate **216** (10.4 g) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 4.17 – 4.05 (m, 1H), 2.65 – 2.50 (m, 1H), 2.42 (ddd, J = 17.7, 9.5, 2.6 Hz, 1H), 2.19 – 2.03 (m, 1H), 1.83 – 1.71 (m, 2H), 1.71 – 1.60 (m, 1H), 1.52 – 1.26 (m, 11H), 1.01 – 0.91 (m, 3H).

Step 4: *tert*-butyl (S)-(8-(dimethyl(oxo)-l6-sulfaneylidene)-7-oxooctan-4-yl)carbamate (217**)**

2-Methylpropan-2-olate potassium (4.21 g, 37.5 mmol) was added as a solid charge to a suspension of trimethyl(oxo)sulfonium iodide (9.35 g, 42.5 mmol) in DMSO (50 mL). The suspension was stirred for one hour, followed by addition of *tert*-butyl (S)-2-oxo-5-propylpyrrolidine-1-carboxylate (**216**) (5.68 g, 25.0 mmol) as a single solid charge, and the suspension was then aged for one hour. Water (500 mL) was added dropwise to the reaction mixture. The aqueous phase was extracted 3x with EtOAc then 3x with 9:1 EtOAc/EtOH. Assembled organic fractions were dried with Na₂SO₄ anhydrous, filtered and concentrated *in vacuo* to afford a brown solid. The crude material was recrystallized in EtOAc and afforded *tert*-butyl (S)-(8-(dimethyl(oxo)-l6-sulfaneylidene)-7-oxooctan-4-yl)carbamate **217** (2.85 g) as a white solid. [M+H]⁺: 320.2. ¹H NMR (400 MHz, CDCl₃) δ 4.51 – 3.97 (m, 2H), 3.54 (s, 1H), 3.39 (s, 6H), 2.24 (t, J = 6.4 Hz, 2H), 1.79 (s, 1H), 1.65 – 1.58 (m, 1H), 1.51 – 1.20 (m, 13H), 0.90 (t, J = 7.0 Hz, 3H).

Step 5: *tert*-butyl (S)-5-oxo-2-propylpiperidine-1-carboxylate (218**)**

A suspension of *tert*-butyl (S)-(8-(dimethyl(oxo)-l6-sulfaneylidene)-7-oxooctan-4-yl)carbamate (**217**) (2.75 g, 8.61 mmol) in toluene (40 mL) was degassed via nitrogen sparging for 30 minutes. The suspension was then added over 1 hour to a 80 °C degassed solution of [Ir(COD)Cl]₂ (57.8 mg, 86.1 μmol) in toluene (80 mL). The reaction mixture was aged at 80 °C for 10 hours, and then cooled to r.t. ISOLUTE® HM-N (10 g) was added to the reaction mixture and concentrated *in vacuo*. The crude material was purified by silica gel chromatography (5 to 100% EtOAc:EtOH (v/v = 75:25) in heptane). Fractions containing desired product were combined and concentrated to afford *tert*-butyl (S)-5-oxo-2-propylpiperidine-1-carboxylate **218** (453 mg). [M-H]⁻: 240.2. ¹H NMR (400 MHz, CDCl₃) δ 4.63 – 4.06 (m, 2H), 3.52 (d, J = 18.9 Hz, 1H), 2.41 (dd, J = 7.4, 5.3 Hz, 2H), 2.22 (dq, J = 13.1, 6.7 Hz, 1H), 1.71 – 1.57 (m, 3H), 1.46 (s, 9H), 1.40 – 1.20 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H).

Step 6: *tert*-butyl (2S,5R)-5-hydroxy-2-propylpiperidine-1-carboxylate (219**)**

To a solution of *tert*-butyl (S)-5-oxo-2-propylpiperidine-1-carboxylate (**218**) (400 mg, 1.66 mmol) in EtOH (10 mL), was added sodium borohydride (94.1 mg, 2.49 mmol) at -5 °C and the mixture was stirred at this temperature for 4 hours. The reaction mixture was concentrated *in vacuo* and saturated aqueous NH₄Cl (30 mL) was added. The aqueous phase was extracted with DCM (4x). The combined organic fractions were dried over Na₂SO₄, filtered and concentrated *in vacuo*. The crude material was purified by silica gel chromatography (15 to 100% EtOAc in heptane). *tert*-butyl (2S,5R)-5-hydroxy-2-propylpiperidine-1-carboxylate **219**

(190 mg) was afforded. [M-BOC]⁺: 144.2. ¹H NMR (400 MHz, CDCl₃) δ 4.12 (q, J = 7.1 Hz, 2H), 3.75 – 3.46 (m, 1H), 2.61 – 2.48 (m, 1H), 1.92 – 1.81 (m, 1H), 1.73 – 1.47 (m, 5H), 1.45 (s, 9H), 1.40 – 1.17 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H).

Step 7: *tert*-butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-propylpiperidine-1-carboxylate (220)

Compound **220** was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (0.37 g, 0.81 mmol) and *tert*-butyl (2S,5R)-5-hydroxy-2-propylpiperidine-1-carboxylate (**219**)

(0.18 g, 0.74 mmol). The reaction mixture was cooled to room temperature, filtered and concentrated *in vacuo*. The crude material was purified by silica gel chromatography (1 to 10% EtOH in DCM). *tert*-Butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-propylpiperidine-1-carboxylate **220** (0.38 g) was afforded as a brown solid. LCMS [M-H]⁻: 614.2.

Step 8: 3-(1-oxo-5-(((3R,6S)-6-propylpiperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione (I-221) (Example 87-1)

Compound **I-221** was made according to General Method VII starting from *tert*-Butyl (2S,5R)-5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2-propylpiperidine-1-carboxylate **220** (0.38 g, 0.61 mmol). The reaction mixture was concentrated *in vacuo*. The crude material was purified by silica gel chromatography (1 to 15% EtOH in DCM, 0.1% Et₃N modifier). Fractions containing desired product were combined and concentrated to afford 3-(1-oxo-5-(((3R,6S)-6-propylpiperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **I-221** (0.11 g) as a white solid. LCMS [M+H]⁺: 386.3. ¹H NMR (400 MHz, DMSO) δ 10.87 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 6.97 (dd, J = 8.4, 2.2 Hz, 1H), 4.97 (dd, J = 13.3, 5.1 Hz, 1H), 4.41 (s, 1H), 4.37 – 4.08 (m, 2H), 3.03 (s, 1H), 2.81 (ddd, J = 18.1, 13.7, 5.4 Hz, 1H), 2.71 (d, J = 13.7 Hz, 1H), 2.55 – 2.45 (m, 1H), 2.35 – 2.20 (m, 1H), 1.99 – 1.79 (m, 2H), 1.60 (t, J = 13.4 Hz, 1H), 1.37 (d, J = 13.2 Hz, 1H), 1.31 – 1.11 (m, 6H), 0.77 (t, J = 6.9 Hz, 3H).


Step 9: 3-(5-(((3R,6S)-1-ethyl-6-propylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-222) (Example 87-2)

To a solution of 3-(1-oxo-5-(((3R,6S)-6-propylpiperidin-3-yl)oxy)isoindolin-2-yl)piperidine-2,6-dione **I-221** (0.11 g, 0.27 mmol) and sodium triacetoxymethylborohydride (0.16 g, 0.74 mmol) in EtOH (2 mL) was added acetaldehyde (0.030 mL, 0.54 mmol) at 0 °C. The reaction stirred at r.t. overnight. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrated to afford 3-(5-(((3R,6S)-1-ethyl-6-propylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-222** (0.088 g, 0.21 mmol, 78%) as an off-white solid. LCMS [M+H]⁺: 414.4. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 2.1 Hz, 1H), 7.04 (dd, J = 8.4, 1.9 Hz, 1H), 5.06 (dd, J = 13.2, 5.1 Hz, 1H), 4.53 (tt, J = 5.9, 2.5 Hz, 1H), 4.38 (d, J = 17.1 Hz, 1H), 4.25 (d, J = 17.1 Hz, 1H), 2.90 (ddd, J = 18.0, 13.5,

5.4 Hz, 1H), 2.78 – 2.53 (m, 6H), 2.46 – 2.28 (m, 1H), 2.08 – 1.92 (m, 1H), 1.89 – 1.74 (m, 1H), 1.73 – 1.54 (m, 3H), 1.53 – 1.28 (m, 3H), 1.28 – 1.10 (m, 1H), 0.98 – 0.82 (m, 6H).

Example 88-1 and 88-2: 3-(5-((6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-224) and 3-(5-((1-ethyl-6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-225)

5 **oxoisindolin-2-yl)piperidine-2,6-dione (I-225)**



Step 1: tert-butyl 5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2,2-dimethylpiperidine-1-carboxylate (223)

Compound **223** was made according to General Method VI starting from 3-(5-bromo-1-oxoisindolin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)piperidine-2,6-dione **INT-1** (1.25 g, 2.75 mmol) and tert-butyl 5-hydroxy-2,2-dimethylpiperidine-1-carboxylate (630 mg, 2.75 mmol). The reaction mixture was cooled to room temperature, filtered and concentrated in vacuo to afford tert-butyl 5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2,2-dimethylpiperidine-1-carboxylate **223** (1.43 g) as an yellow oil. LCMS [M+H]⁺: 600.5.

Step 2: 3-(5-((6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-224) (Example 88-1)

Compound **I-224** was made according to General Method VII starting from tert-butyl 5-((2-(2,6-dioxo-1-((2-(trimethylsilyl)ethoxy)methyl)piperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-2,2-dimethylpiperidine-1-carboxylate **223** (1.43 g, 2.38 mmol). The reaction mixture was diluted with saturated aqueous sodium bicarbonate and extracted with 4:1 DCM:TFE three times. The organic layers were combined and concentrated. The crude material was purified by silica gel chromatography (0 to 100% EtOH:Et₃N (v/v = 100:1) in EtOAc). Fractions containing desired product were combined and concentrated to afford 3-(5-((6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-224** (0.56 g) as a white solid. LCMS [M+H]⁺: 372.3. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 2.2 Hz, 1H), 7.05 (dd, J = 8.4, 2.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.44 – 4.19 (m, 3H), 2.98 (dd, J = 12.8, 3.9 Hz, 1H), 2.94 – 2.83 (m, 1H), 2.71 (dd, J = 12.9, 8.0 Hz, 1H), 2.64 – 2.55 (m, 1H), 2.37 (qd, J = 13.1, 4.4 Hz, 1H), 2.05 – 1.90 (m, 2H), 1.78 – 1.62 (m, 1H), 1.59 – 1.47 (m, 1H), 1.45 – 1.28 (m, 1H), 1.07 (s, 3H), 1.05 (s, 3H).

Step 3: 3-(5-((1-ethyl-6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (I-225) (Example 88-2)

To a solution of 3-(5-((6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-224** (479 mg, 1.29 mmol) and sodium triacetoxyborohydride (683 mg, 3.22 mmol) in EtOH (20 mL) was added acetaldehyde (0.14 mL, 2.5 mmol) at 0 °C. The reaction stirred at r.t. overnight. The reaction was concentrated and purified by silica gel chromatography (0 to 100% EtOAc:EtOH:Et₃N (v/v/v = 75:25:1) in heptane). Fractions containing desired product were combined and concentrated to afford 3-(5-((1-ethyl-6,6-dimethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione **I-225** (0.29 g, 0.72 mmol, 56%) as an off-white solid.

LCMS [M+H]⁺: 400.3. ¹H NMR (400 MHz, DMSO) δ 10.96 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 2.2 Hz, 1H), 7.04 (dd, J = 8.4, 2.2 Hz, 1H), 5.06 (dd, J = 13.3, 5.1 Hz, 1H), 4.45 (td, J = 8.6, 4.2 Hz, 1H), 4.38 (d, J = 17.2 Hz, 1H), 4.25 (d, J = 17.1 Hz, 1H), 2.98 – 2.83 (m, 2H), 2.69 – 2.54 (m, 2H), 2.36 (td, J = 12.3, 3.4 Hz, 2H), 2.10 (dq, J = 13.5, 6.8 Hz, 1H), 2.03 – 1.83 (m, 2H), 1.64 – 1.40 (m, 3H), 1.06 (s, 3H), 0.99 – 0.88 (m, 6H).

Biological Data

Abbreviations

BSA	bovine serum albumin
Cas9	CRISPR associated protein 9
20 CRISPR	Clustered regularly interspaced short palindromic repeats
crRNA	CRISPR RNA
DMEM	Dulbecco's modified eagle media
DMSO	Dimethyl sulfoxide
DTT	Dithiothreitol
25 EDTA	ethylenediaminetetraacetic acid
eGFP	enhanced green fluorescent protein
FACS	fluorescence-activated cell sorting
FBS	fetal bovine serum
FITC	fluorescein
30 Flt3L	Fms-related tyrosine kinase 3 ligand, Flt3L
HbF	Fetal hemoglobin
HEPES	(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
IMDM	Iscoe's modified Dulbecco's medium
KCl	potassium chloride
35 mPB	mobilized peripheral blood
PBS	phosphate buffered saline
rhEPO	recombinant human erythropoietin
rhIL-3	recombinant human interleukin-3
rhIL-6	recombinant human interleukin-6

rhSCF	recombinant human stem cell factor
rhTPO	recombinant human thrombopoietin
RNP	ribonucleoprotein
shRNA	short hairpin RNA
5 tracrRNA	trans-activating crRNA
WIZ	Widely-Interspaced Zinc Finger Containing Protein

Materials and Methods

Example 89: Quantification of WIZ protein levels in HiBit Tag Fusion Protein Assay

The HiBit system from Promega was used to develop high-throughput and quantitative assays to measure changes in WIZ protein levels in response to compounds. The HiBit tag was derived from a split Nanoluciferase and has the following protein sequence: VSGWRLFKKIS (SEQ ID NO: 1). The complementary fragment of Nanoluciferase (known as LgBit, from Promega), was added to the HiBit tag to form an active Nanoluciferase enzyme whose activity can be precisely measured. In this way, the levels of a fusion protein with the HiBit tag can be quantified in cell lysates.

Lentiviral vectors, based on the Invitrogen™ pLenti6.2/V5 DEST backbone were constructed that places the HiBit tag upstream of WIZ and expressed the fusion protein from an HSVTK promoter.

To ensure moderate and consistent expression of the HiBit-WIZ fusion protein across all cells in the population, stable cell lines were constructed from cells harboring a single copy of the construct. Lentivirus packaged with the constructs were made using the ViraPower™ kit from Invitrogen™. 293T cells from ATCC (Catalog number: CRL-3216), were infected with the virus at low multiplicity of infection and selected by 5 µg/mL blasticidin in culture media for 2 weeks.

The levels of HiBit-WIZ tagged fusion proteins in compound-treated cell lines were measured as follows:

On day 1, cells were diluted to 1.0×10^6 cells/ml in normal growth medium. 20 µL of cell suspension were plated in each well of a solid white 384-well plate. Plates were incubated overnight in a 37°C and 5% CO₂ humidified tissue culture incubator.

On day 2, serial dilutions of compounds were made in 384-well plates. Compound plates were set up with DMSO in columns 1, 2, 23, 24, and 10-point compound dilution series in column 3-12 and column 13-22. 10 mM stock solution of compound were placed into column 3 or 13 and a 1:5 serial dilution was carried out until there was a 10-point dilution series per compound. 50 nL of diluted compounds were transferred into the plated cells by Echo® (Labcyte) acoustic transfer. The highest concentration of compound was 25 µM. Plates were incubated overnight (about 18 hours) in a 37°C and 5% CO₂ humidified tissue culture incubator.

On day 3, plates were removed from the incubator and allowed to equilibrate at room temperature for 60 minutes. HiBit substrate (Nano-Glo® HiBit Lytic Detection System, Promega Catalogue number: N3050) was added as described by the manufacturers protocols. Plates were

incubated at room temperature for 30 minutes and luminescence was read using an EnVision® reader (PerkinElmer®). Data was analyzed and visualized using the Spotfire® software package.

WIZ degradation activity of compounds (Table 1)

Table 1 shows WIZ degradation activity of compounds of the disclosure in the WIZ HiBit assay in 293T cells. WIZ Amax reflects the DMSO-normalized, curve-fitted percentage of WIZ-HiBit remaining at 25 μ M. It was calculated by normalizing DMSO controls to 100%, parametric curve fitting of the dose response data (10-point, 5-fold), followed by calculation of response at 25 μ M using the fitted equation.

Table 1:

Ex. No.	WIZ AC ₅₀ (μ M)	WIZ Amax	% degradation of WIZ (100- Amax)
1	0.016	24.04	75.96
2	0.36	88.89	11.11
3	0.002	26.79	73.21
4	0.11	64.40	35.6
5	0.055	77.26	22.74
6	0.031	86.71	13.29
7	0.0011	38.87	61.13
8	0.028	32.98	67.02
9	0.0042	28.52	71.48
10	0.033	45.54	54.46
11	0.11	56.44	43.56
12	0.13	68.54	31.46
13	0.014	27.56	72.44
14	0.057	40.67	59.33
15	0.0084	20.0	80
16	0.0025	40.88	59.12
17	0.014	27.75	72.25
18	0.02	61.38	38.62
19	0.012	37.13	62.87
20	3.75	75.87	24.13
21	0.0035	25.7	74.3
22	0.083	75.65	24.35
23	0.03	42.29	57.71
24	0.01	47.30	52.7
25	0.0075	50.21	49.79

Ex. No.	WIZ AC ₅₀ (μ M)	WIZ Amax	% degradation of WIZ (100- Amax)
26	0.021	58.9	41.1
27	0.13	60.26	39.74
28	0.084	67.1	32.9
29	0.082	69.01	30.99
30	0.079	70.76	29.24
31	0.0089	31.43	68.57
32	0.0017	19.17	80.83
33	0.0015	18.59	81.41
34	0.015	19.98	80.02
35	0.026	68.11	31.89
35A	0.0086	60.81	39.19
35B	0.0061	67.54	32.46
35C	0.011	69.59	30.41
35D	0.0063	62.63	37.37
36	0.057	32.5	67.5
37	>25.0	103.4 3	-
38	0.025	35.65	64.35
39	0.21	47.85	52.15
40	0.77	73.54	26.46
41	0.0001 4	11.40	88.6
42	0.0036	22.9	77.1
43	0.0037	28.07	71.93




Ex. No.	WIZ AC ₅₀ (μ M)	WIZ Amax	% degradation of WIZ (100- Amax)
44	0.06	84.18	15.82
45	0.0076	56.3	43.7
45A	0.040	48.89	51.11
45B	0.044	67.92	32.08
45C	0.049	66.38	33.62
45D	0.051	48.09	51.91
46	>25	101	-
46A	>25.00	109.6 6	-
46B	>25.00	110.9 9	-
46C	>25.00	105.0 3	-
46D	>25.00	110.9 9	-
47	0.088	77.16	22.84
48	>25	101.5	-
49	0.083	91.37	8.63
50	>25	97.62	2.38
51	0.200	87.19	12.81
52	0.0055	23.76	76.24
53	0.071	78.16	21.84
54	>25.00	101.8 9	-
55	0.026	55.08	44.92
56	0.95	83.84	16.16
57	0.17	83.12	16.88
58	0.0049	39.27	60.73
59	0.0026	35.57	64.43
60	0.078	63.04	36.96
62	0.083	72.90	27.1
63	0.0001 2	20.54	79.46



Ex. No.	WIZ AC ₅₀ (μ M)	WIZ Amax	% degradation of WIZ (100- Amax)
64	0.0063	20.55	79.45
65-1	0.0014	18.11	81.89
65-2	0.0012	19.67	80.33
66	0.0333	19.87	80.13
67	0.0112	16.93	83.07
68	>25	105.3 7	-
69	>25	106.4 1	-
70	>25	106.5 9	-
71	0.0453	39.01	60.99
72	0.0415	40.12	59.88
73	0.0238	37.20	62.80
74	0.0089	21.94	78.06
75-1	0.0009	13.40	86.60
75-2	0.0040	16.50	83.50
76-1	0.0016	13.76	86.24
76-2	0.0006	12.82	87.18
77	0.0011	13.55	86.45
78	0.0005	14.27	85.73
79	0.0017	17.29	82.71
80	0.0234	28.59	71.41
81	0.0020	10.74	89.26
82	0.0005	15.01	84.99
83	>25	96.76	3.24
84	1.1735	81.67	18.33
85	0.0672	65.69	34.31
86	>25	75.97	24.03
87-1	0.0359	28.58	71.42
87-2	0.0006	10.29	89.71
88-1	0.1345	50.01	49.99
88-2	0.0007	20.47	79.53

Example 90: Comparative WIZ AC₅₀ and WIZ Degradation Data (Table 2)

Table 2 shows comparative data demonstrating improved WIZ degradation. This assay produced a range of WIZ AC₅₀ and Amax values over several repeat runs due to normal variations in the assay. For a comparison to the compounds described in PCT/IB2020/062070, the updated arithmetic mean values are reported over the number of repeats specified below from the assay described in **Example 89**. Without wishing to be bound by any theory, it is hypothesized that the improved potency of compounds of formula (I) of the present disclosure is due to the conformational restriction of the nitrogen-containing heterocyclic group bonded through oxygen to the base molecule. This increased rigidity of the chemical structures may thus lead to enhanced potency for WIZ by minimizing entropic loss.

Table 2:

Example Number	WIZ AC ₅₀ (μM)	Number of Repeats
Example 1  3-(5-(((R)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (mixture of 2 diastereomers)	0.016	3
Example 13  3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	0.021	3
Comparative Example 1  3-(5-(((R)-1-ethylpiperidin-2-yl)methoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (mixture of 2 diastereomers)	0.051	27
Comparative Example 2	0.026	31

 3-(5-(1-(1-ethylpiperidin-2-yl)ethoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (mixture of 2 diastereomers)		
Comparative Example 3  3-(5-(((R)-1-(cyclopropylmethyl)piperidin-2-yl)methoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	0.032	1

Example 91: Quantification of SALL4 protein levels in HiBiT Tag Fusion Protein Assay

The HiBiT system from Promega was used to develop high-throughput and quantitative assays to measure changes in SALL4 protein levels in response to compounds. The HiBiT tag was derived from a split Nanoluciferase and has the following protein sequence: VSGWRLFKKIS (SEQ ID No: 1). The complementary fragment of Nanoluciferase (known as LgBiT, from Promega), was added to the HiBiT tag to form an active Nanoluciferase enzyme whose activity can be precisely measured. In this way, the levels of a fusion protein with the HiBiT tag can be quantified in cell lysates.

DNA constructs, based on the Invitrogen pLenti6.2/V5 DEST backbone, were constructed with the HiBiT tag upstream of SALL4 and expressed the fusion protein from a CMV promotor.

To ensure moderate and consistent expression of the HiBiT-SALL4 fusion protein across all cells in the population, stable cell lines were derived from clones. GripTite 293 MSR cells (293GT) from ThermoFisher Scientific (Catalog number: CRL-R79507), were stably transfected with prepared constructs via electroporation. Following recovery, cells were selected by 10 ug/mL blasticidin in culture media.

The levels of HiBiT-SALL4 tagged fusion proteins in compound-treated cell lines were measured as follows:

On day 1, cells were diluted to 1.0×10^6 cells/ml in normal growth medium. 20 μ L of cell suspension were plated in each well of a solid white 384-well plate. Plates were incubated overnight in a 37°C and 5% CO₂ humidified tissue culture incubator.

On day 2, serial dilutions of compounds were made in 384-well plates. Compound plates were set up with DMSO in columns 1, 2, 23, 24, and 10-point compound dilution series in column 3-12 and column 13-22. 10 mM stock solution of compound were placed into column 3 or 13 and a 1:5 serial dilution was carried out until there was a 10-point dilution series per compound. 100 nL of diluted compounds were transferred into the plated cells by Echo® (Labcyte) acoustic transfer. The highest concentration of compound was 50 μ M. Plates were incubated overnight (18 hours) in a 37°C and 5% CO₂ humidified tissue culture incubator.


On day 3, plates were removed from the incubator and allowed to equilibrate at room temperature for 60 minutes. HiBiT substrate (Nano-Glo® HiBit Lytic Detection System, Promega Catalogue number: N3050) was added as described by the manufacturers protocols. Plates were incubated at room temperature for 30 minutes and luminescence was read using an EnVision® reader (PerkinElmer®). Data was analyzed and visualized using the Spotfire® software package.




SALL4 degradation activity of comparative compounds (Table 3)

Table 3 shows comparative data demonstrating SALL4 degradation activity of compounds of the disclosure in the SALL4 HiBiT assay in 293T cells. SALL4 Amax reflects the DMSO-normalized, curve-fitted percentage of SALL4-HiBiT remaining at 50 μ M. It was calculated by normalizing DMSO controls to 100%, parametric curve fitting of the dose response data (10-point, 5-fold), followed by calculation of response at 50 μ M using the fitted equation.

This assay produced a range of SALL4 AC₅₀ and Amax values over several repeat runs due to normal variations in the assay. For a comparison to the compounds described in PCT/IB2020/062070, the arithmetic mean values are reported over the number of repeats specified. Results from this assay indicate that compounds of formula (I) do not degrade SALL4 to the same extent as compounds described in PCT/IB2020/062070. The compounds of the present disclosure are therefore expected to have improved toxicological properties (Matyskiela, M.E., Couto, S., Zheng, X. *et al.* SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. *Nat Chem Biol* 14, 981–987 (2018); Donovan, K.A. *et al.* Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. *eLife* 2018;7:e38430).

Table 3:

Example Number	SALL4 AC ₅₀ (μ M)	SALL4 Amax	Number of Repeats
Example 1 	0.049	72.21	3

3-(5-(((R)-1-ethylpiperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (mixture of 2 diastereomers)			
Example 13  3-(5-(((R)-1-(cyclopropylmethyl)piperidin-3-yl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	0.14	70.82	3
Comparative Example 1  3-(5-(((R)-1-ethylpiperidin-2-yl)methoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (mixture of 2 diastereomers)	0.16	51.51	17
Comparative Example 3  3-(5-(((R)-1-(cyclopropylmethyl)piperidin-2-yl)methoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	0.13	52.88	1

Example 92: Small Molecule HbF Induction Assay

Cryopreserved primary human CD34⁺ hematopoietic stem and progenitor cells were obtained from AllCells, LLC. The CD34⁺ cells were isolated from the peripheral blood of healthy donors after mobilization by administration of granulocyte colony-stimulating factor. Cells were differentiated *ex vivo* toward the erythroid lineage using a 2-phase culture method. In the first phase, cells were cultured in StemSpan™ Serum-Free Expansion Media (SFEM) (STEMCELL Technologies Inc.) supplemented with rhSCF (50 ng/mL, Peprotech®, Inc.), rhIL-6 (50 ng/mL, Peprotech®, Inc.), rhIL-3 (50 ng/mL, Peprotech®, Inc.), and rhFlt3L (50 ng/mL, Peprotech®, Inc.), and 1X antibiotic-antimycotic (Life Technologies, Thermo Fisher Scientific) for 6 days at 37°C with 5% CO₂. During the second phase, cells were cultured in erythroid differentiation media at 5,000

cells/mL in the presence of compound for 7 days at 37°C with 5% CO₂. Erythroid Differentiation Media is comprised of IMDM (Life Technologies) supplemented with insulin (10 µg/mL, Sigma Aldrich), heparin (2 U/mL Sigma Aldrich), holo-transferrin (330 µg/mL, Sigma Aldrich), human serum AB (5%, Sigma Aldrich), hydrocortisone (1 µM, STEMCELL Technologies), rhSCF (100 ng/mL, Peprotech®, Inc.), rhIL-3 (5 ng/mL, Peprotech®, Inc.), rhEPO (3 U/mL, Peprotech®, Inc.), and 1X antibiotic- antimycotic. All compounds were dissolved and diluted into dimethylsulfoxide (DMSO) and were added to culture media for a final concentration of 0.3% DMSO for testing in a 10-point, 1:3 dilution series starting at 10 µM.


Staining and Flow Cytometry

For viability analysis, samples were washed and resuspended in phosphate-buffered saline (PBS) and stained with LIVE/DEAD™ Fixable Violet Dead Cell Stain Kit (Life Technologies, L34963) for 20 minutes. Cells were then washed again with PBS and resuspended in PBS supplemented with 2% fetal bovine serum (FBS), and 2 mM EDTA to prepare for cell surface marker analysis. Cells were labeled with allophycocyanin-conjugated CD235a (1:100, BD Biosciences, 551336) and Brilliant Violet-conjugated CD71 (1:100, BD Biosciences, 563767) antibodies for 20 minutes. For analysis of cytoplasmic Fetal Hemoglobin (HbF), cells were fixed and permeabilized using the Fixation (BioLegend®, 420801) and Permeabilization Wash (BioLegend®, 421002) Buffers according to the manufacturer's protocol. During the permeabilization step, cells were stained with phycoerythrin-conjugated or FITC-conjugated HbF-specific antibody (1:10-1:25, Invitrogen™, MHFH04-4) for 30 minutes. Stained cells were washed with phosphate-buffered saline before analysis on the FACSCanto™ II flow cytometer or LSRFortessa™ (BD Biosciences). Data analysis was performed with FlowJo™ Software (BD Biosciences).

HbF induction activity of compounds (Table 4)

mPB CD34+ cells were expanded for 6 days, then erythroid differentiated in the presence of compound for 7 days. Cells were fixed, stained and analyzed by flow cytometry. Table 4 shows HbF induction activity of the compounds. HbF Amax = the highest percentage of cells staining positive for HbF (%HbF+ cells) in the fitted dose-response curve. The baseline %HbF+ cells for DMSO-treated cells is approximately 30-40%.

Table 4:

Example Number	HbF EC ₅₀ (μM)	HbF Amax
1	0.047	66.5
41	0.025	73.1
Comparative Example 1  3-(5-(((R)-1-ethylpiperidin-2-yl)methoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione	0.087	64.1

Example 93: Cell culture for shRNA and CRISPR assays

HEK293T cells were maintained in DMEM high glucose complete media with sodium pyruvate, non-essential amino acids, 10% FBS, 2 mM L-glutamine, 100 U/mL pen/strep, 25 mM HEPES. Unless stated otherwise, all reagents for culturing HEK293T cells were obtained from Invitrogen™.

Mobilized peripheral blood (mPB) CD34+ cells (AllCells, LLC) were maintained in StemSpan™ serum-free expansion media (SFEM) (STEMCELL Technologies Inc.) supplemented with 50 ng/mL each of rhTPO, rhIL-6, rhFLT3L, rhSCF for 2-3 days prior to shRNA transduction or targeted ribonucleoprotein (RNP) electroporation targeting WIZ. All cytokines were obtained from Peprotech®, Inc. Cell cultures were maintained at 37°C and 5%CO₂ in a humidified tissue culture incubator.

Generation of shRNA lentiviral clones targeting WIZ

5'-phosphorylated sense and anti-sense complementary single-stranded DNA oligos of the respective shRNA against WIZ were synthesized by Integrated DNA Technologies, Inc. (IDT). Each DNA oligonucleotide was designed with PmeI/Ascl restriction overhangs on 5'- and 3'- ends, respectively, for subsequent compatible ligation into the lentiviral vector backbone. Equimolar of each of the complementary oligonucleotides were annealed in NEB Buffer 2 (New England Biolabs® Inc.) by heating on a heating block at 98°C for 5 minutes followed by cooling to room temperature on the bench top. Annealed double-stranded DNA oligonucleotides were ligated into pHAGE lentiviral backbone digested with PmeI/Ascl using T4 DNA ligase kit (New England Biolabs). Ligation reactions were transformed into chemically competent Stbl3 cells (Invitrogen™) according to the manufacturer's protocol. Positive clones were verified using the sequencing primer (5'-ctacattttacatgatagg-3'; SEQ ID NO: 2) and plasmids were purified by Alta Biotech LLC.

Lentivirus particles for the respective shRNA constructs were generated by co-transfection of HEK293T cells with pCMV-dR8.91 and pCMV-VSV-G expressing envelope plasmid using Lipofectamine 3000 reagent in 150mm tissue culture dish format as per manufacturer's

instructions (Invitrogen™). Lentivirus supernatant was harvested 48 hours after co-transfection, filtered through a 0.45 µm filter (Millipore) and concentrated using Amicon Ultra 15 with Ultracel-100 membrane (Millipore). Infectious units of each of the lentivirus particle was determined by flow cytometry using eGFP expression as marker of transduction after serial dilution and infection of HEK293T cells.

The shRNA sequences are as follows:

shWIZ_#1 5'-AGCCCACAATGCCACGGAAAT-3' (SEQ ID NO: 3);

shWIZ_#2 5'-GCAACATCTACACCCTCAAAT-3' (SEQ ID NO: 4);

shWIZ_#4 5'-TGACCGAGTGGTACGTCAATG-3' (SEQ ID NO: 5);

shWIZ_#5 5'-AGCGGCAGAACATCAACAAAT-3' (SEQ ID NO: 6).

Lentiviral shRNA transduction and FACS of mPB CD34+ cells

mPB CD34+ transduction was performed on retronectin coated non-tissue culture treated 96 well-flat bottom plates (Corning, Inc.). Briefly, plates were coated with 100 µL of RetroNectin® (1 µg/mL) (TAKARABIO, Inc.), sealed and incubated at 4°C overnight. RetroNectin® was then removed and plates were incubated with BSA (bovine serum albumin) (1%) in PBS for 30 minutes at room temperature. Subsequently, BSA (bovine serum albumin) was aspirated and replaced with 100 µL of lentiviral concentrate and centrifuged at 2000xg for 2 hours at room temperature. Next, residual supernatant was gently pipetted out and ready for transductions of mPB CD34+ cells. Ten thousand cells were plated in 150 µL of StemSpan™ Serum-free Expansion Medium (SFEM) supplemented with 50 ng/mL each of rhTPO, rhIL-6, rhFLT3L, rhSCF to initiate transduction. Cells were cultured for 72 hours prior to assessing transduction efficiencies using eGFP expression as a marker.

eGFP-positive cells were sorted on an FACS Aria™ III (BD Biosciences). Briefly, the transduced mPB CD34+ cell population was washed and re-suspended with FACS buffer containing 1x Hank's buffered saline solution, EDTA (1 mM) and FBS (2%). Sorted eGFP-positive cells were used for the erythroid differentiation assay.

Targeting CRISPR knockout of WIZ

Alt-R CRISPR-Cas9 crRNA and tracrRNA (5'-AGCAUAGCAAGUUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUC GGUGCUUU -3'; SEQ ID NO: 7) were purchased from Integrated DNA Technologies, Inc.. Equimolar tracrRNA was annealed with WIZ targeting crRNA (Table 3) in Tris buffer (10 mM, pH 7.5) by heating at 95°C for 5 minutes using a polymerase chain reaction (PCR) machine (Bio-Rad) followed by cooling to room temperature on the benchtop. Subsequently, a ribonucleoprotein (RNP) complex was generated by mixing annealed tracrRNA:crRNA with 6 µg of Cas9 at 37°C for 5 minutes in 1x buffer containing HEPES (100 mM), KCl (50 mM), MgCl₂ (2.5 mM), glycerol (0.03%), DTT (1 mM) and Tris pH 7.5 (2 mM).

Electroporation of the RNP complex was performed on a 4D-Nucleofector™ (Lonza) as per manufacturer's recommendation. Briefly, 50,000 mPB CD34+ cells resuspended in Primary Cell P3 Buffer with supplement (Lonza) were pre-mixed with 5 µL of RNP complex per well in

nucleocuvettes and incubated for 5 minutes at room temperature. Subsequently, the mixture was electroporated using the CM-137 program. Cells were cultured for 72 hours post-RNP electroporation before initiating erythroid differentiation. The crRNA sequences are shown in Table 5 below.

5 **Table 5:**

Name	Sequence (5' to 3')	Target genomic region	Strand	SEQ ID NO
rg_0111	ACGGAGGCTAAGCGTCGCAA	random guide, non-targeting		8
WIZ_6	AACATCTTTCGGGCCGTAGG	chr19:15427143-15427163	(+)	9
WIZ_9	GACATCCGCTGCGAGTTCTG	chr19:15427488-15427510	(-)	10
WIZ_12	TGCAGCGTCCCGGGCAGAGC	chr19:15425751-15425773	(-)	11
WIZ_14	CAAGCCGTGCCTCATCAAGA	chr19:15425571-15425593	(-)	12
WIZ_15	CGGGCACACCTGCGGCAGTT	chr19:15424942-15424964	(-)	13
WIZ_18	AGTGGGTGCGGCACTTACAG	chr19:15423169-15423191	(-)	14

Erythroid differentiation of shRNA transduced or RNP electroporated mPB CD34+ cells

Erythroid differentiation was initiated by plating 8,000 RNP-electroporated or FACS sorted eGFP+ mPB CD34+ cells per well in 96-well tissue culture plate. Base differentiation media consists of IMDM (Iscove's Modified Dulbecco's Medium), human AB serum (5%), transferrin (330 µg/mL), Insulin (10 µg/mL) and Heparin (2 IU/mL). Differentiation media was supplemented with rhSCF (100 ng/mL), rhIL-3 (10 ng/mL), rhEPO (2.5 U/mL) and hydrocortisone (1 µM). After 4 days of differentiation, the cells were split (1:4) in fresh media to maintain optimal growth density. Cells were cultured for additional 3 days and utilized for assessment of fetal hemoglobin (HbF) expression.

Analysis of HbF gene expression by RNA-seq

Two independent, targeted CRISPR/Cas9 knockout (KO) of WIZ were done using WIZ_6 and WIZ_18 gRNAs or a non-targeting scrambled gRNA negative control in mPB CD34+ HSCs. Cells from KO and negative control were then cultured for 7 days for erythroid differentiation and used for total RNA isolation (Zymo Research, catalogue# R1053). The quality of isolated RNA was determined before sequencing using Agilent RNA 6000 Pico Kit (Agilent, catalogue# 5067-1513).

RNA sequencing libraries were prepared using the Illumina TruSeq Stranded mRNA Sample Prep protocol and sequenced using the Illumina NovaSeq6000 platform (Illumina). Samples were sequenced to a length of 2x76 base-pairs. For each sample, salmon version 0.8.2 (Patro et al. 2017; doi: 10.1038/nmeth.4197) was used to map sequenced fragments to annotated transcripts in the human reference genome hg38 provided by the ENSEMBL database. Per-gene expression levels were obtained by summing the counts of transcript-level counts using tximport (Soneson et al. 2015; doi: 10.12688/f1000research.7563.1). DESeq2 was used to normalize for library size and transcript length differences, and to test for differential expression between samples treated with the gRNAs targeting WIZ and the samples treated with the scrambled gRNA controls (Love et al. 2014; doi: 10.1186/s13059-014-0550-8). Data were visualized using ggplot2 (Wickham H (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York. ISBN 978-3-319-24277-4; <https://ggplot2.tidyverse.org>).

HbF intracellular staining

One hundred thousand cells were aliquoted into U-bottom 96-well plate and stained for 20 min in the dark with diluted LIVE/DEAD fixable violet viability dye as per manufacturer's recommendation (Invitrogen). Cells were washed with FACS staining buffer and subsequently stained with anti-CD71-BV711 (BD Biosciences) and anti-CD235a-APC (BD Biosciences) for 20 mins in the dark. After two rounds of washes with three volumes of 1x PBS, cells were fixed and permeabilized with 1X BD Cytofix/Cytoperm (BD Biosciences) for 30 minutes at room temperature in the dark. Subsequently, cells were washed twice with three volumes of 1x Perm/wash buffer (BD Biosciences). Anti-HbF-FITC (ThermoScientific) was diluted (1:25) in 1x perm/wash buffer, added to permeabilized cells and incubated for 30 minutes at room temperature in the dark. Next, cells were washed twice with three volumes of 1x perm/wash buffer and analyzed by flow cytometry using LSR Fortessa (BD Biosciences). Data was analyzed with FlowJo software.

Results

WIZ KO upregulates HBG1/2 expression upon erythroid differentiation

Targeted KO of WIZ using two independent gRNAs (WIZ_6 and WIZ_18) demonstrated upregulation of fetal hemoglobin genes (HBG1/2), as presented in Figure 1A.

Loss of WIZ induces fetal hemoglobin expression in mPB CD34⁺ derived erythroid cells

In order to validate whether WIZ is a negative regulator of HbF expression, shRNA and CRISPR-Cas9-mediated knockdown and knockout functional genetics approaches were employed. mPB CD34⁺ cells were treated with shRNA or CRISPR-Cas9 reagents and erythroid differentiated for 7 days prior to flow cytometry analysis. Targeted knockdown of WIZ transcript results in 78-91% HbF⁺ cells compared to 40% for the negative control scrambled shRNA. Error bars represent standard error of two biological replicates with three technical replicates each (Figure 1B). CRISPR/Cas9-mediated targeted loss of WIZ results in 62-88% HbF⁺ cells compared to 39% for random guide crRNA. Error bars represent standard error of one biological sample with four technical replicates (Figure 1C). To summarize, the results indicate that loss of WIZ induces HbF in human primary erythroid cells. As such, the zinc finger transcription factor Widely


Interspaced Zinc Finger Motifs (WIZ) was identified as a novel target for HbF induction. These data provide genetic evidence that WIZ is a regulator of fetal hemoglobin expression and represents a novel target for the treatment of sickle cell disease and beta-thalassemia.

Having thus described several aspects of several embodiments, it is to be appreciated
5 various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the disclosure. Accordingly, the foregoing description and drawings are by way of example only.

Those skilled in the art will recognize, or be able to ascertain, using no more than routine
10 experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

Claims

1. A compound of formula (I') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-\text{SO}_2R^6$, $-\text{C}(=\text{O})-R^{2a}$, $-\text{C}(=\text{O})-\text{O}-R^{2a}$, and $-\text{C}(=\text{O})\text{NR}^{2b}R^{2c}$,

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-\text{CN}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;


R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl;

n is 0, 1, 2, 3, 4, or 5; and

m is 0, 1 or 2;

with the proviso that the compound of formula (I') does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.

2. A compound of formula (I'') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_{10} alkyl, $-\text{SO}_2\text{R}^6$, $-\text{C}(=\text{O})-\text{R}^{2a}$, $-\text{C}(=\text{O})-\text{O}-\text{R}^{2a}$, and $-\text{C}(=\text{O})\text{NR}^{2b}\text{R}^{2c}$,

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

R^{2a} is selected from C_1 - C_6 alkyl, and 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S;

R^{2b} and R^{2c} are each independently selected from hydrogen, and C_1 - C_6 alkyl;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;


each R^5 is independently selected from $-\text{CN}$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

R^6 is selected from C_3 - C_8 cycloalkyl, C_1 - C_6 alkyl, a 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O and S, and C_6 - C_{10} aryl;

n is 0, 1, 2, 3, 4, or 5; and

m is 1 or 2.

3. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:



each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, halo, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxyl, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C_3 - C_8 cycloalkyl; or 2 R^1 on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R^2 is selected from hydrogen, C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl,

wherein the C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl, C_2 - C_6 alkynyl, and C_1 - C_{10} alkyl are each independently substituted with 0-5 occurrences of R^3 ;

each R^3 is independently selected from C_1 - C_6 alkoxyl, halo, C_6 - C_{10} aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the C_6 - C_{10} aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-4 occurrences of R^4 ;

each R^4 is independently selected from C_1 - C_{10} alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^5 ;

each R^5 is independently selected from $-CN$, C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, hydroxyl, and C_1 - C_6 haloalkyl;

n is 0, 1, 2, 3 or 4; and

m is 0, 1 or 2;

with the proviso that the compound of formula (I) does not include 3-(1-oxo-5-(pyrrolidin-3-yloxy)isoindolin-2-yl)piperidine-2,6-dione.

4. The compound of formula (I'), (I''), or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein m is 1 or 2.

5. The compound of formula (I'), (I''), or (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein

R^2 is selected from C_3 - C_{11} cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 -

C₆alkynyl, and C₁-C₁₀alkyl, wherein the C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, C₆-C₁₀aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the C₆-C₁₀aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;

n is 0, 1, 2, 3, or 4; and

m is 0, 1 or 2, e.g., m is 1 or 2.

6. The compound of formula (I'), (I'') or (I) according to any one claims 1 to 3 and 5, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, C₁-C₆haloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;

n is 0, 1, 2, 3, or 4; and

m is 0, 1 or 2, e.g., m is 1 or 2.

7. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 3, 5 and 6, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a C₁-C₃ alkylene bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, C₁-C₆haloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₂-C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₆cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C₃-C₆cycloalkyl are each independently substituted with 0-3 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-C₆cycloalkyl;

n is 0, 1, 2, 3, or 4; and

m is 0, 1 or 2, e.g., m is 1 or 2.

8. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, fluoro, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₆cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a C₁-C₂ alkylene bridging ring;

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₂-C₆alkynyl, and C₁-C₆alkyl,

wherein the C₃-C₁₁cycloalkyl is substituted with 0-3 occurrences of R³, wherein the C₁-C₆alkyl is substituted with 0-1 occurrence of R^{3a}, and wherein the C₂-C₆alkynyl is substituted with 0-1 occurrence of R^{3b};

each R³ is independently selected from C₁-C₆alkoxyl, and fluoro;

R^{3a} is selected from 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C_3 - C_8 cycloalkyl, wherein the 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-3 occurrences of R^4 ;

R^{3b} is C_3 - C_8 cycloalkyl;

each R^4 is independently selected from C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, fluoro, and C_3 - C_8 cycloalkyl;

n is 0, 1, 2 or 3; and

m is 1.

9. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

each R^1 is independently selected from hydrogen, C_1 - C_6 alkyl, hydroxyl, fluoro, and C_1 - C_6 alkoxyl; or 2 R^1 on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl;

R^2 is selected from C_3 - C_8 cycloalkyl, 4- to 6-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_2 - C_6 alkynyl, and C_1 - C_6 alkyl,

wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^3 , wherein the C_1 - C_6 alkyl is substituted with 0-1 occurrence of R^{3a} , and wherein the C_2 - C_6 alkynyl is substituted with 0-1 occurrence of R^{3b} ;

each R^3 is independently selected from C_1 - C_6 alkoxyl, and fluoro;

R^{3a} is C_3 - C_8 cycloalkyl, wherein the C_3 - C_8 cycloalkyl is substituted with 0-3 occurrences of R^4 ;


R^{3b} is C_3 - C_8 cycloalkyl;

each R^4 is independently selected from C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, fluoro, and C_3 - C_8 cycloalkyl;


n is 0, 1, 2 or 3; and

m is 1.

10. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA):




11. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB):



12. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^2 is unsubstituted C_1 - C_6 alkyl or $-(CH_2)-R^3$, wherein R^3 is defined according to any one of the preceding claims.

13. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^2 is unsubstituted C_1 - C_6 alkyl or $-(CH_2)-R^{3a}$, wherein R^{3a} is defined according to claim 8 or 9.

14. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,



15. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^2 is selected from methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *sec*-butyl, and *t*-butyl.


16. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein m is 1.

17. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein n is 0, 1, 2 or 3, for example, n is 1.

18. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R¹ is selected from C₁-C₆alkyl, hydroxyl, halo, and C₁-C₆alkoxy; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl.

19. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R¹ is selected from C₁-C₄alkyl, C₁-C₄alkoxyl, and fluoro; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl.

20. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, and 12 to 19, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (I-i), wherein:



(I-i)

R^{1a} is independently selected from hydrogen and C₁-C₆alkyl;

R^{1b} is independently selected from hydrogen and C₁-C₆alkyl;

or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1c} is independently selected from hydrogen and C₁-C₆alkyl;


R^{1d} is independently selected from hydrogen, C₁-C₆alkyl, and C₁-C₆alkoxy;

or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;

R^{1e} is independently selected from hydrogen and C₁-C₆alkyl; and

R² is defined according to any one of the preceding claims.

21. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 10, and 12 to 20, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-i), wherein:



(IA-i)

R^{1a} is independently selected from hydrogen and C_1 - C_6 alkyl;

R^{1b} is independently selected from hydrogen and C_1 - C_6 alkyl;

or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl;

R^{1c} is independently selected from hydrogen and C_1 - C_6 alkyl;


R^{1d} is independently selected from hydrogen, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy;

or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl;

R^{1e} is independently selected from hydrogen and C_1 - C_6 alkyl; and


R^2 is defined according to any one of the preceding claims.

22. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 10, and 12 to 21, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-ii):




(IA-ii).

23. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 10, and 12 to 21, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IA-iii):



(IA-iii).


24. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, and 11 to 20, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-i), wherein:




(IB-i)

- R^{1a} is independently selected from hydrogen and C₁-C₆alkyl;
 R^{1b} is independently selected from hydrogen and C₁-C₆alkyl;
 or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;
 R^{1c} is independently selected from hydrogen and C₁-C₆alkyl;
 R^{1d} is independently selected from hydrogen, C₁-C₆alkyl, and C₁-C₆alkoxy;
 or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₆cycloalkyl;
 R^{1e} is independently selected from hydrogen and C₁-C₆alkyl; and
 R² is defined according to any one of the preceding claims.

25. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 11 to 20, and 24, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-ii):



26. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 11 to 20, and 24, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein formula (I) is formula (IB-iii):



27. The compound of formula (I'), (I'') or (I) according to any one of claims 20 to 26, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1a} and R^{1b} are both hydrogen.

28. The compound of formula (I'), (I'') or (I) according to any one of claims 20 to 27, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1e} is C₁-C₆alkyl, and R^{1a}, R^{1b}, R^{1c}, and R^{1d} are all hydrogen.


29. The compound of formula (I'), (I'') or (I) according to any one of claims 20 to 26, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1a} and R^{1b} are each independently selected from hydrogen and C_1 - C_6 alkyl, or R^{1a} and R^{1b} on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl, and R^{1c} , R^{1d} , and R^{1e} are all hydrogen.

30. The compound of formula (I'), (I'') or (I) according to any one of claims 20 to 26, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R^{1c} and R^{1d} are each independently selected from hydrogen, C_1 - C_6 alkyl and C_1 - C_6 alkoxyl, or R^{1c} and R^{1d} on the same carbon atom together with the same carbon atom to which they are attached form a C_3 - C_6 cycloalkyl, and R^{1a} , R^{1b} , and R^{1e} are all hydrogen.

31. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R^3 is independently selected from 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C_3 - C_8 cycloalkyl, and halo, wherein the 4- to 11-membered heterocyclyl, and C_3 - C_8 cycloalkyl are each independently substituted with 0-2 occurrences of R^4 ; wherein each R^4 is independently selected from C_1 - C_6 alkyl, C_1 - C_6 alkoxyl, halo, and C_3 - C_8 cycloalkyl.


32. The compound of formula (I'), (I'') or (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein each R^4 is independently selected from C_1 - C_6 alkyl, and fluoro.

33. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 12 to 19, and 31 to 32, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (IC):




5


34. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 12 to 19, and 31 to 32, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (ID):




35. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 10, 12 to 19, and 31 to 33, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (IC-i):




36. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 11 to 19, and 31 to 33, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (IC-ii):



37. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 10, 12 to 19, 31 to 32, and 34, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (ID-i):
















38. The compound of formula (I'), (I'') or (I) according to any one of claims 1 to 9, 11 to 19, 31 to 32, and 34, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of formula (ID-ii):


















(ID-ii).















39. A compound of formula (I'), (I'') or (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, selected from:





	
	
	
	
	
	


	
	
	
	
	
	
	











40. A compound of formula (I'), (I'') or (I) according to any one of claims 1 to 3 and 39, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the absolute configuration at the glutarimide stereocentre is *S*.

41. A compound of formula (I'), (I'') or (I) according to any one of claims 1 to 3 and 39, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the absolute configuration at the glutarimide stereocentre is *R*.

5

42. A compound of formula (I'), (I'') or (I) according to any one of claims 1 to 3 and 39 to 41, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, selected from:





43. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

44. A method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

45. A method of degrading WIZ protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

46. A method of inhibiting WIZ protein expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

47. A method of inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression, the method comprising administering to the subject a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

48. A method of inducing or promoting fetal hemoglobin in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

49. A method of reactivating fetal hemoglobin production or expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

50. A method of increasing fetal hemoglobin expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

51. A method of treating a hemoglobinopathy, *e.g.*, a beta-hemoglobinopathy, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
52. A method of treating a sickle cell disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
53. A method of treating beta-thalassemia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
54. A method of treating a disease or disorder that is affected by the modulation of WIZ protein levels comprising administering to the patient in need thereof a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
55. A method of treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
56. A method for reducing WIZ protein levels in a subject comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
57. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use as a medicament.
58. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder selected from sickle cell disease and beta-thalassemia.

59. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating or preventing a disease or disorder in a subject in need thereof.
60. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating or preventing a disorder that is affected by the reduction of WIZ protein levels, in a subject in need thereof.
61. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inhibiting WIZ protein expression in a subject in need thereof.
62. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in degrading WIZ protein in a subject in need thereof.
63. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inhibiting, reducing, or eliminating the activity of WIZ protein or WIZ protein expression in a subject in need thereof.
64. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in inducing or promoting fetal hemoglobin in a subject in need thereof.
65. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in reactivating fetal hemoglobin production or expression in a subject in need thereof.
66. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in increasing fetal hemoglobin expression in a subject in need thereof.
67. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a hemoglobinopathy in a subject in need thereof.
68. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a sickle cell disease in a subject in need thereof.

69. A compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating beta-thalassemia in a subject in need thereof.

70. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

71. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing or promoting fetal hemoglobin.

72. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

73. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

74. The use according to any one of claims 70 to 73, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.

75. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

76. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by inducing fetal hemoglobin.

77. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture

of a medicament for treating a disease or disorder that is affected by reactivating fetal hemoglobin production or expression.

78. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by increasing fetal hemoglobin expression.

79. The use according to any one of claims 75 to 78, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.


80. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder that is affected by the reduction of WIZ protein levels, inhibition of WIZ protein expression or degradation of WIZ protein.

81. Use of a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder that is affected by inducing fetal hemoglobin, reactivating fetal hemoglobin production or expression, or increasing fetal hemoglobin expression.

82. The use according to any one of claims 80 and 81, wherein the disease or disorder is selected from sickle cell disease and beta-thalassemia.

83. A pharmaceutical combination comprising a compound according to any one of claims 1 to 42, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more additional therapeutic agent(s).

84. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use as a medicament, wherein:



(I)

each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-

C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring (e.g., C₁-C₃alkylene bridging ring);

R² is selected from hydrogen, C₃-C₁₁cycloalkyl, 4- to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, C₁-C₆haloalkyl, C₂-

5 C₆alkenyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl,

wherein the C₃-C₁₁cycloalkyl, C₂-C₆alkynyl, and C₁-C₁₀alkyl are each independently substituted with 0-5 (or 0-4, 0-3, 0-2, 0-1) occurrences of R³;

each R³ is independently selected from C₁-C₆alkoxyl, halo, C₆-C₁₀aryl, 5- to 10-membered heteroaryl comprising 1-4 heteroatoms independently selected from N, O, and S, 4-
10 to 11-membered heterocyclyl comprising 1-2 heteroatoms independently selected from N, O, and S, and C₃-C₈cycloalkyl, wherein the C₆-C₁₀aryl, 5- to 10-membered heteroaryl, 4- to 11-membered heterocyclyl, and C₃-C₈cycloalkyl are each independently substituted with 0-4 occurrences of R⁴;

each R⁴ is independently selected from C₁-C₁₀alkyl, C₁-C₆alkoxyl, halo, and C₃-
15 C₈cycloalkyl, wherein the C₃-C₈cycloalkyl is substituted with 0-3 occurrences of R⁵;

each R⁵ is independently selected from -CN, C₁-C₆alkyl, C₁-C₆alkoxyl, hydroxyl, and C₁-C₆haloalkyl;


n is 0, 1, 2, 3, or 4; and

m is 0, 1 or 2.

20

85. The compound for use according to claim 84, wherein the use is defined according to any one of claims 58 to 69.

86. A compound a compound of Fomula (Y)



wherein each R¹ is independently selected from hydrogen, C₁-C₆alkyl, hydroxyl, halo, C₁-C₆haloalkyl, C₁-C₆haloalkoxyl, and C₁-C₆alkoxyl; or 2 R¹ on the same carbon atom together with the same carbon atom to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on adjacent carbon atoms together with the adjacent carbon atoms to which they are attached form a C₃-C₈cycloalkyl; or 2 R¹ on non-adjacent carbon atoms together with the non-adjacent carbon atoms to which they are attached form a bridging ring;

n is 0, 1, 2, 3, 4, or 5;

m is 0, 1 or 2; and

each of PG¹ and PG² is independently a nitrogen protecting group.

87. The compound according to claim 86, wherein PG² is a base labile protecting group and PG¹ is an acid labile protecting group.

88. The compound according to any one of claims 86 and 87, wherein PG² is the SEM protecting group (trimethylsilylethoxymethyl) and PG¹ is the BOC protecting group (tert-butyloxycarbonyl).

Figure 1A




Figure 1B




Figure 1C

